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Abstract 
Atherosclerosis is characterised by the deposition and accumulation of modified lipids in 
the subendothelial space of the arterial wall, as well as vascular remodelling leading to 
atherosclerotic plaque formation.  Restenosis is a known complication of the surgical 
interventions used to treat atherosclerosis and results in neointimal thickening, in part by 
the action of vascular smooth muscle cells (VSMCs).  Various physiological effects have 
previously been attributed to the action of oxidised low density lipoproteins leading to an 
exacerbation of the inflammatory response and vascular remodelling processes in 
atherosclerosis and restenosis.  Little is known to date about the effects of individual 
modified lipids generated by the action of phagocytic myeloperoxidase (MPO) on these 
processes.  The aim of the present study was to investigate the biological effects of 
modified lipids, both chlorinated and oxidised species, in vascular injury and disease, 
focussing primarily on their effects on vascular smooth muscle (VSM).  Primary VSMCs 
were used to examine the effects of these modified lipids at a cellular level. 
Chlorinated lipids, phospholipid chlorohydrins and alpha-chloro fatty aldehydes were 
found to have a limited effect on VSMC proliferation, viability or migration whereas, 
oxidised phospholipids caused a concentration-dependent reduction in all of these vascular 
remodelling processes.  As AMP-activated protein kinase (AMPK) has recently been 
implicated in vascular disease and found to exert anti-apoptotic effects, the impact of 
AMPK signalling on the effects of the modified lipids in VSM was assessed.  Activation of 
AMPK prior to incubation of 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine 
chlorohydrin resulted in an increase in VSMC proliferation while a greater level of VSMC 
death was observed after treatment with the oxidised phospholipid, 1-palmitoyl-2-
oxovaleroyl-sn-glycero-3-phosphocholine than with the lipids alone.  The occurrence of 
these modified lipids in neointima formation was subsequently investigated using a carotid 
artery injury model in healthy and atherosclerotic mice (mice deficient in apolipoprotein E, 
ApoE
-/-
).  Neointimal growth and levels of plasma MPO were increased in ApoE
-/-
 mice 
resulting in elevated levels of lysophosphatidylcholines and altered relative proportions of 
phosphatidylcholines (PCs) in injured carotid arteries compared to their contralateral 
uninjured right carotid arteries.  Finally, in vivo AMPK activation by administration of 5-
aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) in healthy and 
atherosclerotic mice and its effect on the lipid profile of the aorta were characterised.  
Chronic AMPK activation resulted in a reduction in mean arterial and diastolic pressures 
 xx 
 
as well as a dramatic increase in pulse pressure in ApoE
-/-
 mice compared to their saline-
treated littermates.  Plasma MPO was elevated in AICAR-treated ApoE
-/-
 mice with an 
alteration in the relative intensities of PCs in aortae of AMPK activated ApoE
-/-
 mice. 
The present study is the first report of divergent effects of different classes of modified 
lipids on vascular remodelling processes and how these processes may be modulated by 
AMPK signalling in VSM in atherosclerosis.  In addition, this study has generated novel 
data on the relative changes in distribution of PCs in carotid arteries after vascular injury as 
well as in aortic tissue of healthy and atherosclerotic mice after AMPK activation.  
Additional analysis is required to confirm these differences which could offer further 
insight into the involvement of modified lipids in vascular diseases.  This study has also 
highlighted a novel interaction of AMPK signalling and modified lipids in VSM and could 
therefore provide novel therapeutic targets in the treatment of both atherosclerosis and 
restenosis. 
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1.1 Cardiovascular system 
1.1.1 Structural organisation 
The cardiovascular system (CVS) transports and distributes essential substances such as 
gases, nutrients and hormones to various cells and tissues in the body through its intricate 
network of blood vessels.  It is also responsible for the clearance of by-products of 
metabolism and is crucial in the maintenance of body temperature by transport of heat as 
well as monitoring the water content of cells.  The main components of this circulatory 
system are the heart, blood and blood vessels.  Oxygenated blood from the lungs is ejected 
from the left ventricle of the heart and flows through the aorta to be distributed to the 
peripheral tissues.  The muscular aorta undergoes repeated arterial branching, ultimately 
resulting in the formation of thin-walled capillaries which allow for diffusion of gases and 
metabolites between the blood and cells of the body. 
1.1.2 Structure of the arterial wall 
The arterial wall is made up of three concentric layers: the tunica intima, tunica media and 
tunica adventitia with each layer composed of phenotypically distinct cell types (Levick, 
2003).  The innermost layer, the tunica intima, exists as a monolayer of endothelial cells 
attached to a thin layer of connective tissue; the basal lamina.  Endothelial cells encircle 
the lumen of the vessel and are in constant contact with blood releasing vasoactive agents 
such as the potent vasodilators prostacyclin and nitric oxide (NO).  The tunica media 
consists chiefly of vascular smooth muscle cells (VSMCs) arranged helically in a matrix of 
collagen and elastin fibres with the internal and external elastic lamina (EEL) marking the 
boundaries of the layer.  The tunica media is responsible for regulating the arterial 
diameter and therefore vascular tone, as it is the only vascular layer capable of producing a 
contractile response.  The outermost layer, the tunica adventitia, is a connective tissue-rich 
sheath containing collagen and elastin fibres with no distinct outer border.  The adventitia 
aids in the stability and anchoring of the vessel and contains tiny blood vessels called the 
vasa vasorum which supplies nourishment to the medial layer. 
1.1.3 Vascular smooth muscle function 
Vascular smooth muscle (VSM) is continuously active with the concentration of cytosolic 
calcium (Ca
2+
) being the major determinant of vasoconstriction or vasodilation (Levick, 
2003).  The movement of Ca
2+
 in the cytosol results from a change in membrane potential 
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or the activation of receptors by contractile agents (Rang et al., 2007).  This results in the 
production of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol from the hydrolysis of 
phosphatidyl inositol-bisphosphate by phospholipase C.  Following activation, IP3 causes 
Ca
2+
 release from its internal store, the sarcoplasmic reticulum (SR) via the IP3 receptor.  
The calcium-binding protein calmodulin forms a complex with Ca
2+
 which in turn activates 
myosin light chain kinase.  The activated enzyme phosphorylates smooth muscle myosin 
light chain (SM MLC), a process driven by adenosine triphosphate (ATP).  This results in 
the interaction of SM MLC with alpha smooth muscle actin (αSMA) filaments, initiating 
crossbridge cycling and the generation of force which in turn produces contraction.  For 
relaxation to occur, the level of free cytosolic Ca
2+
 must decrease which occurs by the 
movement of Ca
2+
 back into the lumen of the SR via the sarco/endoplasmic reticulum 
Ca
2+
-ATPase (SERCA) pump with the hydrolysis of ATP.  Thus, VSM regulates the 
luminal diameter of the vessel and therefore is fundamental in vascular tone as well as 
arterial blood flow and pressure. 
1.1.4 Cardiovascular disease 
The term cardiovascular disease (CVD) encompasses all diseases involving the heart and 
circulatory system including coronary artery disease (CAD), hypertension and stroke.  
CVD remains the leading cause of premature death (in people below the age of 75) in the 
U.K. today, claiming 28 % of men and 20 % of women in 2008 (www.heartstats.org, 
2012).  CVD is a multifactorial disease with interactions of both genetic and environmental 
risk factors including lifestyle, smoking and diet, playing their part in the prevalence of the 
disease.  CAD and stroke are two of the biggest killers and the unhealthy diet of many 
people living in the West of Scotland results in an extremely high incidence, with the 
highest death rate from CAD in the U.K. occurring in this region.  In contrast, there is a 
low occurrence of CVD and reduced mortality rate within the French population despite a 
high intake of saturated fats in their diet, known as the “French paradox” (Criqui and 
Ringel, 1994).  This is attributed to the high consumption of red wine, containing 
molecules such as the antioxidant resveratrol which is thought to be beneficial in the 
prevention of CVD (reviewed in Lippi et al. (2010)).  With CAD responsible for around a 
third of all deaths in the U.K., it has been reported to cost the health care system around 
£3.2 billion in primary patient care in 2006 with this value increasing up to £3.9 billion 
with the addition of loss of productivity costs (www.heartstats.org, 2012).  Although the 
numbers of people with CVD has been falling in recent years, there is still a vital need for 
continued research within this area leading to new prevention strategies and treatments. 
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1.2 Atherosclerosis 
One of the major causes of both CAD and stroke can arise from the same common 
problem; the presence of atherosclerosis in the vasculature.  Atherosclerosis is a 
progressive disease characterised by a thickening and hardening of the arterial wall, 
affecting large (aorta) and medium-sized (carotid, coronary, etc.) muscular and elastic 
arteries of the CVS (Ross, 1999a).  The narrowing or complete occlusion of the luminal 
area of these arteries results in reduced blood flow and depending on the artery affected 
can ultimately lead to myocardial infarction (MI) or stroke.  High plasma levels of 
circulating cholesterol-containing lipoproteins such as low density lipoproteins (LDL) is a 
primary risk factor as disease progression is attributed to lipid deposition and accumulation 
within the subendothelial space.  The pathology of atherosclerosis matures over many 
years from the initial fatty streak, which can occur from childhood, up to an advanced, 
complex lesion.  However, most clinical manifestations are not observed until the disease 
has progressed extensively and there is a large reduction in the diameter of the arterial 
lumen, usually presenting clinically as angina-like symptoms. 
1.2.1 Classification of atherosclerotic lesions 
In the early nineties, the American Heart Association’s Committee on Vascular Lesions 
devised a numerical classification of atherosclerotic plaques by consideration of the 
composition and structure of the lesions (Stary et al., 1992, Stary et al., 1994, Stary et al., 
1995).  Both type I and II lesions refer to small lipid deposits in the arterial wall, usually 
termed early lesions.  Type I lesions are the first detectable lipid deposits observed in the 
intima of muscular arteries and are not usually visible to the naked eye.  In contrast, type II 
lesions include the formation of fatty streaks in atherosclerosis-prone regions which are 
usually the first recognisable characteristic of atherosclerosis.  Typically, areas susceptible 
to lesion formation are arterial bifurcation points that are subjected to high pressure and 
turbulent flow.  Type III lesions manifest as the link between early and advanced plaque 
formation and termed the transitional lesion.  These lesions accumulate additional 
extracellular lipid pools in the medial layer causing greater intimal thickening.  The first 
plaques classified as advanced are type IV lesions due to the formation of an extensive 
extracellular lipid core while type V lesions also contain fibrous connective tissue.  These 
forms of plaques are largely responsible for the morbidity and mortality associated with 
atherosclerosis.  Large complicated lesions have now been classified as type VI, VII and 
VIII lesions with the presence of surface disruptions and the predominance of calcification 
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and fibrous tissue respectively, which carry a high risk of thrombotic events due to the 
rupture of the fibrous cap of vulnerable plaques (Stary, 2000).  In some cases, this can lead 
to acute closure of the vessel, resulting in a MI or can, in subacute cases, cause transient 
ischaemic events as seen in patients with unstable angina. 
1.2.2 Pathophysiology of atherosclerosis 
Atherosclerosis is now widely acknowledged as an inflammatory disease with the first step 
in disease progression believed to occur via dysfunction of the endothelium (Ross, 1999b).  
This can occur at regions of arterial branching where there is turbulent flow and is 
enhanced by a combination of endogenous factors including elevated levels of modified 
LDL as well as environmental factors such as free radicals present in tobacco smoke 
(Bassiouny et al., 1994, Ross, 1999a).  Chronic infections have also been suggested to 
initiate damage to the intima of the vessel (reviewed in Libby et al. (1997)).  
Compensatory mechanisms that change the homeostatic control of the endothelium 
subsequently occur to overcome the initial damage (Ross, 1999a).  Damage to the 
endothelium and the presence of high plasma levels of circulating LDL leads to deposition 
of these lipids in the subendothelial space of the arterial wall (Davignon and Ganz, 2004).  
Cholesterol-rich LDL is then subjected to oxidative and enzymatic attack which will be 
discussed in greater detail in Section 1.3.2 (Skalen et al., 2002).  The modification of LDL 
results in the activation of endothelial cells which leads to the expression of inflammatory 
cell adhesion molecules and the recruitment of blood-borne monocytes (Shih et al., 1999, 
Glass and Witztum, 2001).  This facilitates the adherence of leukocytes to the damaged 
endothelium and results in the transmigration of these cells into the intimal layer by the 
action of chemokines such as monocyte chemotactic protein-1 (MCP-1).  Once inside the 
arterial wall, migrated monocytes mature into activated intimal macrophages by the action 
of macrophage colony-stimulating factor which also results in the up-regulation of 
scavenger receptors (Yan and Hansson, 2007).  Macrophages internalise oxidised LDL 
(oxLDL) particles in an uncontrolled manner giving rise to lipid-laden foam cells.  An 
illustration of the foam cell and subsequent atherosclerotic plaque formation is presented in 
Figure 1.1.  Macrophage foam cells secrete a variety of pro-inflammatory products such as 
cytokines and reactive oxygen species (ROS) which worsen the inflammatory response, as 
well as resulting in VSMCs proliferation and migration (Libby, 2002).  Accumulation of 
foam cells results in the formation of fatty streaks, the type II plaques which consist mainly 
of inflammatory cells (Stary et al., 1994).  The artery can then undergo positive vascular 
remodelling causing the lumen to be unaffected, thereby negating the effect on blood flow.  
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However, these fatty streaks continue to grow with the accumulation of more foam cells, 
dead macrophages, lipids and VSMCs forming advanced atherosclerotic plaques.  These 
lesions contain fibrous connective tissue which forms a fibrous cap and, with the addition 
of inflammatory cells, lipids and debris over time becomes thinner and more vulnerable, 
exposing the inner layer which is pro-thrombotic (Ross, 1999a).  Fibrous cap erosion can 
occur in numerous ways including inflammation which leads to apoptosis as well as the 
absence of Ca
2+
 in the fibrous cap causing it to become weak and fragile (Mitra et al., 
2004).  This results in exposure of the necrotic lipid core to circulating blood causing 
thrombosis formation and a potentially fatal cardiovascular event. 
1.2.2.1 Inflammatory cell recruitment 
Both monocytes and macrophages are influential in the development of atherosclerotic 
plaques and present at every stage of atherogenesis (reviewed in Moore and Tabas (2011)).  
Monocyte recruitment has been shown to be a rate-limiting step in the formation of lesions 
as they are responsible for the secretion of multiple pro-inflammatory agents including 
cytokines, chemokines and matrix metalloproteinases (MMPs) (Ross, 1995, 1999a).  This 
is significant as these extravasated inflammatory cells can then multiply within the lesion 
leading to the release of additional cytokines and chemokines.  This in turn attracts more 
inflammatory cells to the site of action causing further damage to the endothelium (Ross, 
1999a).  This forms the basis of the response-to-injury hypothesis where the inflammation 
begins as a protective measure and then due to the continued response can become 
detrimental to the vessel (Ross, 1999b).  In atherosclerotic mice, monocyte attachment has 
been observed through all phases of atherosclerosis (Reddick et al., 1994).  This process 
occurs through the binding of these inflammatory cells to various vascular adhesion 
molecules such as P-selectin, vascular cell adhesion molecule-1 (VCAM-1) and 
intracellular adhesion molecule-1 (ICAM-1), expressed on the endothelium.  Mice 
deficient in VCAM-1 display reduced atherosclerosis while the loss of ICAM-1 or P-
selectin is protective against atherosclerosis highlighting the importance of these adhesion 
molecules in disease progression (Collins et al., 2000).  Selectins present on the endothelial 
surface attract and capture circulating leukocytes and monocytes which are then activated 
by endothelial chemokines.  This promotes rolling of the activated cells resulting in firm 
adhesion followed by transmigration into the intima (Muller, 2003).  Once inside the 
arterial wall, monocytes mature to activated macrophages with the overexpression of 
scavenger receptors, notably the scavenger receptor class A (SRA) and the class B 
scavenger receptor, CD36 (Kunjathoor et al., 2002).  This leads to the uncontrolled uptake 
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of oxLDL by macrophages and the formation of lipid-loaded foam cells, a prerequisite for 
the development of atherosclerosis (Suzuki et al., 1997).  However, alternative 
mechanisms of lipid uptake may also be in operation as hyperlipidaemic mice lacking in 
SR-A and CD36 still demonstrate macrophage foam cell formation and atherosclerotic 
lesions (Moore et al., 2005).  The increased quantity of leukocytes such as neutrophils can 
also provide a source for the modification of lipids, discussed in detail in Section 1.3.  
Taken together, this highlights the inflammatory nature of atherosclerosis and the need for 
inflammatory cell recruitment for disease progression. 
1.2.2.2 Involvement of VSMCs 
While inflammatory cells are essential in the development of foam cells and fatty streaks, 
VSMCs become more dominant as atherosclerosis progresses (Raines and Ross, 1993).  In 
a normal adult blood vessel, the VSMC doubling time is greater than 80 years whereas in 
atherosclerosis this is reduced to about 20 years and found to be only about 4 weeks in vein 
grafts.  The phenotype of intimal VSMCs within atherosclerotic lesions is found to differ 
significantly from their medial counterparts (Mosse et al., 1985).  Medial VSMCs usually 
express high levels of smooth muscle myosin heavy chain (SM MHC) and αSMA as these 
proteins are involved in the contractile function of the cell (Owens et al., 2004).  In 
contrast, intimal VSMCs have a high proliferative index and express much lower levels of 
SM MHC and αSMA.  VSMCs exhibit this plasticity as they are not terminally 
differentiated and can therefore undergo phenotypic switching from a quiescent 
“contractile” phenotype to an active “synthetic” state, displayed in Figure 1.1 (Campbell 
and Campbell, 1994, Gomez and Owens, 2012).  This can occur in response to numerous 
pro-inflammatory and atherogenic stimuli including components of the extracellular matrix 
(ECM), cytokines and modified lipids (Thyberg and Hultgardh-Nilsson, 1994, Hautmann 
et al., 1997, Pidkovka et al., 2007).  In addition to macrophages, VSMCs are responsible 
for a significant number of lipid-loaded foam cells in atherosclerosis due to increased 
expression of scavenger receptors facilitating more efficient lipid uptake and foam cell 
formation (Stary et al., 1994, Rong et al., 2003).  VSMCs are also key producers of ECM 
in both healthy and atherosclerotic vessels with synthetic VSMCs able to produce up to 25 
to 46 times more collagen and therefore able to synthesis large amounts of ECM, 
contributing to vascular remodelling (Doran et al., 2008, Ang et al., 1990). 
Synthetic VSMCs also assist in remodelling as they are able to migrate and proliferate 
more readily than their contractile counterparts.  VSMCs undergo proliferation in a 
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regulated cell cycle.  Quiescent VSMCs are usually maintained in a nonproliferative phase, 
gap 0 (G0) and only enter interphase, firstly to the gap 1 (G1) checkpoint when stimulated 
after injury or disease.  During this time, all the factors necessary for DNA replication are 
produced and assembled for the synthetic (S) phase after which VSMCs enter another gap 
phase, G2, in preparation for mitosis (M).  Restriction points at the G1-S and G2-M 
junctions ensure orderly cell cycle progression controlled by cyclins and other regulatory 
proteins (Dzau et al., 2002).  Although an important component of atherosclerosis, the 
proliferation rate of VSMCs in lesions has been revealed to be relatively low using 
antibodies to cell cycle-related proteins with a similar result observed with macrophages 
(Gordon et al., 1990).  VSMC proliferation can be induced by a variety of mechanisms 
including mechanical stress and growth factors (reviewed in Rivard and Andres (2000)).  A 
lower proliferative index may suggest a greater role of migratory VSMCs from the medial 
layer in remodelling of the arterial wall.  There are a variety of signal transduction 
pathways found to induce traction force and therefore VSMC migration, reviewed in 
Gerthoffer (2007).  These include activation of the p38 mitogen-activated protein kinase 
(MAPK) and Rho-activated protein kinase (ROCK).  VSMC migration occurs by 
subsequent remodelling of the cytoskeleton and a change in the matrix adhesiveness 
resulting in activation of motor proteins in the VSMC.  There is also a link between 
migration and proliferation as VSMCs were found to migrate in the G1 phase but not in 
later stages of the cell cycle (Fukui et al., 2000). 
In addition to proliferation and migration, cell death plays a critical role in vascular 
remodelling and contributes to the pathophysiology of atherosclerosis (Gibbons and Dzau, 
1994).  Programmed cell death or apoptosis is an intrinsic mechanism of cell suicide 
involving cell shrinkage and chromatin condensation with subsequent fragmentation of 
DNA.  Defective or inappropriate apoptosis plays a role in remodelling of the vasculature 
in atherosclerosis (Bennett and Boyle, 1998, Mallat and Tedgui, 2000).  Apoptosis in 
VSMCs and macrophages can promote inflammation, accelerate atherosclerosis as well as 
alter the composition of atherosclerotic lesions (Clarke et al., 2008, Ait-Oufella et al., 
2007).  There are a variety of triggers including both intrinsic and extrinsic signals, which 
are thought to induce VSMC apoptosis in atherosclerotic lesions.  Similar to proliferation 
and migration, there are numerous pathways involved in VSMC apoptotic signalling 
including activation of the caspase cascade (reviewed in Bennett and Boyle (1998) and 
Mallat and Tedgui (2000)).  Collectively, this emphasises the significance of VSMCs in 
the development and progression of atherosclerosis as well as in arterial remodelling. 
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Figure 1.1 – Formation of foam cells and plaques in atherosclerosis and the 
importance of VSMCs in disease progression. 
The large clear lumen of a normal artery is drastically reduced after the formation of an 
advanced atherosclerotic plaque.  Lesion formation occurs after endothelial dysfunction 
which causes the expression of adhesion molecules and in turn, the migration of 
inflammatory cells to the site of injury.  This results in the accumulation of macrophages 
as well as the proliferation and migration of VSMCs after phenotypic switching from a 
contractile to a synthetic state.  Lipid-laden foam cells are then formed by the uncontrolled 
uptake of deposited lipid by macrophages and VSMCs.  This results in the formation of 
fatty streaks which develop into advanced atherosclerotic plaques with the addition of a 
fibrous cap. 
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1.2.3 Atherosclerosis and hypertension 
Atherosclerosis and hypertension are closely related but separate cardiovascular disorders 
which combined leads to an extremely high risk of CAD and MI (Lithell, 1994).  Similar to 
atherosclerosis, hypertension is a multifactorial process involving the interaction of genetic 
and environmental factors resulting in an elevation of arterial blood pressure.  
Hypertension is both a predisposing risk factor and a consequence of atherosclerosis and 
causes VSMCs in the arterial wall to grow either by hyperplasia, an increase in number or 
hypertrophy, an increase in mass (Dzau and Gibbons, 1988).  The mechanisms of this 
synergistic effect between atherosclerosis and hypertension are not well understood.  
Previous clinical trials have shown a strong correlation between hypertension and the risk 
of developing atherosclerosis highlighted by the predominance of atherosclerotic plaques 
in areas of the vasculature subjected to high pressures and turbulent flow (Kannel et al., 
1986, Alexander, 1995).  LDL from hypertensive patients is also more vulnerable to 
oxidation in vitro than LDL isolated from normotensive patients (Maggi et al., 1993).  In 
animal models, angiotensin II-induced hypertension increased plaque area in the thoracic 
aorta of atherosclerotic mice compared to their healthy wild type counterparts (Weiss et 
al., 2001).  Both atherosclerosis and hypertension have also been shown to enhance 
oxidative stress within the arterial wall leading to an exacerbated phenotype which can 
further accelerate atherosclerotic progression (Alexander, 1995). 
1.2.4 Animal models of atherosclerosis 
As atherosclerosis is a highly complex multifactorial disease, it has proved difficult to 
produce an animal model with all the characteristics required.  Previously, the majority of 
animal models available for research were large animals such as dogs, pigs and rabbits.  
Dogs are not ideal models as they do not develop spontaneous atherosclerosis and large 
modification of their diet as well as concomitant thyroid suppression was needed in order 
to produce lesions (Geer, 1965).  Similar to dogs, rabbits do not develop spontaneous 
atherosclerosis; however, they respond quickly to dietary cholesterol manipulation and 
produce vascular lesions (Schenk et al., 1966, Drobnik et al., 2000).  Pigs fed with 
cholesterol were found to exhibit similar distribution and morphology to human 
atherosclerotic lesions making them a desirable model (Ratcliffe and Luginbuhl, 1971).  
However, the cost, as well as the difficulties in handling due to their size and weight, has 
made the pig model an impractical choice for many researchers.  The handling issues were 
overcome by the development of mini pigs; however, these animals are still very expensive 
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and difficult to obtain (Swindle et al., 1988).  Mice are ideal experimental models in the 
pursuit of finding and testing new therapeutic agents due to their small size, short breeding 
time, ready availability and simple husbandry.  For atherosclerosis research, the major 
drawback is that mice are highly resistant to atherosclerosis.  The plasma cholesterol in 
mice is mainly found in the anti-atherogenic high density lipoproteins (HDL) and low 
levels in proatherogenic LDL and very low density lipoproteins (VLDL), which is in 
contrast to humans who are high in LDL and low in HDL.  The only exception to this is the 
C57BL/6 mouse strain which when fed on a high cholesterol diet develops lesions.  This 
strain of mouse is one of the most widely used in the production of experimental models of 
human diseases as a genetic background.  Transgenic and knockout mice became the focus 
in the development of a suitable atherosclerotic mouse model with the first genetically 
altered models of atherosclerosis being created in the early nineties. 
1.2.4.1 Mice deficient in apolipoprotein E 
In both mice and humans, apolipoprotein E (ApoE) is one of the major genes involved in 
determining plasma lipid levels and is synthesised in the liver, brain and other tissues.  It is 
also a structural component of all lipoprotein particles except LDL and acts as a ligand for 
the LDL receptor and LDL receptor-related proteins thereby promoting the specific uptake 
of atherogenic particles from the circulation.  In 1992, mice deficient in ApoE (ApoE
-/-
) 
were generated by the inactivation of ApoE by gene targeting in mouse embryonic stem 
cells (Piedrahita et al., 1992, Plump et al., 1992).  Targeting plasmids were used which 
replaced part of the apoE gene and disrupted its structure.  The homozygous animals 
created appeared to be healthy, displayed normal development and were comparable in 
body weight to wild type mice.  However, major differences were observed in relation to 
the lipid and lipoprotein profiles in the ApoE
-/-
 mice.  The total plasma cholesterol levels 
were dramatically increased and were up to five times higher than their wild type 
littermates.  This was due to the loss of clearance of the excess lipoproteins from the 
plasma resulting in an altered lipoprotein profile with ApoE
-/-
 mice having a high level of 
atherogenic VLDL (Jawien et al., 2004).  ApoE
-/-
 mice develop spontaneous 
atherosclerosis, with the first signs of the disease occurring at about 6 to 8 weeks of age.  
These include monocyte adhesion, disruption of the subendothelial elastic lamina and 
initial foam cell formation which is accelerated further by high fat feeding (Nakashima et 
al., 1994, Coleman et al., 2006).  Previous studies have shown ApoE
-/-
 mice to exhibit 
similar blood pressure recordings to control mice (Gervais et al., 2003, Hartley et al., 
2000).  However, continuous blood pressure measurements over a 24 hour period revealed 
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ApoE
-/-
 mice to have elevated systolic and diastolic pressures as well as increased heart 
rate compared to C57BL/6 control mice and an elimination of circadian cycles (Pelat et al., 
2003).  This highlights the ApoE
-/-
 mouse as an attractive animal model due to the benefits 
of using a mouse model as well as displaying a similar morphology to human 
atherosclerosis progression.  In addition, mice deficient in the LDL receptor (LDLr
-/-
) is 
another mouse model used in the investigation of familial hypercholesterolaemia.  LDLr
-/-
 
mice were developed in 1993 and show a more modest change in total plasma cholesterol 
levels compared to ApoE
-/-
 mice (Ishibashi et al., 1993).  The use of mouse models of 
atherosclerosis has greatly accelerated research within this area. 
1.3 Modification of phospholipids and LDL in 
atherosclerosis 
Lipid deposition and accumulation is one of the hallmarks of atherosclerosis.  There are a 
large number of potential targets for phospholipid modification in vivo as phospholipids 
are the major components of both cellular membranes and circulating plasma lipoproteins.  
Glycerophospholipids are a class of phospholipids containing a phosphatidyl group linked 
to a glycerol molecule, which is substituted with two fatty acids.  These phospholipids are 
classified depending on the alkyl chains attached to the phosphatidyl group.  
Phosphatidylcholines (PCs) are the most abundant species with phosphatidylethanolamines 
(PEs) and sphingomyelins (SMs) also contributing a substantial proportion.  
Phosphatidylserines (PSs) are less abundant and found normally in the inner leaflet of the 
plasma membrane while phosphatidylinositols (PIs) are usually cellular rather than 
circulating lipoprotein components.  Apoptotic cells and bodies have been reported to 
contain increased levels of biologically active phospholipid oxidation products, 
highlighting the occurrence of oxidative damage in vascular disease (Huber et al., 2002).  
With regard to lipoproteins, most research has focussed on the formation of oxidised 
phospholipids in LDL particles in CVD and atherosclerosis. 
1.3.1 LDL particles 
Lipoproteins are lipid-protein complexes and their primary function is as a method of 
transport for lipids and primarily cholesterol in the blood due to their insoluble nature.  
LDL is formed in a two step process with a variable fraction of each of the lipoproteins 
being formed at each step (Havel, 1984).  The liver synthesises VLDL which is secreted 
into the bloodstream where lipoprotein lipases in peripheral capillaries partially hydrolyse 
the molecule causing the lipolytic removal of most of the triglycerides present in VLDL.  
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After lipolysis occurs, the particles are called intermediate density lipoproteins (IDL).  IDL 
is then transported back to the liver where further transformation can occur with the 
removal of more triglycerides and alteration of the protein component forming LDL 
particles which transport exogenous and endogenous cholesterol to peripheral tissues.  
LDL leaves the bloodstream through capillary pores or across the endothelium by vesicular 
transport to target tissues.  Any cholesterol that is not used is removed by active transport 
mediated by the ATP-binding cassette transporters, ABCG1 and ABCA1 and is absorbed 
by HDL and subsequently cleared by the liver by reverse cholesterol transport to maintain 
physiological levels of circulating cholesterol (Martini, 2006, Berne et al., 2004). 
The LDL particle is complex containing several different components and proposed to be a 
three-layer spherical molecule usually about 25 nm in diameter.  It comprises a polar 
hydrophilic outer surface, interfacial layer and non-polar hydrophobic core (Hevonoja et 
al., 2000).  One LDL particle is known to contain approximately 600 molecules of free 
cholesterol, 1600 molecules of cholesteryl esters, 185 molecules of triglyerides in the core 
and the outer surface layer comprising of around 700 phospholipid molecules, mainly PCs 
and SM with about 450 and 185 molecules respectively (Gotto et al., 1986).  LDL particles 
also contain other phospholipids such as lysophosphatidylcholines, PEs and PIs to a much 
lesser extent.  In addition to the lipids present, LDL contains a protein component of one 
molecule of apolipoprotein B-100 (ApoB-100) which is made up of 4536 amino acid 
residues and wraps around the surface of the particle (Yang et al., 1986, Knott et al., 
1986).  LDL particles are a heterogeneous group of molecules and vary in both diameter 
and density from about 18 to 25 nm and 1.019 to 1.063 g/ml respectively (Kumar et al., 
2011).  This is important as small dense LDL particles have been identified as an emerging 
cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment 
Panel III (2002) as they are more susceptible to oxidative modification than more buoyant 
particles of LDL (Chait et al., 1993).  The unsaturated nature of the fatty acyl chains of 
phospholipids present in the LDL particle such as cholesteryl esters, triglycerides and 
phospholipids means these molecules are particularly vulnerable to oxidation as well as the 
protein component, ApoB-100. 
1.3.2 Oxidation of LDL 
LDL isolated from plasma of normolipidaemic patients was first found to induce cell death 
in cultured human vascular cells while HDL had no detrimental effects (Hessler et al., 
1979).  Structural modification of LDL was thought to be required in order for the particle 
Chapter 1 – General Introduction 
14 
 
to induce pro-atherosclerotic effects as native LDL was taken up by macrophages at a rate 
that was insufficient to produce lipid-laden cells (Brown and Goldstein, 1983).  Another 
group found that incubation with native LDL did not lead to foam cell formation and later 
found that cultured cells could modify LDL to a form that was recognised by macrophage 
scavenger receptors (Henriksen et al., 1981, 1983).  These structural changes were found 
to be due to oxidative modification of the LDL particles (Steinbrecher et al., 1990).  The 
oxidative hypothesis of atherosclerosis was then proposed whereby oxidative modification 
of LDL is essential for the formation and progression of the disease due to uptake and 
accumulation of oxLDL by macrophages (Witztum, 1994).  The term oxLDL, does not 
describe a well characterised molecular species as different laboratories use different 
conditions and mechanisms of oxidation which leads to different extents to which LDL 
will become oxidised.  There are also large variations due to the heterogeneous nature of 
the native LDL particles.  Depending on the mechanism of oxidation as well as the length 
of incubation, oxidation of LDL can refer to modification of all components of the particle 
including lipids and protein.  However, the term minimally-modified LDL (mmLDL) 
usually refers to a particle where the lipids and not the protein component is oxidised. 
1.3.2.1 Sources of LDL and phospholipid oxidation 
The potential sources of LDL and phospholipid oxidation are shown in Figure 1.2 
including a selection of biological effects attributed to these modifications, discussed in 
Section 1.3.3.  Many cell types, including vascular cells such as endothelial cells and 
VSMCs as well as inflammatory cells such as leukocytes, can modify LDL in vitro 
(reviewed in Witztum and Steinberg (1991)).  One of the principal methods of oxidation is 
via the action of enzymes, both by direct enzymatic attack and their production of reactive 
species.  The enzyme, 12/15-lipoxygenase acts directly by catalysing the oxygenation of 
arachidonic acid at carbon 12 and/or carbon 15 and is capable of oxidising both LDL and 
phospholipids.  12/15-lipoxygenase and apoE double knockout mice fed on a high fat diet 
had reduced atherosclerotic plaque formation compared with ApoE
-/-
 mice expressing the 
enzyme, indicating its importance in vivo (Cyrus et al., 1999).  There are also a number of 
enzymes involved in the production of free radicals with the ability to modify LDL 
including myeloperoxidase (MPO), NAPDH oxidase (Griendling et al., 2000) and nitric 
oxide synthase (NOS) (Vasquez-Vivar et al., 1998).  The mechanism of modification of 
both LDL and phospholipids by the phagocytic enzyme, MPO is of particular interest to 
this study and will be discussed further in Section 1.3.4.  Exogenous sources including 
smoking, UV radiation and atmospheric pollution also have the potential to modify LDL 
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and phospholipids with tobacco smoking containing a large quantity of free radicals in 
both the gas and tar phase (Church and Pryor, 1985).  A commonly used in vitro model for 
producing oxLDL is the exposure of LDL particles to transition metals.  Incubation of 
LDL with copper or iron leads to extensive oxidation of the particles (Steinbrecher et al., 
1984, Heinecke et al., 1984); however the contribution of this source of oxidation in vivo is 
thought to be relatively low.  Furthermore, iron-containing haemoglobin is another source 
for LDL modification by oxidatively cross-linking with ApoB-100 (Ziouzenkova et al., 
1999).  The different mechanisms of oxidation have also been implicated at different stages 
of atherosclerosis, for example, 12/15-lipoxygenase which is thought to be important in 
early plaque formation (reviewed in Gaut and Heinecke (2001)).  Together, this highlights 
different mechanisms and sources available in vivo for the modification of LDL and 
phospholipids which causes a variety of physiological effects witnessed in the progression 
of atherosclerosis. 
1.3.3 Physiological effects of oxidised phospholipids 
Oxidised 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) is often 
used as a model system for the biological effects of oxLDL, as it was found to mimic some 
of its actions in vitro (Watson et al., 1997).  1-palmitoyl-2-glutaroyl-sn-glycero-3-
phosphocholine (PGPC) and 1-palmitoyl-2-oxovaleroyl-sn-glycero-3-phosphocholine 
(POVPC) are the truncated products formed from the autoxidation of 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphocholine (PAPC), present in mmLDL and could be 
critical markers in the progression of atherosclerosis (Watson et al., 1997).  As mentioned 
earlier, phenotypic switching of VSMCs from a contractile state to a synthetic one is 
influential in the primary stages of the disease (Owens et al., 2004).  Oxidised 
phospholipids, POVPC and PGPC induced phenotypic switching of VSMCs with the 
transformation of these cells occurring both in vitro and in vivo (Pidkovka et al., 2007).  
The oxidised phospholipids were found to decrease expression of αSMA and SM MHC as 
well as induce nuclear translocation of a known smooth muscle repressor gene, Krüppel-
like transcription factor 4 (Klf4) (Pidkovka et al., 2007).  POVPC was also found to induce 
Klf4 expression directly in cultured VSMCs (Yoshida et al., 2008).  Furthermore, exposure 
of anti-inflammatory M2 macrophages to oxLDL results in the switching of these cells to a 
pro-inflammatory status causing the accumulation of oxLDL and the enhanced secretion of 
MCP-1 (van Tits et al., 2011).  Oxidised phospholipids and LDL are implicated in nearly 
every stage of the pathogenesis of atherosclerosis. 
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1.3.3.1 Remodelling processes 
Remodelling of the vasculature in atherosclerosis involves various cellular processes such 
as VSMC proliferation, apoptosis, migration, leukocyte adhesion and formation of ECM 
(Gibbons and Dzau, 1994).  The physiological effects of oxidised phospholipids have 
previously been investigated in terms of proliferation and apoptosis of VSMCs while very 
little on the effects of these lipids on migration or production of ECM has been examined.  
A biphasic response has been reported for oxidised phospholipid effects on remodelling 
processes with a proliferative action observed at lower concentrations and apoptosis 
predominating at higher levels (Auge et al., 2002).  The length of exposure of these 
biological active lipids with VSMCs is also an important factor with longer treatments 
resulting in oxidised phospholipid-induced apoptosis (Chahine et al., 2009).  This suggests 
a balance exists in VSMCs between proliferative and apoptotic effects of oxidised 
phospholipids which is an important feature of both atherosclerosis and restenosis; a 
common side effect of cardiological interventions to treat atherosclerosis, characterised by 
the proliferation and migration of VSMCs (Section 1.5). 
Proliferation of vascular cells within vessels is essential for the progression and formation 
of atherosclerotic plaques.  POVPC, but not PGPC, was suggested to be the component of 
mmLDL responsible for stimulating proliferation of VSMCs by activating the production 
of lactosylceramide resulting in the phosphorylation of p44 MAPK (Chatterjee et al., 
2004).  POVPC topically applied to mouse carotid arteries in vivo induced significant 
VSMC proliferation while no effect was observed with PGPC treatment and it has been 
suggested that while POVPC works through the MAPK pathway, PGPC works through 
protein kinase C (Johnstone et al., 2009, Chatterjee et al., 2004, Leitinger, 2005).  This is 
in line with the truncated products of oxPAPC reported to localise in different cellular 
compartments with PGPC found in lysosomes while POVPC formed covalent adducts with 
components of the plasma membrane (Moumtzi et al., 2007).  An inhibitory action of 
oxidised phospholipids has also been observed where VSMC growth was inhibited by 
PGPC and to a greater extent, POVPC (Fruhwirth et al., 2006).  In addition to the effects 
of individual oxidised phospholipids, oxLDL has been reported to stimulate VSMC 
proliferation by increased expression of regulatory proteins involved in entry into and 
progression through the cell cycle (Zettler et al., 2003).  VSMC proliferation stimulated by 
oxLDL, also induced the E-cadherin/β-catenin/T-cell factor pathway, which is influential 
in cell adhesion and therefore the inflammatory response (Bedel et al., 2008).  A 
stimulatory effect on human coronary artery endothelial cell (HCAEC) proliferation has 
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also been observed at a low concentration of oxLDL (Yu et al., 2011).  In addition to the 
effects observed in vascular cells, oxLDL stimulated macrophage proliferation leading to 
the activation of extracellular signal-regulated kinase 1/2 and MAPK (Senokuchi et al., 
2004).  Oxidised phospholipids can therefore induce proliferation of vascular cells and 
macrophages, which leads to the activation of several pathways involved in the immune 
response. 
As discussed earlier, defective or inappropriate apoptosis in the vasculature during 
atherosclerosis impacts greatly on remodelling processes (Bennett and Boyle, 1998, Mallat 
and Tedgui, 2000).  VSMCs are competent phagocytes and are capable of engulfing 
damaged VSMCs undergoing apoptosis; however, this process is greatly reduced by 
oxLDL or hyperlipidaemia in vivo (Clarke et al., 2010).  This observation is emphasised by 
the fact that high levels of oxidised lipids are found in apoptotic cells leading to the release 
of interleukin-1 (IL-1) which further exacerbates the inflammatory response (Chang et al., 
2004, Clarke et al., 2010).  In addition to VSMCs, macrophages incubated with oxLDL 
were shown to activate apoptotic signalling pathways (Hardwick et al., 1996).  These 
effects were also witnessed after incubation with PGPC and POVPC (Stemmer et al., 
2012).  Conversely, oxLDL has also been implicated in the survival of macrophages by 
preventing the production of ceramide via the inhibition of acid sphingomyelinase (SMase) 
activity (Hundal et al., 2003).  In contrast to the proliferative actions observed with 
individual oxidised phospholipids, POVPC and PGPC have also been shown to induce 
apoptosis by the phosphorylation of MAPK and activation of the acid form of SMase 
(Fruhwirth et al., 2006, Loidl et al., 2003).  Ceramide, a hydrolysis product of SMase, 
mimics the action of mmLDL and activates caspase 3 signalling and apoptosis (Loidl et al., 
2004).  LDLr
-/-
 mice crossed with programmed cell death-1 receptor knockout mice, 
exhibited an increase in atherosclerotic lesion size as well as a compositional change with 
plaques containing more macrophages and T-cells compared with control LDLr
-/-
 mice (Bu 
et al., 2011).  OxLDL has also been found to up-regulate expression of the lectin-like 
endothelial receptor for oxLDL and incubation with HCAECs induced apoptosis in a 
concentration- and time-dependent manner (Li and Mehta, 2000).  The activation of 
caspase signalling pathways after oxLDL incubation has also been observed in endothelial 
cells, similar to VSMCs (Chen et al., 2004). 
In addition to the effects of oxidised phospholipids on other remodelling processes, 
POVPC and PGPC have been found to activate VSMC migration and type VIII collagen 
expression, involved in the compositional change of ECM in atherosclerotic lesions (Al-
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Shawaf et al., 2010, Cherepanova et al., 2009).  Collectively, this suggests that oxidised 
phospholipids are not only involved in the production of foam cells but also in a change in 
the vessel architecture witnessed in the formation of atherosclerotic plaques by their effects 
on vascular remodelling. 
1.3.3.2 Endothelial function and inflammatory cell adhesion 
Endothelial dysfunction is believed to be an early event in atherosclerosis with oxidised 
phospholipid-induced apoptosis contributing to this but some less severe effects of 
oxidised phospholipids have been also been associated with it.  OxPAPC treatment of 
endothelial cells activated more than 1000 genes and produced a range of chemokines 
including MCP-1, IL-6 and IL-8, involved in both cell adhesion and migration (Gargalovic 
et al., 2006).  NO is crucial in the regulation of arterial tone and oxLDL was found to 
rapidly reduce the intracellular levels; however, it did not affect the ability of endothelial 
NOS to produce the signalling molecule (Cominacini et al., 2001).  Endothelial cells 
treated with oxPAPC induced the production of the pro-inflammatory cytokine, IL-8 and 
this effect was sustained for up to 24 hours (Yeh et al., 2001).  Subsequently, a NOS 
inhibitor, N-nitro-L-arginine methyl ester, has been found to reduce the oxPAPC-induced 
IL-8 transcription (Gharavi et al., 2006).  Furthermore, sterol-regulatory element-binding 
proteins, transcription factors involved in cholesterol metabolism, are activated by 
oxPAPC and bind to the IL-8 promoter region resulting in increased IL-8 production (Yeh 
et al., 2004). 
Adhesion and transmigration of inflammatory cells into the subendothelial space is also 
vital in the formation of lipid-laden foam cells and atherosclerosis.  In a static adhesion 
system, both oxPAPC and POVPC induced adhesion of monocytic U937 cells and human 
peripheral blood monocytes to human umbilical vein endothelial cells (HUVECs) (Huber 
et al., 2006).  In human aortic endothelial cells, oxPAPC induced expression of mitogen-
activated protein kinase phosphatase-1 (MKP-1) which mediates the production of MCP-1 
and oxPAPC-induced monocyte adhesion was prevented by inhibition of MKP-1 (Reddy et 
al., 2001).  In vivo effects have also been reported with oxPAPC applied topically in a 
pluronic gel to the mouse carotid artery; inducing atherosclerosis-related gene expression 
in the vessel wall and also monocyte adhesion in isolated arteries (Furnkranz et al., 2005).  
Shear stress should also be taken into consideration in adhesion studies as although 
oxPAPC induced adhesion of monocytes to bovine aortic endothelial cells, high shear 
stress significantly reduced the effect of oxPAPC as did, to a lesser extent, low shear (Hsiai 
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et al., 2001).  Both endothelial dysfunction and inflammatory cell adhesion are known to 
be critical in atherosclerosis and contribute to disease progression, in part by the action of 
oxidised phospholipids. 
1.3.3.3 Anti-inflammatory effects of oxidised phospholipids 
In addition to the pro-inflammatory effects which are routinely reported, there are also 
anti-inflammatory actions associated with oxidised phospholipids, primarily via toll-like 
receptor (TLR) signalling (reviewed in Erridge and Spickett (2007)).  OxPAPC, POVPC 
and hydroxyalkenal-containing phospholipids prevent the inflammatory actions of 
lipopolysaccharide including neutrophil binding to endothelial cells and E-selectin up-
regulation via NF-κB activation (Subbanagounder et al., 2002, Leitinger et al., 1999, 
Bochkov et al., 2002).  OxPAPC, as well as its truncated products PGPC and POVPC have 
also been reported to inhibit the activation of TLR2 and TLR4 (Erridge et al., 2008, 
Walton et al., 2003).  In addition to the anti-inflammatory effects observed in vitro, 
oxidised phospholipids have also been found to inhibit the inflammatory responses to 
TLR2 and TLR4 agonists in vivo.  This occurs by competitively inhibiting the interaction 
with accessory proteins that interact directly with bacterial lipids resulting in an inhibition 
in the production of tumour necrosis factor-α and other inflammatory mediators (Bochkov 
et al., 2002, Ma et al., 2004, Erridge et al., 2008).  Taken together, this shows a plethora of 
physiological effects of oxidised phospholipids in inflammatory conditions, in particular 
atherosclerosis. 
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Figure 1.2 – Sources and physiological effects of LDL and phospholipid oxidation. 
LDL can be oxidised by a number of mechanisms including direct enzymatic attack or by 
the production of reactive species by enzymes such as MPO which is significant in this 
study.  Other sources of oxidation include transition metals and haemoglobin as well as 
environmental factors such as smoking.  The truncated oxidised phospholipids, PGPC 
and POVPC have been found to mimic the biological effects of oxLDL in vitro and 
therefore could be the active components of the particle.  Some of these biological effects 
include changes to cell proliferation, apoptosis and induction of leukocyte and monocyte 
binding.  Adapted from Greig et al. (2012). 
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1.3.4 MPO 
MPO is a tetrameric haem-containing enzyme of about 150 kDa, localised in intracellular 
granules of circulating neutrophils and monocytes as well as activated macrophages 
(Klebanoff, 1980, 2005).  It is one of the primary mechanisms for modification of 
phospholipids.  It also generates reactive oxidants which can cause both lipid and protein 
oxidation and is therefore thought to contribute to the inflammatory state in a number of 
diseases including CVD and neurodegenerative disorders.  Patients with unstable CAD 
were found to have increased levels of MPO in comparison with stable CAD and control 
patients while individuals with a deficiency in MPO have displayed a drastically reduced 
rate of CVD compared to people with normal functioning MPO (Zhang et al., 2001, 
Samsamshariat et al., 2011, Kutter et al., 2000).  In atherosclerosis, the active form of 
MPO is present within human lesions and also modifies LDL into a form that is readily 
taken up by macrophages via the CD36 scavenger receptor, aiding in the formation of 
foam cells (Daugherty et al., 1994, Podrez et al., 1999, Podrez et al., 2000b).  
Atherosclerotic lesions of LDLr
-/-
 mice were also found to contain an accumulation of 
neutrophils which stained positively for MPO (van Leeuwen et al., 2008).  However, 
LDLr
-/-
 mice deficient in MPO had exacerbated atherosclerosis with 50 % larger lesions 
than the control group suggesting a protective role of MPO in plaque formation (Brennan 
et al., 2001).  This could be explained by potential species differences with murine MPO 
being less influential in lesion formation in mice or levels observed in mice being between 
10 to 20 % less compared to human samples (Noguchi et al., 2000, Rausch and Moore, 
1975).  In contrast, macrophages from hypercholestrolaemic mice expressing human MPO 
were found to promote atherosclerotic progression (McMillen et al., 2005).  Expression of 
the human MPO promoter polymorphism with G at position -463 (which has been linked 
with higher mRNA and protein expression of MPO) in LDLr
-/-
 male mice resulted in larger 
aortic plaques as well as an increase in serum cholesterol compared to control males 
(Kumar et al., 2004, Castellani et al., 2006).  MPO has also been suggested to play a role 
in plaque rupture due to its co-localisation with the MMP-7, pro-matrilysin and subsequent 
activation (Fu et al., 2001).  Furthermore, MPO has been found to affect the protective 
mechanisms involved in the clearance of modified lipids.  It causes site-specific oxidation 
of apolipoprotein A-I, present in HDL in human atherosclerotic lesions resulting in the 
production of dysfunctional HDL which can no longer promote cholesterol efflux (Shao et 
al., 2006, Shao et al., 2012).  This highlights the impact of MPO in atherosclerosis and has 
led to the suggestion that MPO could be used as a useful prognostic tool in predicting the 
risk of CVD (Baldus et al., 2003, Brennan et al., 2003, Brennan and Hazen, 2003). 
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1.3.4.1 Hypochlorous acid 
One of the major reactions that MPO catalyses is the formation of hypochlorous acid 
(HOCl) from hydrogen peroxide (H2O2); formed from the dismutation of superoxide, and 
chloride (Schultz and Kaminker, 1962).  Each component of the MPO/H2O2/chloride 
system is needed for the oxidation process; however HOCl was also found to generate the 
same products alone (Heinecke et al., 1994).  Subsequently, chloride has been shown to be 
the chlorinating intermediate needed for modification of targets (Hazen et al., 1996, 
Panasenko et al., 2007).  HOCl-modified proteins have been found in atherosclerotic 
lesions in vivo and detected in VSM, monocytes/macrophages and endothelial cells as well 
as the ECM (Hazell et al., 1996, Woods et al., 2003b).  Furthermore, tissue isolated from 
human atherosclerotic lesions had six-fold higher levels of 3-chlorotyrosine, a marker for 
MPO chlorination, than normal aortic intima (Hazen and Heinecke, 1997).  The occurrence 
of HOCl-modified epitopes has also been shown to increase in relation to the severity of 
the atherosclerotic lesion (Malle et al., 2000).  The anion of HOCl, OCl
-
, has been found in 
high concentrations of up to 300 µM at sites of inflammation in rheumatoid arthritis due to 
the presence of neutrophils releasing MPO (Katrantzis et al., 1991).  Similar to MPO, 
HOCl modification of HDL impairs reverse cholesterol transport and therefore prevents 
the clearance of high levels of circulating cholesterol-containing lipoproteins (Marsche et 
al., 2002).  MPO was previously thought to be the only route for producing chlorinated 
species under both physiological and pathophysiological conditions in vivo (reviewed in 
Podrez et al. (2000a) and Nicholls and Hazen (2005)); however, a newly identified haem-
containing peroxidase, vascular peroxidase 1 (VPO1), has also been found to catalyse the 
production of HOCl by a similar mechanism to MPO (Cheng et al., 2008).  Angiotensin II 
significantly increased the level of HOCl which was found to induce a 40 % increase in 
VSMC proliferation compared to control as well as the expression of VPO1 in cultured 
VSMCs (Shi et al., 2011).  Together, this suggests that there is a high probability of 
chlorinated products being formed in inflammatory conditions and in particular, 
atherosclerotic lesions. 
1.3.5 Formation and physiological activity of chlorinated lipids 
HOCl is an oxidising and chlorinating compound and reacts rapidly with a number of 
biological targets including DNA, proteins and lipids (Prutz, 1996).  Modification of 
ApoB-100, the major protein present in LDL, by HOCl transforms the lipoprotein into a 
form which is then taken up by macrophages in an uncontrolled manner (Hazell and 
Stocker, 1993).  In response to the MPO system, protein oxidation of ApoB-100 is thought 
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to occur rapidly with the lipid oxidation of LDL occurring as a secondary reaction over a 
prolonged period of time (Hazell et al., 1994, Hazell et al., 1999, Jerlich et al., 1998).  
Even though the modification of lipids could occur at a slower rate than other biological 
compounds such as protein, there is still a high concentration of lipid targets available for 
modification due to the abundance of plasma membranes and lipoproteins in vivo.  
Additionally, in inflammatory conditions when the concentration of HOCl is greatly 
increased, lipid modification is more prevalent than at lower concentrations of HOCl 
(reviewed in Malle et al. (2006)).  It is thought that the formation of chlorinated lipids in 
atherosclerotic plaques could contribute to the pathology of atherosclerosis in a similar 
manner to oxidised phospholipids. 
1.3.5.1 Phospholipid chlorohydrins 
The predominant products formed from the action of MPO-derived HOCl on unsaturated 
ester phospholipids are chlorohydrins with the reaction occurring in two steps (Figure 1.3).  
HOCl is added across the double bond by electrophilic attack with the chloronium ion 
polarising the bond which is added to one of the carbon atoms (Winterbourn et al., 1992).  
The double bond is then no longer unsaturated with the other carbon atom becoming 
positively charged where the remaining hydroxide ion (OH
-
) is added.  Water can be 
subsequently lost from the molecule with the exchange of hydrogen for chlorine in 
comparison to the native lipid.  HOCl causes the formation of mono- and bis-chlorohydrins 
when incubated with mono- or di-unsaturated PCs and with polyunsaturated lipids; mono-
chlorohydrins are the first products formed and longer incubation times are needed for the 
production of bis-chlorohydrins (Arnhold et al., 2001).  Lysophospholipids are also formed 
from this reaction and occur by the loss of a fatty acid chain from the lipid with the 
probability of occurrence increasing with the degree of unsaturation of the molecule 
(Arnhold et al., 2002).  The reaction for chlorohydrin formation has been found to be pH 
dependent with optimal conditions at about pH 6, as at a pH lower than 7.4, chlorohydrins 
were the only significant products formed (Winterbourn et al., 1992, Arnhold et al., 2001).  
Chlorohydrins have been detected after treatment with the MPO system or HOCl with 
LDL and cultured cells (Jerlich et al., 2000, Spickett et al., 2001).  Cholesterol is another 
target for MPO-derived HOCl forming cholesterol α- and β-chlorohydrins (van den Berg et 
al., 1993, Heinecke et al., 1994).  Electrospray mass spectrometry (ESMS) is routinely 
utilised for monitoring chlorohydrin formation as well as the conversion of native lipids to 
their respective chlorohydrins as it limits the breakdown of the molecules in comparison to 
other methods such as gas chromatography-mass spectrometry (Carr et al., 1996).  The 
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addition of HOCl across the unsaturated bond of a phospholipid causes an increase in the 
mass-to-charge ratio (m/z) of 52 indicating the formation of a mono-chlorohydrin. 
 
Figure 1.3 – Formation of phospholipid chlorohydrins. 
HOCl is added across unsaturated bonds of phospholipids by electrophilic attack forming 
phospholipid chlorohydrins.  Adapted from Spickett (2007). 
Phospholipid chlorohydrins have demonstrated toxicity in a number of cell types including 
myeloid and endothelial cells by depletion of ATP levels as well as activation of the 
caspase 3 signalling cascade (Dever et al., 2003, Vissers et al., 1999, Vissers et al., 2001).  
This is thought to occur due to the high polarity of chlorohydrins leading to disruption of 
the plasma membrane after treatment (Carr et al., 1996, Carr et al., 1997).  Furthermore, 
pro-inflammatory effects have been observed with chlorohydrins inducing leukocyte 
adhesion in C57BL/6 and ApoE
-/-
 mice via the up-regulation of P-selectin (Dever et al., 
2006, Dever et al., 2008).  Phospholipid chlorohydrins have also been found to alter the 
biophysical properties of erythrocytes after suspected incorporation into the plasma 
membrane (Robaszkiewicz et al., 2010).  Similar to the CVS, HOCl modification of SM in 
dopaminergic PC12 neurons in vitro caused a decrease in cell viability suggesting potential 
neurotoxic properties (Nusshold et al., 2010).  Chlorohydrins of oleic acid have also been 
detected in plasma in human patients as well as in a rat model of acute pancreatitis 
(Franco-Pons et al., 2013).  Although, phospholipid chlorohydrins have yet to be observed 
in diseased vessels in vivo, lysophosphatidylcholine-chlorohydrins have been detected in 
human atherosclerotic plaques with a 60-fold increase in human tissue compared to control 
(Messner et al., 2008b).  While smooth muscle is an integral component of atherosclerotic 
plaques and vascular remodelling, there are currently no studies researching the effects of 
phospholipid chlorohydrins on these processes in relation to VSMCs. 
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1.3.5.2 Alpha-chloro fatty aldehydes 
Plasmalogens are present in the plasma membrane of mammalian cells and in particular 
vascular cells in the CVS including VSM (Gross, 1984, Ford and Gross, 1989, Hazen et 
al., 1993).  They contain a vinyl ether linkage between the sn-1 aliphatic chain and the 
glycerol backbone and play a role in regulation of transmembrane ion channels and the 
storage of arachidonic acid (Ford and Gross, 1989, Ford and Hale, 1996).  The vinyl ether 
bond of plasmalogens has been found to be susceptible to attack by MPO-derived HOCl 
forming alpha-chloro fatty aldehydes including 2-chlorohexadecanal (2-ClHDA) and also 
lysophospholipids (Albert et al., 2001).  The amount of lysophospholipids formed is found 
to increase with the degree of unsaturation of the native plasmalogen (Lessig et al., 2007).  
Activation of neutrophils in the presence of bovine pulmonary artery endothelial cells 
resulted in the modification of endothelial plasmalogens producing 2-ClHDA which also 
acts as a neutrophil chemoattractant (Thukkani et al., 2002).  Chlorinating species 
produced by the MPO system have also been found to modify plasmalogens present within 
LDL particles forming alpha-chloro fatty aldehydes and these compounds have been 
detected in human atherosclerotic lesions in vivo as well as lysophosphatidylcholine 
species (Thukkani et al., 2003a, Thukkani et al., 2003b).  2-ClHDA is reported to be a 
natural inhibitor of endothelial NO biosynthesis at low micromolar concentrations and 
found to accumulate in rat hearts subjected to MI where it also caused myocardial damage 
(Marsche et al., 2004, Thukkani et al., 2005).  In the murine brain, inflammation resulting 
from a single systemic injection of endotoxin generated 2-ClHDA as a result of HOCl 
attack of membrane plasmalogens (Ullen et al., 2010).  2-ClHDA can also be oxidised to 
its respective chlorinated fatty acids by endothelial cells and these metabolites have also 
been found in vivo (Wildsmith et al., 2006, Anbukumar et al., 2010).  Alpha-chloro fatty 
aldehydes and their metabolites also displayed pro-inflammatory actions causing increased 
expression of cyclooxygenase-2 (COX-2) in HCAECs and could be influential in 
atherosclerosis development (Messner et al., 2008a).  However like phospholipid 
chlorohydrins, very little is known about the effects of alpha-chloro fatty aldehydes on 
VSM function, a cell type crucial in the atherosclerotic phenotype. 
1.4 Treatments for atherosclerosis 
The rupture of a vulnerable advanced atherosclerotic lesion leads to thrombus formation 
which can result in the complete occlusion of a coronary artery and therefore MI.  Patient 
survival depends on the restoration of the coronary blood flow as well as the time taken to 
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achieve this.  However, the first clinical manifestations of atherosclerosis are usually 
evident as angina-like symptoms such as chest, shoulder or neck pain as well as shortness 
of breath on exertion.  This results from the formation of atherosclerotic plaques reducing 
blood flow through the artery and can be up to 70 % occluded before symptoms occur 
(Brown et al., 1982).  There are a variety of treatments for atherosclerosis including both 
surgical and pharmacological, which have varying degrees of success. 
1.4.1 Pharmacological treatment of atherosclerosis 
There are currently no optimal pharmacological therapies in the treatment of 
atherosclerosis as knowledge of the mechanisms of plaque progression and destabilisation 
are incomplete (Stoll and Bendszus, 2006).  Drugs are typically used in combination with 
lifestyle changes including modification of the patient’s diet and increasing the amount of 
daily exercise.  Therapeutic strategies are mainly designed to prevent lesion progression 
and plaque rupture and therefore to halt and maintain atherosclerotic plaque stability.  
These include the use of inhibitors of the renin-angiotensin system to prevent lesion 
progression through a reduction in MCP-1 and macrophage infiltration as well as Ca
2+
 
channel blockers; however, both have shown minimal success in patients (Enseleit et al., 
2001, MacMahon et al., 2000, Pitt et al., 2000).  Drugs to inhibit thrombus formation such 
as anti-platelet therapy and anti-coagulants are used to maintain an anti-thrombotic 
environment and inhibitors of MMPs could be a novel tool in maintaining atherosclerotic 
plaque stability (Rang et al., 2007, George, 2000).  Lipid-lowering drugs are used as 
primary prevention in the treatment of atherosclerosis for patients who are at a high risk of 
a cardiovascular event due to elevated levels of serum cholesterol.  Statins are inhibitors of 
hydroxymethylglutaryl-CoA (HMG-CoA) reductase, a rate-limiting enzyme in cholesterol 
biosynthesis.  This results in the decreased production of cholesterol in the liver and an up-
regulation of LDL receptor synthesis with subsequent clearance of circulating LDL from 
the plasma (Rang et al., 2007).  As mentioned previously, MPO has been highlighted as a 
potential biomarker for CVD and a recent study found rosuvastatin to significantly reduce 
MPO levels as well as oxLDL in stable heart failure patients (Andreou et al., 2010).  
Inhibitors of MPO could provide a novel strategy in atherosclerosis therapy leading to a 
reduction in the formation of modified lipids and therefore lesion progression. 
1.4.2 Surgical intervention in the treatment of atherosclerosis  
In addition to pharmacological therapies, surgical interventions are routinely used for the 
restoration of blood flow through an atherosclerotic vessel.  One method of 
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revascularisation to treat arterial occlusion is coronary artery bypass grafting (CABG).  
This involves the transplantation of a healthy segment of a blood vessel from another part 
of the body to the diseased artery, bypassing the obstructed portion and thereby restoring 
blood flow to the myocardium.  The blood vessels routinely used in this procedure as a 
coronary conduit are either a small artery (the internal thoracic artery) or a peripheral vein 
(the saphenous vein) (Martini, 2006).  Endarterectomies can also be used where the 
atherosclerotic artery is removed and replaced with plastic tube grafts although this 
procedure is not always possible. 
Percutaneous coronary intervention (PCI) was introduced in 1979 as a less invasive 
alternative to CABG surgery in the treatment of occluded arteries in atherosclerosis 
(Gruntzig et al., 1979).  Percutaneous transluminal coronary angioplasty (PTCA) involves 
the insertion of a catheter through a large peripheral artery under anaesthesia or more 
commonly now, just under light sedation.  The catheter is advanced and guided to the 
stenotic artery followed by controlled inflation of a distensible balloon at the tip which 
dilates the vessel (Gruntzig et al., 1979).  This results in a widening of the lumen of the 
diseased artery and restoration of blood flow, providing relief from the angina-like 
symptoms associated with atherosclerosis.  The major drawback associated with PCI is 
restenosis of the treated vessel where the previously occluded artery narrows again after 
PTCA resulting in the loss of the beneficial effects of the treatment (discussed in further 
detail in Section 1.5).  The consequence of this is a recurrence of the angina-like symptoms 
and a need for repeated revascularisation of the affected artery.  Angiographic restenosis is 
defined as the presence of greater than 50 % occlusion of the lumen in the previously 
stenotic artery (Teirstein et al., 1997).  Originally, the rate of restenosis was high after 
balloon angioplasty due to vessel recoil and became a common complication, occurring in 
up to 50 % of patients and usually developing within the first 6 months (Fischman et al., 
1994).  This led to the introduction of intravascular bare-metal stents in the late 1980s to 
combat the problem of restenosis as elastic recoil is minimal during stent deployment due 
to the rigid scaffolding of the stent in comparison with PTCA (Sigwart et al., 1987). 
Bare-metal stents are a small tubular mesh of stainless steel or cobalt-chromium and are 
positioned in the stenotic vessel in a similar manner to PTCA with the insertion of a 
catheter through a peripheral artery.  The catheter is then advanced to the affected artery 
where controlled inflation of the balloon occurs resulting in expansion and deployment of 
the stent which in turn widens the lumen of the artery.  The use of bare-metal stents 
resulted in a reduction in the incidence of restenosis by 20 to 30 %; however, signs of 
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restenosis still occurred as little as 5 months after stent deployment in selected patients and 
therefore remains an important complication of the treatment (Fattori and Piva, 2003, 
Moussa et al., 1997).  Additional detrimental factors have also been found with the use of 
stents in comparison with PTCA including under expansion during implantation, late stent 
thrombosis or hypersensitivity to one of the components of the stent (Jukema et al., 
2012b). 
1.5 Restenosis 
Despite the improvements in revascularisation techniques, the major limitation affecting 
the long-term success of all forms of PCI is the formation of neointimal thickening.  
Restenosis is thought to be a consequence of exaggerated wound healing after vascular 
injury to restore adequate blood flow in stenotic vessels.  The recurrence of luminal 
narrowing results from neointimal hyperplasia and rapid vascular remodelling of the 
treated vessel with excessive VSMC proliferation and migration as well as ECM 
production, presented diagrammatically in Figure 1.4.  The condition is observed clinically 
as the presentation of recurrent angina and similar to atherosclerotic plaques, the lesions 
have been divided into four groups by angiographic classification.  Lesions of less than 10 
mm in length are classified as focal class I whereas diffuse class II, III and IV lesions are 
characterised as being greater than 10 mm in length (Mehran et al., 1999).  One of the first 
detailed models of restenosis was proposed by Forrester et al. (1991), highlighting platelet 
aggregation, inflammatory cell infiltration as well as ECM remodelling and medial VSMC 
modulation and proliferation as markers of the response.  This model was modified by 
Libby et al. (1992) who suggested a cascade mechanism after vascular injury and 
highlighted the importance of inflammation in the restenotic phenotype.  Murine models as 
well as larger animals such as rabbits and pigs are routinely used in restenosis research 
using wire-, balloon- or stent-induced injury of the endothelium of the carotid, coronary, 
femoral or subclavian arteries, to initiate neointima formation and restenosis development 
(Lindner et al., 1993, Kantor et al., 1999, Hadoke et al., 1995). 
1.5.1 Pathophysiology of restenosis 
A complex cascade of events leads to restenosis.  These mechanisms can be divided into an 
“early” (days to weeks) phase and a “late” (days or weeks to months) stage.  The initial 
consequences after placement of the stent are stretch of the entire artery as well as 
endothelium denudation which stimulates an acute inflammatory response (Costa and 
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Simon, 2005).  Compression of the atherosclerotic lesion exposes the subendothelial pro-
thrombogenic core of the plaque to circulating blood and often results in dissection of the 
medial and occasionally, the adventitial layer of the arterial wall (Inoue and Node, 2009).  
Following this, deposition of platelets and fibrin at the site of injury results in rapid 
thrombus formation and leukocyte recruitment which are early indicators of the onset of 
restenosis (Libby and Simon, 2001).  Activation of platelets leads to the expression of 
adhesion molecules on their surface such as P-selectin.  This results in the adhesion of 
circulating leukocytes and monocytes and their subsequent transmigration by the action of 
chemical gradients of chemokines such as MCP-1 and growth factors (Welt and Rogers, 
2002).  These are released from resident macrophages and VSMCs within the arterial wall.  
Activated platelets at the site of injury secrete growth factors such as platelet derived 
growth factor (PDGF) that stimulate VSMC proliferation and migration (Walker et al., 
1986).  Damage to the endothelium therefore triggers an aggressive form of atherosclerosis 
due to acute platelet and fibrin deposition with the activation of these platelets leading to 
the release of a variety of inflammatory and growth mediators resulting in thrombus 
formation and vasoconstriction (Welt and Rogers, 2002).  These pro-inflammatory 
responses are sustained for several weeks following injury of the vessel and lead to the 
proliferation of vascular components such as VSMCs and ECM which are key features of 
the late phase of restenosis (Libby et al., 1992). 
The cellular proliferation phase involves phenotypic modulation of medial VSMCs as they 
migrate to form the neointima; a process similar to fibrous cap formation in atherosclerosis 
(Mitra and Agrawal, 2006).  The late stage of restenosis typically occurs days to weeks 
after the initial vascular injury and lasts up to 6 months.  Quiescent contractile VSMCs 
become stimulated by the mechanical injury and inflammatory response which triggers the 
progression through the G1/S transition of the cell cycle (Tanner et al., 1998, Nabel, 2002).  
VSMCs closest to the region of injury undergo maximal apoptosis with surviving VSMCs 
migrating towards the arterial lumen (Perlman et al., 1997, Hanke et al., 1990).  In 
addition, dead or damaged vascular cells release growth factors such as basic fibroblast 
growth factor and epidermal growth factor which act as mitogens for medial VSMC 
proliferation as well as migration (Lindner and Reidy, 1991, Casscells, 1992).  Non-
dividing VSMCs as well as proliferating VSMCs can migrate to the intima after vascular 
injury (Clowes and Schwartz, 1985).  In an atherosclerotic rabbit model, cell proliferation 
was found to peak 4 days earlier than apoptosis after angioplasty with apoptosis inversely 
correlated with restenosis (Durand et al., 2002).  In contrast, balloon injury in healthy 
rabbits displayed an increase in VSMC apoptosis via caspase 3 after 24 hours followed by 
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significant proliferation 28 days after injury (Spiguel et al., 2010).  This is in agreement 
with a study using carotid balloon injury in the ApoE
-/-
 mouse model where apoptosis was 
increased 1 hour after injury while proliferation rates peaked at 7 days and were still 
elevated up to 28 days following surgery (Matter et al., 2006).  VSMC proliferation is 
thought to be maximal at 5 to 7 days after injury with around 10 to 20 % of the total medial 
VSMCs proliferating.  In addition to VSMCs, there is evidence of proliferating cells from a 
myeloid lineage within restenotic tissue (Welt and Rogers, 2002). 
As mentioned previously, VSMCs are key producers of ECM and during the chronic 
proliferative phase, VSMCs are also responsible for increasing the volume of intimal tissue 
by a coordinated increase in ECM synthesis (Inoue and Node, 2009).  This results in fewer 
cellular components and can last for several months (Lee et al., 1993).  ECM is the major 
component of mature restenotic plaques with a shift towards ECM synthesis rather than 
VSMC proliferation (Schwartz et al., 1992).  Partial re-endothelialisation of the injured 
surface also occurs during this phase with growth factors such as vascular endothelial 
growth factor facilitating endothelial regrowth (Brindle, 1993).  Complete re-
endothelialisation is possible as quickly as 30 days after PCTA; however, regenerated 
endothelium may be dysfunctional or may also never fully regrow depending on the extent 
of denudation (Hamon et al., 1995, Weidinger et al., 1990). 
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Figure 1.4 – Vascular remodelling processes involved in restenosis. 
Intravascular ultrasound images (left) and schematic representations (right) depict the 
progression from a normal healthy coronary artery (A) to coronary stenosis due to the 
formation of an advanced atherosclerotic plaque (B) followed by the restoration of normal 
blood flow by widening of the lumen after stent deployment (C) to the subsequent 
restenosis (D).  The vascular remodelling processes which occur after PCI include an 
inflammatory response which stimulates thrombus formation and neointimal proliferation 
from ECM formation and VSMC proliferation.  Adapted from Jukema et al. (2012b). 
A
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1.5.2 Potential involvement of modified lipids in restenosis 
Mechanical injury to the atherosclerotic artery during stent deployment results in 
compression and damage to the plaque with exposure and disruption of the modified lipid-
containing core, suggesting a potential lipid involvement in restenosis.  The total plasma 
cholesterol levels in ApoE
-/-
 mice were found to be markedly elevated after carotid balloon 
injury which was in parallel with neointima formation (Matter et al., 2006).  In contrast, 
vascular remodelling was impaired after coronary balloon angioplasty in 
hypercholesterolaemic mini pigs causing a reduction in VSMC migration with the effects 
attributed to the action of oxLDL (Theilmeier et al., 2002).  Restenosis is an inflammatory 
condition which relies on the recruitment of leukocytes such as neutrophils, which are a 
source of MPO.  This could therefore lead to an increase in the production of modified 
lipids in the neointima.  Balloon-injured vessels showed a significant increase in leukocyte 
adhesion 24 hours following injury in rabbit subclavian arteries as well as up-regulation of 
adhesion molecules such as P-selectin (Kennedy et al., 2000).  There is also evidence of 
sustained inflammation with inflammatory cells remaining in close proximity to the stents 
in rabbit iliac arteries up to 28 days after placement (Kennedy et al., 2004, Coats et al., 
2008).  Increased leukocyte adhesion has also been demonstrated up to 28 days following 
surgery in a wire injury mouse model (Tennant et al., 2008).  Neutropaenic rabbits, which 
have a low number of neutrophils, were found to have a significantly reduced level of 
neointima formation after 28 days (Miller et al., 2001).  Furthermore, arterial segments 
from ApoE
-/-
 mice treated in vitro with a phospholipid chlorohydrin formed from the action 
of the MPO system, displayed an increase in leukocyte adhesion in a concentration-
dependent manner as well as an increase in P-selectin expression (Dever et al., 2008).  
Stent deployment also results in neutrophil activation, which is associated with neointimal 
thickening (Inoue et al., 2006).  VSMC proliferation was evident 24 hours after the topical 
application of POVPC to mouse carotid arteries in vivo (Johnstone et al., 2009).  In 
addition to oxidised phospholipids, an increase in the presence of MPO and HOCl-
modified proteins has been found to correlate with an increase in the intima-to-media ratio 
in human iliac arteries (Hazell et al., 2001).  HOCl was also found to mediate neointimal 
hyperplasia in a time- and dose-dependent matter, initially causing apoptosis followed by 
vascular proliferation in a rat model of balloon injury (Yang et al., 2006).  Together, this 
highlights the importance of inflammatory cell recruitment in neointima formation in 
injured vessels and with the presence of LDL and inflammatory cells could lead to the 
production of significant quantities of modified lipids in the vessel wall.  However, very 
Chapter 1 – General Introduction 
33 
 
little is known about the potential involvement of these modified lipids, both oxidised and 
chlorinated species, in the development of restenotic lesions. 
1.5.3 Current and future treatments for restenosis 
Several therapeutic options have been proposed and implemented to increase the long-term 
success of PCI and reduce the incidence of restenosis.  One of the most promising 
advances in the treatment of restenosis was the development of drug-eluting stents (DES).  
The drug is encapsulated in a polymer which allows the drug to diffuse slowly over time or 
the polymer is degraded in order to release the drug which has been directly coated onto 
the surface on the stent.  DES provide a combination of mechanical support with the 
controlled release of drugs capable of potentially reducing neointima formation.  DES 
coated with anti-proliferative drugs have shown to be beneficial with paclitaxel, effectively 
reducing neointimal hyperplasia after 4 weeks in a porcine model of coronary restenosis 
and in rabbit iliac arteries (Heldman et al., 2001, Drachman et al., 2000).  In addition, local 
delivery of anti-proliferative agents has also proved effective in reducing hyperactivity of 
injured vessels to constrictor agents in porcine coronary arteries (Kennedy et al., 2006).  
Immunosuppressive drugs such as rapamycin and anti-platelet therapies have proved to be 
beneficial causing a reduction in neointima formation (reviewed in Costa and Simon 
(2005) and Fattori and Piva (2003)).  Drugs targeting other areas in the development of 
restenosis such as inhibition of inflammatory chemokines and ECM deposition have also 
resulted in reduced neointima formation in animal models (Grassia et al., 2009, Backes et 
al., 2010).  After the introduction of DES, patients experienced lower rates of target vessel 
and lesion revascularisation as well as MI and death compared to the use of bare-metal 
stents (Hannan et al., 2008).  However, other studies have found DES to correlate with 
higher rates of reappearance of stenosis (Steinberg et al., 2009).  Although clinical 
application of DES has proved difficult with differences present between animal models 
and humans, this form of treatment still results in a widely successful outcome compared 
to bare-metal stents with a reduction in restenosis and neointima formation leading to 
target vessel revascularisation.  However, restenosis remains a complication in a number of 
patients after surgical intervention in the treatment of atherosclerosis.  This had led to the 
investigation of novel potential therapies such as biodegradable stents and endothelial 
progenitor cell capturing stents to reduce neointima formation after PCI (reviewed in 
Jukema et al. (2012a)). 
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1.6 Adenosine monophosphate-activated protein kinase 
In hyperproliferative diseases like atherosclerosis and restenosis, adenosine 
monophosphate-activated protein kinase (AMPK) may play an important role due to the 
increased number of cells present.  AMPK has been shown to be involved in a plethora of 
cardio and vasculoprotective functions including stimulation leading to a reduction in 
monocyte adhesion to endothelial cells and cholesterol synthesis in the liver (reviewed in 
Ewart and Kennedy (2012)).  A selection of the physiological effects which result from 
AMPK activation are displayed in Figure 1.5.  AMPK is a key regulator of cellular energy 
homeostasis and involved in the maintenance of energy stores.  The enzyme was first 
discovered in 1973 and is now commonly referred to as a cellular “fuel gauge” (Beg et al., 
1973, Carlson and Kim, 1973, Hardie and Carling, 1997).  AMPK is a highly conserved 
heterotrimeric complex consisting of a catalytic α subunit and two regulatory subunits; β 
and γ, with each subunit having two or more isoforms which are expressed in different cell 
and tissue types (Davies et al., 1994, Stapleton et al., 1994).  For the catalytic domain, the 
α1 subunit predominates in the vasculature while in cardiac and skeletal muscle, the α2 
subunit is the primary isoform (Stapleton et al., 1997, Davis et al., 2006).  In contrast, 
equal distributions of α1 and α2 subunits are found in the liver (Woods et al., 1996). 
1.6.1 Regulatory mechanism and signalling of AMPK 
Activation of AMPK occurs via phosphorylation of the threonine residue at position 172 in 
the activation loop of the catalytic α domain contained within the N-terminus (Hawley et 
al., 1996).  The regulatory γ subunits contain areas termed “Bateman domains” with the 
capacity to bind one molecule of either adenosine monophosphate (AMP) or ATP (Cheung 
et al., 2000, Bateman, 1997, Scott et al., 2004).  ATP occupies these domains in well 
energised cells with AMPK in an inactive locked state.  However, when there is a 
depletion of ATP and an elevation of AMP levels, for example during periods of stress 
such as hypoxia or glucose deprivation, AMP competitively displaces ATP leading to the 
phosphorylation of AMPK at the threonine residue.  The binding of AMP to the Bateman 
domains induces a conformational change of AMPK and also makes it a less desirable 
substrate for AMPK phosphatases resulting in an increased proportion of phosphorylated 
AMPK (Scott et al., 2004, Towler and Hardie, 2007).  AMPK is subsequently 
dephosphorylated by the action of protein phosphatases when the stores of cellular energy 
have increased and the cell is no longer stressed.  AMPK activation can also occur by 
alternative upstream kinase pathways termed AMPK kinases, including the tumour 
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suppressor protein, liver kinase B1 (LKB1) and calcium/calmodulin-dependent protein 
kinase kinase β (CAMKKβ) (Woods et al., 2003a, Hurley et al., 2005).  In addition to 
endogenous activation, AMPK can be modulated by pharmacological agents such as 
activation by 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) that 
mimics the action of AMP.  AICAR is transported inside the cell via the adenosine 
transporter where it is phosphorylated to form the AMP analogue, zeatin riboside-5-
monophosphate (ZMP) (Merrill et al., 1997).  A-769662 is another extremely potent 
AMPK activator which directly stimulates the enzyme by mimicking the effects of AMP as 
well as inhibiting de-phosphorylation (Göransson et al., 2007).  AMPK signalling directly 
regulates a number of enzymes involved in energy consumption within the cell such as 
acetyl-coA carboxylase (ACC) which is directly phosphorylated by AMPK leading to the 
inhibition of enzyme activity and reduced fatty acid synthesis (reviewed in Hardie (2004)). 
1.6.2 Involvement of AMPK in vascular disease 
Pathologies of the CVS such as atherosclerosis, restenosis and hypertension evoke stress 
signals in vascular tissue leading to potential changes in cellular energy thus AMPK has 
been implicated in the progression of several diseases (Motoshima et al., 2006, Li and 
Keaney, 2010).  In atherosclerosis, activation of AMPK by AICAR results in a reduction in 
endoplasmic reticulum (ER) stress and inhibition of macrophage proliferation, both 
induced by high levels of circulating oxLDL (Dong et al., 2010, Ishii et al., 2009).  The 
expression of serine/threonine protein phosphatase 2A, one of the enzymes responsible for 
the inactivation of AMPK, was increased 40-fold by incubation of human monocytes with 
oxLDL (Kang et al., 2006).  AICAR treatment has also been found to reduce ER stress and 
protect endothelial cells against the effects of modified LDL (Dong et al., 2010).  AMPK 
activation has also been found to exert anti-apoptotic effects in a number of cell types 
including endothelial cells, therefore promoting cell survival (Ido et al., 2002, Kim et al., 
2008, Liu et al., 2010).  In addition, AMPK has been associated with inflammatory cells 
such as neutrophils, which are the primary source of MPO and involved in the 
modification of LDL (Alba et al., 2004).  AMPK activation attenuated neutrophil activity 
and metformin, an anti-diabetic drug known to activate AMPK, decreased MPO levels in 
lung tissue (Zhao et al., 2008, Tsoyi et al., 2011).  In addition, AMPK has been implicated 
in reverse cholesterol transport, as activation increased protein levels of ABCG1 and 
ABCA1 resulting in cholesterol efflux from foam cells derived from macrophages as well 
as reduced plaque formation in ApoE
-/-
 mice (Li et al., 2010a, Li et al., 2010b).  
Therapeutic agents used in the treatment of atherosclerosis such as statins have also been 
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shown to partially mediate their effects through the action of AMPK, as reviewed in Ewart 
and Kennedy (2011).  Incubation with atorvastatin increased phosphorylation of AMPK 
and its downstream target ACC, both in vitro and in vivo (Sun et al., 2006).  In addition, 
AMPK is implicated in restenosis.  Mice deficient in AMPKα2 (AMPKα2-/-) had a 
dramatic increase in the formation of neointima after wire injury of the carotid artery 
compared to wild type controls (Song et al., 2011).  This is in agreement with another 
study where a reduction in AMPK activity led to an increase in neointima development 
after arterial injury in a murine model (Yu et al., 2012).  Local administration of the 
AMPK activator, AICAR also reduced neointima formation 2 weeks after balloon injury in 
rat carotid arteries (Stone et al., 2013).  Furthermore, endothelium-selective expression of 
constitutively-active AMPK was protective against vascular injury and promoted re-
endothelialisation in a murine diabetic model (Li et al., 2012). 
The activation of AMPK is also been associated with hypertension and blood pressure 
regulation where prior studies have shown a reduction in mean arterial pressure in both 
rodents and humans following acute administration of the AMPK activator, AICAR (Foley 
et al., 1989, Bosselaar et al., 2011).  Spontaneously hypertensive rats dosed with AICAR 
also showed an acute drop in mean arterial pressure which was not seen in the control 
group of Wistar-Kyoto rats, suggesting AMPK could play a role in reducing hypertension 
(Ford et al., 2012).  Long-term administration of AICAR or resveratrol, which has been 
described as another activator of AMPK, again caused a reduction in mean arterial pressure 
in obese Zucker rats (Buhl et al., 2002, Rivera et al., 2009).  Furthermore, short-term 
calorie restriction in the spontaneously hypertensive rats resulted in increased activity of 
AMPK which led to a reduction in blood pressure (Dolinsky et al., 2010).  Together, this 
highlights the involvement of AMPK in vascular disease and suggests that AMPK 
activation could play a critical role in reducing the elevated blood pressure found in both 
atherosclerosis and hypertension. 
1.6.2.1 AMPK signalling in VSM 
VSMCs are crucial in the development of hyperproliferative diseases such as 
atherosclerosis and restenosis as the proliferation and migration of VSMCs as well as their 
role in ECM production results in lesion formation.  AMPK activation by AICAR has been 
found to inhibit human aortic VSMC proliferation induced by both PDGF and foetal calf 
serum (FCS) in a dose-dependent manner (Igata et al., 2005).  This effect was also seen in 
rat aortic VSMC proliferation and migration and found to be dependent on AMPK (Peyton 
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et al., 2011).  Furthermore, angiotensin II-stimulated rat VSMC proliferation was inhibited 
by AMPK activation using AICAR (Nagata et al., 2004).  OxLDL was found not to 
directly induce AMPK phosphorylation in rabbit femoral VSMCs but AICAR has been 
shown to cause a concentration-dependent reduction in oxLDL-induced macrophage 
proliferation (Brito et al., 2009, Ishii et al., 2009).  In addition to its activity on individual 
VSMCs, AMPK has been found to have an effect on vascular reactivity affecting both 
endothelial and VSM function.  AICAR-induced vasorelaxation in mouse aortic rings in 
both endothelium-intact and -denuded vessels and this was abolished in mice deficient in 
AMPKα1 (AMPKα1-/-), suggesting that AMPKα1 was responsible for this action (Goirand 
et al., 2007).  In addition, mesenteric artery and aortic rings isolated from AMPKα1-/- and 
AMPKα2-/- mice produced larger contractions than their wild type controls (Wang et al., 
2011b).  Vasorelaxation to AICAR was also enhanced in hypertensive rats compared to 
their normotensive controls, which was thought to be NO dependent (Ford and Rush, 
2011).  Little is known about the effects of individual modified lipids, which are elevated 
during atherosclerosis, on vascular reactivity; however, one study has found oxLDL to 
reduce endothelium-dependent relaxation to acetylcholine in rabbit aorta and coronary 
arteries (Buckley et al., 1996).  Together, this suggests a dysregulation of AMPK 
signalling occurs during CVD such as atherosclerosis and hypertension with little known to 
date about the impact of AMPK signalling on the effects of individual modified lipids in 
VSM. 
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Figure 1.5 – AMPK activation and its cardio and vasculoprotective functions. 
Endogenous and pharmacological activation of AMPK results in phosphorylation of the 
enzyme leading to several physiological effects in the vasculature, heart and liver which 
could be beneficial in CVD such as atherosclerosis, restenosis and hypertension.  These 
effects include increased vasorelaxation in VSM, decreased inflammation and ER stress 
in the endothelium, decreased cholesterol synthesis in the liver and decreased 
hypertrophy in the heart.  Adapted from Ewart and Kennedy (2012). 
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1.7 Aims of this thesis 
In summary, atherosclerosis is characterised by the deposition and accumulation of 
modified lipids in the subendothelial space of the arterial wall as well as vascular 
remodelling leading to atherosclerotic plaque formation.  Restenosis is a known 
complication of the surgical interventions used to treat atherosclerosis and results in 
neointimal thickening, in part by the action of VSMCs.  Various physiological effects have 
been attributed to the action of oxLDL leading to an exacerbation of the inflammatory 
response.  However, little is known to date about the effects of individual modified lipids 
including oxidised and chlorinated species, on vascular remodelling processes which are 
prominent in these disease phenotypes.  In addition, AMPK has recently been implicated in 
both vascular diseases but the impact of this signalling pathway on the effects of individual 
modified lipids is presently unknown. 
The principal research aim of this thesis was to investigate the influence of modified lipids, 
both chlorinated and oxidised species, in vascular injury and disease focussing primarily 
on their effects on VSM.  This was achieved through the following experimental study 
aims: 
 In vitro characterisation of the effects of modified lipids on vascular remodelling 
processes including VSMC proliferation, viability and migration. 
 Assessment of the impact of AMPK signalling on the effects of modified lipids in 
VSM in vitro. 
 In vivo evaluation of vascular injury in healthy and atherosclerotic mice and 
determination of the occurrence of modified lipids in neointima formation. 
 In vivo characterisation of AMPK activation in healthy and atherosclerotic mice. 
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CHAPTER 2 
GENERAL MATERIALS AND 
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Materials 
2.1 Chemicals and Reagents 
All chemicals were supplied by Sigma-Aldrich (Poole, U.K.) unless otherwise stated and 
were of the highest grade obtainable.  Phospholipids were obtained from Avanti Polar 
Lipids (Alabama, U.S.A.) and all cell culture reagents were obtained from Gibco (Paisley, 
U.K.) unless otherwise stated.  All Western blot materials were supplied by Life 
Technologies (Paisley, U.K.) unless otherwise stated. 
Methods 
2.2 Lipid preparation and synthesis 
All native phospholipids were purchased in powder form and aliquoted using high 
performance liquid chromatography (HPLC) grade methanol.  The phospholipids were 
then dried under a steady flow of oxygen-free nitrogen gas and stored at -80 °C until 
reconstituted for use. 
2.2.1 Chlorohydrin formation 
1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC) and 1-stearoyl-2-linoleoyl-sn-
glycero-3-phosphocholine (SLPC) were all prepared individually from their respective 
native lipids.  Aliquots of the phospholipids were resuspended in equal volumes of Hanks’ 
balanced salt solution (HBSS) at a concentration of 10 mg/ml and vortexed for 1 minute.  
The solution was sonicated for 15 minutes, forming lipid micelles and vortexed for a 
further minute producing a milky homogeneous suspension.  Lipid vesicles were treated 
with 10-fold molar excess (per double bond) of sodium hypochlorite (NaOCl) solution at 
pH 6 for 15 minutes at 35 °C, forming lipid chlorohydrins.  The concentration of the stock 
solution of NaOCl was determined spectrophotometrically at 292 nm (ε292 = 350 M
-1
 cm
-1
).  
Excess hypochlorite was removed by passing the solution through a reverse phase Sep-
Pak® column (Waters, Elstree, U.K.).  The chlorinated phospholipids were eluted from the 
column in 0.5 ml of methanol and 1 ml of 1:1 methanol:chloroform and dried using 
oxygen-free nitrogen gas. 
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2.2.2 Measurement of stability of chlorohydrins 
Chlorohydrins were prepared as mentioned in Section 2.2.1 with the addition of 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) at a concentration of 10 mg/ml to the 
aliquots of the individual phospholipids.  DPPC is a saturated phospholipid and therefore 
was chosen as a stable comparator for the expected breakdown of the chlorohydrins.  Lipid 
chlorohydrins with DPPC were reconstituted in phosphate buffered saline (PBS, containing 
154 mM NaCl, 100 mM Na2HPO4 and 25 mM NaH2PO4 at pH 7.4) with samples being 
incubated at 37 °C and aliquots taken at several time points including zero, 24 hours and 
up to 72 hours to measure the stability of the lipid chlorohydrin in relation to DPPC. 
2.2.3 Quantification of phospholipids by ESMS 
The formation and stability of chlorohydrins was monitored using ESMS.  1 µl aliquots of 
the chlorohydrin sample were diluted 200 fold with 9:1 methanol:water.  ESMS was 
performed on a LCQ-Duo mass spectrometer (ThermoFinnigan, Waltham, U.S.A.) in 
positive-ion mode with direct infusion of the sample.  Spectra, in the range of m/z 400-
1000 for SOPC and SLPC, were acquired for 2 minutes.  Formation of chlorohydrins was 
assessed by the loss of the native phospholipid and the addition of m/z 52 or 54 
(differences being due to the pattern of the chloride isotope with the addition of either 
35
Cl 
or 
37
Cl) to the native phospholipid which was usually seen in its sodiated form (an 
additional m/z 23 added to the value).  
2.2.4 Alpha-chloro fatty aldehyde synthesis 
The alpha-chloro fatty aldehyde, 2-ClHDA, was synthesised and provided by Professor 
Andrew R. Pitt (Aston University, U.K.) following an adapted method described by 
Thukkani et al. (2002).  Briefly, hexadecanol was partially oxidised to hexadecanal at -70 
°C using the classical Swern oxidation method utilising pyridinium chlorochromate in 
oxygen-free CH2Cl2 as a catalyst (Dubey et al., 2008, Mancuso et al., 1978).  This is where 
an alcohol is oxidised to its corresponding carbonyl compound at low temperatures 
producing high yields.  Hexadecanal then underwent acid methanolysis forming dimethyl 
acetal hexadecanal by reaction with methanol and catalytic p-toluenesulfonic acid.  The 
dimethyl acetal of 2-ClHDA was then synthesised using an acetal chlorination system 
utilising MnO2-trimethylchlorosilane, as it has previously been shown to give a more 
quantitative yield for the halogenation of aldehydes than previous methods (Bellesia et al., 
1992).  2-ClHDA was finally produced by refluxing 1:1 trifluoroacetic 
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acid:dichloromethane and then purified by flash chromatography using silica and eluted 
with 7:3 hexane:dichloromethane to give solid 2-ClHDA (17 % overall yield).  The 
synthesis of the compound was confirmed by analysis as follows: 1H-NMR (in CDCl3) δ 
9.47 (1H, d); 4.16 (1H, m); 1.89 (2H, m); 1.26 (24H, m); 0.88 (3H, m).  m/z (ESMS) 275.2 
[M-H]
+
.  IR = 2924, 2850, 1470, 1188, 1121, 1080, 723 cm
-1
. 
2.3 Tissue culture 
Tissue culture was performed in sterile conditions using biological safety class II vertical 
laminar flow cabinets.  Tissue explants were incubated and cells were grown at 37 °C and 
maintained with 5 % CO2 and 95 % air. 
2.3.1 Maintenance of primary cell cultures 
The adherent cells were grown as a single layer, typically in 75 cm
3
 culture flasks, and 
media was removed by aspiration and replenished every 2 days.  Cells were routinely 
passaged when approximately 95 % confluence was reached to prevent cell cycle arrest 
and loss of surface contact of the cells.  For passaging, cells were washed in sterile 
Dulbecco’s PBS (Sigma-Aldrich, Poole, U.K.) and incubated with 2 ml of trypsin-
ethylenediamine tetra-acetic acid (trypsin-EDTA) at 37 °C, usually for a minimum of 3 
minutes.  The addition of the complete media stopped the action of the trypsin-EDTA 
solution and allowed sub-culturing of the cell suspension.  Cells were counted using a 
haemocytometer to ensure seeding at the correct density where appropriate. 
2.3.2 Rabbit aortic smooth muscle cells 
Aortae from male New Zealand white rabbits (2.5 to 3.5 kg body weight) were excised and 
cleaned of any connective tissue and fat.  The outer and inner surface of the vessel was 
scraped, removing the adventitia and intima respectively, to prevent the contamination of 
other cell types in the culture.  Aortic explants were initially cultured in 6 well plates in 1:1 
Waymouth’s MB 752/1 and Ham’s F12 and GlutaMAX™ supplemented with 1 % (v/v) 
penicillin-streptomycin solution (Sigma-Aldrich, Poole, U.K.) and 10 % (v/v) FCS.  Cells 
were checked visually for the distinctive smooth muscle cell characteristics and for the 
positive immunostaining of αSMA (described in Section 2.3.2.1).  Once the cells reached 
confluence, the aortic explants were removed and the cells were transferred to 75 cm
3
 
culture flasks and used between passages 3 to 8. 
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2.3.2.1 Immunostaining for αSMA 
Cells were seeded at 10,000 cells per well on chamberslides, incubated at 37 °C for 24 
hours and then fixed with 2 % (w/v) paraformaldehyde for 10 minutes.  Cells were then 
washed 3 times with PBS and permeabilised with 0.5 % (v/v) Triton X-100 in PBS for 15 
minutes at room temperature.  This was followed by 3 washes in PBS and then incubation 
with 10 % (v/v) heat inactivated serum for 30 minutes at 37 °C from the appropriate 
species that the secondary antibody was raised in which was horse in this case.  αSMA 
(Abcam, Cambridge, U.K.) was diluted 1 in 50 in 10 % (v/v) heat inactivated serum then 
incubated overnight at 4 °C.  The following day, the cells were washed 3 times in PBS and 
incubated with horse anti-mouse secondary antibody (Pierce Antibodies, Thermo 
Scientific, Loughborough, U.K.) for 1 hour at 37 °C and washed a further 3 times in PBS.  
4’,6-diamidino-2-phenylindole (DAPI) was added to identify the nucleus of the cells and 
slides were mounted with coverslips and kept overnight in the dark at room temperature.  
Green fluorescence was then observed using fluorescein isothiocynate (FITC) at a 
magnification of 10 x. 
2.3.3 Measurement of cell proliferation 
Cell proliferation was measured by the incorporation of the thymidine analogue, 
bromodeoxyuridine (BrdU), into newly synthesised DNA during the S phase of the cell 
cycle (Calbiochem, Nottingham, U.K.).  This assay is based on the traditional [
3
H] 
thymidine proliferation assay with the principal difference being the replacement of [
3
H] 
thymidine with BrdU.  It is a non-radioactive compound allowing the assessment of 
proliferation with an enzyme-linked immunosorbent assay (ELISA) rather than 
scintillation counting, therefore eliminating the use of harmful radioactive substances.  
Cells were seeded in a 96 well plate at a density of 10,000 cells per well and quiesced in 
0.1 % (v/v) FCS-containing media for 24 hours.  Cells were incubated with the agonist of 
interest for the requisite length of time.  Where appropriate, antagonists were added 30 
minutes prior to incubation with agonists.  The BrdU label was added to each well 24 
hours prior to the end of the measurement.  The assay was performed as per the 
manufacturer’s instructions.  Briefly, BrdU was incorporated into the proliferating cells.  
These were then fixed and partial denaturation of DNA occurred to allow the detection of 
the BrdU by a monoclonal antibody.  Horseradish peroxidase (HRP)-conjugated goat anti-
mouse binds to the antibody and facilitates the conversion of the substrate, tetra-
methylbenzidine (TMB) from a colourless solution to blue, which turns yellow upon the 
addition of the stop solution.  Absorbance was measured spectrophotometrically at dual 
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wavelengths of 450 nm and 540 nm using a SpectraMax® M2 microplate reader 
(Molecular Devices, California, U.S.A.). 
2.3.4 Assessment of cell viability 
Bioluminescent detection of cellular ATP was employed to determine cell viability as ATP 
is present in all metabolically active cells using a ViaLight™ Plus kit (Lonza, Basel, 
Switzerland).  Cells were seeded in a 96 well plate at a density of 10,000 cells per well and 
quiesced in 0.1 % (v/v) FCS-containing media for 24 hours.  Cells were incubated with the 
agonist of interest for the required length of time.  Where appropriate, antagonists were 
added 30 minutes prior to incubation with agonists.  The assay was performed as per the 
manufacturer’s instructions.  Briefly, the cell lysis buffer was added to release cellular 
ATP from the cells.  Following this, ATP monitoring reagent plus was added to the lysed 
cells containing luciferase which catalyses the conversion of ATP and luciferin into 
emitted light.  Luminescence was then measured using a POLARstar OPTIMA microplate 
reader (BMG Labtech, Germany). 
2.3.5 Measurement of cell migration 
Cell migration was measured using a CHEMICON® QCM™ chemotaxis cell migration 
assay and was based on the traditional Boyden chamber method containing an 8 µm pore 
membrane (Millipore, Watford, U.K.).  Cells were quiesced in 0.1 % (v/v) FCS-containing 
media for 24 hours preceding stimulation.  For the pretreatment group, cells were 
incubated for 2 hours with each lipid separately prior to harvesting.  Each lipid was added 
singly to the top chamber of the insert for the chronic incubation group.  Cells were 
harvested and seeded in serum-free media into the upper chamber of the migration insert at 
30,000 cells per well of a 24 well plate.  10 % (v/v) FCS-containing media was utilised as a 
chemotactic agent in the lower chamber to stimulate cell migration.  The assay was 
performed as per the manufacturer’s instructions.  After 24 hours, the remaining cells and 
media present in the upper chamber were discarded and the membrane was stained.  Non-
migrated cells were removed from the interior side of the insert using a cotton bud before 
the insert was placed in the extraction buffer.  An aliquot of the stained extraction buffer 
was assayed and absorbance was measured spectrophotometrically at 560 nm using a 
SpectraMax® M2 microplate reader. 
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2.4 Western blotting 
To determine the relative expression of the proteins of interest, sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS PAGE) and immunoblotting were performed 
using the Novex® NuPAGE® gel electrophoresis system (Life Technologies, Paisley, 
U.K.). 
2.4.1 Treatment of rabbit aortic smooth muscle cells 
Rabbit aortic smooth muscle cells were seeded in 6 well plates and grown to approximately 
90 % confluence.  The cells were then quiesced in 0.1 % (v/v) FCS-containing media for 
24 hours.  The cells were incubated with the lipids alone or an agonist or antagonist for 
AMPK (as indicated in the relevant results chapter) for the appropriate length of time 
followed by, in some cases, a 2 hour treatment with the lipids.  Subsequently, the reaction 
was stopped by placing the 6 well plate on ice.  The media was aspirated from the wells 
followed by the addition of ice-cold cell lysis buffer (50 mM Tris pH 7.4, 50 mM NaF, 1 
mM Na4PPi, 1 mM EGTA, 1mM EDTA, 1 % (v/v) Triton X-100, 1 mM dithiothreitol 
(DTT), 1 % (v/v) cocktail of protease inhibitors) to each well for 5 minutes.  Cell lysates 
were collected by scraping and stored at -80 °C for protein determination and Western 
blotting. 
2.4.2 Preparation of mouse aorta and liver 
Thoracic aortae and livers from male C57BL/6 and ApoE
-/-
 mice, between 20 and 30 g, 
were excised immediately after death and cleaned of fat and connective tissue.  The 
samples were snap frozen and stored at -80 °C until use.  Aortae were pulverised in liquid 
nitrogen using a mortar and pestle into a fine powder and re-suspended in ice-cold cell 
lysis buffer while sections of liver were homogenised using a micro-rotary blade.  Protein 
samples were transferred into ice-cold centrifuge tubes and stored at -80 °C until use. 
2.4.3 Quantification of protein concentration 
Protein concentrations were determined according to the Bradford method (Bradford, 
1976).  Cell lysates, aortae and liver samples were centrifuged at 6200 x g for 5 minutes in 
a Pico 17 Thermo Scientific Heraeus bench-top centrifuge (Fisher Scientific, 
Loughborough, U.K.).  Supernatants were transferred to fresh ice-cold microcentrifuge 
tubes.  Standard dilutions of bovine serum albumin (BSA) ranging from 0.1 mg/ml to 1 
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mg/ml were used to generate a standard protein curve with distilled water as a blank.  
Protein samples from VSMCs and aortae were diluted in distilled water at a ratio of 5:1 
and 50:1 for liver samples.  10 µl of each sample and standards were added in triplicate to 
a 96 well plate followed by 100 µl of Pierce® Coomassie Plus (Bradford) assay reagent 
(Thermo Scientific, Loughborough, U.K.).  Absorbance was read at 595 nm using a 
FLUOstar OPTIMA microplate reader (BMG Labtech, Germany).  The mean absorbance 
from each sample was generated in triplicate and the protein concentration was determined 
by comparison with the BSA standard curve (Figure 2.1). 
 
Figure 2.1 – Representative BSA standard curve. 
 
2.4.4 SDS PAGE 
Protein samples were mixed with 7.5 µl of DTT and 12.5 µl of NuPAGE® LDS sample 
buffer as a load dye, to a total volume of 50 µl and heated at 70 °C for 20 minutes prior to 
protein loading.  Samples were loaded on NuPAGE® Novex® 4-12 % Bis-Tris mini gels 
(1.0 mm thick, 10 or 12 wells) at 5 or 10 µg of protein per well.  20 µl of Novex® sharp 
pre-stained protein standard was added to the gel as a marker of protein size.  Gels were 
run at 200 V for approximately 45 minutes in NuPAGE® MES SDS running buffer.  After 
that, proteins were transferred onto a nitrocellulose membrane (pore size 0.45 µm) at 30 V 
for 1 hour and 30 minutes in NuPAGE® transfer buffer supplemented with 10 % (v/v) 
methanol. 
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2.4.5 Immunoblotting 
After protein transfer was complete, nitrocellulose membranes were blocked for 1 hour in 
5 % (w/v) dried milk powder suspended in Tris-buffered saline supplemented with 0.1 % 
(v/v) Tween-20 (TBST) at room temperate while shaking.  Membranes were then rinsed in 
TBST and incubated overnight at 4 °C in primary antibody diluted in 5 % (w/v) BSA 
suspended in TBST.  A summary of the primary and secondary antibodies used along with 
dilutions are presented in Table 2.1.  Following this, membranes were washed in TBST 
and incubated for 2 hours at room temperature in HRP-conjugated secondary antibody 
diluted in 5 % BSA in TBST.  Once complete, membranes were washed in TBST.  
Visualisation of protein bands was performed using a Pierce® enhanced 
chemiluminescence (ECL) detection kit (Thermo Scientific, Loughborough, U.K.).  
Membranes were incubated in 1:1 mix of ECL reagents for 60 seconds, blotted and placed 
in a light-sensitive cassette.  Chemiluminescence of protein bands was detected with a 
Kodak X-Omat 2000 processor using Kodak blue-sensitive X-ray film. 
2.4.6 Quantification of expression of protein 
The antibody-detected protein bands on the developed X-ray film were scanned into a GS-
800™ Calibrated Densitometer (BioRad, Hemel Hempstead, U.K.).  Densitometrical 
analysis of the bands was performed using Quantity One BioRad software (BioRad, Hemel 
Hempstead, U.K.).  Housekeeping proteins, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) or α tubulin were used as protein loading controls therefore data were expressed 
as a ratio of protein of interest to the loading control or as a ratio of phosphorylated to the 
total amount of protein present. 
2.5 Small vessel wire myography 
Mouse carotid arteries were excised immediately after death and cleaned of all fat and 
connective tissue.  The intimal layer of the artery was removed by gently rubbing the 
interior of the vessel with a human hair to eliminate the action of the endothelium in the 
response.  The vessels were cut into 2 mm segments and mounted on two stainless steel 
wires in a two-channel small vessel wire myograph (Danish Myo Technology, Aarhus, 
Denmark), with one of the wires connected to a force transducer and the other to an 
adjustable jaw (Figure 2.2).  Vessels were incubated at 37 °C in Krebs-Henseleit buffer 
(containing: 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 25 mM NaHCO3, 1.03 mM 
KH2PO4, 11 mM glucose and 2.5 mM CaCl2) and gassed continuously with 95 % O2 and 5 
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% CO2.  The artery segments were equilibrated for at least 30 minutes at resting tension.  A 
predetermined active tension of 0.25 g was then applied to the artery for a further 30 
minutes (Methven et al., 2009).  Chart™ 5 Pro software (ADInstruments, Chalgrove, 
U.K.) was used to record and measure vessel responses to reagents.  At the beginning of 
each experiment, the contractile response to 40 mM KCl was measured to establish the 
viability of the segments and also to sensitise the vessel before other pharmacological 
agents were added. 
 
Figure 2.2 – Representative diagram of mouse carotid artery mounted in small 
vessel wire myograph. 
2 mm segments of vessel were mounted on two 40 µM stainless steel wires with one 
connected to a force transducer and a computer to record the changes in tone of the 
artery.  The other wire was connected to an adjustable jaw for the application of the 
desired amount of tension on the vessel. 
2.5.1 Cumulative concentration-response curve 
After the vessel had been sensitised, the segments of mouse carotid arteries were incubated 
with 25 µM of modified lipid or vehicle (equivalent volume of Krebs’ solution).  
Following this, the vessels were pre-constricted with the thromboxane A2 receptor agonist, 
9,11-dideoxy-11α,9α-epoxymethanoprostaglandin F2α (U46619, Sigma-Aldrich, Poole, 
U.K.) at a concentration of 3x10
-8
 M, producing a submaximal contraction established 
from previous experiments in the laboratory.  Cumulative concentration-response curves to 
AICAR were performed in a range of increasing concentrations from 1x10
-4
 M to 1x10
-2
 M 
at 10 minute intervals.  Data were expressed as a percentage of relaxation of the U46619-
induced tone of the vessel. 
Force
transducer
Adjustable 
jaw
Computer
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Table 2.1 – Summary of antibodies and dilutions used for immunoblotting. 
Protein Molecular 
Weight 
Host 
Species 
Primary 
Dilution 
Secondary 
Dilution 
Source and 
Product Number 
ACC 
 
280 kDa Rabbit 1:1000 1:2000 Cell Signalling 
Technology 
#3676 
AMPKα 
 
62 kDa Rabbit 1:1000 1:2000 Cell Signalling 
Technology 
#2603 
Caspase 3 
 
32 kDa Rabbit 1:1000 1:1000 Abcam 
ab90437 
GAPDH 
 
37 kDa Mouse 1:40000 1:2000 Abcam 
ab8245 
Phospho ACC 
(Ser79) 
280 kDa Rabbit 1:1000 1:2000 Cell Signalling 
Technology 
#3661 
Phospho AMPKα 
(Thr172) 
62 kDa Rabbit 1:1000 1:2000 Cell Signalling 
Technology 
#2535 
α tubulin 50 kDa Mouse 1:5000 1:2000 Abcam 
ab7291 
Primary and secondary antibodies were diluted in TBST supplemented with 5 % BSA and 
incubated at 4 °C overnight and at room temperature for 2 hours respectively.  Rabbit 
polyclonal and mouse monoclonal HRP-conjugated secondary antibodies were obtained 
from Abcam (Cambridge, U.K.). 
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2.6 Animal models 
All experiments were performed in accordance with the United Kingdom Animals 
(Scientific Procedure) Act of 1986.  All in vivo experimentation was performed under the 
project licence, 60/4114, held by Dr Simon Kennedy (University of Glasgow, U.K.) and 
the personal licence, 60/11726.  Mice were housed at the Central Research Facility at the 
University of Glasgow and maintained on 12 hour cycles of light and dark and at ambient 
temperature.  Mice were fed a standard chow diet unless otherwise stated and allowed free 
access to both food and water.  A diagram of the in vivo experimental design is depicted in 
Figure 2.3. 
2.6.1 C57BL/6 mice 
C57BL/6 mice were utilised as a control for all experiments in this study as this strain of 
mouse is the genetic background for the atherosclerotic ApoE
-/-
 mice.  Male mice were 
age-matched in all studies and obtained from Harlan (Oxon, U.K.). 
2.6.2 ApoE-/- mice 
ApoE
-/-
 mice are an extensively used model of atherosclerosis, as described in Section 
1.2.4.1.  These mice have a significant increase in plasma levels of circulating lipoproteins 
including LDL and VLDL leading to the development of atherosclerotic plaques which 
resemble the human form (Zadelaar et al., 2007).  ApoE
-/-
 mice, generated from a C57BL/6 
background, were obtained from Charles River (Margate, U.K.) and further bred in-house.  
Mice were fed on a commercially available cholesterol rich diet during the high fat feeding 
regime which started at 6 weeks of age for mice undergoing carotid artery injury surgery 
and 8 weeks for all other mice. 
2.6.3 Mouse carotid artery injury model 
Immediately prior to surgery, 8 week old male mice received an intraperitoneal (i.p.) 
injection of an analgesic, buprenorphine (0.1 mg/kg) and 2.5 mg of the anti-platelet drug, 
dipyridamole (Persantin®).  Sterile saline (0.5 ml via subcutaneous injection) was also 
administered to prevent dehydration of the animal during surgery.  All surgical procedures 
were performed under aseptic conditions.  Carotid artery injury surgery was performed 
following an adapted method described by Tennant et al. (2008).  General anaesthesia was 
induced by 3 % (v/v) isoflurane supplemented with oxygen (flow rate of 0.5 litres/minute) 
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and maintained at 1.5 % (v/v) isoflurane via a face mask throughout the procedure.  The 
depth of anaesthesia was monitored throughout the surgery using the hind limb reflex with 
the other paws secured with tape.  A small skin incision was made in the ventral side of the 
neck to expose the trachea.  Blunt dissection was performed to navigate through muscle 
and connective tissue inferior to the trachea, exposing about 0.5 cm of the left common 
carotid artery.  Precise dissection was used to detach the vagus nerve from the artery and 
two silk ligatures (size 6-0, Fine Science Tools, Heidelberg, Germany) were positioned at 
the proximal and distal ends of the vessel.  The distal ligature was tied tightly and an 
arterial clip (Fine Science Tools, Heidelberg, Germany) was positioned at the most 
proximal end to temporarily occlude the blood flow in the vessel.  A small incision was 
made in the artery and a piece of a modified flexible nylon wire, adapted by melting the 
end to create a blunt spherical tip, was inserted into the incision site and held loosely in 
place by tightening of the proximal ligature.  Once the arterial clip was removed, the nylon 
wire was advanced and rotated down the carotid artery into the thoracic aorta and this was 
repeated several times to ensure the removal of the endothelium.  Once the nylon wire was 
removed, the arterial clip was replaced and the proximal ligature was tied tightly and 
secured just below the incision site.  Upon removal of the clip, the area was bathed with 
heparinised saline and a continuous line of subcutaneous sutures (size 6-0, Vircyl, Ethicon, 
Edinburgh, U.K.) was used to close the skin incision.  For post-operative care, the mice 
received i.p. injection of buprenorphine (0.1 mg/kg) and were transferred to a heating mat 
and maintained at 37 °C until recovery.  ApoE
-/-
 mice were transferred from a normal chow 
diet to the high fat diet 2 weeks prior to the procedure and continued on the high fat diet 
until termination, 2 weeks after surgery.  Sham-operated mice were studied as controls 
following the same procedure without the insertion of the nylon wire. 
2.6.3.1 Termination of procedure 
Mice were sacrificed 14 days after the carotid artery injury surgery by i.p. injection of 200 
mg/kg of sodium pentobarbital (Euthatal) to allow for tissue and blood collection.  Blood 
was collected by cardiac puncture into K2 EDTA Microtainers® (BD Biosciences, Oxford, 
U.K.) and centrifuged at 1500 x g for 10 minutes to produce plasma, which was removed 
and stored at -80 °C until use.  Carotid arteries and aortae were dissected and cleaned of 
any connective tissue and divided randomly into groups; either fixed for histological 
analysis or snap frozen in liquid nitrogen for mass spectrometry analysis.  Heart, liver and 
spleen weight was also recorded. 
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Figure 2.3 – In vivo experimental design. 
For the carotid artery injury model (Section 2.6.3), C57BL/6 and ApoE-/- mice (on high fat 
diet at 6 weeks of age) were subjected to either sham or vascular injury of left carotid 
artery with the procedure terminated at 10 weeks old and tissue and blood samples 
collected (A).  For chronic AICAR administration (Section 2.6.4), C57BL/6 and ApoE-/- 
mice (on high fat diet at 8 weeks of age) were injected with either vehicle or AICAR for 2 
weeks followed by haemodynamic measurements after which tissue and blood samples 
were collected (B). 
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2.6.4 AICAR administration 
To investigate the effect of AICAR (Toronto Research Chemicals Inc., Ontario, Canada) 
on atherosclerosis progression and blood pressure, 10 to 12 week old C57BL/6 mice on 
normal chow and ApoE
-/-
 mice fed on the high fat diet for 1 month and continued for the 
duration of the dosing regimen, were administered a daily i.p. injection of either saline 
vehicle or AICAR (400 mg/kg) for 14 days.  After the completion of the 14 day period, 
haemodynamic measurements were performed.  Mice were weighed at the beginning of the 
dosing regimen as well as at day 7 to adjust the dose due to potential fluctuations in body 
weight. 
2.6.5 Haemodynamic measurements 
Haemodynamic measurements were performed by the cannulation of the left common 
carotid artery.  Mice were weighed before the beginning of each experiment.  General 
anaesthesia and isolation of the carotid artery was achieved using the same method as the 
mouse carotid artery injury model as described in Section 2.6.3.  A polyurethane cannula 
(Harvard Apparatus, Boston, U.S.A.) filled with heparinised saline was inserted at the 
incision site, approximately 4 mm into the lumen of the carotid artery and secured in place 
with the proximal ligature.  The cannula was connected to an Elcomatic E751A pressure 
transducer and MP35 data acquisition system (BIOPAC© Systems Inc., Santa Barbara, 
U.S.A.).  Upon removal of the arterial clip and restoration of blood flow, the mean arterial 
blood pressure was measured. 
2.6.5.1 Tissue and blood collection 
Once the haemodynamic measurements were complete, the mice were sacrificed by 
cervical dislocation.  Blood was collected via cardiac puncture and prepared as described 
in Section 2.6.3.1.  Carotid arteries and aortae were dissected and cleaned of any 
connective tissue.  Vessels were snap frozen in liquid nitrogen and stored at -80 °C for 
immunoblotting and mass spectrometry analysis.  Heart, liver and spleen weight was also 
recorded. 
2.6.6 Measurement of plasma MPO 
The MPO content of plasma from C57BL/6 and ApoE
-/-
 mice was analysed using a mouse 
MPO ELISA kit (Hycult® Biotech Inc., Uden, Netherlands).  Plasma samples, collected 
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from C57BL/6 and ApoE
-/-
 mice after carotid artery injury and chronic AICAR 
administration, were diluted 1 in 16 in dilution buffer.  This concentration was chosen after 
a preliminary experiment with increasing dilutions of mouse plasma.  The assay was 
performed as per the manufacturer’s instructions.  The samples and a standard curve, 
ranging from 1.6 ng/ml to 100 ng/ml (Figure 2.4), were added to a microtiter plate coated 
with antibodies that recognise mouse MPO in the plasma.  The bound mouse MPO binds to 
a biotinylated tracer antibody which in turn binds to a streptavidin-peroxidase conjugate.  
The conjugate then facilitates the conversion of the substrate, TMB, from a colourless to 
blue solution with the reaction stopped by the addition of oxalic acid.  Absorbance was 
measured spectrophotometrically at 450 nm using a SpectraMax® M2 microplate reader. 
 
Figure 2.4 – Representative MPO standard curve. 
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2.7 Histology 
2.7.1 Fixation 
Left and right mouse carotid arteries and aortae were dissected from the cadaver from the 
vascular injury study, freed of any connective tissue and fixed in 10 % (v/v) neutral 
buffered formalin (10 % formalin, 90 % H2O, 33 mM NaH2PO4, 45 mM Na2HPO4) 
overnight.  Tissues were processed through a gradient of alcohol solutions to Histoclear (a 
xylene substitute, Thermo Scientific, Loughborough, U.K.) with the terminal step into 
paraffin wax.  This was performed in a Citadel 1000 tissue processor (Thermo Shandon, 
Runcorn, U.K.) in the following sequence: 
Table 2.2 – Sequence for processing samples for histological analysis. 
Solution Length of incubation of sample 
70 % ethanol 15 minutes 
85 % ethanol 15 minutes 
90 % ethanol 25 minutes 
95 % ethanol 25 minutes 
100 % ethanol 15 minutes 
100 % ethanol 15 minutes 
100 % ethanol 15 minutes 
Histoclear 30 minutes 
Histoclear 30 minutes 
Paraffin wax 30 minutes 
Paraffin wax 30 minutes 
 
Samples were positioned and held vertically to embed the vessels in the correct orientation 
in the paraffin wax for sectioning using a Shandon Histocenter 3 embedding centre (Fisher 
Scientific, Loughborough, U.K.).  Paraffin blocks were cut into 4 µm slices to expose the 
transverse sections of the embedded arteries using a Leica Finesse 325 Microtome (Fisher 
Scientific, Loughborough, U.K.). 
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2.7.2 Haematoxylin and eosin staining 
Haematoxylin and eosin (H&E) stain the nucleus and cytoplasm of cells respectively and 
was used to investigate neointima formation in the vascular injury study.  Paraffin was 
removed from the cut sections and rehydrated through an alcohol gradient of 100 %, 90 % 
and 70 % ethanol for 5 minutes each and washed in deionised water for a further 5 
minutes.  Sections were then stained with haematoxylin for 4 minutes and washed in 
deionised water before being placed in acid alcohol (1 % (v/v) HCl in ethanol) for 30 
seconds.  Slides were washed in deionised water for 1 minute, placed in eosin for 2 
minutes before a further 5 minute wash in deionised water.  Sections were then dehydrated 
by incubation in 70 %, 90 % and 100 % ethanol followed by 10 minutes in Histoclear.  
Finally, cover slips were fixed using DPX mounting medium (VWR BDH Prolabo, 
Leicestershire, U.K.).  Nuclei appeared blue/purple whereas cytoplasm was stained pink. 
2.7.3 Immunohistochemistry 
Paraffin was removed from the cut sections and rehydrated through an alcohol gradient of 
100 %, 90 % and 70 % ethanol for 5 minutes each and washed in running water.  Heat-
induced antigen retrieval was then performed with the sections incubated in 10 mM citric 
acid at pH 6.0 at 95-100 °C for 10 minutes and allowed to cool to room temperature.  
Carotid artery sections were washed in running water for 10 minutes and then endogenous 
peroxidase activity was blocked by the incubation of 3 % (v/v) H2O2 in methanol for 20 
minutes.  Following this, sections were washed in running water for 10 minutes and 
incubated with 2.5 % normal horse blocking serum for all non-specific binding in a 
humidified chamber for 1 hour at room temperature.  The arterial sections were then 
incubated with the primary antibody diluted in 1 % (w/v) BSA in PBS (Sigma Aldrich, 
Poole, U.K.) in a humidified chamber.  A summary of the primary antibodies used along 
with dilutions and lengths of incubations are found in Table 2.3.  A blank and negative 
control was carried out for each experiment using 1 % BSA in PBS and rabbit IgG 
antibody diluted in 1 % BSA in PBS respectively.  Following this, sections were washed 
twice in PBS for 10 minutes and incubated with ImmPRESS™ anti-rabbit Ig antibody 
(Vector Laboratories, Peterborough, U.K.) for 1 hour at room temperature in a humidified 
chamber with the exception of sections stained for phosphorylated and total AMPK.  These 
sections were incubated with a biotinylated secondary antibody followed by treatment with 
streptavidin-peroxidase solution using the Histostain®-Plus Bulk kit (Life Technologies, 
Paisley, U.K.), both for 10 minutes at room temperature to amplify the signal.  All sections 
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were next washed twice in PBS for 10 minutes each.  DAB chromagen solution (3,3-
diaminobenzidine and hydrogen peroxidase solution, Vector Laboratories, Peterborough, 
U.K.) was utilised for immunoperoxidase staining with the solution incubated with the 
sections until a dark brown staining was evident.  This was typically between 2 and 5 
minutes and the reaction was stopped by washing the sections in water.  Sections were then 
counterstained with haematoxylin to visualise the nucleus of the cells by incubation for 4 
minutes followed by washing in warm water for 5 minutes to “blue” the nuclei.  Finally, 
the sections were dehydrated by incubation in 70 %, 90 % and 100 % ethanol followed by 
10 minutes in Histoclear.  Cover slips were then fixed using DPX mounting medium.  
Staining was visualised using a light microscope and positive immunostaining was seen as 
a brown/dark brown and nuclei appearing blue/purple.  Sections were photographed using 
QCapture Pro 6.0 software and analysed with Image-Pro® Analyzer 7.0 software (Media 
Cybernectics, Marlow, U.K.). 
 
Table 2.3 – Summary of antibodies, dilutions and length of incubations used for 
immunohistochemistry. 
Protein Dilution and Length of 
Incubation 
Source and Product 
Number 
Active caspase 3 1 in 50 for 2 hours at room 
temperature 
Abcam 
ab2302 
αSMA 1 in 200 for 2 hours at room 
temperature 
Abcam 
ab5694 
AMPKα 1 in 100 overnight at 4 °C Abcam 
ab131512 
Ki67 1 in 100 for 2 hours at room 
temperature 
Abcam 
ab15580 
Phospho AMPKα 
(Thr172) 
1 in 100 overnight at 4 °C Cell Signalling Technology 
#2535 
All primary antibodies were diluted in 1 % (w/v) BSA in PBS.  
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2.8 Detection of lipids in murine arteries  
2.8.1 Lipid extraction from mouse carotid arteries and aortae 
The lipid content of mouse carotid arteries and aortae from both the vascular injury and 
chronic AMPK activation studies were investigated using a modified version of the Bligh-
Dyer procedure, previously used for cell extractions (Spickett et al., 2001).  Equal volumes 
of solvents and aqueous solutions were used for lipid extraction.  Vessels were incubated 
in 1.5 ml Ultra High Recovery microcentrifuge tubes (Starlab, Milton Keynes, U.K.) in 
methanol containing 100 µg/ml of butylated hydroxytoluene (BHT), which is used as an 
antioxidant.  Tissue samples were vortexed for 30 seconds and sonicated in a water bath 
for 15 minutes.  Chloroform was then added to the sample and vortexed for 30 seconds and 
left overnight in the fridge for the lipids to extract.  An aqueous layer of 0.88 % (w/v) KCl 
in water was added and vortexed for a further 30 seconds before incubation in the fridge 
for 20 minutes.  The sample was then centrifuged at 13800 x g for 1 minute, separating the 
solvents and KCl into separate layers.  The chloroform layer was removed using a 
Hamilton syringe into a fresh microcentrifuge tube and particular care was taken to avoid 
removal of any of the aqueous layer.  The samples were then dried under a steady flow of 
oxygen-free nitrogen gas and stored at -80 °C until use. 
2.8.2 Quantification of lipids by ESMS 
Dried lipid extracts were reconstituted in 100 µl of 20 % (v/v) chloroform in methanol and 
vortexed for 1 minute.  The samples were then diluted 1 in 10 in methanol which allowed 
the samples to be further diluted for analysis using ESMS in either positive- or negative-
ion mode performed on an QTRAP® 5500 mass spectrometer (Figure 2.5, AB SCIEX, 
Warrington, U.K.).  For analysis using positive-ion mode with direct infusion, samples 
were diluted 1 in 100 for aortae, 1 in 50 for left injured carotids and 1 in 25 for right 
carotids with 1 % (v/v) aqueous formic acid in methanol, giving a final dilution of the lipid 
extracts of 1 in 1000, 1 in 500 and 1 in 250 respectively.  Spectra, in the range of m/z 300-
1000, were acquired for 2 minutes.  Precursor ion scanning was performed for m/z 184.1 
for PCs and SMs and m/z 369.1 for cholesterol and cholesteryl esters, as well as neutral ion 
loss for 141.1 Da for PEs.  For analysis using negative-ion mode with direct infusion, 
samples were diluted 1 in 10 for aortae, 1 in 5 for left injured carotids and 1 in 2.5 for right 
carotids with 10 % (v/v) 5 mM ammonium acetate in methanol, giving a final dilution of 
the lipid extracts of 1 in 100, 1 in 50 and 1 in 25 respectively.  Spectra in the range of m/z 
300-1000 were acquired for 4 minutes.  Precursor ion scanning was performed for m/z 
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241.0 for PIs and neutral loss scan for 87.0 Da for PSs.  Collision energy of 45 eV was 
used for all scans except for precursor ion scanning for m/z 369.1 where 30 eV was used.  
Ion intensities for each m/z value were normalised by dividing the value by the obtained 
total ion count value, giving a percentage using PeakView® software (AB SCIEX, 
Warrington, U.K.).  Ion intensities were evaluated by comparing the percentage m/z values 
from one sample group with the percentage m/z values from a different sample group. 
 
Figure 2.5 – Photograph of QTRAP® 5500 mass spectrometer. 
 
2.9 Statistical analysis 
All results are expressed as mean ± standard error of the mean (SEM) where n represents 
the number of experiments performed.  Data were analysed with GraphPad Prism 5.0 
software (California, U.S.A.) using either a paired or unpaired Student’s t test, one-way 
analysis of variance (ANOVA) followed by a Dunnett’s or Newman-Keuls’ post hoc test 
or two-way ANOVA followed by Bonferroni’s post hoc test as appropriate and described 
in the respective methods of each chapter.  In all cases, a p value of less than 0.05 was 
considered statistically significant. 
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CHAPTER 3 
THE INFLUENCE OF MODIFIED 
LIPIDS ON VSMCs
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3.1 Introduction 
VSMCs situated in the medial layer of vessels are in a quiescent phenotypic state, 
producing SM MHC and αSMA; both are involved in contractile function (Owens et al., 
2004, Doran et al., 2008).  VSMCs can then switch into a synthetic state where they have a 
higher rate of proliferation and produce more scavenger receptors, allowing the 
uncontrolled uptake of lipids and therefore formation of foam cells (Owens et al., 2004, 
Campbell and Campbell, 1994).  Phenotypic switching of VSMCs is critical in the 
development of atherosclerosis and also restenosis, as both processes are characterised by a 
thickening of the arterial wall.  This highlights the importance of VSMCs in arterial 
disease progression, while the modification of LDL and formation of oxidised 
phospholipids also contributes significantly to the pathophysiology of atherosclerosis 
(Witztum and Steinberg, 1991).  These oxidised phospholipids, such as oxPAPC and its 
constituent POVPC, have been found to decrease SM MHC and αSMA leading to an 
increase in the expression of pro-inflammatory genes encoding chemokines such as MCP-1 
thereby inducing the phenotypic switching process of VSMCs and enhancing the 
inflammatory state (Pidkovka et al., 2007). 
Oxidised phospholipids PGPC and POVPC, are the predominant truncated products 
formed from the autoxidation of PAPC and mimic the biological effects of mmLDL and 
hence could be critical markers of atherosclerotic progression (Watson et al., 1995, Watson 
et al., 1997).  However, conflicting results have been observed in relation to VSMCs, with 
a biphasic response involving a proliferative effect at low concentrations and apoptosis 
predominating at higher concentrations (Auge et al., 2002, Fruhwirth et al., 2006, 
Johnstone et al., 2009).  Oxidised phospholipids have also demonstrated other pro-
inflammatory effects in human aortic endothelial cells with incubation of oxPAPC 
inducing expression of MKP-1, which leads to the production of MCP-1 and chemotaxis of 
monocytes (Reddy et al., 2001).  In addition, oxPAPC induced monocyte adhesion and 
inflammation in atherosclerotic mice in vivo (Furnkranz et al., 2005). 
Production of oxidised lipids and modification of LDL is thought to occur by a number of 
ways including by the action of metals and the phagocytic enzyme, MPO.  Attention has 
focused on MPO’s ability to produce chlorinated species at physiological and pathological 
conditions in vivo as it catalyses the production of HOCl from H2O2 and chloride anions 
(Schultz and Kaminker, 1962).  There is growing evidence of the involvement of MPO and 
HOCl in atherosclerosis with the active form of the enzyme being found in human 
Chapter 3 – Influence of Modified Lipids on VSMCs 
63 
 
atherosclerotic plaques as well as HOCl-modified LDL (Daugherty et al., 1994, Hazell et 
al., 1996).  Wildtype mice overexpressing human MPO in macrophages were produced 
using the Visna virus promoter and then repopulated in bone marrow of lethally irradiated 
LDLr
-/-
 mice.  These hypercholesterolaemic mice expressing human MPO have also been 
found to promote atherosclerotic progression (McMillen et al., 2005).  HOCl can be added 
across the unsaturated bonds of phospholipids by electrophilic attack forming lipid 
chlorohydrins (Winterbourn et al., 1992).  Phospholipid chlorohydrins have demonstrated 
toxicity in myeloid cells and endothelial cells, thought to be due to their high polarity 
which leads to disruption of the membrane (Dever et al., 2003, Vissers et al., 2001, Carr et 
al., 1997).  Pro-inflammatory effects have also been observed with chlorohydrins inducing 
leukocyte adhesion in ApoE
-/-
 mice, primarily through the upregulation of P-selectin 
(Dever et al., 2008).  Alpha-chloro fatty aldehydes are another class of chlorinated species 
produced by the action of MPO, formed by the addition of HOCl across the vinyl ether 
bond of plasmalogens (Albert et al., 2001).  Activation of neutrophils results in the 
production of 2-ClHDA which has been found to be a natural inhibitor of endothelial NO 
biosynthesis as well as accumulating during MI (Thukkani et al., 2002, Marsche et al., 
2004, Thukkani et al., 2005).  Unlike chlorohydrins, there is evidence of alpha-chloro fatty 
aldehydes in human atherosclerotic plaques with potential proatherogenic properties 
through inducing P-selectin expression in primary HCAECs (Thukkani et al., 2003b).  
However, considering the mounting evidence of biological effects of modified lipids, little 
is known about the actions of different classes of modified lipids on VSMC proliferation, 
viability and migration which are all important remodelling processes in the development 
of atherosclerosis and also restenosis. 
3.1.1 Aims 
The aims investigated in this chapter were: 
 To determine the stability of phospholipid chlorohydrins over a 72 hour period. 
 To determine the effect of either short- or long-term modified lipid incubation on 
VSMC proliferation, viability and migration. 
 To elucidate the mechanism of cell death induced by modified lipids.  
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3.2 Methods 
3.2.1 Lipid preparation and analysis 
SOPC and SLPC were modified to form lipid chlorohydrins as detailed in Section 2.2.1.  
Native phospholipids were incubated with HBSS to form lipid micelles and chlorinated 
with excess HOCl.  DPPC was added to each of the native phospholipids to assess the 
stability of each chlorohydrin.  Excess HOCl was removed using a reverse phase Sep-
Pak® column and dried under nitrogen.  Lipid chlorohydrins were reconstituted in PBS 
with chlorohydrin formation and stability analysed by ESMS over a 72 hour period.  2-
ClHDA was synthesised by Professor Andrew R. Pitt (Aston University, U.K.) and 
oxidised phospholipids were purchased from Avanti Polar Lipids.  For cell experiments, all 
lipids were reconstituted in culture medium and added to the cells at increasing 
concentrations. 
3.2.2 VSMC proliferation 
Immunostaining for αSMA was first performed to characterise the origin of the primary 
cell culture as described in Section 2.3.2.1.  VSMC proliferation was then assessed by 
determining the incorporation of BrdU into newly synthesised DNA using an ELISA kit 
(as detailed in Section 2.3.3).  For pretreatment experiments, cells were incubated with 1-
100 µM of each lipid for 2 or 6 hours prior to stimulation with 10 % FCS and the addition 
of BrdU for 24 hours at 37 °C.  For assessing the effect of chronic incubation, cells were 
stimulated with 10 % FCS and the addition of BrdU along with 1 to 100 µM of each lipid 
for 24 hours. 
3.2.3 VSMC viability 
Cell viability was measured by the bioluminescent detection of cellular ATP as it is present 
in all metabolically active cells (described in Section 2.3.4).  For pretreatment experiments, 
cells were incubated with 1-100 µM of each lipid for 2 or 6 hours prior to stimulation with 
10 % FCS for 24 hours at 37 °C.  For assessing the effect of chronic incubation, cells were 
stimulated with 10 % FCS along with 1-100 µM of each lipid for 24 hours. 
3.2.4 Western blotting 
Expression of caspase 3 was measured by Western blot analysis as detailed in Section 2.4.  
VSMCs were seeded in 6 well plates and grown to 80 % confluency before quiescing in 
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0.1 % FCS for 24 hours.  Following exposure to each lipid (1-100 µM) for 2 hours, VSMC 
lysates were prepared.  Protein estimation analysis from these lysates was carried out and 
protein was added at 10 µg per well.  Immunoblotting was performed with antibodies 
against caspase 3 and α tubulin (all antibody dilutions found in Table 2.1) which was used 
as a loading control followed by densitometrical analysis of the detected protein bands. 
3.2.5 VSMC migration 
Cell migration was measured using a QCM chemotaxis cell migration assay which is based 
on the Boyden chamber method containing an 8 µm pore membrane (as described in 
Section 2.3.5).  For the acute incubation, cells were pretreated in quiescing medium with 
each lipid (1-100 µM for chlorinated lipids and 1-25 µM for oxidised phospholipids) prior 
to harvesting.  Lipid (1-100 µM) was added to the top chamber of the insert for chronic 
incubation. 
 
Figure 3.1 – Illustration of chemotactic cell migration assay. 
Cells were seeded in serum-free media in the top of the insert (with or without lipid) with 
media supplemented with 10 % (v/v) FCS in the lower chamber acting as a chemotactic 
agent.  Cells migrated through the porous membrane and adhered to the underside where 
they were stained and cell migration was measured colourimetrically. 
3.2.6 Statistical analysis 
All results are displayed as mean ± SEM and n represents the number of independent 
experiments performed.  Data were analysed using a two-way ANOVA for the control 
BrdU experiments, a one-way ANOVA followed by Dunnett’s post hoc test for all 
proliferation, viability and migration experiments and a one-way ANOVA followed by 
Newman-Keuls’ post hoc test for caspase 3 expression. 
  
Media + 10 % FCS
Serum free media
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3.3 Results 
3.3.1 Detection and assessment of the stability of phospholipid 
chlorohydrins 
The conversion of native phospholipids to their respective chlorohydrins was observed 
using ESMS in positive-ion mode with an increase in the m/z of 52 for the mono-
chlorohydrins and 104 for bis-chlorohydrins.  Phospholipid chlorohydrins were 
reconstituted in PBS to assess stability over a 72 hour time period with samples taken at 7, 
24, 48 and 72 hours.  Representative spectra from the initial sample time point are shown 
in Figure 3.2.  Treatment of native SOPC (m/z 788) with HOCl resulted in complete 
conversion to the mono-chlorohydrin, identified by the peak at m/z 862 due to the addition 
of a sodium (Na
+
) ion.  In contrast, DPPC (m/z 734) was unaffected by incubation with 
HOCl with a peak seen at about m/z 756, again in its sodiated form.  A smaller additional 
peak was observed at m/z 864 representing the chlorine isotope distribution pattern with 
the addition of 
37
Cl as chlorine exists as a mixture in a ratio of 3:1 of 
35
Cl to 
37
Cl.  
Treatment of SLPC (m/z 786) resulted primarily in the conversion to the bis-chlorohydrin, 
observed at around m/z 912 (plus Na
+
 ion).  Furthermore, a peak was observed at about 
m/z 916 indicating the addition of 
37
Cl rather than 
35
Cl.  DPPC was again unaffected by the 
electrophilic attack with a peak observed at about m/z 756.  A further peak was seen at 
about m/z 894 due to the loss of water from the chlorohydrin product, corresponding to the 
loss of m/z 18.  The stability of the chlorohydrin products was measured as a percentage of 
the stable DPPC peak.  SOPC chlorohydrins (SOPC ClOH) remained stable over the initial 
24 hour period and remained consistently larger than the DPPC peak.  The peaks began to 
reduce steadily after this time point down to about 130 % of the DPPC peak after 72 hours.  
SLPC chlorohydrins (SLPC ClOH) followed a similar trend to the stability of SOPC ClOH 
but the amount of chlorohydrin product was reduced.  Due to the complete conversion to 
the mono-chlorohydrin, SOPC ClOH was selected for subsequent experiments with 24 
hours incubation. 
3.3.2 Effect of pretreatment of modified lipids on VSMC 
proliferation and viability 
Immunostaining for αSMA was performed to confirm the origin of the primary cell 
culture.  Strong green fluorescence indicates positive staining for αSMA and therefore 
VSMCs (Figure 3.3).  Increasing concentrations of FCS were used to test the efficiency of 
the BrdU proliferation assay; 10 % FCS induced the largest rate of proliferation and was 
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therefore employed for all subsequent experiments (Figure 3.4).  The influence of modified 
lipids (both chlorinated and oxidised) on VSMC proliferation and viability was then 
investigated.  Acute effects were monitored after 2 hour incubation of the modified lipids 
in quiescing medium after which the cells were stimulated with 10 % FCS for 24 hours 
(with the addition of BrdU in the proliferation experiments). 
Pretreatment of 2 hours with both chlorinated lipids, SOPC ClOH (Figure 3.5) and 2-
ClHDA (Figure 3.6), had no effect on either VSMC proliferation or viability.  In contrast, 
incubation with oxidised lipids, PGPC (Figure 3.7) and POVPC (Figure 3.8), caused a 
significant reduction in VSMC proliferation and viability with only 17.6 ± 6.5 % and 64.1 
± 8.5 % of viable cells remaining at 50 µM of lipid compared to the 10 % FCS control 
respectively.  The mechanism of cell death was investigated by assessing activation of 
caspase 3, an extensively used marker of programmed cell death or apoptosis.  Caspase 3 is 
produced as an inactive pro-enzyme and is processed by upstream proteases such as 
caspase 8 and self proteolysis to its active form; therefore a reduction in the level of 
caspase 3 would infer activation.  Cells were also photographed to assess the 
morphological changes in the VSMCs after 2 hours incubation with the modified lipids.  
Chlorinated lipids had no effect on either morphological changes or caspase 3 levels in 
VSMCs after a 2 hour treatment (Figure 3.9).  In contrast, morphological changes were 
initially seen at 25 µM PGPC and 50 µM POVPC with cells appearing granular and the 
formation of vesicles suggesting apoptotic bodies had formed (Figure 3.10).  This was 
increased at the higher concentrations of both of the oxidised lipids with almost complete 
obliteration of all cells at 100 µM PGPC.  Caspase 3 levels were reduced with increasing 
concentrations of both PGPC and POVPC; however a reduction in the expression of the 
protein loading control, α tubulin, was also observed at the higher concentrations (50 and 
100 µM).  These concentrations were therefore discounted from the analysis and no overall 
differences were observed.  A longer period of 6 hours incubation in quiescing medium 
was utilised for modified lipids, where viable cells were still present after the 2 hour 
treatment to ensure all effects were witnessed (Figure 3.11).  6 hour treatment with SOPC 
ClOH caused a concentration-dependent reduction in VSMC viability with 54.1 ± 6.1 % of 
viable cells at 100 µM, whereas no effect was witnessed with 2-ClHDA incubation.  
POVPC caused a dramatic reduction in VSMC viability (similar to the 2 hour incubation 
with the other oxidised lipid, PGPC) with 35.5 ± 4.9 % of viable cells at 25 µM POVPC.  
Incubation with increasing concentrations of HOCl, which was used to chlorinate the 
phospholipids, had no effect on VSMC proliferation after either 1 hour or 2 hours 
treatment (Figure 3.12). 
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Figure 3.2 – Stability of SOPC and SLPC ClOH over 72 hour period. 
Native SOPC and SLPC were chlorinated to their respective chlorohydrins and stability 
was measured as a percentage of the stable phospholipid, DPPC using positive-ionisation 
ESMS (C).  Red dashed line indicates 24 hours which was the length of incubation used 
for all subsequent cell experiments.  Spectra shown for SOPC (A) and SLPC (B) are 
representative of first sample collection at time zero. 
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Figure 3.3 – Immunostaining of primary cell culture for αSMA. 
To confirm the origin of the primary cell culture, cells were fixed and permeabilised before 
incubation overnight with the primary antibody for αSMA.  Secondary antibody was then 
added and DAPI was also used to localise the nucleus of the cells.  Green fluorescence 
was visualised using FITC at 10 x objective highlighting the presence of rabbit aortic 
VSMCs. 
 
 
Figure 3.4 – Effect of increasing concentrations of FCS on BrdU incorporation in 
proliferating VSMCs in culture. 
To test the efficiency of the non-radioactive proliferation assay, an increasing number of 
VSMCs were incubated with increasing concentrations of FCS for 24 hours with the 
addition of BrdU.  ***p<0.001 vs 0.1 % FCS, n = 3 and performed in triplicate. 
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Figure 3.5 – Effect of 2 hour pretreatment of SOPC ClOH on VSMC proliferation and 
viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  VSMCs were incubated for 2 hours with increasing 
concentrations of SOPC ClOH in quiescing media and then stimulated with 10 % FCS for 
24 hours with the addition of BrdU in proliferation measurements.  n = 6 and performed in 
triplicate. 
0
25
50
75
100
125
B
rd
U
 I
n
c
o
rp
o
ra
ti
o
n
(%
 o
f 
c
o
n
tr
o
l)
10 % FCS - + + + + + +
SOPC ClOH (µM) - - 1 10 25 50 100
A
B
0
25
50
75
100
125
A
T
P
 d
e
te
c
te
d
(%
 o
f 
c
o
n
tr
o
l)
10 % FCS - + + + + + +
SOPC ClOH (µM) - - 1 10 25 50 100
Chapter 3 – Influence of Modified Lipids on VSMCs 
71 
 
 
Figure 3.6 – Effect of 2 hour pretreatment with 2-ClHDA on VSMC proliferation and 
viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  VSMCs were incubated for 2 hours with increasing 
concentrations of 2-ClHDA in quiescing media and then stimulated with 10 % FCS for 24 
hours with the addition of BrdU in proliferation measurements.  n = 6 and performed in 
triplicate. 
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Figure 3.7 – Effect of 2 hour pretreatment with PGPC on VSMC proliferation and 
viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  VSMCs were incubated for 2 hours with increasing 
concentrations of PGPC in quiescing media and then stimulated with 10 % FCS for 24 
hours and the addition of BrdU in proliferation measurements.  ***p<0.001 vs 10 % FCS 
control, n = 6 and performed in triplicate. 
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Figure 3.8 – Effect of 2 hour pretreatment with POVPC on VSMC proliferation and 
viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  VSMCs were incubated for 2 hours with increasing 
concentrations of POVPC in quiescing media and then stimulated with 10 % FCS for 24 
hours with the addition of BrdU in proliferation measurements.  **p<0.01 and ***p<0.001 
vs 10 % FCS control, n = 6 and performed in triplicate. 
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Figure 3.9 – Effect of 2 hour pretreatment of chlorinated lipids on VSMC 
morphological changes and caspase 3 expression. 
VSMCs were photographed at 20 x magnification to visualise morphological changes after 
the cells were treated with SOPC ClOH (A) and 2-ClHDA (B) for 2 hours.  Caspase 3 
expression (a marker of apoptosis) was investigated after 2 hours incubation with each 
chlorinated lipid and the graph is expressed as the fold change of caspase 3 divided by α 
tubulin to adjust for protein loading (D).  Blots shown are representative (C).  n = 3. 
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Figure 3.10 – Effect of 2 hour pretreatment of oxidised lipids on VSMC 
morphological changes and caspase 3 expression. 
VSMCs were photographed at 20 x magnification to visualise morphological changes after 
the cells were treated with PGPC (A) and POVPC (B) for 2 hours.  Caspase 3 expression 
(a marker of apoptosis) was investigated after 2 hours incubation with each oxidised lipid 
and the graph is expressed as the fold change of caspase 3 divided by α tubulin to adjust 
for protein loading (D).  Blots shown are representative (C).  n = 3. 
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Figure 3.11 – Effect of 6 hour pretreatment with chlorinated lipids and selected 
oxidised phospholipid on VSMC viability. 
Increasing concentrations of SOPC ClOH (A), 2-ClHDA (B) and POVPC (C) were 
incubated for 6 hours in quiescing medium followed by stimulation with 10 % FCS for 24 
hours after which detection of ATP was used to measure VSMC viability.  **p<0.01 and 
***p<0.001 vs 10 % FCS control, n = 3 and performed in triplicate. 
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Figure 3.12 – Effect of HOCl incubation on VSMC proliferation. 
Cells were treated with increasing concentrations of HOCl for either 1 hour (A) or 2 hours 
(B) then stimulated with 10 % FCS and incubated with BrdU for 24 hours, VSMC 
proliferation was then measured by the amount of BrdU incorporation.  n = 4 and 
performed in triplicate. 
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3.3.3 Effect of chronic incubation of modified lipids on VSMC 
proliferation and viability 
The chronic effects of the modified lipids were investigated with the lipids incubated with 
VSMCs for 24 hours along with stimulation with 10 % FCS (and the addition of BrdU in 
proliferation experiments). 
Chlorinated lipids, either SOPC ClOH (Figure 3.13) or 2-ClHDA (Figure 3.14), incubated 
for 24 hours had no effect on VSMC proliferation or viability.  Chronic treatment with 
PGPC caused an increase in VSMC proliferation and viability which was in stark contrast 
to the effects observed with 2 hour pretreatment, with 155.8 ± 12.6 % of viable cells 
present at 50 µM PGPC compared to 10 % FCS control (Figure 3.15).  Similarly, the effect 
of 2 hour incubation was reversed for POVPC as chronic treatment had no effect on 
VSMC proliferation or viability compared to 10 % FCS control (Figure 3.16).  
3.3.4 Effect of modified lipids on VSMC migration 
The effect of modified lipids on VSMC migration was also investigated as it is another 
process critical in vascular remodelling.  VSMCs were either pretreated with modified 
lipid for 2 hours and then migration was assessed in the presence of the chemoattractant, 
10 % FCS or VSMCs were incubated with modified lipids during the migration process for 
24 hours. 
Pretreatment of 2 hours with chlorinated lipids had no effect on FCS-induced VSMC 
migration (Figure 3.17).  The higher concentrations of oxidised phospholipids (50 and 100 
µM) were discounted due to the high levels of cell death observed in proliferation and 
viability experiments.  No effect was seen after 2 hours incubation of oxidised lipids prior 
to FCS-induced VSMC migration (Figure 3.18).  Chlorinated lipids incubated with 
VSMCs in the top chamber for 24 hours had no effect on FCS-induced VSMC migration; 
however an apparent increase was observed at the highest concentrations of SOPC ClOH 
but this was not significant (Figure 3.19).  24 hour incubation with oxidised phospholipids 
caused a marked reduction in FCS-induced VSMC migration at the highest concentration 
with 48.4 ± 7.1 % and 73.3 ± 4.4 % of migrated cells at 100 µM PGPC and POVPC 
respectively (Figure 3.20).  A greater effect was again observed with PGPC which was in 
agreement with the proliferation and viability measurements. 
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Figure 3.13 – Effect of chronic treatment of SOPC ClOH on VSMC proliferation and 
viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  Increasing concentrations of SOPC ClOH were 
incubated while VSMCs were stimulated with 10 % FCS for 24 hours with addition of BrdU 
in proliferation measurements.  n = 4-6 and performed in triplicate. 
0
25
50
75
100
125
B
rd
U
 I
n
c
o
rp
o
ra
ti
o
n
(%
 o
f 
c
o
n
tr
o
l)
10 % FCS - + + + + + +
SOPC ClOH (µM) - - 1 10 25 50 100
0
25
50
75
100
125
A
T
P
 d
e
te
c
te
d
(%
 o
f 
c
o
n
tr
o
l)
10 % FCS - + + + + + +
SOPC ClOH (µM) - - 1 10 25 50 100
A
B
Chapter 3 – Influence of Modified Lipids on VSMCs 
80 
 
 
Figure 3.14 – Effect of chronic treatment of 2-ClHDA on VSMC proliferation and 
viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  Increasing concentrations of 2-ClHDA were 
incubated while VSMCs were stimulated with 10 % FCS for 24 hours with the addition of 
BrdU in proliferation measurements.  n = 6 and performed in triplicate. 
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Figure 3.15 – Effect of chronic treatment of PGPC on VSMC proliferation and 
viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  Increasing concentrations of PGPC were incubated 
while VSMCs were stimulated with 10 % FCS for 24 hours with the addition of BrdU in 
proliferation measurements.  *p<0.05 vs 10 % FCS control, n = 6 and performed in 
triplicate. 
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Figure 3.16 – Effect of chronic treatment of POVPC on VSMC proliferation and 
viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  Increasing concentrations of POVPC were 
incubated while VSMCs were stimulated with 10 % FCS for 24 hours with the addition of 
BrdU in proliferation measurements.  n = 6 and performed in triplicate. 
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Figure 3.17 – Effect of prior incubation of chlorinated lipids on FCS-induced VSMC 
migration. 
Cells incubated with increasing concentrations of SOPC ClOH (A) or 2-ClHDA (B) for 2 
hours and then harvested to assess VSMC migration in the presence of the 
chemoattractant, 10 % FCS, in the bottom chamber of the assay.  n = 4. 
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Figure 3.18 – Effect of prior incubation of oxidised lipids on FCS-induced VSMC 
migration. 
Cells incubated with increasing concentrations of PGPC (A) or POVPC (B) for 2 hours and 
then harvested to assess VSMC migration in the presence of the chemoattractant, 10 % 
FCS, in the bottom chamber of the assay.  n = 4-5. 
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Figure 3.19 – Effect of incubation of chlorinated lipids during FCS-induced VSMC 
migration. 
Cells were incubated with increasing concentrations of chlorinated lipids, SOPC ClOH (A) 
or 2-ClHDA (B), in the top chamber for 24 hours during the migration process induced by 
the chemoattractant, 10 % FCS, in the bottom chamber of the assay.  n = 4. 
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Figure 3.20 – Effect of incubation of oxidised lipids during FCS-induced VSMC 
migration. 
Cells were incubated with increasing concentrations of oxidised lipids, PGPC (A) or 
POVPC (B), in the top chamber for 24 hours during the migration process induced by the 
chemoattractant, 10 % FCS, in the bottom chamber of the assay.  ***p<0.001 vs 10 % 
FCS control, n = 4. 
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3.4 Discussion 
The results provided in this study show for the first time the effects of chlorinated lipids on 
VSMC remodelling processes and highlight the differences between chlorinated and 
oxidised lipid species.  Chlorinated lipids had no effect on VSMC proliferation, viability or 
migration while oxidised phospholipids caused a concentration-dependent reduction in all 
of these remodelling processes. 
The identification of native phospholipids and their respective chlorohydrins using ESMS 
in positive-ion mode has been used for a number of years to successfully detect both 
modified lipids in LDL molecules as well as isolated chlorohydrin preparations (Jerlich et 
al., 2000, Carr et al., 1996).  The addition of standard molecules such as DPPC can be used 
as an indicator of signal intensity as well as the potential breakdown of chlorohydrins and 
makes relative quantification of peaks possible (Arnhold et al., 2001).  SOPC was selected 
as an example of the effects of phospholipid chlorohydrins as it is a significant component 
of LDL and less likely to hydrolyse to its respective lysolipids than other unsaturated 
species (Dever et al., 2008).  Complete conversion to its mono-chlorohydrin was observed 
with stability over 24 hours which was the longest period of incubation used in cell 
experiments.  This is in agreement with previous studies as SOPC has only one unsaturated 
bond and therefore one site for chlorination, leading to increased stability in comparison 
with other phospholipids with multiple adjacent unsaturated bonds (Arnhold et al., 2001, 
Arnhold et al., 2002).  Additionally, a significant reduction in cellular ATP in myeloid cell 
lines, both monocytes and neutrophils, was observed with SOPC ClOH at a lower 
concentration (25 µM) compared with 1-stearoyl-2-arachidonoyl-sn-glycero-3-
phosphocholine (SAPC) and SLPC ClOH where higher concentrations (50 and 100 µM 
respectively) were needed to elicit the same response (Dever et al., 2003). 
The levels of modified lipids found in pathophysiological conditions have proved hard to 
quantify with the large number of different structures present and the limited availability of 
suitable standards.  In areas of inflammation such as rheumatoid arthritis, the presence of 
OCl
-
, the anion present in HOCl, has been found to reach concentrations of up to 300 µM, 
due to the presence of neutrophils releasing MPO (Katrantzis et al., 1991).  The levels of 
oxidised phospholipids have mainly been measured using mass spectrometry coupled to 
HPLC for both human and animal samples.  In human atherosclerotic plaque samples, 
POVPC was found between 20 to 40 µg per gram of tissue with slightly higher levels, of 
between 40 to 100 µg per gram of tissue, being reported in rabbit aorta for POVPC and 
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PGPC (Ravandi et al., 2004, Watson et al., 1997, Subbanagounder et al., 2000).  This 
suggests that modified lipids are present within in the micromolar range and these 
concentrations of lipids were utilised for all in vitro experiments in this study. 
Within this concentration range, the chlorinated lipids used were found to have little to no 
effect on VSMC proliferation, viability or migration after both incubation times.  The only 
exception was SOPC ClOH which caused a significant reduction in cellular ATP at the 
highest concentration after 6 hours treatment in quiescing medium.  The majority of work 
published previously has observed toxicity with incubation of chlorohydrins thought to be 
via disruption of the membrane due to their high polarity (Carr et al., 1997).  However, 
necrotic cell death has also been reported in HUVECs with incubation of halohydrins and 
an increase in caspase 3 levels suggesting apoptosis has been observed in myeloid cells 
(Dever et al., 2006, Vissers et al., 2001).  Together, this would suggest chlorohydrins 
could have an effect on intracellular mechanisms rather than just physical disruption of the 
membrane.  This is also highlighted in the time-dependent effects observed with SOPC 
ClOH incubation (Dever et al., 2003).  The lack of cytotoxicity described in this study may 
be due to the different cell type used, as VSMCs were more resistant to the effects of 
chlorohydrins than myeloid and endothelial cells.  There could also be an effect due to 
species differences as rabbit VSMCs were used for all in vitro experiments and human 
cells were utilised in the majority of other studies.  In contrast to chlorohydrins, very little 
is known about the actions of alpha-chloro fatty aldehydes as the few studies conducted 
focussed primarily on endothelial cells.  2-ClHDA was found to inhibit endothelial NO 
biosynthesis and induce expression of COX-2 in endothelial cells (Marsche et al., 2004, 
Messner et al., 2008a).  2-ClHDA was thought to be an exciting prospect with the 
identification of this class of chlorinated lipids in atherosclerotic lesions in vivo; however, 
no effects were observed on the vascular remodelling processes examined in this study. 
The direct action of HOCl incubation on VSMCs was also investigated as very low 
concentrations, in the nanomolar range, have been shown to induce apoptosis in HUVECs 
(Vissers et al., 1999).  Incubation with HOCl in the same concentration range as the 
modified lipids had no effect on VSMC proliferation after either 1 hour or 2 hours 
treatment.  In contrast, a study investigating a newly identified haem-containing 
peroxidase, VPO1, reported enhanced VSMC proliferation after 1 hour incubation with 20 
µM HOCl (Shi et al., 2011).  VPO1 is thought to catalyse the production of HOCl from 
H2O2 and chloride similar to the action of MPO (Cheng et al., 2008). 
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In stark contrast to the effects observed with the chlorinated lipids, oxidised phospholipids 
caused a dramatic concentration-dependent reduction in VSMC proliferation and viability 
after 2 hours incubation.  The investigation into the mechanism of cell death induced by 
the oxidised phospholipids proved inconclusive in this study.  There was a substantial 
amount of non-specific binding of the antibodies producing “dirty” blots which was 
probably due to the antibody used being raised in the same species as the origin of the 
VSMCs.  However, the cell death observed in this study is in agreement with other results 
after the incubation of oxidised phospholipids.  Modified lipids have been found to induce 
apoptotic signalling pathways by the activation of SMase and, in particular, the acid form 
of the enzyme which is known to be involved in the earlier stages of apoptosis (Loidl et al., 
2003).  This leads to the formation of ceramide, a hydrolysis product of SM, which in turn 
causes the phosphorylation of MAPK and caspase 3 signalling (Loidl et al., 2004).  Effects 
have also been seen in vivo with LDLr
-/-
 mice crossed with mice deficient in programmed 
cell death-1 receptor exhibiting a large increase in atherosclerotic plaque size and a change 
in composition of the lesion containing more macrophages than the LDLr
-/-
 control mice 
(Bu et al., 2011).  A biphasic response of oxidised phospholipids has been previously 
reported with proliferation occurring at low concentration and apoptosis predominating at 
high concentrations (Auge et al., 2002, Johnstone et al., 2009).  The results of this study do 
not seem to follow this trend; however, with the chronic incubation of oxidised 
phospholipids in the presence of the growth supplement, FCS, the predominant cell death 
was abolished and an increase in proliferation was observed.  This would suggest that the 
presence of serum phospholipases causes a breakdown of the detrimental effects of 
oxidised phospholipids and, in turn, produces a proliferative product.  This is in partial 
agreement with a previous study; however, the antiproliferative nature of the lipids was 
still seen with the oxidised phospholipid treatment in the presence of FCS (Fruhwirth et al., 
2006). 
Little is known about the effects of modified lipids on VSMC migration, which is another 
important process in vascular remodelling and central to the restenotic phenotype.  POVPC 
and PGPC have been found to induce VSMC migration and increase the expression of type 
VIII collagen, important in the composition of ECM in atherosclerotic plaques 
(Cherepanova et al., 2009).  In this study, pretreatment for 2 hours with PGPC and POVPC 
appeared to have no lasting effects on VSMCs and therefore there was no effect on the 
FCS-induced migration.  However, when VSMC migration was stimulated in the presence 
of the oxidised phospholipids, a concentration-dependent decrease was observed.  The 
effect seen was markedly less than in the proliferation and viability experiments, 
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suggesting the migration of VSMCs could be occurring faster than the detrimental action 
of the oxidised phospholipids.  This is consistent with the initial activation of MAPK, 
occurring within 15 minutes, which is one of the proposed mechanisms of VSMC 
migration, leading to movement of VSMCs by the action of PDGF, and therefore could be 
occurring before the effect of the oxidised phospholipids (Nelson et al., 1998). 
The greater effect of the oxidised phospholipids, in all cellular experiments and in both 
treatment conditions, was seen with PGPC rather than POVPC, despite the fact that the 
latter had previously been suggested to be the more potent of the two truncated oxidation 
products of PAPC (Fruhwirth et al., 2006, Loidl et al., 2003).  Hermetter’s group have 
consistently found POVPC to be more apoptogenic than PGPC, which is thought to be due 
to its aldehyde moiety compared with the carboxylic acid functional group found on 
PGPC.  Using fluorescently labelled analogues of PGPC and POVPC, the phospholipids 
were found to localise in separate compartments of the VSMCs with PGPC located in 
lysosomes while POVPC formed covalent adducts with the plasma membrane (Moumtzi et 
al., 2007).  However, recently this group have reported a higher toxicity with PGPC in 
cultured macrophages believed to be due to more efficient membrane blebbing in apoptotic 
cells (Stemmer et al., 2012).  As oxLDL is very heterogeneous in its composition, it is 
useful to characterise its effects by using individual lipids in order to attribute the effects 
seen to each component. 
Previous studies have found apoptosis to peak at about 24 hours after vascular injury while 
proliferation occurs later in the process, at around 4 days after injury (Yang et al., 2006, 
Matter et al., 2006).  This correlates with the oxidised phospholipid data described in this 
study, where VSMC death was induced after a short incubation time of only 2 hours.  
Modified lipids could also be involved in the latter proliferative stages of vascular injury 
leading to the formation of neointima; however, this would be difficult to measure in vitro.  
Longer incubations with modified lipids would not be possible in quiescing medium, and 
incubating VSMCs with medium containing growth supplements such as FCS along with 
modified lipids would lead to the breakdown of these lipids by serum phospholipases 
(Fruhwirth et al., 2006).  This is a key limitation of the in vitro VSMC model as effects of 
longer incubations in quiescing medium with modified lipids could not be attributed solely 
to the lipids because, in absence of growth supplements, the cells would likely induce 
programmed cell death processes due to the lack of available nutrients.  The different 
classes of modified lipids may also have different durations of action and be involved in 
different cell processes for example; the oxidised phospholipids could participate in the 
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primary effects seen while chlorinated lipids could be involved in the later stages.  PGPC 
could be involved in the early cell death as it induces substantial death after 2 hours in the 
in vitro experiments.  This effect could be followed by the action of POVPC as the level of 
cell death observed was significantly increased after 6 hours incubation compared to 2 
hours.  SOPC ClOH and other chlorohydrins may be involved in the last stage of cell 
death, as a significant reduction in cell death was witnessed after 6 hours treatment at the 
higher concentrations.  This would suggest a cumulative effect of the modified lipids 
inducing cell death which is one of the first processes seen after vascular injury and in the 
formation of neointima.  In vivo analysis of injured or atherosclerotic vessels could provide 
a better insight into the actions of these different classes of modified lipids on important 
cellular processes involved in vascular remodelling. 
3.5 Conclusions 
In summary, both chlorinated species, chlorohydrins and alpha-chloro fatty aldehydes, had 
little to no effect on rabbit VSMC proliferation, viability or migration except that SOPC 
ClOH induced a concentration-dependent depletion of cellular ATP after a prolonged 
incubation of 6 hours.  In contrast, the truncated oxidation products of PAPC, PGPC and 
POVPC, caused a large concentration-dependent reduction in VSMC proliferation, 
migration and cellular ATP with the greater effect seen with PGPC.  The effects reported 
were further enhanced by a longer treatment time with POVPC, which is thought to 
operate through apoptotic signalling pathways.  This is the first study to investigate the 
effects of chlorinated lipids on VSMC processes; these processes being essential in 
vascular remodelling.  This study also highlights the divergent effects of different classes 
of modified lipids which are all known components of modified LDL and therefore critical 
in atherosclerosis progression. 
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CHAPTER 4 
THE IMPACT OF AMPK 
SIGNALLING ON THE EFFECTS OF 
MODIFIED LIPIDS IN VSM
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4.1 Introduction 
AMPK is a key regulator of energy homeostasis and is commonly referred to as a cellular 
“fuel gauge” (Hardie and Carling, 1997).  It is a highly conserved heterotrimeric complex 
consisting of a catalytic α subunit and two regulatory subunits; β and γ, with each having 
two or more isoforms that are expressed in different cell and tissue types (Davies et al., 
1994, Stapleton et al., 1994).  Activation of AMPK occurs via phosphorylation of the 
threonine residue at position 172 in the activation loop of the catalytic α domain (Hawley 
et al., 1996).  AMPK can only become activated when the regulatory subunits undergo 
conformational change to expose the catalytic site.  The regulatory γ subunits contain areas 
termed “Bateman domains” with the capacity to bind one molecule of either AMP or ATP 
(Bateman, 1997, Cheung et al., 2000, Scott et al., 2004).  In well energised cells, ATP is 
bound to AMPK, which keeps it in an inactive locked state.  In situations where there is a 
depletion of ATP and an elevation of AMP, such as during periods of cellular stress, 
hypoxia or glucose deprivation, AMP displaces ATP leading to the phosphorylation of 
AMPK at the threonine residue.  Furthermore, AMPK activity can be modulated by 
pharmacological agents such as AICAR which mimics the action of AMP.  AICAR is 
transported into the cell via the adenosine transporter where it is phosphorylated to form 
the AMP analogue, ZMP (Merrill et al., 1997).  Another agent, A-769662 is an extremely 
potent AMPK activator which directly stimulates AMPK by mimicking the effects of AMP 
as well as inhibiting enzyme de-phosphorylation (Göransson et al., 2007).  AMPK 
signalling directly regulates a number of enzymes involved in energy consumption within 
the cell.  AMPK can correct the energy imbalance by inhibiting ATP-consuming events 
such as fatty acid and cholesterol biosynthesis by directly phosphorylating the enzymes 
responsible: ACC and HMG-CoA reductase respectively, leading to the inhibition of 
enzyme activity. 
AMPK has been implicated in CVD including atherosclerosis where AMPK activation has 
found to be beneficial in altering the inflammatory response as it reduces leukocyte 
adhesion to human aortic endothelial cells and alleviates atherosclerosis in ApoE
-/-
 mice in 
vivo (Ewart et al., 2008, Li et al., 2010a).  VSMCs are also critical in the progression of 
atherosclerosis with AMPK activation by AICAR found to inhibit human and rat aortic 
VSMC proliferation and migration, induced by both FCS and PDGF (Igata et al., 2005, 
Peyton et al., 2011).  Angiotensin II-stimulated rat VSMC proliferation was also inhibited 
when AMPK is activated by AICAR (Nagata et al., 2004).  Furthermore, AMPK activation 
reduces oxLDL-induced macrophage proliferation and oxLDL-induced ER stress in vivo 
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(Ishii et al., 2009, Dong et al., 2010).  Chlorinated and oxidised lipids are critical in the 
progression of atherosclerosis and previously shown to induce apoptosis in both vascular 
and myeloid cells (Vissers et al., 2001, Dever et al., 2003, Fruhwirth et al., 2006, 
Johnstone et al., 2009).  Whereas, AMPK activation has been found to exert anti-apoptotic 
effects in a number of cell types including endothelial cells (Ido et al., 2002, Kim et al., 
2008, Liu et al., 2010).  To date nothing is known about how AMPK signalling could 
modulate the effects of the individual chlorinated and oxidised lipids used in this thesis 
within VSMCs.  Understanding these pathways better may improve the understanding of 
how these modified lipids are important in the progression of atherosclerosis. 
Furthermore, AMPK has been found to have an effect on vascular reactivity affecting both 
endothelial and VSM function.  AICAR induced vasorelaxation in mouse aortic rings, both 
in endothelium-intact and -denuded vessels, and was abolished in AMPKα1-/- mice 
suggesting AMPKα1 in VSM was responsible for this action (Goirand et al., 2007).  
Vasorelaxation to AICAR was also enhanced in spontaneously hypertensive rats compared 
to their normotensive controls and this effect was thought to be NO-dependent (Ford and 
Rush, 2011).  Due to the vascular remodelling which occurs as a result of atherosclerosis, 
the relaxant properties of VSM may be impaired.  OxLDL has been found to reduce 
endothelium-dependent relaxation to acetylcholine in rabbit aorta and coronary arteries by 
affecting the vasodilator function (Simon et al., 1990, Buckley et al., 1996).  Together, this 
suggests there could be a dysregulation of AMPK signalling in vascular disease with little 
known to date about the influence of AMPK in modulating the effects of modified lipids in 
VSM. 
4.1.1 Aims 
The aims investigated in this chapter were: 
 To examine the effect of AMPK activation or inhibition on VSMC proliferation, 
viability and protein expression. 
 To investigate the interaction of AMPK signalling and modified lipids on VSMC 
proliferation, viability and protein expression. 
 To determine the effect of modified lipid incubation on AICAR-induced relaxation 
in VSM.  
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4.2 Methods 
4.2.1 Smooth muscle proliferation 
A schematic diagram displaying the experimental protocol for all VSMCs experiments is 
shown in Figure 4.1.  Cell proliferation was assessed by determining the incorporation of 
BrdU into newly synthesised DNA using an ELISA kit (as detailed in Section 2.3.3).  In 
control experiments, the AMPK activator, 6,7-dihydro-4-hydroxy-3-(2’-hydroxy[1,1’-
biphenyl]-4-yl)-6-oxo-thieno[2,3-b]pyridine-5-carbonitrile (A-769662, Tocris Bioscience, 
Bristol, U.K.) or the AMPK inhibitor, 6-[4-2-piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-
yl-pyrrazolo[1,5-a]-pyrimidine (Compound C, Sigma Aldrich, Poole, U.K.) were incubated 
separately for 45 and 30 minutes respectively prior to stimulation with 10 % FCS and the 
addition of BrdU for 24 hours at 37 °C.  VSMCs were also pretreated with A-769662 and 
Compound C followed by incubation with modified lipids in the range of 1 to 100 µM for 
2 hours prior to stimulation with 10 % FCS and the addition of BrdU for 24 hours at 37 °C. 
4.2.2 Smooth muscle viability 
Cell viability was measured by the bioluminescent detection of cellular ATP (described in 
Section 2.3.4).  Similar to proliferation experiments, A-769662 and Compound C were 
incubated for 45 and 30 minutes respectively prior to stimulation with 10 % FCS for 24 
hours at 37 °C.  VSMCs were pretreated with A-769662 and Compound C (45 and 30 
minutes respectively) followed by incubation with modified lipids in the range of 1 to 100 
µM for 2 hours prior to stimulation with 10 % FCS for 24 hours at 37 °C. 
4.2.3 Western blotting 
Expression of AMPKα and ACC was measured by Western blot analysis as detailed in 
Section 2.4.  VSMCs were seeded in 6 well plates and grown to 80 % confluency before 
quiescing in 0.1 % FCS for 24 hours.  Cells were incubated with A-769662, Compound C 
or 25 µM of the modified lipids for 45 minutes, 30 minutes or 2 hours respectively.  Cells 
were also pretreated with A-769662 or Compound C prior to the incubation of modified 
lipids for 2 hours.  Following exposure to the different reagents, VSMC lysates were 
prepared and protein estimation analysis was carried out with the addition of 10 µg of 
protein per well.  Immunoblotting was then performed with antibodies against AMPKα, 
ACC and the loading control, GAPDH (all antibody dilutions found in Table 2.1) then 
densitometrical analysis was performed. 
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Figure 4.1 – Schematic diagram of in vitro VSMC experiments for AMPK activation 
or inhibition prior to modified lipid incubation. 
Rabbit aortic VSMCs were treated with AMPK activator, A-769662 or AMPK inhibitor, 
Compound C for 45 or 30 minutes respectively, followed by the modified lipid treatment for 
2 hours in quiescing medium.  Bullet point represents point at which the experiment was 
performed. 
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4.2.4 Small vessel wire myography 
Mouse carotid arteries were cut into 2 mm segments and mounted on two 40 µm diameter 
wires in a small artery wire myograph as detailed in Section 2.5.  Arterial rings were 
maintained in Krebs’ solution at 37 °C and gassed continuously with 95 % O2 and 5 % 
CO2.  Following a 30 minute equilibration period, the vessels were set to a predetermined 
optimal tension of 0.25 g.  Viability of arterial segments was measured with 40 mM KCl.  
Following this, the vessels were washed and incubated with either 25 µM of the modified 
lipid or vehicle for 30 minutes and then pre-constricted with U46619 for a further 30 
minutes.  A cumulative concentration-response curve to AICAR was then performed at a 
concentration range from 1x10
-4
 M to 1x10
-2
 M at 10 minute intervals (Figure 4.2). 
 
 
 
Figure 4.2 – Representative myography recording for AICAR-induced relaxation. 
Mouse carotid arteries were incubated either in the presence or absence of modified lipids 
at 25 µM for 30 minutes.  The vessels were then contracted to U46619 for a further 30 
minutes.  AMPK activator, AICAR, was then added at 10 minute intervals at increasing 
concentrations from 1x10-4 to 1x10-2 M. 
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4.2.5 Statistical analysis 
All results are presented as mean ± SEM and n represents the number of independent 
experiments performed.  Data were analysed using a one-way ANOVA followed by either 
a Dunnett’s post hoc test for control experiments or a Newman-Keuls’ post hoc test for 
Western blotting analysis, a two-way ANOVA for comparison of AMPK treatment and 
modified lipids with modified lipids alone and for comparison of the cumulative 
concentration response curves to AICAR, and a paired Student’s t-test for the U46619 
contraction. 
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4.3 Results 
4.3.1 Effect of AMPK activation or inhibition in VSMCs 
The effects of AMPK activator, A-769662 and inhibitor, Compound C on VSMC 
proliferation and viability were investigated in VSMCs by incubating for 45 and 30 
minutes respectively (Figure 4.3).  Vehicle treatment (1 % (v/v) DMSO) in quiescing 
medium had no effect on either VSMC proliferation or viability.  AMPK activation with 
A-769662 for 45 minutes prior to stimulation with 10 % FCS had no effect on either 
VSMC proliferation or viability.  However, Compound C alone caused an inhibition of 
proliferation at 40 µM with only 16.4 ± 7.2 % proliferating cells but had no effect on 
viability with 81.2 ± 9.2 % of viable cells present.  In contrast, at 100 µM, Compound C 
appeared to have toxic effects with only 0.9 ± 0.9 % of proliferating cells and 3.0 ± 1.2 % 
of viable cells present. 
The effects of 10 µM of AMPK activator, A-769662 and inhibitor, Compound C on 
expression of phosphorylated and total AMPKα and its downstream target, ACC by 
immunoblotting were next investigated.  Inhibition of AMPK with Compound C was also 
investigated by treatment for 30 minutes prior to the AMPK activators, A-769662 or 
AICAR.  Graphs are expressed as the fold change of the phosphorylated form of the 
enzyme over the total amount giving an indication of activity of either enzyme (Figure 
4.4).  Phosphorylation of ACC causes enzyme inhibition, thus limiting the pathway to fatty 
acid synthesis.  Vehicle treatment (1 % DMSO) in quiescing medium had no effect on 
either AMPKα or ACC phosphorylation in VSMCs.  There was also no effect on AMPKα 
observed after incubation with any of the AMPK activators or the inhibitor.  In contrast, 
changes in relative expression of ACC were seen following incubations with A-769662 
and in the presence of Compound C.  A-769662 caused about a 2-fold increase in the ratio 
of ACC compared to the control while Compound C pretreatment did not affect this 
increase.  AMPK inhibition by Compound C alone had no effect on the relative ACC 
expression but significantly reduced the relative ratio of ACC in comparison to the 
phosphorylation induced by A-769662.  Similarly, AMPK inhibition prior to AMPK 
activation by AICAR caused a significant reduction in the relative ACC expression 
compared to the same conditions with A-769662.  The concentration selected for all 
subsequent VSMC experiments was 10 µM for both agents as A-769662 and Compound C 
induced an activation or inhibition of AMPK respectively but had no effect alone on 
VSMC proliferation and viability at this concentration. 
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Figure 4.3 – Effect of AMPK activation or inhibition on VSMC proliferation and 
viability. 
BrdU incorporation (A and C) and detection of ATP (B and D) were utilised to measure 
VSMC proliferation and viability respectively.  Increasing concentrations of AMPK 
activator, A-769662 (A and B) and inhibitor, Compound C (B and D) were incubated for 45 
and 30 minutes respectively and then stimulated with 10 % FCS for 24 hours.  V = vehicle 
(1 % DMSO in quiescing medium).  ***p<0.001 vs 10 % FCS control, n = 3 and performed 
in triplicate. 
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Figure 4.4 – Effect of AMPK activators and inhibitors on AMPKα and ACC 
expression in VSMCs. 
VSMCs were incubated with vehicle of 1 % DMSO, AMPK activator, A-769662 (10 µM) or 
AMPK inhibitor, Compound C (10 µM) for 45 and 30 minutes respectively.  Compound C 
was also incubated for 30 minutes prior to incubation with AMPK activators, A-769662 or 
AICAR.  Graphs are expressed as the fold change of the phosphorylated form of each 
enzyme divided by the total amount of AMPKα (B) and ACC (C) to measure the activation 
of the enzyme.  Blots shown are representative (A).  *p<0.05 and **p<0.01 vs control, 
††p<0.01 and †††p<0.001 vs A-769662, ‡‡p<0.01 vs Compound C + A-769662, n = 3. 
VehicleA-769662Compound C + A-769662Compound CCompound C + AICAR
0
1
2
3
Vehicle
A-769662
Compound C + A-769662
Compound C
Compound C + AICAR
P
h
o
s
p
h
o
/T
o
ta
l 
A
M
P
K

VehicleA-769662Compound C + A-769662Compound CCompound C + AICAR
0
1
2
3
Vehicle
A-769662
Compound C + A-769662
Compound C
Compound C + AICAR
P
h
o
s
p
h
o
/T
o
ta
l 
A
C
C
A-769662 - - + + - -
Compound C
AICAR
-
-
-
-
-
-
+
-
+
-
+
+
A-769662 - - + + - -
Compound C
AICAR
-
-
-
-
-
-
+
-
+
-
+
+
PhosphoAMPKα
GAPDH
Total AMPKα
Phospho ACC
Total ACC
A
B
C **
*
††
†††
‡‡
‡‡
Chapter 4 – Impact of AMPK Signalling on the Effects of Modified Lipids 
102 
 
4.3.2 Effect of AMPK activation or inhibition prior to modified lipid 
treatment on VSMC proliferation and viability 
To determine if AMPK activation or inhibition prior to incubation of modified lipids could 
modulate the effects witnessed in VSMCs in Chapter 3, the effect of activation of AMPK 
by A-769662 or inhibition with Compound C prior to modified lipid treatment was 
investigated.  In all experiments, a concentration of 25 µM was selected for each of the 
modified lipids as it caused biological effects whilst retaining cell viability (described fully 
in Chapter 3).  The effects of the full range of concentrations of both chlorinated and 
oxidised lipids after AMPK activation or inhibition are presented in Table 4.1 and 4.2 
respectively. 
At 25 µM, the chlorinated lipids, SOPC ClOH and 2-ClHDA, alone had no effect on either 
VSMC proliferation or viability.  With AMPK activated prior to chlorinated lipid 
treatment, there was a significant increase in VSMC proliferation with SOPC ClOH 
showing 139.9 ± 17.2 % of proliferating cells compared to 98.5 ± 2.7 % with SOPC ClOH 
alone (Figure 4.5).  However, SOPC ClOH treatment had no effect on cell viability while 
2-ClHDA had no consequence on either viability or proliferation.  Oxidised phospholipids, 
PGPC and POVPC, caused a concentration-dependent reduction in VSMC proliferation 
and viability although at 25 µM POVPC, there was not a significant decrease.  When 
AMPK was activated prior to 2 hour treatment with PGPC, there was no significant 
difference on VSMC proliferation or viability compared to the lipid alone (Figure 4.6).  In 
contrast, AMPK activation prior to POVPC incubation caused a significant reduction in 
both VSMC proliferation and viability with 52.8 ± 7.8 % of viable cells present compared 
with 83.0 ± 6.0 % of viable cells with 25 µM of the lipid alone.  Thus, AMPK activation 
increased the susceptibility of VSMCs to POVPC-induced inhibition of proliferation while 
prior AMPK activation stimulated SOPC ClOH-induced proliferation in VSMCs. 
When AMPK was inhibited prior to chlorinated lipid treatment, there was no effect on 
VSMC proliferation but a significant increase was observed in VSMC viability after 2-
ClHDA treatment compared with incubation of the lipid alone (Figure 4.7).  When AMPK 
was inhibited prior to oxidised phospholipid treatment, there was no further effect seen 
with PGPC incubation but a further significant reduction with POVPC incubation in both 
VSMC proliferation and viability with 56.5 ± 9.4 % of proliferating cells, compared with 
83.0 ± 6.0 % with POVPC alone, was seen (Figure 4.8). 
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Figure 4.5 – Effect of AMPK activation prior to 2 hour chlorinated lipid treatment on 
VSMC proliferation and viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  VSMCs were incubated for 45 minutes with AMPK 
activator, A-769662 prior to 2 hours treatment with 25 µM SOPC ClOH or 2-ClHDA in 
quiescing media and then stimulated with 10 % FCS for 24 hours with the addition of BrdU 
in proliferation measurements.  **p<0.01 vs SOPC ClOH alone, n = 4-6 and performed in 
triplicate. 
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Figure 4.6 – Effect of AMPK activation prior to 2 hour oxidised phospholipid 
treatment on VSMC proliferation and viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  VSMCs were incubated for 45 minutes with AMPK 
activator, A-769662 prior to 2 hours treatment with 25 µM PGPC or POVPC in quiescing 
media and then stimulated with 10 % FCS for 24 hours with the addition of BrdU in 
proliferation measurements.  *p<0.05 and **p<0.01 vs POVPC alone, n = 4-6 and 
performed in triplicate. 
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Figure 4.7 – Effect of AMPK inhibition prior to 2 hour chlorinated lipid treatment on 
VSMC proliferation and viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  VSMCs were incubated for 30 minutes with AMPK 
inhibitor, Compound C prior to 2 hours treatment with 25 µM SOPC ClOH or 2-ClHDA in 
quiescing media and then stimulated with 10 % FCS for 24 hours with the addition of BrdU 
in proliferation measurements.  n = 3-6 and performed in triplicate. 
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Figure 4.8 – Effect of AMPK inhibition prior to 2 hour oxidised phospholipid 
treatment on VSMC proliferation and viability. 
BrdU incorporation (A) and detection of ATP (B) were utilised to measure VSMC 
proliferation and viability respectively.  VSMCs were incubated for 30 minutes with AMPK 
inhibitor, Compound C prior to 2 hours treatment with 25 µM PGPC or POVPC in 
quiescing media and then stimulated with 10 % FCS for 24 hours with the addition of BrdU 
in proliferation measurements.  *p<0.05 and **p<0.01 vs POVPC alone, n = 3-6 and 
performed in triplicate. 
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Table 4.1 – Percentage of proliferating or viable VSMCs after AMPK activation or 
inhibition prior to 2 hour incubation with increasing concentrations of chlorinated 
lipids. 
  
Chlorinated Lipid Concentration (µM) 
Treatment Assay 
type 
1 10 25 50 100 
SOPC ClOH BrdU 101.4 ± 
2.1 
98.4 ± 3.8 98.5 ± 2.7 96.1 ± 1.3 95.0 ± 4.0 
 ATP 106.3 ± 
2.4  
107.7 ± 
3.5 
102.9 ± 
3.6 
98.5 ± 4.1 96.3 ± .7 
A-769662 + 
SOPC ClOH 
BrdU 142.1 ± 
11.1** 
141.5 ± 
14.6*** 
139.9 ± 
17.2** 
140.7 ± 
16.2*** 
116.4 ± 
9.5 
 ATP 120.2 ± 
12.1 
120.6 ± 
9.0 
116.9 ± 
8.3 
114.0 ± 
13.5 
101.5 ± 
15.5 
Compound C 
+ SOPC ClOH 
BrdU 109.0 ± 
17.5 
117.4 ± 
8.4 
98.2 ± 6.6 132.4 ± 
24.9 
109.9 ± 
17.1 
ATP 112.1 ± 
10.3 
117.1 ± 
10.9 
118.7 ± 
10.2 
112.0 ± 
14.2 
114.2 ± 
10.1 
2-ClHDA BrdU 100.4 ± 
2.9 
96.1 ± 4.4 103.0 ± 
5.2 
99.8 ± 6.6 97.1 ± 7.7 
 ATP 101.8 ± 
1.7 
98.3 ± 3.8 97.1 ± 3.4 103.0 ± 
2.9 
101.0 ± 
3.4 
A-769662 + 
2-ClHDA 
BrdU 105.1 ± 
10.1 
110.5 ± 
7.8 
111.6 ± 
8.6 
117.3 ± 
14.2 
85.9 ± 
15.5 
 ATP 108.6 ± 
4.0 
118.4 ± 
3.4‡‡ 
117.9 ± 
5.2‡‡ 
112.6 ± 
5.0 
113.1 ± 
6.7 
Compound C 
+ 2-ClHDA 
BrdU 99.3 ± 2.6 89.0 ± 1.8 86.2 ± 8.3 83.7 ± 
13.1 
93.3 ± 
22.3 
 ATP 110.5 ± 
8.5 
110.1 ± 
4.7 
118.2 ± 
10.9 
118.3 ± 
8.3 
114.4 ± 
8.9 
All valves are a percentage of 10 % FCS control.  **p<0.01 and ***p<0.001 vs SOPC 
alone, ‡‡p<0.01 vs 2-ClHDA alone, n = 3-6 and performed in triplicate. 
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Table 4.2 – Percentage of proliferating or viable VSMCs after AMPK activation or 
inhibition prior to 2 hour incubation with increasing concentrations of oxidised 
phospholipids. 
  
Oxidised Phospholipid Concentration (µM) 
Treatment Assay 
type 
1 10 25 50 100 
PGPC BrdU 103.5 ± 
3.8 
103.0 ± 
5.9 
53.4 ± 5.8 24.4 ± 4.6 0.2 ± 1.0 
 ATP 100.2 ± 
3.8 
88.5 ± 6.1 53.8 ± 4.7 17.6 ± 6.5 0.5 ± 3.1 
A-769662 + 
PGPC 
BrdU 115.5 ± 
10.2 
88.5 ± 
11.8 
42.8 ± 6.4 14.0 ± 4.6 -0.24 ± 0.4 
 ATP 104.6 ± 
2.4 
86.8 ± 8.2 46.5 ± 5.7 10.5 ± 1.6 0.7 ± 0.2 
Compound C 
+ PGPC 
BrdU 97.0 ± 4.2 82.3 ± 
12.3 
55.7 ± 6.4 27.6 ± 5.1 2.5 ± 2.0 
ATP 99.7 ± 9.8 90.3 ± 
13.6 
54.9 ± 
16.6 
15.3 ± 8.9 2.3 ± 1.2 
POVPC BrdU 107.5 ± 
9.9 
104.1 ± 
4.5 
98.4 ± 8.3 83.0 ± 7.9 58.2 ± 
11.3 
 ATP 99.9 ± 4.1 97.1 ± 4.3 83.0 ± 6.0 64.1 ± 8.5 39.7 ± 
10.5 
A-769662 + 
POVPC 
BrdU 112.9 ± 
7.9 
100.3 ± 
14.0 
60.5 ± 
15.5** 
36.0 ± 
16.3*** 
7.7 ± 
4.5*** 
 ATP 111.7 ± 
6.9 
102.8 ± 
10.1 
52.8 ± 7.8 23.8 ± 7.2 7.6 ± 3.3 
Compound C 
+ POVPC 
BrdU 97.7 ± 9.7 83.9 ± 4.5 56.5 ± 9.4 27.9 ± 3.0 9.4 ± 2.5 
 ATP 100.5 ± 
4.6 
84.9 ± 4.2 54.7 ± 
3.0** 
27.1 ± 
5.4*** 
7.6 ± 3.5** 
All valves are a percentage of 10 % FCS control.  **p<0.01 and ***p<0.001 vs POVPC 
alone, n = 3-6 and performed in triplicate. 
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4.3.3 Effect of AMPK activation or inhibition prior to modified lipid 
incubation on AMPKα and ACC expression 
To investigate the effects of modified lipids on the relative protein expression of AMPKα 
and its downstream target, ACC, AMPK was activated with A-769662 for 45 minutes or 
inhibited with Compound C for 30 minutes in VSMCs, followed by 2 hours treatment with 
each of the modified lipids then Western blotting was performed.  Each of the graphs are 
expressed as the fold change of the phosphorylated form over the total amount of the 
enzyme. 
There was no effect on the relative expression of AMPKα under any conditions with any 
incubation of either class of modified lipids.  In contrast, A-769662, in the presence and 
absence of SOPC ClOH, caused a trend towards an increase in the ratio of ACC but this 
was not significant (Figure 4.9).  SOPC ClOH alone had no effect but there was a 
significant reduction in the ratio of ACC with AMPK inhibition followed by incubation 
with SOPC ClOH compared with VSMCs treated in the same way with A-769662.  Similar 
to SOPC ClOH, A-769662, in the presence and absence of 2-ClHDA, again caused a trend 
towards an increase in the relative expression of ACC but this was not significant (Figure 
4.10).  2-ClHDA had no effect on ACC expression alone which was similar for Compound 
C alone or with the inhibitor prior to 2-ClHDA incubation. 
There was an apparent 2-fold increase in the relative ratio of ACC expression in VSMCs 
with A-769662 treatment and a significant 2.5-fold increase with A-769662 treatment 
followed by PGPC incubation; this was significant compared to the untreated control 
(Figure 4.11).  PGPC incubation alone had no effect on the relative ratio of phosphorylated 
to total ACC expression which was similar for Compound C alone or with the inhibitor 
prior to PGPC incubation.  A-769662, in the presence or absence of POVPC, caused an 
increase in the ratio of ACC expression; this was only significant for the combination of 
the activator and oxidised phospholipid (Figure 4.12).  Similar to the rest of modified 
lipids, POVPC alone had no effect on the relative ACC expression as did Compound C and 
the inhibitor followed by POVPC. 
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Figure 4.9 – Effect of AMPK activation and inhibition prior to 2 hour SOPC ClOH 
incubation on AMPKα and ACC expression. 
VSMCs were incubated with A-769662 or Compound C alone or prior to 25 µM SOPC 
ClOH treatment for 2 hours in quiescing medium after which the cells were lysed and 
immunoblotting was performed.  Graphs are expressed as the fold change of the 
phosphorylated form of each enzyme divided by the total amount of AMPKα (B) and ACC 
(C) to measure the activation of the enzyme.  Blots shown are representative (A).  *p<0.05 
vs A769662 + SOPC ClOH, n = 3. 
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Figure 4.10 – Effect of AMPK activation and inhibition prior to 2 hour 2-ClHDA 
incubation on AMPKα and ACC expression. 
VSMCs were incubated with A-769662 or Compound C alone or prior to 25 µM 2-ClHDA 
treatment for 2 hours in quiescing medium after which the cells were lysed and 
immunoblotting was performed.  Graphs are expressed as the fold change of the 
phosphorylated form of each enzyme divided by the total amount of AMPKα (B) and ACC 
(C) to measure the activation of the enzyme.  Blots shown are representative (A).  *p<0.05 
vs Compound C alone, †p<0.05 vs Compound C + 2-ClHDA, n = 3. 
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Figure 4.11 – Effect of AMPK activation and inhibition prior to 2 hour PGPC 
incubation on AMPKα and ACC expression. 
VSMCs were incubated with A-769662 or Compound C alone or prior to 25 µM PGPC 
treatment for 2 hours in quiescing medium after which the cells were lysed and 
immunoblotting was performed.  Graphs are expressed as the fold change of the 
phosphorylated form of each enzyme divided by the total amount of AMPKα (B) and ACC 
(C) to measure the activation of the enzyme.  Blots shown are representative (A).  
**p<0.01 vs control, †p<0.05 vs A-769662 + PGPC, n = 3. 
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Figure 4.12 – Effect of AMPK activation and inhibition prior to 2 hour POVPC 
incubation on AMPKα and ACC expression. 
VSMCs were incubated with A-769662 or Compound C alone or prior to 25 µM POVPC 
treatment for 2 hours in quiescing medium after which the cells were lysed and 
immunoblotting was performed.  Graphs are expressed as the fold change of the 
phosphorylated form of each enzyme divided by the total amount of AMPKα (B) and ACC 
(C) to measure the activation of the enzyme.  Blots shown are representative (A).  
**p<0.01 vs control, †p<0.05 vs A-769662 + POVPC, n = 3. 
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4.3.4 Effect of modified lipid incubation of AICAR-induced 
relaxation 
To determine if incubation of modified lipids altered vascular reactivity, the effect of 
modified lipid treatment on the AICAR-induced relaxation in mouse carotid arteries was 
assessed.  Firstly, the effect of modified lipid treatment on U46619-induced contraction 
was investigated in the vessels (Figure 4.13).  As with the in vitro VSMC experiments, 
chlorinated lipids, SOPC ClOH and 2-ClHDA, had no effect on the contraction to the 
thromboxane A2 receptor agonist, U46619, in the arterial rings.  Similar to the chlorinated 
lipids, POVPC treatment had no effect on the U46619-induced contraction but PGPC 
caused a significant reduction in contraction from 0.22 ± 0.04 g to 0.07 ± 0.01 g.  
Vasorelaxation was induced with increasing concentrations of the AMPK activator, 
AICAR (Figure 4.14).  Neither chlorinated lipid had any effect on the AICAR-induced 
relaxation.  In contrast, both oxidised phospholipids caused a concentration-dependent 
decrease in the relaxation to AICAR with PGPC abolishing almost all of the relaxation 
observed. 
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Figure 4.13 – Effect of modified lipid incubation on U46619-induced contraction in 
mouse carotid arteries. 
25 µM SOPC ClOH (A), 2-ClHDA (B), PGPC (C) and POVPC (D) were incubated for 30 
minutes prior to U46619-induced contraction in mouse carotid arteries performed using 
small vessel wire myography.  **p<0.01 vs control, n = 5-6. 
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Figure 4.14 – Effect of modified lipid incubation on AICAR-induced relaxation in 
mouse carotid arteries. 
Concentration-response curves to AICAR were produced by small vessel wire myography 
with 25 µM SOPC ClOH (A), 2-ClHDA (B), PGPC (C) and POVPC (D) incubated for 30 
minutes prior to U46619-induced contraction and relaxation to AICAR.  ***p<0.001 vs 
control, n = 5-6. 
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4.4 Discussion 
This study revealed for the first time the effects of AMPK signalling on the actions of 
individual modified lipids in VSM and on vascular reactivity with AICAR-induced 
relaxation in arterial rings.  Activation of AMPK prior to SOPC ClOH incubation resulted 
in increased VSMC proliferation while POVPC was found to reduce VSMC proliferation 
and cellular ATP under the same conditions.  Oxidised phospholipids also reduced 
AICAR-mediated vasorelaxation in mouse carotid arteries.   
The impact of AMPK signalling in CVD and in particular atherosclerosis is a relatively 
new concept with an increasing amount of research in the last ten years focussing on this 
area.  To confirm the presence and to investigate AMPK signalling in rabbit aortic VSM, 
Western blot analysis was utilised to measure phosphorylation of the threonine residue at 
position 172.  Also analysed by this technique was its downstream target, ACC which is 
deactivated by AMPK by the phosphorylation of the serine residue at position 79.  
Measurement of ACC phosphorylation provides further evidence of targeted AMPK 
activation as AICAR and A-769662 are not known to have any non-specific effects that 
could involve the activation of ACC at this phosphorylation site.  No effects were observed 
in the phosphorylation status of AMPKα with any of the AMPK activators or inhibitors in 
this experimental protocol.  In contrast, the AMPK activator, A-769662 increased the 
phosphorylation status of ACC by 2-fold while the AMPK inhibitor, Compound C had no 
effect.  This could result from the subsequent dephosphorylation of AMPK after activation 
of its downstream signalling pathway resulting in an observed change in phosphorylation 
of ACC and not AMPK as the activity of AMPK has been found to reduce 45 minutes after 
stimulation (Morrow et al., 2003).  Furthermore, inhibition of AMPK by Compound C had 
no effect on A-769662-induced phosphorylation of AMPKα.  This is consistent with a 
previous study in rat skeletal muscle cells which suggested that A-769662 abrogated the 
effect of Compound C (Benziane et al., 2009).  Compound C alters the conformation of the 
activation loop of AMPK preventing activation by this route; however, A-769662 activates 
AMPK both allosterically and by inhibiting its dephosphorylation therefore AMPK can 
still be phosphorylated in the presence of Compound C (Handa et al., 2011).  This would 
suggest that the length of experimental protocol was sufficient to stimulate AMPK 
signalling and highlights AMPK stimulation by the activator, A-769662. 
In contrast to the effects observed on phosphorylation, incubation with the potent activator, 
A-769662 had no effect on the proliferation or viability of rabbit aortic VSMCs.  This is in 
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contrast with previous studies where AMPK activation caused a concentration- and time-
dependent decrease in VSMC proliferation with AICAR (Igata et al., 2005).  This could be 
due to the different mechanisms by which the activators induce phosphorylation of AMPK 
as well as the different experimental protocols utilised.  In this study, AMPK was activated 
when VSMCs were in a quiescent state for 45 minutes and then stimulated with 10 % FCS 
medium for 24 hours while in the study by Igata et al. (2005), VSMCs were stimulated 
with either PDGF or FCS in the presence of AICAR for 4 days.  This suggests that the 
AMPK-mediated inhibition of VSMC proliferation is potentially dependent on the 
phenotypic state of the VSMCs where AMPK activation only inhibits growth in 
proliferating VSMCs and therefore has no lasting effects in quiescent cells.  In contrast, 
AMPK inhibition by Compound C caused cytostatic actions at 40 µM and cytotoxic effects 
at 100 µM in VSMCs.  Compound C is a cell-permeable potent agent which inhibits 
AMPK by competitively displacing ATP (Zhou et al., 2001).  It is found to block AMPK 
activity with an IC50 value in the range of 0.1 to 0.2 µM (Bain et al., 2007) and previous 
studies have found Compound C to inhibit proliferation of non-vascular cells including 
preadipocytes and glioma cells (Nam et al., 2008, Vucicevic et al., 2009).  Compound C 
has also recently been shown to inhibit VSMC proliferation and migration by an AMPK-
independent mechanism resulting in the inhibition of cell cycle progression in VSMCs 
(Peyton et al., 2011).  Similar to the action of AICAR, VSMCs were primarily arrested in 
the G0/G1 phase of the cell cycle after Compound C treatment and this was linked to 
altered expression and phosphorylation of various cell cycle regulatory proteins such as 
cyclin A and D1 (Peyton et al., 2011).  Peyton et al. (2011) also found Compound C to be 
cytostatic in VSMCs using a concentration range up to 10 µM.  Apoptosis has also been 
observed in other cell types at similar concentrations suggesting cell-specific effects of 
Compound C (Jin et al., 2009, Jang et al., 2010).  In this study, Compound C was 
cytostatic at 40 µM and cytotoxic at 100 µM suggesting a switch from cytostatic to 
cytotoxic effects of Compound C at higher concentrations in VSMCs thus, 10 µM was 
selected for all subsequent VSMC experiments in this study. 
AMPK signalling has previously been implicated in modulating the effects of modified 
lipids with activation of AMPK found to suppress oxLDL-induced macrophage 
proliferation and lessen the atherosclerotic burden in high fat fed ApoE
-/-
 mice (Ishii et al., 
2009, Li et al., 2010a).  In addition, AMPK activation has been found to exert anti-
apoptotic effects in a number of cell types including endothelial cells (Ido et al., 2002, Kim 
et al., 2008, Liu et al., 2010).  The impact of AMPK signalling on modulating the effects 
of individual modified lipids in VSMCs witnessed in Chapter 3 was subsequently 
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investigated in this study.  VSMCs stimulated with A-769662 prior to SOPC ClOH 
incubation caused a significant increase in proliferation, not mirrored in viability, and no 
effects were observed with 2-ClHDA on remodelling processes.  This suggests that AMPK 
activation prior to SOPC ClOH treatment results in the stimulation of proliferation 
pathways which SOPC ClOH cannot trigger alone.  AMPK activation prior to oxidised 
phospholipid treatment had no effect on PGPC-induced cell death but a greater effect was 
observed after POVPC treatment suggesting AMPK activation prior to POVPC incubation 
results in enhanced stimulation of cell death pathways than POVPC alone.  This could be a 
protective measure to clear damaged or dying cells, resulting from the action of oxidised 
phospholipids, faster via AMPK signalling.  Similar to the action of oxLDL, all of the 
individual modified lipids were found not to cause phosphorylation of AMPKα directly 
(Brito et al., 2009).  The study also found incubation of oxLDL and resveratrol together 
resulted in no AMPK activation suggesting oxLDL prevented the resveratrol-induced 
activation of AMPK (Brito et al., 2009).  This was not the case with the individual 
modified lipids used in this study.  In contrast, AMPK signalling has previously been 
found to be influential in atherosclerosis and lipid accumulation with activation reducing 
oxLDL-induced macrophage proliferation and foam cell formation (Ishii et al., 2009, Li et 
al., 2010a). 
In addition to the effects observed with modulation of AMPK in VSMCs, AICAR-
mediated AMPK activation resulted in a concentration-dependent relaxation of 
preconstricted denuded mouse carotid arteries.  As the murine arterial segments were 
denuded of endothelium, the effects witnessed are likely caused by the activation of 
AMPK in VSM.  AICAR concentrations used were within a range previously shown to 
activate AMPK in various tissues and induce AMPK phosphorylation (Morrow et al., 
2003, Nagata et al., 2003).  AMPK-induced relaxation has previously been shown in 
mouse aortic rings where almost complete relaxation was observed at 3x10
-3
 M AICAR 
after preconstriction to phenylephrine (Goirand et al., 2007).  However, relaxation induced 
by AICAR was only about 60 % of the U46619 contraction in this study.  This could be 
due to different vascular beds and contracting agents used as well as the differences in the 
administration of AICAR.  In this study, AICAR was added to the myograph bath at 10 
minutes intervals producing a cumulative concentration-response curve whereas in the 
study by Goirand et al. (2007), the response to AICAR was allowed to plateau before the 
next concentration was added thus their study protocol was significantly longer.  This is 
important as AICAR has previously been shown to increase the amount of phosphorylated 
AMPK in a time-dependent manner in rabbit and human aortic VSMCs (Igata et al., 2005), 
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suggesting if AICAR has longer to act then more AMPK is phosphorylated and this could 
account for the total relaxation of the aortic rings seen by Goirand et al. (2007). 
Due to the presence of lesions and accumulation of VSMC proliferation in the arterial wall, 
atherosclerotic vessels are not as susceptible to relaxation in comparison to healthy 
controls (Freiman et al., 1986, Shimokawa and Vanhoutte, 1989).  Atherosclerosis 
significantly reduces the relaxing capacity of arteries with impairment to both 
endothelium-dependent and -independent actions in arteries isolated from ApoE
-/-
 mice 
(Crauwels et al., 2003, d'Uscio et al., 2001).  These effects could be partly due to the 
increased concentrations of modified lipids in the vascular wall as oxLDL has been found 
to inhibit endothelial-dependent relaxation in pig and rabbit coronary arteries (Simon et al., 
1990, Buckley et al., 1996).  However, the contribution of individual modified lipids has 
not previously been investigated in relation to vascular reactivity.  Chlorinated lipids had 
no effect on U46619-induced contraction or on AICAR-induced relaxation of mouse 
carotid arteries.  In contrast, oxidised phospholipids caused a significant reduction in 
AICAR-relaxation with PGPC almost abolishing all the relaxation observed.  PGPC was 
also found to significantly reduce the U46619-mediated contraction while POVPC had no 
effect. This could be due to toxicity or a loss of viability of the VSM after oxidised lipids 
incubation.  Oxidised phospholipids have also previously been implicated in cellular 
calcium handling with low concentrations of PGPC and POVPC evoking increases in 
intracellular Ca
2+
 via transient receptor potential proteins which make up cationic channels 
in human embryonic kidney cells (Al-Shawaf et al., 2010).  This could potentially explain 
the differences in relaxation which were observed after incubation with oxidised 
phospholipids.  Similar to the effects witnessed in VSMCs in Chapter 3, PGPC had a 
greater impact on AICAR-induced relaxation compared to POVPC. 
Although the mechanism of AICAR-induced relaxation is presently unknown, this study 
suggests that the action is not dependent on the endothelium.  This is in further agreement 
with previously published work by Goirand et al. (2007), where to confirm their 
observations from endothelium intact and denuded vessels, rings of aorta were incubated 
with a NOS inhibitor and no significant change in the response to AICAR was seen.  These 
findings indicate that AICAR-mediated AMPK activation results in relaxation by a direct 
action on VSM.  Arterial relaxation can occur by alteration of the calcium handling 
machinery in VSMCs with hypoxia, known to activate AMPK, found to alter the 
phosphorylation/dephosphorylation cascade of SM MLC as well as interfering with Ca
2+
 
homeostasis by altering the regulation of potassium channels (Wardle et al., 2006, Thorne 
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et al., 2004).  Vascular remodelling including VSMC proliferation and migration and the 
reduced ability to alter vascular tone in the presence of oxidised phospholipids can lead to 
poor blood pressure regulation and therefore hypertension.  Since AMPK activation has 
been shown to have vasorelaxant effects on VSM, which is impaired in the presence of 
these modified lipids, it has emerged as a potential target for the treatment of 
atherosclerosis and hypertension. 
4.5 Conclusions 
In summary, AMPK activation by A-769662 had no effect on VSMC proliferation or 
viability whereas Compound C, which inhibits AMPK activity, caused cytostatic and 
cytotoxic effects in VSMCs at increasing concentrations.  Although the modified lipids 
used were found not to cause phosphorylation of AMPKα or its downstream target ACC 
directly, SOPC ClOH induced VSMC proliferation after AMPK was stimulated.  POVPC 
was found to reduce VSMC proliferation and cellular ATP under the same conditions.  In 
addition to the effects on VSMCs, oxidised phospholipids reduced AICAR mediated 
vasorelaxation in mouse carotid arteries with the greater effect seen using PGPC.  This is 
the first study to investigate AMPK signalling on the effects of individual modified lipids 
in VSM as well as utilising the more potent AMPK activator, A-769662.  This study also 
highlights the differing effects of modified lipid classes on vascular reactivity which is 
critical in atherosclerotic progression and the elevated blood pressures found in 
hypertension. 
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CHAPTER 5 
THE OCCURRENCE OF MODIFIED 
LIPIDS IN NEOINTIMA FORMATION 
IN MICE
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5.1 Introduction 
As atherosclerosis develops, advanced complex plaques are formed that protrude into the 
lumen of the vessel and can result in complete occlusion of the affected artery.  PCI is 
commonly utilised to alleviate the angina pain which is a consequence of the reduced 
lumen and restore blood flow through the atherosclerotic vessel.  PTCA is used for 
revascularisation by controlled inflation of a balloon to dilate the vessel either alone or in 
combination with deployment of a stent to provide a rigid scaffold; resulting in a widening 
of the lumen (Gruntzig et al., 1979, Sigwart et al., 1987).  The major limitation affecting 
the long-term success of all forms of PCI is restenosis, which is thought to be an 
exaggerated form of wound healing after vascular injury.  Restenosis is characterised by a 
recurrence of luminal narrowing resulting from neointimal hyperplasia and rapid vascular 
remodelling of the treated vessel.  The formation of neointima occurs by excessive VSMC 
proliferation and migration as well as the production of large amounts of ECM. 
The pathophysiology of restenosis involves a complex cascade of events.  The initial 
consequence of PCI is stretch of the entire artery and endothelial denudation.  Mechanical 
injury results in compression and damage to the atherosclerotic plaque and exposure of the 
pro-thrombogenic core to circulating blood.  This leads to recruitment of inflammatory 
cells by the expression of adhesion molecules on activated platelets and thrombus 
formation caused by the deposition of fibrin (Libby and Simon, 2001, Inoue and Node, 
2009).  These pro-inflammatory responses are sustained for several weeks following injury 
of the vessel (Libby et al., 1992).  Balloon-injured vessels show a significant increase in 
leukocyte adhesion 24 hours after injury in rabbit subclavian arteries, as well as up-
regulation of adhesion molecules such as P-selectin and VCAM-1 (Kennedy et al., 2000).  
There is also evidence of sustained inflammation with inflammatory cells remaining in 
close proximity to the stent struts in rabbit iliac arteries up to 28 days after placement 
(Kennedy et al., 2004, Coats et al., 2008).  In addition, increased leukocyte adhesion has 
been demonstrated ex vivo up to 28 days following surgery in a mouse wire injury model 
(Tennant et al., 2008).  The importance of circulating inflammatory cells was demonstrated 
in neutropaenic rabbits which had a significantly reduced extent of neointima formation 
after 28 days (Miller et al., 2001).  Stent deployment also results in neutrophil activation 
which is associated with neointimal thickening (Inoue et al., 2006). 
Disruption of the atherosclerotic plaque during PCI results in the exposure of the modified 
lipid-containing core to circulating blood and the other components of the lesion.  The 
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presence of extravasated leukocytes such as neutrophils within the lesion could lead to an 
increase in the production of modified lipids such as chlorinated and oxidised species in 
the neointima by the action of the MPO system.  Arterial segments from ApoE
-/-
 mice 
treated in vitro with a phospholipid chlorohydrin formed by MPO, displayed an increase in 
leukocyte adhesion in a concentration-dependent manner as well as an increase in P-
selectin expression (Dever et al., 2008).  VSMC proliferation was also evident 24 hours 
after the topical application of oxidised phospholipid, POVPC to mouse carotid arteries in 
vivo (Johnstone et al., 2009).  Furthermore, an increase in the presence of MPO and HOCl-
modified proteins was found to correlate with an increase in the intima-to-media ratio in 
human iliac arteries (Hazell et al., 2001).  HOCl was also found to mediate neointimal 
hyperplasia in a time- and dose-dependent matter, initially causing apoptosis followed by 
vascular proliferation in a rat model of balloon injury (Yang et al., 2006).  The total plasma 
cholesterol level in ApoE
-/-
 mice was also found to be markedly elevated after carotid 
balloon injury which was in parallel with neointima formation (Matter et al., 2006). 
In addition, AMPK, an enzyme involved in cellular energy homeostasis, has been 
implicated in vascular disease.  In the previous chapter, AMPK signalling was found to 
alter the effects of modified lipids on vascular remodelling processes.  In addition, mice 
deficient in AMPKα2 had a dramatic increase in the formation of neointima after wire 
injury of the carotid artery compared to wild type controls and a reduction in AMPK 
activity also led to an increase in neointima development after arterial injury (Song et al., 
2011, Yu et al., 2012).  Taken together, this suggests that inflammation in the vessel 
following injury may induce lipid modification which drives the proliferative response.  
One possible mechanism for this response is via alterations in VSM AMPK signalling and 
to date this link between modified lipids and AMPK has not been investigated in an in vivo 
model of vascular injury. 
5.1.1 Aims 
The aims investigated in this chapter were: 
 To determine the extent of neointima formation after carotid artery injury in mice. 
 To investigate the occurrence of modified lipids in neointima formation in 
C57BL/6 and ApoE
-/-
 mice. 
 To assess the role of AMPK in neointima formation.  
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5.2 Methods 
5.2.1 Carotid artery injury 
Male C57BL/6 mice on normal chow and male ApoE
-/-
 mice at 8 to 10 weeks of age 
(weighing between 21 and 30 g) were fed on a high fat diet for 2 weeks prior to the 
vascular injury surgery.  ApoE
-/-
 mice were continued on the high fat diet throughout the 
study period and all mice were weighed at the start of the procedure, at day 7 and at the 
end of the procedure.  Vascular injury was performed by isolation of the left common 
carotid artery and insertion of a modified flexible nylon wire as outlined in Section 2.6.3.  
Sham operated animals followed the same procedure without the insertion of the flexible 
nylon wire into the carotid artery.  At the end of the procedure, mice were sacrificed by an 
i.p. injection of 200 mg/kg of sodium pentobarbital (Euthatal).  Blood was collected by 
cardiac puncture into EDTA-coated tubes and centrifuged at 1500 x g for 10 minutes to 
produce plasma.  Heart, liver and spleen weights were also recorded at time of death. 
5.2.2 MPO assay 
The MPO content of the plasma from sham-operated and injured C57BL/6 and ApoE
-/-
 
mice was analysed using a mouse MPO ELISA kit as described in Section 2.6.6.  Samples 
were diluted 1 in 16 in dilution buffer and the assay was performed as per the 
manufacturer’s instructions.  Absorbance was measured spectrophotometrically at 450 nm. 
5.2.3 Histology 
Carotid artery and aorta sections were processed, cut and stained as detailed in Section 2.7.  
Vessels from the sham-operated and injured animals were excised immediately after death 
and placed in neutral buffered formalin overnight.  Arteries were processed through a 
gradient of alcohols to Histoclear and embedded vertically in paraffin wax before being cut 
into 4 µm sections.  H&E staining was performed to assess the extent of neointima 
formation.  Immunohistochemistry was utilised to investigate the composition of the 
neointima with antibodies against αSMA, Ki67 (a proliferation marker), active caspase 3 
(an indicator of apoptosis) as well as phosphorylated and total AMPKα.  Sections were 
analysed using Image-Pro® software and the intima-media thickness was measured to 
assess neointima formation after H&E staining.  The pixel density of positive DAB 
staining was calculated as a percentage of the neointimal area for quantification of the 
immunohistochemistry. 
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5.2.4 Detection of lipids in carotid arteries 
Lipids were extracted and analysed from the left and right carotid arteries of sham-
operated and injured C57BL/6 and ApoE
-/-
 mice as described in Section 2.8.  Vessels were 
incubated in equal volumes of methanol containing the antioxidant BHT, chloroform and 
an aqueous solution to extract lipids then dried under a steady flow of oxygen-free nitrogen 
gas.  Dried lipid extracts were reconstituted and further diluted in methanol.  For analysis 
using positive-ion mode, samples were diluted 1 in 50 for left injured carotids and 1 in 25 
for right carotids with 1 % aqueous formic acid in methanol and scans performed for PCs 
and SMs, PEs, cholesterol and cholesteryl esters.  Spectra, in the range of m/z 300-1000, 
were acquired for 2 minutes.  For analysis using negative-ion mode, samples were diluted 
1 in 5 for left injured carotids and 1 in 2.5 for right carotids with 10 % 5 mM ammonium 
acetate in methanol and scans performed for PIs and PSs.  Spectra in the range of m/z 300-
1000 were acquired for 4 minutes.  Samples were analysed by identifying consistent 
differences between spectra from different sample groups. 
5.2.5 Statistical analysis 
All results are displayed as mean ± SEM and n represents the number of mice used for 
each experiment.  Data were analysed using a one-way ANOVA followed by a Newman-
Keuls’ post hoc test for analysis of spectra and two-way ANOVA followed by 
Bonferroni’s post hoc test for all other measurements taken.  
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5.3 Results 
5.3.1 Extent of neointima formation in C57BL/6 and ApoE-/- mice 
after vascular injury 
Histological analysis of H&E stained sections was performed to assess the extent of 
neointimal growth in C57BL/6 and ApoE
-/-
 mice after the carotid artery injury procedure 
(Figure 5.1).  The contralateral right carotid artery was cut and stained as an uninjured 
control.  There was no significant difference in neointima formation observed between 
C57BL/6 sham-operated and injured carotid arteries.  However, there was a substantial 
increase in neointimal growth in injured vessels of ApoE
-/-
 mice compared to their sham-
operated counterparts.  In addition, there was a significant increase in the intima to media 
ratio in injured ApoE
-/-
 arteries compared to their C57BL/6 counterparts.  There was no 
difference in the circumference and therefore size of the carotid arteries which was 
calculated by measuring the EEL of the vessels (Figure 5.2).  In contrast, there was no 
evident injury in aorta of either strain or no atherosclerotic plaques were observed in the 
ApoE
-/-
 mice (Figure 5.3).  Body weight was monitored throughout the study and no 
differences were found between strains or between sham-operated and injured mice (Table 
5.1).  No differences in the whole heart weight were observed between C57BL/6 and 
ApoE
-/-
 mice, while liver weight was reduced in ApoE
-/-
 mice that underwent the vascular 
injury procedure compared to injured C57BL/6 mice.  There was also a marked increase in 
spleen weight in the injured group of ApoE
-/-
 mice in relation to their C57BL/6 injured 
controls. 
Table 5.1 – Body and organ weight measurements of C57BL/6 and ApoE-/- mice 
before and 14 days after carotid artery injury procedure. 
 C57BL/6 ApoE -/- 
Sham Injured Sham Injured 
Start weight (g) 25.4 ± 0.9 25.6 ± 0.8 23.9 ± 0.6 24.4 ± 0.5 
Final weight (g) 25.8 ± 1.0 26.1 ± 0.7 25.4 ± 0.8 24.5 ± 0.5 
Heart/Body weight (%) 0.49 ± 0.02 0.48 ± 0.02 0.48 ± 0.02 0.47 ± 0.02 
Liver/Body weight (%) 5.26 ± 0.25 5.74 ± 0.10 4.99 ± 0.20 5.18 ± 0.10‡ 
Spleen/Body weight (%) 0.37 ± 0.03 0.31 ± 0.01 0.42 ± 0.03 0.40 ± 0.02‡‡ 
Organ weight was taken as a percentage of the body weight.  ‡p<0.05 and ‡‡p<0.01 vs 
C57BL/6 injured, n = 6-10. 
Chapter 5 – Occurrence of Modified Lipids in Neointima Formation 
128 
 
 
Figure 5.1 – Neointimal growth in the carotid arteries of C57BL/6 and ApoE-/- mice 
after sham-operated and carotid artery injury procedure. 
Representative histological sections of the left and right common carotid arteries (LC and 
RC respectively) from sham-operated and injured C57BL/6 (A) and ApoE-/- mice (B) using 
H&E staining.  Nuclei appear blue/purple whereas cytoplasm is stained pink.  Neointimal 
growth in left carotid arteries after vascular injury was assessed as a ratio of intima to 
media thickness (C).  Scale bar = 100 µm, magnification x 10.  ‡‡p<0.01 vs C57BL/6 
injured, ††p<0.01 vs ApoE-/- sham, n = 3-4. 
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Figure 5.2 – Circumference of carotid arteries of sham-operated and injured 
C57BL/6 and ApoE-/- mice. 
The EEL was measured to calculate the circumference and therefore size of the carotid 
artery sections in sham-operated and injured C57BL/6 and ApoE-/- mice.  n = 3-4. 
 
 
 
Figure 5.3 – Aortic sections from C57BL/6 and ApoE-/- mice after carotid artery 
injury. 
Representative histological sections of aorta from injured C57BL/6 and ApoE-/- mice using 
H&E staining.  Nuclei appear blue/purple whereas cytoplasm is stained pink.  Scale bar = 
250 µm, magnification x 4. 
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5.3.2 Structural composition of neointima in C57BL/6 and ApoE-/- 
mice after vascular injury 
Due to the differences observed in neointimal growth between C57BL/6 and ApoE
-/-
 mice, 
the composition of the lesions in sham-operated and injured left common carotid arteries 
was investigated by immunohistochemistry.  The contribution of VSMCs was assessed by 
the presence of αSMA in the neointimal area (Figure 5.4).  No significant differences were 
observed between the sections of carotid arteries from mice in each treatment group; 
however, a trend towards an increase in αSMA was seen in sham-operated ApoE-/- mice 
compared to their C57BL/6 counterparts.  The effect of vascular injury on remodelling 
processes was also assessed by expression of the proliferative marker, Ki67 and the 
activity of the apoptosis marker, caspase 3.  There were no significant differences in the 
number of Ki67-positive cells in the neointima in either strain of mice or in the treatment 
groups (Figure 5.5).  Furthermore, there was minimal caspase 3 activity in the sham-
operated or injured carotid arteries in either strain of mice 14 days after procedure (Figure 
5.6). 
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Figure 5.4 – αSMA staining in left carotid arteries of sham-operated and injured 
C57BL/6 and ApoE-/- mice. 
Representative histological sections of left common carotid arteries (LC) from sham-
operated and injured C57BL/6 and ApoE-/- mice stained with anti-αSMA and 
counterstained with haematoxylin (A).  Positive immunoreactivity for αSMA was measured 
as a percentage of positive staining divided by the neointimal area (B).  Scale bar = 100 
µm, magnification x 10.  n = 3. 
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Figure 5.5 – Ki67 staining in left carotid arteries of sham-operated and injured 
C57BL/6 and ApoE-/- mice. 
C57BL/6 mouse spleen was utilised as a positive control for the anti-Ki67 antibody (A).  
Scale bar = 50 µm, magnification x 20.  Representative histological sections of left 
common carotid arteries (LC) from sham-operated and injured C57BL/6 and ApoE-/- mice 
stained with anti-Ki67 and counterstained with haematoxylin (B).  Scale bar = 100 µm, 
magnification x 10.  Positive immunoreactivity for Ki67 was measured as a percentage of 
positive staining divided by the neointimal area (C).  n = 3. 
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Figure 5.6 – Active caspase 3 staining in left carotid arteries from sham-operated 
and injured C57BL/6 and ApoE-/- mice. 
Representative histological sections of left common carotid arteries (LC) from sham-
operated and injured C57BL/6 and ApoE-/- mice stained with anti-active caspase 3 and 
counterstained with haematoxylin (A).  Positive immunoreactivity for active caspase 3 was 
measured as a percentage of positive staining divided by the neointimal area (B).  Scale 
bar = 100 µm, magnification x 10.  n = 3. 
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5.3.3 Occurrence of modified lipids in neointima formation after 
vascular injury 
The influence of vascular injury on the MPO content of plasma from healthy C57BL/6 
mice and ApoE
-/-
 mice fed on high fat diet for 1 month was investigated.  A dramatic 
increase in MPO levels in sham-operated ApoE
-/-
 mice compared to their C57BL/6 
counterparts was observed from 267.7 ± 18.0 ng/ml to 865.7 ± 117.2 ng/ml (Figure 5.7).  
This increase was mirrored in the injured mice with the MPO content of plasma at 934.3 ± 
74.5 ng/ml in ApoE
-/-
 mice compared to 219.7 ± 21.0 ng/ml in C57BL/6 mice. 
The distribution of several classes of phospholipids, present at various proportions in LDL 
particles including PCs, PEs, PSs and PIs as well as cholesterol and cholesteryl esters in 
uninjured right and injured left common carotid arteries were studied using ESMS.  The 
differences between the two strains of mice were investigated as well as the effect of 
carotid artery injury.  The percentage relative abundances of the signals detected from all 
phospholipid species in the left and right carotid arteries are displayed in Table 5.2 and 5.3 
respectively. 
Precursor ion scanning of m/z 184.1 in positive-ion mode is selective for SMs and PCs, the 
most abundant phospholipid in mammals, but showed no difference in distribution within 
individual samples in each group (Figure 5.8).  Lysolipids were present in all samples at 
m/z 496.7 (16:0) and 524.7 (18:0) with significantly higher proportions relative to other 
signals found in ApoE
-/-
 mice, especially in the sham-operated mice.  There was an 
apparent reduction in lysolipids present in the uninjured right carotid arteries compared to 
the left.  Furthermore, there was an elevation in the relative levels of PCs, m/z 758.9 
(16:0/18:2) and 786.9 (18:0/18:2) in the left carotid arteries of both sham-operated and 
injured ApoE
-/-
 mice which were reduced in the right carotid arteries to percentage values 
more similar to the C57BL/6 mice.  There also appears to be a trend towards an increase in 
m/z 810.9 (18:0/20:4) in relation to other signals in uninjured right carotid arteries of 
C57BL/6 mice compared to their injured counterparts.  In addition, relative levels of SM, 
m/z 787.9 (22:0) were significantly increased in the left carotid arteries of ApoE
-/-
 mice 
with a similar trend observed in the lipid extracts from the contralateral right arteries.  The 
spectra were then expanded between m/z 550 and 700 to display any changes in chain-
shortened PCs, which are breakdown products of phospholipid oxidation, as they could be 
masked by the high signal of native PCs and long-chain products (Figure 5.9).  Repeating 
signals were observed in the spectra at m/z 564, 592, 620, 648 and 676 at different 
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intensities within the groups suggesting a polyethylene contaminant as the peaks are 
separated by 28 Da and were, therefore, discounted from the analysis (Jaber and Wilkins, 
2005).  No detectable changes were observed in the formation of chain-shortened PCs in 
any of the sample groups. 
Neutral loss scans for 141.1 and 87 Da were performed to detect changes in PE and PS 
expression respectively (Figure 5.10 and Figure 5.11).  PEs and PSs were found at a much 
lower concentration than PCs and there was high signal to noise ratio in spectra in both left 
and right carotid artery samples.  Precursor ion scanning for m/z 241 in positive-ion mode 
is selective for PIs and found no significant changes across the groups (Figure 5.12).  
Although there were no significant changes across groups in the left carotid arteries of 
either strain of mice, there appeared to be an increase in relative intensity of the PI, m/z 
885.9 (18:0/20:4) in comparison with the uninjured right arteries.  In addition to the several 
classes of phospholipids, precursor ion scanning for m/z 369.1 was performed to detect 
cholesterol and cholesteryl esters present in the aortae (Figure 5.13).  The major product 
ion for each treatment group was m/z 369.6, indicating the dehydration product of 
protonated cholesterol.  No detectable changes were observed in the formation of 
cholesteryl esters in any of the sample groups. 
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Figure 5.7 – Effect of carotid artery injury on MPO plasma content of C57BL/6 and 
ApoE-/- mice. 
Blood samples were taken from each mouse at sacrifice by cardiac puncture into EDTA-
coated tubes.  Blood was centrifuged at 1500 x g for 10 minutes to produce plasma.  The 
MPO content of mouse plasma was measured by an ELISA and absorbance read 
spectrophotometrically at 450 nm.  ***p<0.001 vs C57BL/6 sham, ‡‡‡p<0.001 vs C57BL/6 
injured, n = 6. 
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Figure 5.8 – Detection of PCs and SMs from left and right carotid arteries of sham-
operated and injured C57BL/6 and ApoE-/- mice. 
Precursor ion scanning for m/z 184.1 by positive-ionisation ESMS was performed to 
identify PCs and SMs present in left and right common carotid arteries from C57BL/6 
sham-operated (A), C57BL/6 injured (B), ApoE-/- sham-operated (C) and ApoE-/- injured 
mice (D).  Individual spectra were overlaid to highlight any potential differences in 
distributions within and between groups.  n = 2-3. 
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Figure 5.9 – Detection of chain-shortened PCs from left and right carotid arteries of 
sham-operated and injured C57BL/6 and ApoE-/- mice. 
Precursor ion scanning for m/z 184.1 by positive-ionisation ESMS was performed to 
identify PCs present in left and right carotid arteries from C57BL/6 sham-operated (A), 
C57BL/6 injured (B), ApoE-/- sham-operated (C) and ApoE-/- injured mice (D).  Individual 
spectra were expanded between m/z 550 and 700 to focus on chain-shortened PCs and 
overlaid to highlight any potential differences in distributions within and between groups.  
n = 2-3. 
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Figure 5.10 – Detection of PEs from left and right carotid arteries of sham-operated 
and injured C57BL/6 and ApoE-/- mice. 
Neutral loss of 141.1 Da by positive-ionisation ESMS was performed to identify PEs 
present in left and right common carotid arteries from C57BL/6 sham-operated (A), 
C57BL/6 injured (B), ApoE-/- sham-operated (C) and ApoE-/- injured mice (D).  Individual 
spectra were overlaid to highlight any differences in distributions within and between 
groups.  n = 2-3. 
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Figure 5.11 – Detection of PSs from left and right carotid arteries of sham-operated 
and injured C57BL/6 and ApoE-/- mice. 
Neutral loss of 87 Da by negative-ionisation ESMS was performed to identify PSs present 
in left and right common carotid arteries from C57BL/6 sham-operated (A), C57BL/6 
injured (B), ApoE-/- sham-operated (C) and ApoE-/- injured mice (D).  Individual spectra 
were overlaid to highlight any differences in distributions within and between groups.  n = 
2-3. 
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Figure 5.12 – Detection of PIs from left and right carotid arteries of sham-operated 
and injured C57BL/6 and ApoE-/- mice. 
Precursor ion scanning of m/z 241 by negative-ionisation ESMS was performed to identify 
PIs present in left and right common carotid arteries from C57BL/6 sham-operated (A), 
C57BL/6 injured (B), ApoE-/- sham-operated (C) and ApoE-/- injured mice (D).  Individual 
spectra were overlaid to highlight any differences in distributions within and between 
groups.  n = 2-3. 
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Figure 5.13 – Detection of cholesterol and cholesteryl esters from left and right 
carotid arteries of sham-operated and injured C57BL/6 and ApoE-/- mice. 
Precursor ion scanning of m/z 369.1 by positive-ionisation ESMS was performed to 
identify cholesterol and cholesteryl esters present in left and right common carotid arteries 
from C57BL/6 sham-operated (A), C57BL/6 injured (B), ApoE-/- sham-operated (C) and 
ApoE-/- injured mice (D).  Individual spectra were overlaid to highlight any differences in 
distributions within and between groups.  n = 2-3. 
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Table 5.2 – Relative abundances of detected phospholipid species in left common 
carotid arteries of sham-operated and injured C57BL/6 and ApoE-/- mice. 
m/z 
(H) 
PL 
class 
Major 
species 
Relative abundance of ions (% of base peak) 
C57BL/6 
sham 
C57BL/6 
injured 
ApoE-/- 
sham 
ApoE-/- 
injured 
496.7 LPC 16:0 20.8 ± 3.4 21.0 ± 3.1 50.5 ± 3.3*** 35.5 ± 3.4†,‡ 
524.7 LPC 18:0 16.8 ± 1.3 11.0 ± 1.2 34.0 ± 1.0*** 22.3 ± 1.7†††,‡‡‡ 
703.9 SM 16:0 46.1 ± 3.0 34.8 ± 4.1 38.1 ± 1.4 31.3 ± 5.6 
732.9 PC 16:0/16:1 17.2 ± 1.5 18.7 ± 1.4 13.9 ± 0.9 11.5 ± 2.8 
734.9 PC 16:0/16:0 83.0 ± 4.7 73.5 ± 13.5 62.2 ± 3.0 52.0 ± 6.4 
758.9 PC 16:0/18:2 72.1 ± 7.1 84.6 ± 4.6 100 ± 0.0** 100 ± 0.0 
760.9 PC 16:0/18:1 71.0 ± 5.1 71.4 ± 6.4 74.8 ± 5.0 68.8 ± 8.0 
768.8 PE 18:0/20:4 22.4 ± 5.3 11.7 ± 6.6 19.7 ± 4.0 20.5 ± 9.9 
782.9 PC 16:0/20:4 100 ± 0.0 99.5 ± 0.5 81.5 ± 5.5 75.4 ± 11.3 
784.9 PC 18:0/18:3 26.6 ± 1.6 26.8 ± 0.6 27.0 ± 0.4 25.0 ± 3.1 
786.9 PC 18:0/18:2 41.4 ± 4.7 40.1 ± 1.0 60.8 ± 2.3** 65.3 ± 1.6‡‡ 
787.9 SM 22:0 12.8 ± 0.9 16.1 ± 1.01 22.2 ± 1.7** 23.7 ± 0.7‡‡ 
806.9 PC 16:0/22:6 24.7 ± 1.3 24.5 ± 0.4 22.1 ± 1.5 20.1 ± 2.3 
810.9 PC 18:0/20:4 69.1 ± 2.2 59.5 ± 3.1 52.0 ± 3.6 45.6 ± 9.6 
813.0 SM 24:1 9.7 ± 0.5 10.1 ± 0.6 8.4 ± 1.4 7.1 ± 1.8 
834.9 PC 18:0/22:6 10.0 ± 1.2 10.6 ± 0.2 7.8 ± 0.5 6.7 ± 1.2 
885.9 PI 18:0/20:4 23.6 ± 3.9 19.3 ± 13.8 23.9 ± 2.7 33.5 ± 11.1 
Relative abundances for each m/z value (protonated adduct ions) were calculated as a 
percentage of the largest peak in the individual spectra.  Significant differences in 
distribution of ions are highlighted in bold.  PL = phospholipid, LPC = 
lysophosphatidylcholine, ND = not detected.  ***p<0.001 vs C57BL/6 sham, ‡p<0.05 and 
‡‡‡p<0.001 vs C57BL/6 injured, †p<0.05 and †††p<0.01 vs ApoE-/- sham, n = 3. 
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Table 5.3 – Relative abundances of detected phospholipid species in right common 
carotid arteries of sham-operated and injured C57BL/6 and ApoE-/- mice. 
m/z 
(H) 
PL 
class 
Major 
species 
Relative abundance of ions (% of base peak) 
C57BL/6 
sham 
C57BL/6 
injured 
ApoE-/- 
sham 
ApoE-/- 
injured 
496.7 LPC 16:0 17.5 ± 0.9 16.5 ± 2.9 10.7 ± 1.3 15.4 ± 2.1 
524.7 LPC 18:0 8.4 ± 2.4 8.3 ± 2.1 5.1 ± 0.4 10.8 ± 0.0 
703.9 SM 16:0 36.1 ± 18.7 28.0 ± 8.1 19.9 ± 1.8 43.0 ± 1.8 
732.9 PC 16:0/16:1 17.4 ± 0.5 15.7 ± 1.3 11.3 ± 3.0 16.7 ± 0.2 
734.9 PC 16:0/16:0 60.3 ± 17.2 46.0 ± 13.4 29.5 ± 0.3 49.1 ± 1.3 
758.9 PC 16:0/18:2 76.4 ± 4.1 68.0 ± 2.5 63.1 ± 0.8 66.8 ± 5.2 
760.9 PC 16:0/18:1 75.6 ± 4.8 65.0 ± 2.8 67.4 ± 3.7 77.2 ± 6.5 
782.9 PC 16:0/20:4 100 ± 0.0 81.9 ± 7.1 100 ± 0.0 95.2 ± 4.9 
784.9 PC 18:0/18:3 28.1 ± 2.3 27.2 ± 0.0 31.3 ± 3.4 31.2 ± 1.6 
786.9 PC 18:0/18:2 39.4 ± 6.3 31.7 ± 2.5 43.4 ± 4.3 39.5 ± 1.7 
787.9 SM 22:0 11.5 ± 1.1 11.7 ± 0.3 16.1 ± 0.3 20.8 ± 0.5 
806.9 PC 16:0/22:6 24.5 ± 1.4 16.4 ± 2.2 23.0 ± 0.1 21.7 ± 2.2 
810.9 PC 18:0/20:4 56.7 ± 1.6 44.8 ± 5.1 63.6 ± 4.2 60.0 ± 0.8 
813.0 SM 24:1 12.2 ± 0.1 10.9 ± 1.3 10.5 ± 1.8 11.5 ± 1.1 
834.9 PC 18:0/22:6 7.6 ± 0.3 7.3 ± 0.3 10.4 ± 0.5 9.8 ± 0.8 
885.9 PI 18:0/20:4 4.6 ± 4.6 3.3 ± 0.9 5.0 ± 0.5 2.6 ± 2.6 
Relative abundances for each m/z value (protonated adduct ions) were calculated as a 
percentage of the largest peak in the individual spectra.  PL = phospholipid, LPC = 
lysophosphatidylcholine, ND = not detected.  n = 2. 
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5.3.4 Role of AMPK in neointima formation 
AMPK, involved in energy homeostasis, has been recently implicated in restenosis and 
therefore its expression in sham-operated and injured carotid arteries from the two mouse 
strains was studied.  The total amount of AMPKα was found to be elevated in injured 
carotid arteries in both strains but there was only a significant increase in sham-operated 
ApoE
-/-
 mice compared to their C57BL/6 counterparts (Figure 5.14).  In addition, there was 
minimal phosphorylated AMPKα present in the sham-operated or injured carotid arteries in 
either strain of mice 14 days after procedure.  However, there was a trend towards an 
increase in phosphorylation in the ApoE
-/-
 mice compared to the C57BL/6 mice (Figure 
5.15). 
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Figure 5.14 – Total AMPKα staining in left carotid arteries from sham-operated and 
injured C57BL/6 and ApoE-/- mice. 
Representative histological sections of left common carotid arteries (LC) from sham-
operated and injured C57BL/6 and ApoE-/- mice stained with anti-total AMPKα and 
counterstained with haematoxylin (A).  Positive immunoreactivity for total AMPKα was 
measured as a percentage of positive staining divided by the neointimal area (B).  Scale 
bar = 100 µm, magnification x 10.  n = 3-4. 
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Figure 5.15 – Phosphorylated AMPKα staining in left carotid arteries from sham-
operated and injured C57BL/6 and ApoE-/- mice. 
Representative histological sections of left common carotid arteries (LC) from sham-
operated and injured C57BL/6 and ApoE-/- mice stained with anti-phosphorylated AMPKα 
and counterstained with haematoxylin (A).  Positive immunoreactivity for phosphorylated 
AMPKα was measured as a percentage of positive staining divided by the neointimal area 
(B).  Scale bar = 100 µm, magnification x 10.  n = 3-4. 
C57BL/6 ApoE 
-/-
0
1
2
3
4
Sham
Injured
P
o
s
it
iv
e
 p
h
o
s
p
h
o
 A
M
P
K

 (
%
)
C57BL/6 sham LC
ApoE-/- sham LC
C57BL/6 injured LC
ApoE-/- injured LC
Blank
IgG
A
B
Chapter 5 – Occurrence of Modified Lipids in Neointima Formation 
148 
 
5.4 Discussion 
The present study characterises for the first time the phospholipid molecular species 
present in the carotid arteries of C57BL/6 and ApoE
-/-
 mice after carotid artery injury.  
Increased neointima formation was observed in injured ApoE
-/-
 mice compared with sham-
operated controls and healthy C57BL/6 mice treated in the same way.  Plasma MPO and 
LPCs were also found to be elevated in ApoE
-/-
 mice and vascular injury altered the 
relative proportions of several PCs present in the arterial wall of ApoE
-/-
 mice compared 
with C57BL/6 mice.  Total AMPK expression was also increased in sham-operated ApoE
-/-
 
mice compared to their C57BL/6 counterparts. 
After PCI and mechanical injury to the arterial wall, neointima formation occurs mainly by 
the proliferation and migration of VSMCs leading to a narrowing of the previously stenotic 
vessel.  In this study, the left common carotid artery was injured by insertion of a flexible 
nylon wire several times to cause endothelial denudation and then subsequently ligated.  
The same procedure was performed for the sham-operated mice without the insertion of 
the nylon wire.  This means there was mechanical injury to the carotid artery due to 
removal of the endothelium as well as stretching of the vessel.  The blood flow was also 
disrupted in this study due to ligation of the artery which has been utilised by many other 
studies and could induce unrelated compensatory mechanisms (Kumar and Lindner, 1997, 
Godin et al., 2000, Kawasaki et al., 2001).  However, vascular lesions in humans can 
develop at sites where haemodynamics are altered and are often associated with low shear 
stress (Ku et al., 1985).  In this study, neointima formation was dramatically increased in 
injured ApoE
-/-
 mice compared to their sham-operated controls, while no significant 
differences were observed in healthy C57BL/6 mice treated in the same way.  This 
observation has previously been seen following both wire and balloon injuries in ApoE
-/-
 
mice (Zhu et al., 2000, Grassia et al., 2009, Matter et al., 2006).  In addition, 
overexpression of human apoE3 transgene in mice resulted in a reduction in neointimal 
formation (Zhu et al., 2000).  This suggests that there is an increased susceptibility for 
neointima formation in mice deficient in apoE compared to healthy controls.  ApoE has 
previously been shown to exhibit cytostatic effects causing the inhibition of PDGF-induced 
VSMC proliferation and migration by growth arrest in the G0 phase of the cell cycle 
(Ishigami et al., 1998).  LDL receptor-related protein (LRP) has also been implicated in the 
enhanced rate of VSMC proliferation and migration found in atherosclerosis, as apoE was 
unable to inhibit PDGF-induced VSMC migration in VSMCs deficient in LRP (Swertfeger 
et al., 2002).  Together, this suggests that PDGF signalling is altered in ApoE
-/-
 mice which 
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may explain the significant increase in neointimal growth observed in injured carotid 
arteries of ApoE
-/-
 mice compared to their C57BL/6 controls.  As the flexible nylon wire 
was extended to the aortic arch and aorta, H&E staining was performed to examine any 
damage in this region.  No differences in the morphology of the aorta in either strain of 
mouse were seen or any atherosclerotic plaque formation in the ApoE
-/-
 mice.  This could 
be due to the length of time the mice were on the high fat diet; however the first signs of 
disease have previously been reported at 6 to 8 weeks without the high fat diet to accelerate 
the progression (Nakashima et al., 1994, Coleman et al., 2006).  The high levels of 
circulating cholesterol-containing lipoproteins could be deposited in the denuded area of 
the injured carotid artery as disruption of the endothelium is critical in the initiation of 
atherosclerotic plaque and foam cell formation. 
The structural composition of the neointima was investigated in both C57BL/6 mice and 
ApoE
-/-
 mice by immunohistochemistry.  No change in Ki67 or active caspase 3 expression 
was observed in the strain of mouse or in sham-operated or injured vessels.  This could be 
due to the small sample size available or the 14 day time point studied. Many studies 
investigating neointima formation have looked at different time points post-operation.  
Apoptosis was found to be elevated 1 hour and 1 day after balloon distension injury in 
ApoE
-/-
 mice while proliferation was increased 7 and 28 days post injury (Matter et al., 
2006).  An increase in VSMC apoptosis via a caspase 3 dependent mechanism was also 
upregulated 24 hours after procedure in balloon injured New Zealand white rabbits 
(Spiguel et al., 2010).  In contrast, cell proliferation was found to peak approximately 4 
days prior to the peak in apoptosis after angioplasty in atherosclerotic rabbits (Durand et 
al., 2002).  There was also evidence of apoptosis in patients undergoing either directional 
atherectomy for primary atherosclerotic lesions or recurrent arterial narrowing but it was 
typically limited to less than 2 % of cells in the specimen (Isner et al., 1995).  This study is 
in agreement, as minimal caspase 3 activity was detected 14 days after the vascular injury 
procedure.  In contrast, an increase in proliferation was still evident in these studies 14 
days after surgery.  In the present study, it must be remembered that the carotid arteries 
were injured as well as ligated causing a change in the haemodynamics of the vessel.  This 
in turn may have led to a faster response as mechanisms were occurring to compensate for 
both the change in vessel diameter as well as the removal of endothelium causing complete 
occlusion in a number of vessels.  In addition to markers of the remodelling processes, 
there was no change in αSMA between different strains of mice, between sham-operated or 
injured vessels with αSMA accounting for between 10 and 15 % of the neointimal area.  
Proliferation and migration of VSMCs is one of the hallmarks of restenosis resulting in 
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intimal thickening with both non-dividing and proliferating VSMCs contributing to the 
neointima (Clowes and Schwartz, 1985).  Quiescent VSMCs are normally maintained in a 
nonproliferative phase but become activated after mechanical injury to the arterial wall.  
There is a decrease in VSMC differentiation markers in intimal VSMCs 7 days after injury; 
this returns to normal levels by day 14 (Regan et al., 2000).  This phenotypic modulation 
of VSMCs after injury results in the increased propensity of these cells to proliferate and 
migrate resulting in neointima formation.  Although, there was no difference between 
strains of mice in the extent of αSMA present or proliferative index at day 14, the 
neointimal growth was greater in the injured ApoE
-/-
 mice suggesting that proliferation 
occurred at an earlier time point. 
In addition to the effects of vascular injury on VSMC remodelling processes, the lipid 
involvement in neointima formation in injured carotid arteries was investigated.  The 
enhanced inflammatory state after vascular injury results in recruitment of inflammatory 
cells such as neutrophils which could lead to an increase in the production of reactive 
oxidants and therefore modified lipids in the neointima by the action of the MPO system.  
The plasma MPO content was found to be elevated in ApoE
-/-
 mice compared to C57BL/6 
mice controls.  Incubation of MPO and its product, HOCl in a temporarily isolated carotid 
artery was found to induce neointima hyperplasia in a rat model (Yang et al., 2006).  In 
addition, HOCl-induced apoptosis, in both the intima and medial layers, was followed by a 
proliferative response (Yang et al., 2006).  In this study, only the plasma MPO was 
measured and therefore the levels in the neointima could be greater due to the infiltration 
of inflammatory cells at the site of injury leading to the secretion of MPO.  The levels of 
MPO have been shown to be elevated in human atherosclerotic plaques and therefore a 
similar effect could be found in restenotic lesions (Daugherty et al., 1994).  It would be 
beneficial to measure the levels of circulating neutrophils in C57BL/6 and ApoE
-/-
 mice to 
establish if this accounts for the elevation in plasma MPO. 
MPO is a known route for producing modified lipids in vivo; both chlorinated and oxidised 
species.  The distribution of several classes of phospholipids, including the main 
phospholipids present in LDL particles such PCs, PEs, PSs and PIs as well as cholesterol 
and cholesteryl esters was assessed in uninjured right and injured left common carotid 
arteries.  ESMS was utilised to detect different classes of modified lipids as precursor ion 
and neutral loss scanning allows the detection of certain types of phospholipids or oxidised 
products but does not specify individual species (Spickett et al., 2011).  Analysis of the 
injured and uninjured carotid arteries identified PCs, LPCs, SMs and PIs as well as 
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cholesterol present within the samples.  There were increased relative levels of lysolipids at 
m/z 496.7 and 524.7 in ApoE
-/-
 mice compared to the contralateral right carotid arteries 
and the C57BL/6 control mice.  Lysolipids have previously been found to be elevated in 
the intima and inner media of the atherosclerotic aorta of squirrel monkeys (Portman and 
Alexander, 1969).  Chlorohydrins of polyunsaturated phospholipids have been reported to 
break down readily to lysolipids (Arnhold et al., 2002).  Lysophosphatidylcholine has also 
been shown to stimulate expression of MCP-1 in rat aortic VSMCs as well as induce pro-
inflammatory cytokine production and recruitment of monocytes (Rong et al., 2002, 
Olofsson et al., 2008).  This could therefore lead to an exacerbated inflammatory response 
which in turn could increase the production of modified lipids within the atherosclerotic 
plaque as well as at the site of injury.  Phospholipid chlorohydrins have yet to be observed 
in diseased vessels in vivo while lysophosphatidylcholine-chlorohydrins have been 
detected in human atherosclerotic plaques with a 60-fold increase in human tissue 
compared to control (Messner et al., 2008b).  The precursor ion scan for m/z 184.1 
displayed roughly similar distribution of PCs and SMs between groups and contralateral 
carotid arteries; however, an increase in relative abundance of m/z 758.9 and 786.9 was 
observed in left carotid arteries of ApoE
-/-
 mice compared to injured C57BL/6 carotid 
arteries.  These peaks likely corresponds to the protonated adducts of PCs, 16:0/18:2 and 
18:0/18:2 respectively.  A trend towards an increase in m/z 810.9 in relation to other 
signals was also observed in the uninjured right carotid arteries of ApoE
-/-
 mice compared 
to their injured counterparts, corresponding to the protonated adduct of PC 18:0/20:4.  This 
suggests that injured carotid arteries are enriched with linoleoyl-containing PCs.  These 
unsaturated phospholipids could then undergo modification by MPO leading to an increase 
in modified lipids present at the site of injury.  There was also a relative increase in m/z 
787.9 in left carotid arteries of ApoE
-/-
 mice, which likely corresponds to the protonated 
adduct of SM 22:0.  Elevated levels of plasma SM have previously been shown to be a risk 
factor in CAD which is often associated with atherosclerosis (Jiang et al., 2000).  Chain-
shortened PCs were not detected which could be due to low concentrations compared to 
their native phospholipids within these samples or they may be metabolised or detoxified 
in vivo (Spickett et al., 2011).  Separation of oxidation products by coupling liquid 
chromatography to ESMS could provide more insight into their presence and role in 
neointima formation. 
Similarly to PCs and SMs, the distribution and proportions of PEs, PSs and PIs were also 
investigated.  There was a low signal to noise ratio in the spectra of PEs and PSs, 
suggesting that these phospholipids were present at low levels within both injured and 
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uninjured arteries; therefore it was not possible to obtain sufficiently adequate data to 
determine whether differences occurred between these groups.  There was an apparent 
relative increase in m/z 885.9 in injured vessels compared to their uninjured controls, 
corresponding to the protonated adduct of PI 18:0/20:4.  This suggests that increased levels 
of PIs are associated with lesion formation.  Moreover, precursor scanning of m/z 369.1 
was utilised for detection of cholesterol and cholesteryl esters present in carotid arteries of 
C57BL/6 and ApoE
-/-
 mice.  The protonated dehydration product of cholesterol, m/z 369.6, 
was consistently the largest peak in all samples.  Together, this highlights a difference in 
proportion of several phospholipids present in carotid arteries of ApoE
-/-
 mice after the 
vascular injury procedure compared to the uninjured contralateral artery and the healthy 
mice controls.  In addition, the detection of chlorinated lipids in the vessels was not 
performed due to time constraints.  The high levels of plasma MPO in ApoE
-/-
 mice would 
suggest an increase in the presence of HOCl-modified lipids in the vessels and further 
analysis of these samples would give a more complete indication of the occurrence of 
modified lipid species in the vascular wall. 
A limitation of the present study is the lack of internal or external standards in the ESMS 
analysis of the injured and uninjured carotid arteries.  Standards are commonly used as 
quantification of levels within samples by the addition of a lipid at a known concentration.  
Saturated lipids can also be used as a “base peak” in spectra for example m/z 734 (PC 
16:0/16:0), for comparison of peak intensities with signals from mono- and 
polyunsaturated lipids.  However, in these spectra m/z 734.9 was found to vary between 
samples and therefore not suitable for this role.  This could reflect the oxidation of 
polyunsaturated lipids such as m/z 758.9 and 782.9, therefore their intensity is reduced and 
the levels of saturated lipids (such as m/z 734.9) appear to fluctuate.  In contrast, there 
would be further limitations in using standards in these samples as the sizes of the arteries 
varied and were not weighed before lipid extraction, thus the lipid concentrations cannot be 
calculated.  The amount of lipid is likely to vary within the artery therefore, while 
standards may indicate the absolute concentration, all lipids should fluctuate depending on 
the total lipid content extracted.  Comparisons were made instead between the relative 
intensities of the lipids present in these samples, which allow information about changes in 
the lipid profile in the different strains and in response to treatments.  It should also be 
noted that ESMS is not a quantitative technique in itself, due to the different ionisation 
efficiencies of lipid classes, therefore PC levels cannot be directly compared with PEs or 
PSs, etc.  There is also further variation within the PC class as short chains ionise better 
than long chains.  However, all these differences should be the same between samples, thus 
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it is valid to look for changes in relative intensities and patterns between samples in this 
study. 
In addition to the modified lipids present in the neointima, AMPK has recently been 
implicated in vascular disease as it has been shown to suppress VSMC proliferation 
(Nagata et al., 2004, Igata et al., 2005, Peyton et al., 2011).  In the previous chapter, 
AMPK signalling was found to alter the effect of modified lipids on vascular remodelling 
processes.  In this study, total AMPKα was found to be significantly increased in 
neointimal growth in sham-operated ApoE
-/-
 mice compared to their C57BL/6 
counterparts.  This could be due to an increase in cell number within the neointima 
formation resulting in an increase in AMPK present.  Minimal phosphorylated AMPKα 
was detected in the neointimal sections; however, there was a trend towards an increase in 
the ApoE
-/-
 mice.  Deletion of the AMPKα2 subunit in mice has been shown to cause an 
increase in neointima formation and VSMCs derived from aorta of AMPKα2-/- mice were 
found to exhibit increased proliferation rate compared to wild type and AMPKα1-/- mice 
(Song et al., 2011).  In addition, decreased AMPK activity in VSMCs has been associated 
with receptor for advanced glycation endproducts (RAGE) ligand-induced signalling to 
promote neointima formation in mice (Yu et al., 2012).  Together, this suggests a 
protective role of AMPK in neointima formation and the elevation of total AMPK in 
neointima observed in this study could be a compensatory mechanism to combat the 
neointimal growth. 
5.5 Conclusions 
In summary, increased neointima formation was observed in injured ApoE
-/-
 mice 
compared to C57BL/6 mice and sham-operated controls, while there was no change in 
αSMA, Ki67 or active caspase 3 expression in any treatment groups 14 days after surgery.  
Plasma MPO content was elevated and altered phospholipid levels in ApoE
-/-
 mice were 
observed with a large increase in the formation of lysolipids.  Total AMPKα expression 
was also increased in ApoE
-/-
 mice compared to their C57BL/6 counterparts.  This is the 
first study to investigate the effects of carotid artery injury on the lipid profile in neointima 
formation in C57BL/6 and ApoE
-/-
 mice.  However, further analysis is required to confirm 
these differences and to investigate the formation of oxidised species within the 
vasculature after injury.  This study also examined a role of AMPK in vascular injury in 
ApoE
-/-
 mice and highlights its actions in vascular disease. 
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CHAPTER 6 
THE EFFECT OF AMPK 
ACTIVATION IN HEALTHY AND 
ATHEROSCLEROTIC MICE
Chapter 6 – Effect of AMPK Activation in Atherosclerosis 
155 
 
6.1 Introduction 
Atherosclerosis and hypertension are closely related but separate cardiovascular disorders 
which combined lead to high risk of CAD and MI.  Previous clinical trials have shown a 
strong correlation between hypertension and the risk of developing atherosclerosis 
highlighted by the predominance of atherosclerotic plaques in areas of the vasculature 
subjected to high pressures (Kannel et al., 1986, Alexander, 1995).  LDL from 
hypertensive patients is also more vulnerable to oxidation in vitro than LDL isolated from 
normotensive patients (Maggi et al., 1993).  In animal models, angiotensin II-induced 
hypertension increased lesional area in the thoracic aorta of ApoE
-/-
 mice fed a high fat diet 
compared to their counterparts on normal chow diet (Weiss et al., 2001).  Both 
atherosclerosis and hypertension have been shown to enhance oxidative stress within the 
arterial wall, leading to an exacerbated phenotype that can accelerate atherosclerotic 
progression (Alexander, 1995). 
ApoE
-/-
 mice develop spontaneous hypercholesterolaemia and atherosclerosis, with the first 
signs of disease occurring at 6 to 8 weeks of age.  These include monocyte adhesion, 
disruption of the subendothelial elastic lamina and initial foam cell formation which is 
accelerated further by high fat feeding (Nakashima et al., 1994, Coleman et al., 2006).  
Some studies have shown ApoE
-/-
 mice to exhibit similar blood pressure recordings to 
control mice (Gervais et al., 2003, Hartley et al., 2000).  However, continuous blood 
pressure measurements over a 24 hour period revealed ApoE
-/-
 mice to have elevated 
systolic and diastolic pressures as well as heart rate and an elimination of circadian cycles 
compared to C57BL/6 control mice (Pelat et al., 2003).  The majority of studies examining 
mean arterial pressure have been in older atherosclerotic mice and little is known about the 
effect of short-term high fat feeding on these haemodynamic measurements. 
AMPK regulates cellular energy homeostasis and responds to changes in the AMP to ATP 
ratio.  Under states of stress, it is activated by a depletion of ATP or an elevation of AMP 
concentration.  In atherosclerosis, activation of AMPK by AICAR, a known activator of 
AMPK, has been shown to reduce ER stress and inhibit macrophage proliferation, both 
induced by high levels of circulating oxLDL (Dong et al., 2010, Ishii et al., 2009).  
OxLDL also caused a 40-fold increase in expression of serine/threonine protein 
phosphatase 2A in human monocytes, the enzyme responsible for inactivating AMPK 
(Kang et al., 2006).  In addition, AMPK has been implicated in reverse cholesterol 
transport, as activation increased protein levels of ABCG1 and ABCA1, which resulted in 
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cholesterol efflux from foam cells derived from macrophages and reduced plaque 
formation in ApoE
-/-
 mice (Li et al., 2010a, Li et al., 2010b).  AMPK has also been 
associated with neutrophils, which are the primary source of MPO, a phagocytic enzyme 
involved in one of the mechanisms by which LDL can become modified (Alba et al., 
2004).  AMPK activation attenuated neutrophil activity and metformin, an anti-diabetic 
drug known to activate AMPK, decreased MPO levels in lung tissue (Zhao et al., 2008, 
Tsoyi et al., 2011).  Therapeutic agents such as statins, extensively used in the treatment of 
atherosclerosis due to their effects on lipid lowering, have also been shown to partially 
mediate their effects through the action of AMPK, reviewed in Ewart and Kennedy (2011).  
Incubation with atorvastatin increased phosphorylation of AMPK and its downstream 
target ACC, both in vitro and in vivo (Sun et al., 2006).  Together, this highlights the 
emerging evidence for the importance of functional AMPK signalling to prevent lipid 
accumulation and the development of atherosclerosis. 
The activation of AMPK has also been associated with blood pressure regulation where 
prior studies have shown a reduction in mean arterial pressure in both rodents and humans, 
following acute administration of the AMPK activator, AICAR (Foley et al., 1989, 
Bosselaar et al., 2011).  Furthermore, spontaneously hypertensive rats dosed with AICAR 
showed an acute drop in blood pressure which was not seen in the control group of Wistar-
Kyoto rats suggesting AMPK could play a role in reducing hypertension (Ford et al., 
2012).  Long-term administration of AICAR or resveratrol, which has been described as 
another activator of AMPK, also reduced mean arterial pressure in obese Zucker rats (Buhl 
et al., 2002, Rivera et al., 2009).  This suggests that AMPK activation could play a critical 
role in the reduction of blood pressure in both atherosclerosis and hypertension.  However, 
to date there is no information available on the effect of chronic AMPK activation on 
blood pressure regulation and lipid profile in atherosclerotic mice and how this would also 
affect the activity of AMPK and its downstream targets in health and early atherosclerosis. 
6.1.1 Aims 
The aims investigated in this chapter were: 
 To determine the effect of short-term high fat feeding on blood pressure and AMPK 
expression in ApoE
-/- 
mice. 
 To examine the effect of chronic AMPK activation on blood pressure, protein 
expression and MPO content in healthy and atherosclerotic mice.  
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6.2 Methods 
6.2.1 Chronic AICAR administration 
Male C57BL/6 mice on normal chow and male ApoE
-/-
 mice fed on a high fat diet for 1 
month prior (10 to 12 weeks of age, weighing between 20 and 31 g) were administered a 
daily i.p. injection of either saline (vehicle) or AICAR at 400 mg/kg for 14 days. ApoE
-/-
 
mice were continued on the high fat diet throughout the dosing period.  Mice were weighed 
at the start of the dosing regimen, at day 7 to adjust the AICAR dose due to potential 
weight fluctuations and at the end of the study period.   
6.2.2 Haemodynamic measurements 
Haemodynamic measurements were performed by cannulation of the left common carotid 
artery as outlined in Section 2.6.5.  A representative arterial blood pressure trace is shown 
in Figure 6.1.  At the end of the procedure, mice were sacrificed by cervical dislocation 
and following this, blood was collected by cardiac puncture into EDTA-coated tubes and 
centrifuged at 1500 x g for 10 minutes to produce plasma.  Heart, liver and spleen weights 
were also recorded at time of death and snap frozen for future use. 
 
Figure 6.1 – Representative arterial blood pressure trace from cannulation of the 
left common carotid artery. 
A four second recording in a vehicle-treated C57BL/6 mouse.  Systolic and diastolic 
pressures were measured by taking an average of three individual peaks or troughs 
respectively.  Heart rate was measured by dividing the time the trace takes to complete 
ten consecutive waves by 600 (as measured in beats per minute (bpm)). 
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6.2.3 Western blotting 
Expression of ACC and AMPKα were measured by Western blot analysis as detailed in 
Section 2.4.  Thoracic aortae and liver from male C57BL/6 and ApoE
-/-
 mice that had been 
administered with either vehicle or AICAR for 14 days, were excised immediately after 
death. Protein estimation analysis from lysates was carried out and protein was added at 5 
µg for aorta and 10 µg for liver samples per well.  Immunoblotting was performed with 
antibodies against phosphorylated and total ACC and AMPKα as well as GAPDH which 
was used as a loading control (all antibody dilutions found in Table 2.1).  Densitometrical 
analysis was then performed. 
6.2.4 MPO assay 
MPO content of the plasma from vehicle- and AICAR-treated C57BL/6 and ApoE
-/-
 mice 
was analysed using a mouse MPO ELISA kit as described in Section 2.6.6.  Samples were 
diluted 1 in 16 in dilution buffer and the assay was performed as per the manufacturer’s 
instructions.  Absorbance was measured spectrophotometrically at 450 nm. 
6.2.5 Detection of lipids in aortae by ESMS 
Lipids were extracted from aortae of chronically treated C57BL/6 and ApoE
-/-
 mice with 
either vehicle or AICAR and analysed as described in Section 2.8.  Vessels were incubated 
in equal volumes of methanol containing BHT, chloroform and an aqueous solution to 
extract lipids then dried under a steady flow of oxygen-free nitrogen gas.  Dried lipid 
extracts were reconstituted and further diluted in methanol.  For analysis using positive-ion 
mode, aortic samples were diluted 1 in 100 with 1 % aqueous formic acid in methanol and 
scans performed for PCs and SMs, PEs, cholesterol and cholesteryl esters.  For analysis 
using negative-ion mode, aortic samples were diluted 1 in 10 with 10 % 5 mM ammonium 
acetate in methanol and scans performed for PIs and PSs.  Aortic samples were analysed 
by identifying consistent differences between spectra from different sample groups. 
6.2.6 Statistical analysis 
All results are displayed as mean ± SEM and n represents the number of mice used.  Data 
were analysed using an unpaired Student’s t test for the body weight measurements, one-
way ANOVA followed by Newman-Keuls’ post hoc test for analysis of spectra and two-
way ANOVA followed by Bonferroni’s post hoc test for all other measurements.  
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6.3 Results 
6.3.1 Effect of chronic AICAR administration on blood pressure 
and weight in healthy and atherosclerotic mice 
Values for all weights and haemodynamic measurements are summarised in Table 6.1 as 
mean ± SEM. 
For each haemodynamic measurement, a histogram (A in each graph) and scatter dot plot 
(B in each graph) is shown to highlight the mean values as well as the distribution of the 
data.  Mean arterial pressure was significantly increased in the vehicle-treated ApoE
-/-
 mice 
compared to their age-matched C57BL/6 controls from 94.1 ± 1.5 mmHg to 112.2 ± 1.5 
mmHg (Figure 6.2).  AICAR treatment had no effect on mean arterial pressure in C57BL/6 
mice but lowered the value almost to the baseline (98.5 ± 1.8 mmHg) in the ApoE
-/-
 mice.  
A similar trend was observed with the diastolic pressure in both C57BL/6 and ApoE
-/-
 mice 
(Figure 6.3).  The vehicle-treated ApoE
-/- 
group had a significantly elevated systolic 
pressure of 115.3 ± 1.6 mmHg compared to their C57BL/6 counterparts (105.1 ± 1.3 
mmHg) whereas administration of AICAR had no effect in either strain of mouse (Figure 
6.4).  Vehicle-treated ApoE
-/-
 mice had a reduced pulse pressure of 5.3 ± 0.5 mmHg 
compared to their C57BL/6 controls (18.3 ± 0.9 mmHg; Figure 6.5).  Furthermore, AICAR 
treatment had no effect on C57BL/6 mice but increased the pulse pressure of ApoE
-/-
 mice 
to 24.4 ± 1.5 mmHg, similar to healthy C57BL/6 mice levels.  Heart rate was also 
increased in ApoE
-/-
 mice dosed with the saline vehicle compared to their C57BL/6 
controls from 317.7 ± 13.9 bpm to 410.7 ± 15.1 bpm (Figure 6.6).  AICAR administration 
had no effect on heart rate in either strain of mouse. 
Body weight was monitored throughout the dosing regimen to allow for the adjustment of 
the AICAR dose as required (Figure 6.7).  ApoE
-/-
 mice had increased body weights 
compared to their age-matched C57BL/6 controls at the beginning of the experimental 
protocol.  This was maintained during the study and at the final body weight measurement.  
The percentage change in body weight at the midpoint of the investigation (day 7) and at 
the end, in relation to their start weights, was also investigated to take into account the 
differing start weights of the mice.  C57BL/6 mice consistently gained weight over the 14 
day period, with AICAR treatment having no effect compared to the vehicle-treated mice.  
In contrast, both groups of ApoE
-/-
 mice lost weight over the study period with a significant 
percentage loss in ApoE
-/-
 mice treated with AICAR between the midpoint and final weight 
measurements. 
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Organ weights were also measured as a percentage of the final body weight for each mouse 
(Figure 6.8).  No differences in the whole heart weight were observed between C57BL/6 
and ApoE
-/-
 mice.  Furthermore, chronic AICAR treatment had no effect on whole heart 
weight in either strain of mouse.  Liver weight was reduced in ApoE
-/-
 mice compared to 
C57BL/6 mice whereas administration of AICAR increased liver weights in both strains of 
mice compared to their saline-treated controls.  There was also a marked increase in spleen 
weight in both ApoE
-/-
 groups in relation to their C57BL/6 controls which was unaffected 
by AICAR treatment.  
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Figure 6.2 – Effect of AICAR dosing on mean arterial pressure of C57BL/6 and 
ApoE-/- mice. 
Mean arterial pressure was measured by cannulation of the left common carotid artery.  
***p<0.001 vs C57BL/6 vehicle, †††p<0.001 vs ApoE-/- vehicle, n = 6-10. 
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Figure 6.3 – Effect of AICAR dosing on diastolic pressure of C57BL/6 and ApoE-/- 
mice. 
Mean diastolic pressure was calculated from the arterial blood pressure traces by taking 
an average of three troughs from three separate waves.  ***p<0.001 vs C57BL/6 vehicle, 
†††p<0.001 vs ApoE-/- vehicle, n = 6-10. 
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Figure 6.4 – Effect of AICAR dosing on systolic pressure of C57BL/6 and ApoE-/- 
mice. 
Mean diastolic pressure was calculated from the arterial blood pressure traces by taking 
an average of three peaks from three separate waves.  ***p<0.001 vs C57BL/6 vehicle, n 
= 6-10. 
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Figure 6.5 – Effect of AICAR dosing on pulse pressure of C57BL/6 and ApoE-/- mice. 
Mean pulse pressure was calculated by subtracting the mean diastolic from the mean 
systolic pressure in each animal.  ***p<0.001 vs C57BL/6 vehicle, †††p<0.001 vs ApoE-/- 
vehicle, n = 6-10. 
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Figure 6.6 – Effect of AICAR dosing on heart rate of healthy and atherosclerotic 
mice. 
Heart rate was measured by dividing the time the arterial blood pressure trace takes to 
complete ten consecutive waves by 600 (as measured in bpm).  **p<0.01 vs C57BL/6 
vehicle, n = 7-10. 
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Figure 6.7 – Effect of 14 day dosing regimen on body weight of C57BL/6 and ApoE-/- 
mice. 
The weight of each mouse was recorded at the beginning (A), midpoint (day 7) and at the 
end of the procedure (B).  *p<0.05 and ***p<0.001 vs C57BL/6, n = 18-20.  The 
percentage change in body weights from start to day 7 and to final weight were also 
measured (C).  *p<0.05 vs ApoE-/- AICAR day 7 weight, n = 9-10. 
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Figure 6.8 – Effect of AICAR dosing on organ weight of C57BL/6 and ApoE-/- mice. 
Heart (A), liver (B) and spleen (C) weights were calculated as a percentage of the final 
body weight of the mice.  *p<0.05 and **p<0.01 vs C57BL/6 vehicle, ‡‡‡p<0.001 vs 
C57BL/6 AICAR, †††p<0.001 vs ApoE-/- vehicle, n = 9-10. 
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Table 6.1 – Weight and haemodynamic measurements of C57BL/6 and ApoE-/- mice 
before and after 14 days of AICAR administration. 
 C57BL/6 ApoE -/- 
Vehicle AICAR Vehicle AICAR 
Start weight (g) 25.0 ± 0.5 21.7 ± 0.4*** 28.0 ± 0.6*** 26.5 ± 0.6‡‡‡ 
Final weight (g) 26.1 ± 0.3 22.9 ± 0.4*** 26.9 ± 0.6 25.3 ± 0.5†,‡‡ 
Heart /Body weight 
(%) 
0.54 ± 0.02 0.50 ± 0.01 0.51 ± 0.02 0.47 ± 0.01 
Liver/Body weight 
(%) 
4.91 ± 0.13 5.55 ± 0.18** 4.42 ± 0.16* 5.24 ± 0.10††† 
Spleen/Body 
weight (%) 
0.29 ± 0.01 0.27 ± 0.01 0.38 ± 0.03** 0.38 ± 0.02‡‡‡ 
MAP (mmHg) 94.1 ± 1.5 96.8 ± 1.2 112.2 ± 1.5*** 98.5 ± 1.8††† 
DAP (mmHg) 86.8 ± 1.8 88.5 ± 1.0 110.0 ± 1.7*** 88.4 ± 1.8††† 
SAP (mmHg) 105.1 ± 1.3 110.3 ± 2.2 115.3 ± 1.6*** 112.8 ± 2.2 
PP (mmHg) 18.3 ± 0.9 21.8 ± 2.6 5.3 ± 0.5*** 24.4 ± 1.5††† 
HR (bpm) 317.7 ± 13.9 344.7 ± 20.2 410.7 ± 15.1** 381.9 ± 15.1 
Organ weight was taken as a percentage of the body weight.  Mean arterial pressure 
(MAP), diastolic arterial pressure (DAP), systolic arterial pressure (SAP), pulse pressure 
(PP) and heart rate (HR) were calculated from the trace from the cannula inserted in the 
left common carotid artery of C57BL/6 and ApoE-/- mice.  Data are expressed as mean ± 
SEM.  *p<0.05, **p<0.01 and ***p<0.001 vs C57BL/6 vehicle, ‡‡p<0.01 and ‡‡‡p<0.001 vs 
C57BL/6 AICAR, †p<0.05 and †††p<0.001 vs ApoE-/- vehicle, n = 6-10. 
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6.3.2 Effect of chronic AICAR treatment on expression of AMPKα 
and ACC in mouse aorta and liver 
The expression of phosphorylated and total AMPKα and its downstream target, ACC, were 
investigated in both mouse aortae and liver to assess the influence of chronic AMPK 
activation with AICAR on this pathway.  Phosphorylated and total levels of each protein 
were divided by the density of the GAPDH band to adjust for protein loading.  
Phosphorylated levels of AMPKα and ACC were also divided by the total values of each 
protein to measure the activation of these enzymes. 
Phosphorylated AMPKα levels in aortae were elevated in C57BL/6 mice dosed with 
AICAR and reduced in ApoE
-/-
 mice treated in the same way (Figure 6.9).  There was no 
effect on the amount of total AMPKα in C57BL/6 mice but a reduction was seen in ApoE-/- 
mice administered AICAR.  In contrast, the ratio of phosphorylated to total AMPKα was 
significantly higher in aortae of C57BL/6 mice treated with AICAR while no effect was 
seen in ApoE
-/-
 mice.  Similarly to AMPKα, phosphorylated ACC was increased in aortae 
of C57BL/6 mice treated with AICAR for 14 days compared to their vehicle-treated 
controls (Figure 6.10).  In comparison with their C57BL/6 counterparts, there was a trend 
towards a reduction in the amount of phosphorylated ACC in vehicle-treated ApoE
-/-
 mice 
and a significant decrease of phosphorylated ACC present in aortae of ApoE
-/-
 mice treated 
with AICAR.  A similar effect was observed with total ACC in the aortae with increased 
levels in C57BL/6 mice dosed with AICAR and a significant reduction in vehicle-treated 
and AICAR-dosed ApoE
-/-
 mice.  Administration of AICAR had no effect on the 
phosphorylated to total ACC ratio in either strain of mouse but was significantly elevated 
in atherosclerotic ApoE
-/-
 mice compared to their healthy C57BL/6 controls. 
No differences were observed in phosphorylated AMPKα levels in the liver across any of 
the groups (Figure 6.11).  However, there was a significant reduction in total AMPKα 
expression in ApoE
-/-
 mice liver in both vehicle- and AICAR-treated groups in relation to 
their C57BL/6 controls.  There was a large elevation in the phosphorylated to total 
AMPKα ratio in ApoE-/- mice livers compared their C57BL/6 counterparts and a slight 
decrease in ApoE
-/-
 mice treated with AICAR compared to their vehicle-treated controls.  
Reduced levels of phosphorylated ACC were seen in ApoE
-/-
 mice compared to their 
healthy C57BL/6 controls with AICAR administration had no effect (Figure 6.12).  A 
similar trend was seen for total ACC but this did not reach significance.  No differences 
were observed in the phosphorylated to total ACC ratio across any of the groups. 
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Figure 6.9 – Effect of AICAR dosing on phosphorylated and total AMPKα 
expression in aortae of C57BL/6 and ApoE-/- mice. 
Phosphorylated (B) and total (C) AMPKα were divided by GAPDH to adjust for protein 
loading to measure the amount of each form of the protein present and phosphorylated 
was divided by total AMPKα to measure the activation of the enzyme (D).  Blots shown 
are representative (A).  **p<0.01 and ***p<0.001 vs C57BL/6 vehicle, ‡p<0.05 and 
‡‡p<0.01 vs C57BL/6 AICAR, n = 4. 
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Figure 6.10 – Effect of AICAR dosing on phosphorylated and total ACC expression 
in aortae of C57BL/6 and ApoE-/- mice. 
Phosphorylated (B) and total (C) ACC were divided by GAPDH to adjust for protein 
loading to measure the amount of each form of the protein present and phosphorylated 
was divided by total ACC to measure the activation of the enzyme (D).  Blots shown are 
representative (A).  *p<0.05 and **p<0.01 vs C57BL/6 vehicle, ‡p<0.05 and ‡‡p<0.01 vs 
C57BL/6 AICAR, n = 4. 
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Figure 6.11 – Effect of AICAR dosing on phosphorylated and total AMPKα 
expression in liver of C57BL/6 and ApoE-/- mice. 
Phosphorylated (B) and total (C) AMPKα were divided by GAPDH to adjust for protein 
loading to measure the amount of each form of the protein present and phosphorylated 
was divided by total AMPKα to measure the activation of the enzyme (D).  Blots shown 
are representative (A).  **p<0.01 and ***p<0.001 vs C57BL/6 vehicle, ‡‡p<0.01 and 
‡‡‡p<0.001 vs C57BL/6 AICAR, †p<0.05 vs ApoE-/- vehicle, n = 4. 
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Figure 6.12 – Effect of AICAR dosing on phosphorylated and total ACC expression 
in liver of C57BL/6 and ApoE-/- mice. 
Phosphorylated (B) and total (C) ACC were divided by GAPDH to adjust for protein 
loading to measure the amount of each form of the protein present and phosphorylated 
was divided by total ACC to measure the activation of the enzyme (D).  Blots shown are 
representative (A).  *p<0.05 vs C57BL/6 vehicle, ‡p<0.05 vs C57BL/6 AICAR, n = 4. 
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6.3.3 Effect of AICAR administration on modified lipids in healthy 
and atherosclerotic mice 
The influence of chronic AICAR treatment on the MPO content of plasma from healthy 
C57BL/6 mice and ApoE
-/-
 mice fed on high fat diet for 6 weeks was investigated (Figure 
6.13).  A dramatic increase in MPO levels in ApoE
-/-
 mice compared to their C57BL/6 
controls was observed from 151.9 ± 17.9 ng/ml to 598.2 ± 55.0 ng/ml.  AICAR treatment 
had no effect on C57BL/6 mice but significantly increased MPO in the plasma of ApoE
-/-
 
mice to 762.7 ± 71.1 ng/ml. 
The distribution of several classes of phospholipids, present at various proportions in LDL 
particles including PCs, PEs, PSs and PIs as well as cholesterol and cholesteryl esters, in 
aortae were observed by ESMS.  The differences between vehicle-treated C57BL/6 and 
ApoE
-/-
 mice were investigated and the effect of chronic AMPK activation.  The 
percentage relative abundances of the signals detected from all phospholipid species are 
displayed in Table 6.2. 
Precursor ion scanning of m/z 184.1 in positive-ion mode is selective for SMs and PCs, the 
most abundant phospholipid in mammals, and exhibited similar distribution within 
individual samples in each group (Figure 6.14).  Peaks at m/z 496.7 (16:0) and 524.7 
(18:0) were consistently seen in all groups indicating the presence of lysolipids.  All 
treatment groups displayed roughly similar distribution of ions with the most abundant 
product ion occurring at m/z 782.9 (16:0/20:4); however, there were some notable changes 
in PC and SM expression between strains of mice and AICAR administration groups.  The 
only difference observed in AICAR-treated mice was a reduction in intensity of m/z 732.9 
(16:0/16:1) relative to other signals in ApoE
-/-
 mice.  In vehicle-treated ApoE
-/-
 mice 
compared to their C57BL/6 counterparts, there was also a relative elevation in m/z 810.9 
(18:0/20:4).  The only differences observed in SM expression were a relative increase in 
m/z 787.9 (22:0) in AICAR-treated ApoE
-/-
 mice compared to their vehicle-treated 
counterparts and C57BL/6 mice treated in the same way. The spectra were then expanded 
between m/z 550 and 700 to display any changes in chain-shortened PCs as they could be 
masked by the high signal of native PCs and long-chain products (Figure 6.15).  Repeating 
signals were observed in the spectra at m/z 564, 592, 620, 648 and 676 at different 
intensities within the groups (highest in one of the samples from the AICAR-treated ApoE
-
/-
 group) suggesting a polyethylene contaminant as the peaks are separated by 28 Da and 
were, therefore, discounted from the analysis (Jaber and Wilkins, 2005).  No detectable 
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changes were observed in the formation of chain-shortened PCs in any of the sample 
groups. 
A neutral loss scan for 141.1 Da in positive-ion mode was performed to detect changes in 
PE expression in murine aortae (Figure 6.16).  PEs were found at a much lower 
concentration than PCs but there was an increase in relative intensity of m/z 768.8 
(18:0/20:4) in ApoE
-/-
 mice after chronic activation in comparison to their saline-treated 
controls and C57BL/6 mice treated in the same way.  In addition, m/z 760.9 was only 
detectable in vehicle-treated C57BL/6 mice.  Similar to PEs, the concentration of PSs, 
detected by a neutral loss scan of 87 Da in negative-ion mode, in the aortic samples was 
relatively low and no significant differences were observed within or between the 
treatment groups (Figure 6.17).  Precursor ion scanning for m/z 241 in positive-ion mode is 
selective for PIs and a trend towards a reduction in m/z 885.9 (18:0/20:4) relative to other 
signals was observed in both AICAR-treated mice compared to their vehicle-treated 
controls (Figure 6.18).  In addition to the several classes of phospholipids, precursor ion 
scanning for m/z 369.1 was performed to detect cholesterol and cholesteryl esters present 
in the aortae (Figure 6.19).  The major product ion for each treatment group was m/z 369.6, 
indicating the dehydration product of protonated cholesterol, with no detectable changes in 
the formation of cholesteryl esters in any of the sample groups. 
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Figure 6.13 – Effect of AICAR treatment on MPO content of C57BL/6 and ApoE-/- 
mouse plasma. 
Blood samples were taken from each mouse at sacrifice by cardiac puncture into EDTA-
coated tubes.  Blood was centrifuged at 1500 x g for 10 minutes to produce plasma.  The 
MPO content of mouse plasma was measured by an ELISA and absorbance read 
spectrophotometrically at 450 nm.  ***p<0.001 vs C57BL/6 vehicle, ‡‡‡p<0.001 vs C57BL/6 
AICAR, †p<0.05 vs ApoE-/- vehicle, n = 8-9. 
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Figure 6.14 – Detection of PCs and SMs from aortae of vehicle- and AICAR-treated 
C57BL/6 and ApoE-/- mice. 
Precursor ion scanning for m/z 184.1 by positive-ionisation ESMS was performed to 
identify PCs and SMs present in aortae from C57BL/6 vehicle- (A) and AICAR-treated 
mice (B) and ApoE-/- vehicle- (C) and AICAR-treated mice (D).  Individual spectra were 
overlaid to highlight any potential differences in distributions within and between groups.  
n = 3. 
A
B
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Figure 6.15 – Detection of chain-shortened PCs from aortae of vehicle- and AICAR-
treated C57BL/6 and ApoE-/- mice. 
Precursor ion scanning for m/z 184.1 by positive-ionisation ESMS was performed to 
identify PCs present in aortae from C57BL/6 vehicle- (A) and AICAR-treated mice (B) and 
ApoE-/- vehicle- (C) and AICAR-treated mice (D).  Individual spectra were expanded 
between m/z 550 and 700 to focus on chain-shortened PCs and overlaid to highlight any 
potential differences in distributions within and between groups.  n = 3. 
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Figure 6.16 – Detection of PEs from aortae of vehicle- and AICAR-treated C57BL/6 
and ApoE-/- mice. 
Neutral loss of 141.1 Da by positive-ionisation ESMS was performed to identify PEs 
present in aortae from C57BL/6 vehicle- (A) and AICAR-treated mice (B) and ApoE-/- 
vehicle- (C) and AICAR-treated mice (D).  Individual spectra were overlaid to highlight any 
differences in distributions within and between groups.  n = 3. 
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Figure 6.17 – Detection of PSs from aortae of vehicle- and AICAR-treated C57BL/6 
and ApoE-/- mice. 
Neutral loss of 87 Da by negative-ionisation ESMS was performed to identify PSs present 
in aortae from C57BL/6 vehicle- (A) and AICAR-treated mice (B) and ApoE-/- vehicle- (C) 
and AICAR-treated mice (D).  Individual spectra were overlaid to highlight any differences 
in distributions within and between groups.  n = 3. 
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Figure 6.18 – Detection of PIs from aortae of vehicle- and AICAR-treated C57BL/6 
and ApoE-/- mice. 
Precursor ion scanning of m/z 241 by negative-ionisation ESMS was performed to identify 
PIs present in aortae from C57BL/6 vehicle- (A) and AICAR-treated mice (B) and ApoE-/- 
vehicle- (C) and AICAR-treated mice (D).  Individual spectra were overlaid to highlight any 
potential differences in distributions within and between groups.  n = 3. 
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Figure 6.19 – Detection of cholesterol and cholesteryl esters from aortae of vehicle- 
and AICAR-treated C57BL/6 and ApoE-/- mice. 
Precursor ion scanning for m/z 369.1 by positive-ionisation ESMS was performed to 
identify cholesterol and cholesteryl esters present in aortae from C57BL/6 vehicle- (A) and 
AICAR-treated mice (B) and ApoE-/- vehicle- (C) and AICAR-treated mice (D).  Individual 
spectra were overlaid to highlight any potential differences in distributions within and 
between groups.  n = 3. 
A
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Table 6.2 – Relative abundances of detected phospholipid species in aortae of 
vehicle- and AICAR-treated C57BL/6 and ApoE-/- mice. 
m/z 
(H) 
PL class Major 
species 
Relative abundance of ions (% of base peak) 
C57BL/6 
vehicle 
C57BL/6 
AICAR 
ApoE-/- 
vehicle 
ApoE-/- 
AICAR 
496.7 LPC 16:0 10.9 ± 1.0 12.4 ± 0.0 11.0 ± 0.6 13.6 ± 3.5 
524.7 LPC 18:0 5.4 ± 0.1 8.8 ± 0.7 8.0 ± 0.7 8.6 ± 1.7 
703.9 SM 16:0 30.6 ± 3.4 36.2 ± 0.6 41.2 ± 9.1 32.8 ± 12.5 
732.9 PC 16:0/16:1 17.3 ± 0.8 20.4 ± 1.0 13.7 ± 3.0 11.0 ± 1.4‡ 
734.9 PC 16:0/16:0 41.9 ± 4.8 47.2 ± 3.1 35.3 ± 8.4 31.8 ± 4.6 
758.9 PC 16:0/18:2 79.5 ± 13.9 62.6 ± 9.0 51.9 ± 6.9 67.2 ± 9.6 
760.9 PC 16:0/18:1 70.6 ± 3.0 81.6 ± 4.6 74.9 ± 7.9 87.0 ± 6.7 
768.8 PE 18:0/20:4 33.1 ± 13.5 20.2 ± 4.6 40.8 ± 14.1 100 ± 0.0††,‡‡ 
782.9 PC 16:0/20:4 93.1 ± 6.9 100 ± 0.0 100 ± 0.0 87.0 ± 10.3 
784.9 PC 18:0/18:3 33.0 ± 4.7 27.1 ± 1.3 26.2 ± 2.7 36.4 ± 4.6 
786.9 PC 18:0/18:2 40.6 ± 6.2 36.4 ± 4.7 38.6 ± 2.4 74.9 ± 19.5 
787.9 SM 22:0 16.0 ± 2.4 12.3 ± 1.7 13.5 ± 2.4 27.7 ± 4.9†,‡ 
788.8 PS 18:0/18:1 ND 6.1 ± 0.8 8.0 ± 0.7  2.0 ± 2.5 
790.8 PE 18:0/18:0 44.2 ± 13.0 ND ND ND 
806.9 PC 16:0/22:6 20.1 ± 1.5 22.8 ± 1.1 22.7 ± 0.5 18.1 ± 3.0 
810.9 PC 18:0/20:4 48.8 ± 5.7 58.0 ± 1.9 69.7 ± 1.7* 52.6 ± 6.7 
813.0 SM 24:1 9.4 ± 0.9 10.5 ± 0.4 13.0 ± 0.8 11.6 ± 2.3 
834.9 PC 18:0/22:6 8.5 ± 1.0 10.9 ± 0.6 11.7 ± 0.3 10.1 ± 2.9 
838.8 PS 18:0/22:4 2.3 ± 2.3 10.0 ± 0.2 6.2 ± 0.6 5.0 ± 0.0 
885.9 PI 18:0/20:4 42.5 ± 28.8 16.5 ± 2.4 38.6 ± 11.1 22.9 ± 3.3 
903.1 PI ? ND 19.4 ± 0.5 ND ND 
Relative abundances for each m/z value (protonated adduct ions) were calculated as a 
percentage of the largest peak in the individual spectra.  Significant differences in 
distribution of ions are highlighted in bold.  PL = phospholipid, ND = not detected.  *p<0.05 
vs C57BL/6 vehicle, ‡p<0.05 and ‡‡p<0.01 vs C57BL/6 AICAR, †p<0.05 and ††p<0.01 vs 
ApoE-/- vehicle, n = 3. 
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6.4 Discussion 
This study is the first to report the effects of AMPK activation on blood pressure regulation 
in ApoE
-/-
 mice and its effect on the lipid profile of aortic tissue.  Chronic administration of 
AICAR resulted in a reduction in mean arterial and diastolic pressures in high fat fed 
ApoE
-/-
 mice.  In addition, MPO was elevated in AICAR-treated ApoE
-/-
 mice with the 
lipid profile altered in AMPK activated ApoE
-/-
 mice compared to their C57BL/6 mice 
controls. 
As hypertension is both a predisposing risk factor as well as a consequence of the 
progression of atherosclerosis, investigating potential mechanisms involved in these 
diseases would be beneficial for the treatment of both hypertension and atherosclerosis.  
The ability of arteries to maintain vascular tone is altered as a result of atherosclerosis 
which has serious implications for blood pressure regulation and therefore hypertension.  
The majority of previous studies examining mean arterial pressure have been in older 
atherosclerotic mice and little is known about the effect of short-term high fat feeding on 
these haemodynamic measurements.  Mean arterial, diastolic and systolic pressures as well 
as heart rate were all elevated in ApoE
-/-
 mice fed on the high fat diet for 6 weeks 
compared to their C57BL/6 controls.  In addition, pulse pressure was significantly reduced 
in vehicle-treated ApoE
-/-
 mice in relation to their C57BL/6 counterparts.  This highlights 
the altered haemodynamic state found in young high fat fed ApoE
-/-
 mice, which has only 
previously been shown in mice of around 6 or 7 months of age.  The first signs of disease 
can occur as early as 6 to 8 weeks of age in ApoE
-/-
 mice, which include monocyte 
adhesion, disruption of the subendothelial elastic lamina and initial foam cell formation 
(Nakashima et al., 1994, Coleman et al., 2006).  Yang et al. (1999) reported no differences 
in haemodynamic measurements between age-matched 6 week old ApoE
-/-
 and C57BL/6 
mice but an increase in mean arterial pressure and left ventricular weight to body weight 
ratio in 7.5 month old ApoE
-/-
 mice.  Unlike in this study, these mice were not fed on a 
high fat diet that accelerates the formation and progression of atherosclerosis.  Continuous 
blood pressure measurements over a 24 hour period revealed ApoE
-/-
 mice at a similar age 
to this study having elevated systolic and diastolic pressures as well as increased heart rate 
compared to C57BL/6 control mice (Pelat et al., 2003).  The increase in blood pressure in 
ApoE
-/-
 mice is possibly due to a reduction in arterial elasticity from ECM gene expression 
which in turn causes arterial stiffening (Kothapalli et al., 2012).  This results in the 
formation of less compliant vessels and the elevated pressures found in hypertension. 
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ApoE
-/-
 mice fed on a high fat diet for 6 weeks also had a significantly larger body weight 
compared to age-matched C57BL/6 mice at the start of the study.  This suggests that 6 
weeks of the high fat diet is causing elevated levels of circulating lipoproteins, sufficient 
for fat storage to occur in these mice.  However, older ApoE
-/-
 mice have previously been 
shown to have reduced body weight compared to wild type controls, with the loss of the 
apoE gene found to be protective against obesity in C57BL/6 mice (Hartley et al., 2000, 
Karagiannides et al., 2008).  In addition, C57BL/6 mice gained weight throughout the two 
week dosing period while ApoE
-/-
 mice consistently lost weight.  The steady loss in weight 
could be due to the heightened state of stress that the atherosclerotic mice are under due to 
disease progression, therefore making them more likely to lose weight than their C57BL/6 
mice counterparts.  There was no difference in heart weight normalised to body weight in 
C57BL/6 or ApoE
-/-
 mice, while mature ApoE
-/-
 mice display an increased heart to body 
weight ratio compared to wild type controls (Hartley et al., 2000).  Left ventricular 
hypertrophy did not accompany the elevated mean arterial pressure observed in the ApoE
-/-
 
mice, which could be due to the short length of time these mice were on the high fat diet.  
The whole heart weight could also be replaced with a measurement of left ventricular mass 
which is a routinely used indicator of cardiac hypertrophy.  In addition, liver to body 
weight was reduced in vehicle-treated ApoE
-/-
 mice compared to C57BL/6 mice.  ApoE is 
primarily synthesised in the liver therefore the knockout of apoE
 
may result in a reduction 
in weight due to decreased production.  Furthermore, the lack of apoE results in altered 
cytokine production in young mice livers and lipid metabolism dysfunction, which could 
also affect the liver size (Yin et al., 2010).  Spleen weights normalised to body weight 
were also substantially larger in both groups of ApoE
-/-
 mice, which is thought to be due to 
altered immune responses in mice deficient in apoE (Laskowitz et al., 2000). 
AICAR was chosen as the AMPK activator in this study as it phosphorylates AMPK 
without altering the levels of ATP (Corton et al., 1994).  As the mechanism of action of 
AICAR occurs by mimicking the effect of AMP, there are also some non-specific effects 
associated with this agonist via activation of glycogen phosphorylase and fructose-1,6-
bisphosphate, both processes involved in the pathology of diabetes (Longnus et al., 2003, 
Vincent et al., 1996).  ZMP formed from the metabolism of AICAR can also either mimic 
AMP or guanosine monophosphate (GMP) depending on the rotation of the C4 to C6 
bond, which induces apoptosis in Jurkat cells independent of AMPK (Lopez et al., 2003).  
A-769662 is a potent and specific activator of AMPK and was used in the in vitro 
investigation of AMPK in VSM in Chapter 4.  However, A-769662 was not utilised for 
this 2 week dosing study as it is only soluble in DMSO at the concentration needed for 
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successful in vivo AMPK activation.  DMSO has several reported detrimental side-effects 
including nausea, cardiac arrest and hypertension, which would interfere with the 
observations attributed to AMPK activation over this dosing period (Santos et al., 2003). 
AMPK activation by AICAR resulted in a reduction of mean arterial and diastolic 
pressures in ApoE
-/-
 mice, similar to levels found in control C57BL/6 mice.  A dramatic 
elevation in pulse pressure was also witnessed in ApoE
-/-
 mice compared to their vehicle-
treated controls.  These effects have previously been reported with acute AICAR 
administration in spontaneously hypertensive rats and humans (Foley et al., 1989, 
Bosselaar et al., 2011, Ford et al., 2012).  Long-term AMPK activation has also resulted in 
a reduction in blood pressure in rats (Buhl et al., 2002, Rivera et al., 2009).  The acute 
reduction in blood pressure has previously been attributed to increased NO bioavailability 
leading to vasodilatation of arteries (Ford et al., 2012).  However, this is a fast, short-
lasting response and unlikely to be the only signalling pathway responsible for the effect 
over the 2 week dosing period.  This could therefore suggest a direct action on the VSM 
which would contribute to a more prolonged period of action, for example, by alterations 
in the calcium handling machinery in VSM.  In contrast, AICAR administration has been 
shown to have no effect on angiotensin II-induced hypertension in Wistar rats; however, 
AICAR was found to improve endothelial and vascular function in this study (Schulz et al., 
2008).  Chronic administration of another AMPK activator, metformin has also displayed a 
reduction in systolic blood pressure in Otsuka Long-Evans Tokushima fatty rats in vivo 
(Kosegawa et al., 1996). 
In addition to the haemodynamic measurements, AICAR administration caused a 
significant reduction in body weight in ApoE
-/-
 mice at the end of the dosing regimen 
compared to the midpoint measurement.  Hypothalamic AMPK activity is involved in 
modifying food intake and activation of the AMPK pathway has been found to induce 
hyperphagia and weight gain (Xue and Kahn, 2006, Blanco Martinez de Morentin et al., 
2011).  This is in contrast to the findings of this study; however, AMPK signalling is 
thought to be dysfunctional in atherosclerosis and therefore altered responses would not be 
unusual.  In addition, AICAR administration in rats resulted in a lower content of 
abdominal fat thought to be due to an increase in degradation of adipose tissue (Buhl et al., 
2002).  Chronic AMPK activation caused a moderate increase in the liver to body weight 
ratio in both strains of mice.  This is consistent with previous published data on the longer 
term administration of 4 and 7 weeks in non-obese and obese rats respectively (Winder et 
al., 2000, Buhl et al., 2002).  Winder and colleagues hypothesised that this liver 
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hypertrophy enabled faster metabolism of AICAR to the target tissues after the daily 
injection.  No differences in whole heart to body weight ratio were observed after AICAR 
treatment.  However, left ventricular hypertrophy has been associated with atherosclerosis 
in hypertensive patients and AMPK activity has also been implicated in a reduction in 
cardiac hypertrophy (Roman et al., 1995, Chan et al., 2004). 
The changes observed in body, organ and haemodynamic measurements were 
accompanied by alterations in AMPK signalling in aortic and liver tissue in ApoE
-/-
 and 
AICAR-treated mice.  Chronic AICAR administration in C57BL/6 mice was found to 
cause an upregulation of the phosphorylation status of AMPK and its downstream targets 
in the aorta, which would indicate a potential increase in activity of the enzyme.  In 
comparison with their C57BL/6 counterparts, there was a significant reduction in the 
amount of phosphorylated and total AMPKα and ACC in ApoE-/- mice treated with 
AICAR.  Vehicle-treated ApoE
-/-
 mice also had reduced levels of total ACC in relation to 
their C57BL/6 controls, which resulted in an elevation in the phosphorylated to total ratio 
of ACC.  This suggests that AMPK is dysregulated in the arterial wall in atherosclerosis 
and the reduced levels leading to reduced AMPK activation, losing the potentially 
beneficial action of AMPK in the disease.  This could be due to higher levels of protein 
phosphatase 2A, which is partly responsible for inactivating AMPK (Kang et al., 2006).  In 
hypertensive rats, a decrease in phosphorylated AMPK was also observed with no change 
in the total amount of the enzyme (Ford et al., 2012). 
In the liver, there was a reduction in the total amount of AMPKα in both vehicle- and 
AICAR-treated ApoE
-/-
 mice in comparison with their C57BL/6 counterparts.  This 
resulted in a large elevation in the phosphorylated to total ACC ratio with a slight 
reduction observed in the AICAR-treated group.  There were also reduced levels of 
phosphorylated ACC in vehicle-treated ApoE
-/-
 mice.  In another study, AMPK activity 
was increased 3.6-fold in the liver only 1 hour after administration of AICAR and an 
increase in ZMP up to 1.59 ± 0.1 µmol/g wet muscle weight, with ZMP levels undetectable 
in control animals (Buhl et al., 2002).  This suggests the rapid metabolism of AICAR by 
the liver into ZMP resulting in the subsequent activation of AMPK signalling.  In addition, 
levels of phosphorylated AMPK in hepatic tissue were reduced in obese Zucker rats by 
approximately 50 % compared to their lean counterparts (Rivera et al., 2009).  AMPK 
activation has previously been shown to increase hepatic fatty acid oxidation and therefore 
may facilitate the catabolism of free fatty acids and triglycerides (Velasco et al., 1997).  As 
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ACC is responsible for fatty acid synthesis, inhibition of the enzyme could result in 
decreased lipid accumulation within the arterial wall. 
To investigate the effect of AMPK activation on the circulating inflammatory status, the 
MPO content of plasma was measured and found to be increased in ApoE
-/-
 mice compared 
to their C57BL/6 mice controls.  This is consistent with MPO being elevated in 
atherosclerosis and a potentially important indicator of CVD progression (Brennan and 
Hazen, 2003, Baldus et al., 2003, Daugherty et al., 1994).  Previously published data on 
circulating levels of MPO in mouse plasma suggest that the levels observed in this study 
were dramatically higher at 598.2 ng/ml in ApoE
-/-
 mice compared to about 160 ng/ml in 
LDLr
-/-
 mice fed on a high fat diet for 6 weeks.  However, these were female animals so 
there could be potential gender and strain differences (van Leeuwen et al., 2008).  In 
addition, AICAR treatment significantly increased MPO in the plasma of ApoE
-/-
 mice 
compared to the vehicle-treated controls.  A previous study has shown AMPK activation to 
cause a decrease in MPO levels; however, this was measured in lung tissue and not in the 
circulation (Tsoyi et al., 2011).  AMPK is present in neutrophils and phosphorylated by 
AMPK activators; this could lead to the release of MPO (Alba et al., 2004).  However, 
AICAR was demonstrated to have no effect on MPO levels in the pulmonary circulation 
(Zhao et al., 2008).  As ApoE
-/-
 mice have an existing inflammatory state which is 
highlighted by their enlarged spleens, daily AICAR injections could have exacerbated this 
and led to higher levels of circulating MPO.  In contrast, long-term AICAR administration 
has been found to reduce plasma triglycerides, free fatty acids and increase HDL by two-
fold (Buhl et al., 2002). 
In addition, ESMS was utilised to detect different classes of modified lipids in aortic tissue 
as precursor ion and neutral loss scanning allows the detection of certain types of 
phospholipids or oxidised products without specifying individual species (Spickett et al., 
2011).  The precursor ion scan for m/z 184.1 displayed roughly similar distribution of PCs 
and SMs between groups; however, a decrease in relative abundance of m/z 732.9 in 
AICAR-treated ApoE
-/-
 mice compared to their C57BL/6 controls and an increase in m/z 
810.9 in vehicle-treated ApoE
-/-
 mice compared with their C57BL/6 controls was observed.  
These peaks likely corresponds to the protonated adducts of PCs, 16:0/16:1 and 18:0/20:4 
respectively.  There was a relative increase in m/z 787.9 corresponding to SM 22:0 in 
ApoE
-/-
 mice dosed with AICAR.  In addition, in the neutral loss scan for 141.1 Da, an 
increase in relative intensity of m/z 768.8 (PE 18:0/20:4) was observed in AICAR-treated 
ApoE
-/-
 mice compared to both their vehicle-treated controls and AICAR dosed C57BL/6 
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mice.  This could have resulted from a change in the ratio of m/z 768.8 and 790.9.  
However, the levels of PEs, PSs and PIs were relatively low in all samples, therefore the 
differences could be resulting from differing intensities of the signals of the lipid extracts.  
Further analysis would be needed with the use of suitable standards to characterise these 
differences fully and to make firm conclusions.  Together, this suggests an increase in 
arachindonoyl-containing species in ApoE
-/-
 mice when AMPK is chronically activated.  
This is in contrast with previous reports; when hepatocytes were incubated with AICAR, 
there was a reduction in synthesis of PC and PE, thought to be due to a reduction in 
availability of choline and decreased activity of the pace-setting enzyme, 
CTP:phosphoethanolamine cytidylyltransferase, respectively (Houweling et al., 2002).  
However, the inhibition of hepatic PC synthesis has also been shown to be independent of 
AMPK (Jacobs et al., 2007).  Moreover, precursor scanning of m/z 369.1 was utilised for 
detection of cholesterol and cholesteryl esters present in aorta of C57BL/6 and ApoE
-/-
 
mice.  The protonated dehydration product of cholesterol was consistently the largest peak 
in all samples at m/z 369.6.  Activation of AMPK is known to inhibit cholesterol 
biosynthesis by inactivating HMG-CoA reductase in response to ATP depletion (Kemp et 
al., 1999).  In addition, AMPK activation has previously been implicated in reverse 
cholesterol transport as activation increased protein levels of ABCG1 and ABCA1, which 
resulted in cholesterol efflux from macrophage derived foam cells and reduced plaque 
formation in ApoE
-/-
 mice (Li et al., 2010a, Li et al., 2010b).  This highlights the effect of 
AMPK activation on lipid synthesis, which could be influential in reducing the plaque 
burden in atherosclerosis but further work is required to characterise these modified lipids 
fully.  In addition, the detection of chlorinated lipids in the vessels was not performed due 
to time constraints.  The high levels of plasma MPO in ApoE
-/-
 mice would suggest an 
increase in the presence of HOCl-modified lipids in the vessels and further analysis of 
these samples would give a better indication of the occurrence of modified lipids in the 
vascular wall. 
6.5 Conclusions 
In summary, atherosclerotic ApoE
-/-
 mice have elevated mean arterial, diastolic and 
systolic pressures and increased heart rate compared to age-matched healthy C57BL/6 
mice as well as a reduction in pulse pressure.  AMPK activation by chronic AICAR 
treatment resulted in a significant reduction in mean arterial and diastolic pressures, in 
addition to a dramatic increase in pulse pressure in ApoE
-/-
 mice compared to their saline-
treated counterparts.  Plasma MPO levels were elevated in ApoE
-/-
 mice and alteration of 
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the proportion of PCs, SMs and PEs was observed.  This is the first study to investigate the 
effect of AMPK activation on blood pressure regulation in ApoE
-/-
 mice.  This study also 
examines for the first time the effect of AMPK activation on the lipid profile of aortic 
tissue in ApoE
-/-
 mice as indicated by differences in the fatty acid chain distribution of 
PCs, although further work is required to confirm these findings. 
 191 
 
CHAPTER 7 
GENERAL DISCUSSION
Chapter 7 – General Discussion 
192 
 
Various physiological effects have previously been attributed to oxLDL, including an 
exacerbation of the inflammatory response and vascular remodelling processes in 
atherosclerosis and restenosis.  However, little is known to date about the effects of 
individual modified lipids in these disease phenotypes.  The overall aim of this thesis was 
to investigate the biological effects of modified lipids, both chlorinated and oxidised 
species, in vascular injury and disease focussing primarily on their effects on VSM.  
Primary VSMCs were used to examine the effects of these modified lipids at a cellular 
level.  As AMPK has recently been implicated in vascular disease and also lipid synthesis, 
the impact of AMPK signalling on the effects of individual modified lipids in VSM was 
also investigated.  Subsequently, the occurrence of these modified lipids in neointima 
lesions was assessed using a carotid artery injury model in healthy and atherosclerotic 
mice.  Finally, in vivo AMPK activation in healthy and atherosclerotic mice and its effect 
on the lipid profile of the aorta were characterised. 
As oxLDL is very heterogeneous in its composition, it is important to characterise its 
effects by using individual modified lipids, in order to attribute the effects seen to each 
component of the particle.  In atherosclerosis, the active form of MPO is present within 
human lesions and modifies LDL into a form that is readily taken up by macrophages; 
aiding in the formation of foam cells (Daugherty et al., 1994, Podrez et al., 1999).  
Chlorinated lipids, phospholipid chlorohydrins and alpha-chloro fatty aldehydes are 
derived from modification by this MPO/H2O2/chloride system of both phospholipids and 
plasmalogens, respectively (Jerlich et al., 2000, Arnhold et al., 2001, Albert et al., 2001).  
Oxidised phospholipids PGPC and POVPC are the truncated products formed from the 
autoxidation of PAPC which have previously been found to mimic some of the biological 
effects of mmLDL (Watson et al., 1995, Watson et al., 1997).  The present study found 
chlorinated lipids to have no effect on VSMC proliferation, viability or migration after 2 
hours incubation, whereas oxidised phospholipids caused a concentration-dependent 
reduction in all of these vascular remodelling processes, with PGPC having the greater 
effect (Chapter 3).  In addition, SOPC ClOH caused a significant reduction in cellular ATP 
after 6 hours treatment at the highest concentrations.  This is the first study to investigate 
the effects of chlorinated lipids on VSM and to highlight the differing effects between 
modified lipid species.  Chlorinated lipids have previously been shown to induce pro-
inflammatory actions such as leukocyte adhesion and generation of ROS (Dever et al., 
2006, Dever et al., 2008) but, in the present study, no acute effects on VSMC remodelling 
processes were found.  This could suggest that phospholipid chlorohydrins and alpha-
chloro fatty aldehydes could be more involved in the inflammatory response of 
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atherosclerosis rather than in remodelling processes that result in changes to the vessel 
architecture.  In addition, VSMCs could be more resistant to the actions of chlorinated 
lipids in comparison to myeloid and endothelial cells.  In stark contrast, a biphasic 
response has previously been reported for oxidised phospholipid effects on remodelling 
processes with a proliferative action observed at lower concentrations and apoptosis 
predominating at higher levels (Auge et al., 2002, Fruhwirth et al., 2006, Johnstone et al., 
2009).  In areas of inflammation, the presence of OCl
-
, the deprotonated form of HOCl, has 
previously been found to reach concentrations of up to 300 µM (Katrantzis et al., 1991).  
In human atherosclerotic plaque samples, POVPC was found between 20 to 40 µg per 
gram of tissue with slightly higher levels, of between 40 to 100 µg per gram of tissue being 
reported in rabbit aorta for POVPC and PGPC (Ravandi et al., 2004, Watson et al., 1997, 
Subbanagounder et al., 2000).  This suggests that the concentrations of modified lipids 
used in the present study are relevant to those found within the in vivo setting. 
AMPK is a key regulator of energy homeostasis and is commonly referred to as a cellular 
“fuel gauge” (Hardie and Carling, 1997).  Activation of AMPK has previously been found 
to be beneficial in atherosclerosis as it reduced leukocyte adhesion to human aortic 
endothelial cells and alleviated the plaque burden in ApoE
-/-
 mice in vivo (Ewart et al., 
2008, Li et al., 2010a).  In addition, AMPK activation has been found to exert anti-
apoptotic effects in a number of cell types including endothelial cells (Ido et al., 2002, Kim 
et al., 2008, Liu et al., 2010).  As the modified lipids used in this study have been found to 
induce cell death in VSMCs and other cell types, the influence of AMPK on modulating 
the effects of these lipids was next investigated.  Although modified lipid treatment did not 
phosphorylate AMPK directly, this is the first study to find that modulation of the AMPK 
pathway changes the response of the VSMCs to modified lipids (Chapter 4).  Activation of 
AMPK prior to incubation of SOPC ClOH and POVPC made VSMCs more susceptible to 
proliferation and toxicity respectively.  This suggests that activation of the AMPK 
signalling pathway prior to the addition of modified lipids results in greater effects than 
incubation of the lipids alone.  This could be a protective measure to clear damaged or 
dying cells, resulting from the action of the oxidised phospholipid, more quickly via 
AMPK signalling while activation of AMPK prior to SOPC ClOH treatment initiates 
proliferation pathways in VSMCs that the lipid alone cannot stimulate.  In addition, 
differing effects of modified lipids were found on vascular reactivity of mouse carotid 
arteries in response to activation of AMPK.  Similarly to the initial cell experiments, 
chlorinated lipids were found to have no effect on AICAR-induced relaxation whereas 
oxidised phospholipids caused a concentration-dependent reduction in relaxation with 
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PGPC producing a greater reduction.  Atherosclerosis significantly reduces the relaxing 
capacity of arteries with impairment of both endothelium-dependent and -independent 
actions in arteries isolated from ApoE
-/-
 mice.  These effects could therefore be partly due 
to the increased levels of modified lipids in the vascular wall (Crauwels et al., 2003, 
d'Uscio et al., 2001).  This study has therefore produced novel data on the impact of 
AMPK signalling on the effects of modified lipids and highlighted again the differing 
effects of modified lipid species in VSMCs. 
The divergent effects witnessed with incubation of the different classes of modified lipids 
used in this study could suggest a different duration of action for each species due to the 
higher level of toxicity observed with modified lipids at longer treatment times.  The 
modified lipids could also be involved in different cellular processes; for example, the 
oxidised phospholipids could participate in the primary effects and chlorinated lipids could 
be involved in the latter stages of remodelling.  This could be further enhanced by the 
activation of the AMPK signalling pathway in VSMCs resulting in enhanced cell death 
with POVPC and an elevation in proliferation with SOPC ClOH.  A schematic diagram 
displaying the potential interactions of the modified lipids and AMPK signalling is shown 
in Figure 7.1.  This pathway could be activated by cellular changes in ATP evoked by the 
modified lipids as well as by a stress response to changes in energy homeostasis due to the 
progression of atherosclerosis.  In addition, there could be an interaction of these lipids 
with upstream kinases known to phosphorylate AMPK such as LKB1 and CAMKKβ, 
which with the addition of pharmacological activation of AMPK, result in the observed 
alteration in the response of modified lipids in VSMCs.  PGPC could be responsible for the 
initial cell death as it induced substantial death after 2 hours in the in vitro experiments.  
This effect could be followed by the action of POVPC as it is less potent than PGPC or 
additional to the effects of PGPC with prior activation of AMPK.  SOPC ClOH and other 
chlorohydrins may be involved in a proliferative stage with activation of the AMPK 
signalling pathway or in the last stage of cell death, as a significant reduction in cell death 
was witnessed after 6 hours treatment at the higher concentrations.  This would suggest a 
cumulative effect of the modified lipids on vascular remodelling processes in the 
vasculature.  Due to their previously reported biphasic response (Auge et al., 2002, 
Fruhwirth et al., 2006, Johnstone et al., 2009), modified lipids could also be involved in 
the latter proliferative stages of vascular injury leading to the formation of neointima; 
however, this would be difficult to measure in vitro.  MPO has been implicated in all 
stages of atherosclerosis (Nicholls and Hazen, 2009), therefore with the higher levels of 
circulating lipoproteins resulting in elevated levels of modified lipids, it would be feasible 
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for these lipids to be present and involved in all phases of the vascular remodelling 
processes.  Longer incubations with modified lipids would not be possible in quiescing 
medium, and incubating VSMCs with medium containing growth supplements such as 
FCS along with modified lipids would lead to the breakdown of these lipids by serum 
phospholipases (Fruhwirth et al., 2006).  This is a key limitation of the in vitro VSMC 
model as the effects of longer incubations in quiescing medium with modified lipids could 
not be attributed solely to the lipids because, in absence of the growth supplements, the 
cells would likely induce programmed cell death processes due to lack of available 
nutrients. 
 
Figure 7.1 – Schematic diagram of the proposed interaction of modified lipids and 
AMPK signalling in VSMCs. 
Phosphorylation of AMPK results in VSMCs being more susceptible to cell death and 
proliferation after treatment with oxidised phospholipids and chlorohydrins, respectively. 
Endothelial dysfunction is widely reported to initiate the remodelling process with the 
intimal layer critical in vascular remodelling due to the release and activation of substances 
involved in growth, death and migration of vascular and inflammatory cells (Gibbons and 
Dzau, 1994).  Investigation of the effects of the modified lipids used in this study on 
endothelial cells would aid in the understanding of the actions of these lipids on the 
vascular remodelling processes, as would the identification of the signalling pathways 
activated or inhibited by modified lipids in vascular cells.  In addition, incubation of 
modified lipids in a co-culture of endothelial cells and VSMCs would better represent the 
in vivo setting and could highlight novel interactions of the lipids and vascular cells and the 
potential release of vasoactive substances from the endothelial cells to act on the VSMCs.  
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As AMPK has previously been found to exert anti-apoptotic effects in endothelial cells, the 
modulation of this pathway on the effects of the modified lipids used in this study could 
also further expand the beneficial actions attributed to AMPK in vascular diseases. 
To substantiate the observations witnessed in the cellular experiments, in vivo analysis was 
performed to investigate the presence of modified lipids in the arterial wall after both 
vascular injury and chronic AMPK activation in C57BL/6 and ApoE
-/-
 mice.  Restenosis is 
a known complication of the surgical interventions used to treat atherosclerosis and results 
in neointimal thickening, in part by the action of VSMCs.  To investigate the occurrence of 
different classes of modified lipids in neointima in vivo, a carotid artery mouse injury 
model was used in C57BL/6 and ApoE
-/-
 mice.  The present study characterises for the first 
time, the phospholipid molecular species present in the arterial wall of the carotid arteries 
of C57BL/6 and ApoE
-/-
 mice after carotid artery injury (Chapter 5).  Neointima formation 
was greatly increased in ApoE
-/-
 mice compared with sham-operated controls and healthy 
C57BL/6 mice, while no changes were observed in the VSM content of the neointimal 
growth or on the proliferative and apoptotic processes investigated.  In previous studies, 
apoptosis was found to be elevated immediately after balloon distension injury in ApoE
-/-
 
mice and via a caspase 3-dependent mechanism in balloon injured rabbits while 
proliferation was increased 7 and 28 days post injury (Matter et al., 2006, Spiguel et al., 
2010).  In the present study, it must be remembered that the carotid arteries were injured as 
well as ligated causing a change in the haemodynamics of the vessel.  This in turn could 
have led to a faster response, explaining the observation that no changes in proliferative or 
apoptotic processes were detected 14 days after injury.  These remodelling mechanisms 
were occurring to compensate for both the change in vessel diameter as well as the 
removal of endothelium causing complete occlusion in a number of vessels.  Total 
AMPKα was also found to be significantly increased in the neointimal growth in sham-
operated ApoE
-/-
 mice compared to their C57BL/6 counterparts.  This could be due to an 
increase in cell number within the neointima resulting in an increase in AMPK present, or 
could be a protective measure to try and counteract the neointimal hyperplasia. 
The interest in the beneficial role of AMPK in vascular diseases has increased substantially 
over the last few years.  This study has revealed for the first time the involvement of 
AMPK in blood pressure regulation in ApoE
-/-
 mice with chronic administration of AICAR 
resulting in a reduction in mean arterial and diastolic pressures in high fat fed ApoE
-/-
 mice 
(Chapter 6).  These effects have previously been reported with acute AICAR 
administration in spontaneously hypertensive rats and humans (Foley et al., 1989, 
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Bosselaar et al., 2011, Ford et al., 2012).  The acute reduction in blood pressure has 
previously been attributed to increased NO bioavailability leading to vasodilatation of 
arteries (Ford et al., 2012).  However, this is a fast, short-lasting response and unlikely to 
be the only signalling pathway responsible for the effect over the 2 week dosing period.  
This could therefore suggest a direct action on the VSM, which would contribute to a more 
prolonged period of action, for example, by alterations in the calcium handling machinery 
in VSM.  In comparison with their C57BL/6 counterparts, there was a significant decrease 
in the amount of phosphorylated and total AMPKα and ACC in ApoE-/- mice treated with 
AICAR compared with their C57BL/6 controls and a reduction in the levels of total ACC 
in vehicle-treated ApoE
-/-
 mice.  This suggests that AMPK is dysregulated in the arterial 
wall in atherosclerosis and the reduced levels could lead to a reduction in AMPK 
activation, losing the potentially beneficial action of AMPK in halting disease progression.  
In addition, this is one of the first studies to report an elevation in blood pressure of young 
ApoE
-/-
 mice fed only on a high fat diet for 1 month.  Studies have previously focussed on 
haemodynamic measurements of older mice where the atherosclerotic phenotype would be 
more pronounced or found no changes at this younger age compared with control mice 
(Yang et al., 1999, Hartley et al., 2000). 
The MPO plasma content was found to be elevated in all groups of ApoE
-/-
 mice in both 
the carotid injury and chronic AMPK activation studies suggesting an increase in the 
inflammatory status of atherosclerotic mice.  This could result in a higher level of modified 
lipids produced in the arterial wall which are pro-inflammatory and essential in the 
formation of atherosclerotic lesions.  Plasma MPO was further elevated in ApoE
-/-
 mice 
administered AICAR compared to their saline-treated counterparts. Measurement of the 
levels of circulating neutrophils in C57BL/6 and ApoE
-/-
 mice, to see if this accounts for 
the elevation in plasma MPO, would be beneficial.  A novel pharmacological MPO 
inhibitor, INV-315 has recently been produced which resulted in a reduction in oxidative 
stress and enhancement of cholesterol efflux in an atherosclerotic mouse model (Liu et al., 
2012).  This suggests that inhibition of MPO could result in a reduction in atherosclerotic 
plaque formation and potentially a reduction in modified lipid production.  Inhibition of 
MPO in the carotid injury model could provide valuable information on the formation of 
neointima and the lipid profile of the arterial wall after inhibition of one of the routes for 
the production of modified lipids.  Recently, AMPKα2-/- mice were crossed with C57BL/6 
ApoE
-/-
 mice to generate mice with a double knockout of apoE
 
and AMPKα2 (Wang et al., 
2011a).  Investigation of the plasma MPO content of these mice would also be beneficial in 
understanding the relationship between MPO and AMPK in atherosclerotic mice. 
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In addition, both the carotid injury and chronic AMPK activation studies revealed 
significant changes in the relative intensities of several phospholipids, primarily PCs, in the 
arterial tissue of C57BL/6 and ApoE
-/-
 mice.  In the carotid injury study, a higher 
proportion of lysolipids was detected in the injured carotid arteries of ApoE
-/-
 mice 
compared to both their uninjured controls as well as the C57BL/6 control mice.  This is 
consistent with a previous study where lysolipids were elevated in the intima and inner 
media of atherosclerotic aortae of squirrel monkeys, which is likely to be exacerbated in 
the hyperproliferative state after vascular injury (Portman and Alexander, 1969).  Injured 
carotid arteries also appeared to be enriched with linoleoyl-containing PCs.  These 
unsaturated phospholipids could undergo modification by the MPO system, leading to an 
increase in modified lipids present at the site of injury.  Additional targeted scanning for 
neutral losses of 36 and 38 Da (H
35
Cl and H
37
Cl) as well as neutral loss of 18 Da, as ions 
containing –OH groups lose water, could confirm the presence and highlight the relative 
levels of chlorohydrins and other chlorinated species within the arterial wall after vascular 
injury.  There was not sufficient time to perform this analysis in this study; however, this 
could form the basis of future work within this area.  The distribution of phospholipids was 
also found to be altered after chronic AICAR administration in ApoE
-/-
 mice, suggesting a 
novel interaction between AMPK activation and the formation of modified lipids.  A more 
pronounced effect may be witnessed with longer term high fat feeding of ApoE
-/-
 mice, 
which would accelerate the progression of atherosclerosis and therefore the levels of 
circulating and modified lipids.  Investigation of the involvement of modified lipids in 
neointima formation after carotid artery injury in the double knockout mice of apoE and 
AMPKα2 could also provide further evidence on the interaction of AMPK signalling and 
modified lipids in atherosclerosis.  
A limitation of the ESMS analysis used in this study is the lack of internal or external 
standards in the lipid extracts from the injured and uninjured carotid arteries as well as the 
aortae of mice chronically administered AICAR.  Standards are commonly used for 
quantification of levels within samples by the addition of a lipid at a known concentration.  
However, there would also be limitations in using standards in these samples as the sizes of 
the arteries varied and were not pre-weighed before lipid extraction therefore the lipid 
concentrations cannot be calculated.  Additionally, the amount of lipid is likely to vary 
within the artery and while standards may indicate the absolute concentration, all the lipids 
should fluctuate together depending on the total lipid content extracted.  Comparisons were 
made instead between the relative intensities of the lipids present in these samples, which 
generated information about changes in the lipid profile in the different strains and in 
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response to treatments.  It should also be noted that ESMS is not a quantitative technique 
in itself, due to the different ionisation efficiencies of lipid classes, therefore PC levels 
cannot be directly compared with PEs or PSs, etc.  There is also further variation within the 
PC class as short chains ionise better than long chains.  However, all these differences 
should be the same between samples, therefore it is valid to look for changes in relative 
intensities and patterns between samples in this study.  Additional analysis by liquid 
chromatography coupled with tandem mass spectrometry would enable the confirmation of 
the observed changes in proportions of the phospholipids studied in this thesis, as well as 
provide essential information on the oxidation products present which are critical in the 
progression of atherosclerosis. 
7.1 Conclusions 
In summary, this thesis has shown for the first time the divergent effects of different 
classes of modified lipids as well as modulation of AMPK signalling resulting in altered 
modified lipid responses in VSMCs.  The present study has displayed a novel mechanism 
of blood pressure regulation by chronic activation of AMPK in ApoE
-/-
 mice.  It has also 
generated novel data on the relative changes in distribution of PCs in carotid arteries after 
carotid artery injury as well as in aortic tissue after chronic AMPK activation in both 
healthy and atherosclerotic mice.  Additional analysis is required to confirm the relative 
differences in PCs which could offer further insight into the involvement of modified lipids 
in vascular diseases.  Furthermore, this study has highlighted a novel interaction of AMPK 
signalling and modified lipids in VSM and could therefore provide novel therapeutic 
targets in the treatment of both atherosclerosis and restenosis. 
 200 
 
List of References 
(2002) Third report of the National Cholesterol Education Program (NCEP) Expert Panel 
on detection, evaluation, and treatment of high blood cholesterol in adults (Adult 
Treatment Panel III) final report. Circulation, 106, 3143-3421. 
AIT-OUFELLA, H., KINUGAWA, K., ZOLL, J., SIMON, T., BODDAERT, J., 
HEENEMAN, S., BLANC-BRUDE, O., BARATEAU, V., POTTEAUX, S., MERVAL, 
R., ESPOSITO, B., TEISSIER, E., DAEMEN, M. J., LESECHE, G., BOULANGER, C., 
TEDGUI, A. & MALLAT, Z. (2007) Lactadherin deficiency leads to apoptotic cell 
accumulation and accelerated atherosclerosis in mice. Circulation, 115, 2168-2177. 
AL-SHAWAF, E., NAYLOR, J., TAYLOR, H., RICHES, K., MILLIGAN, C. J., 
O'REGAN, D., PORTER, K. E., LI, J. & BEECH, D. J. (2010) Short-term stimulation of 
calcium-permeable transient receptor potential canonical 5-containing channels by 
oxidized phospholipids. Arterioscler Thromb Vasc Biol, 30, 1453-1459. 
ALBA, G., EL BEKAY, R., ALVAREZ-MAQUEDA, M., CHACON, P., VEGA, A., 
MONTESEIRIN, J., SANTA MARIA, C., PINTADO, E., BEDOYA, F. J., BARTRONS, 
R. & SOBRINO, F. (2004) Stimulators of AMP-activated protein kinase inhibit the 
respiratory burst in human neutrophils. FEBS Lett, 573, 219-225. 
ALBERT, C. J., CROWLEY, J. R., HSU, F. F., THUKKANI, A. K. & FORD, D. A. 
(2001) Reactive chlorinating species produced by myeloperoxidase target the vinyl ether 
bond of plasmalogens - Identification of 2-chlorohexadecanal. J Biol Chem, 276, 23733-
23741. 
ALEXANDER, R. W. (1995) Theodore Cooper Memorial Lecture. Hypertension and the 
pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial 
inflammatory response: a new perspective. Hypertension, 25, 155-161. 
ANBUKUMAR, D. S., SHORNICK, L. P., ALBERT, C. J., STEWARD, M. M., 
ZOELLER, R. A., NEUMANN, W. L. & FORD, D. A. (2010) Chlorinated lipid species in 
activated human neutrophils: lipid metabolites of 2-chlorohexadecanal. J Lipid Res, 51, 
1085-1092. 
ANDREOU, I., TOUSOULIS, D., MILIOU, A., TENTOLOURIS, C., ZISIMOS, K., 
GOUNARI, P., SIASOS, G., PAPAGEORGIOU, N., PAPADIMITRIOU, C. A., 
DIMOPOULOS, M. A. & STEFANADIS, C. (2010) Effects of rosuvastatin on 
myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-
controlled study. Atherosclerosis, 210, 194-198. 
ANG, A. H., TACHAS, G., CAMPBELL, J. H., BATEMAN, J. F. & CAMPBELL, G. R. 
(1990) Collagen synthesis by cultured rabbit aortic smooth-muscle cells. Alteration with 
phenotype. Biochem J, 265, 461-469. 
ARNHOLD, J., OSIPOV, A. N., SPALTEHOLZ, H., PANASENKO, O. M. & 
SCHILLER, J. (2001) Effects of hypochlorous acid on unsaturated phosphatidylcholines. 
Free Radic Biol Med, 31, 1111-1119. 
ARNHOLD, J., OSIPOV, A. N., SPALTEHOLZ, H., PANASENKO, O. M. & 
SCHILLER, J. (2002) Formation of lysophospholipids from unsaturated 
 201 
 
phosphatidylcholines under the influence of hypochlorous acid. BBA-Gen Subjects, 1572, 
91-100. 
AUGE, N., GARCIA, V., MAUPAS-SCHWALM, F., LEVADE, T., SALVAYRE, R. & 
NEGRE-SALVAYRE, A. (2002) Oxidized LDL-induced smooth muscle cell proliferation 
involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. 
Arterioscler Thromb Vasc Biol, 22, 1990-1995. 
BACKES, A., SEAY, U., SEDDING, D. G., TILLMANNS, H. H. & BRAUN-
DULLAEUS, R. C. (2010) Inhibition of matrix deposition: a new strategy for prevention 
of restenosis after balloon angioplasty. J Cardiovasc Pharmacol, 55, 213-218. 
BAIN, J., PLATER, L., ELLIOTT, M., SHPIRO, N., HASTIE, C. J., MCLAUCHLAN, 
H., KLEVERNIC, I., ARTHUR, J. S., ALESSI, D. R. & COHEN, P. (2007) The 
selectivity of protein kinase inhibitors: a further update. Biochem J, 408, 297-315. 
BALDUS, S., HEESCHEN, C., MEINERTZ, T., ZEIHER, A. M., EISERICH, J. P., 
MUNZEL, T., SIMOONS, M. L. & HAMM, C. W. (2003) Myeloperoxidase serum levels 
predict risk in patients with acute coronary syndromes. Circulation, 108, 1440-1445. 
BASSIOUNY, H. S., ZARINS, C. K., KADOWAKI, M. H. & GLAGOV, S. (1994) 
Hemodynamic stress and experimental aortoiliac atherosclerosis. J Vasc Surg, 19, 426-434. 
BATEMAN, A. (1997) The structure of a domain common to archaebacteria and the 
homocystinuria disease protein. Trends Biochem Sci, 22, 12-13. 
BEDEL, A., NEGRE-SALVAYRE, A., HEENEMAN, S., GRAZIDE, M. H., THIERS, J. 
C., SALVAYRE, R. & MAUPAS-SCHWALM, F. (2008) E-cadherin/beta-catenin/T-cell 
factor pathway is involved in smooth muscle cell proliferation elicited by oxidized low-
density lipoprotein. Circ Res, 103, 694-701. 
BEG, Z. H., ALLMANN, D. W. & GIBSON, D. M. (1973) Modulation of 3-hydroxy-3-
methylglutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat 
liver cytosol. Biochem Biophys Res Commun, 54, 1362-1369. 
BELLESIA, F., BONI, M., GHELFI, F., GRANDI, R., PAGNONI, U. M. & PINETTI, A. 
(1992) Acetal chlorination with MNO2-trimethylchlorosilane. Tetrahedron, 48, 4579-4586. 
BENNETT, M. R. & BOYLE, J. J. (1998) Apoptosis of vascular smooth muscle cells in 
atherosclerosis. Atherosclerosis, 138, 3-9. 
BENZIANE, B., BJORNHOLM, M., LANTIER, L., VIOLLET, B., ZIERATH, J. R. & 
CHIBALIN, A. V. (2009) AMP-activated protein kinase activator A-769662 is an inhibitor 
of the Na
+
-K
+
-ATPase. Am J Physiol Cell Physiol, 297, C1554-1566. 
BERNE, R. M., LEVY, M. N., KOEPPEN, B. M. & STANTON, B. A. (2004) Physiology 
5th Edition, USA, Mosby, Elsevier Science. 
BLANCO MARTINEZ DE MORENTIN, P., GONZALEZ, C. R., SAHA, A. K., 
MARTINS, L., DIEGUEZ, C., VIDAL-PUIG, A., TENA-SEMPERE, M. & LOPEZ, M. 
(2011) Hypothalamic AMP-activated protein kinase as a mediator of whole body energy 
balance. Rev Endocr Metab Disord, 12, 127-140. 
 202 
 
BOCHKOV, V. N., KADL, A., HUBER, J., GRUBER, F., BINDER, B. R. & 
LEITINGER, N. (2002) Protective role of phospholipid oxidation products in endotoxin-
induced tissue damage. Nature, 419, 77-81. 
BOSSELAAR, M., SMITS, P., VAN LOON, L. J. & TACK, C. J. (2011) Intravenous 
AICAR during hyperinsulinemia induces systemic hemodynamic changes but has no local 
metabolic effect. J Clin Pharmacol, 51, 1449-1458. 
BRADFORD, M. M. (1976) A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye binding. Anal 
Biochem, 72, 248-254. 
BRENNAN, M. L., ANDERSON, M. M., SHIH, D. M., QU, X. D., WANG, X. P., 
MEHTA, A. C., LIM, L. L., SHI, W. B., HAZEN, S. L., JACOB, J. S., CROWLEY, J. R., 
HEINECKE, J. W. & LUSIS, A. J. (2001) Increased atherosclerosis in myeloperoxidase-
deficient mice. J Clin Invest, 107, 419-430. 
BRENNAN, M. L. & HAZEN, S. L. (2003) Emerging role of myeloperoxidase and 
oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol, 14, 353-359. 
BRENNAN, M. L., PENN, M. S., VAN LENTE, F., NAMBI, V., SHISHEHBOR, M. H., 
AVILES, R. J., GOORMASTIC, M., PEPOY, M. L., MCERLEAN, E. S., TOPOL, E. J., 
NISSEN, S. E. & HAZEN, S. L. (2003) Prognostic value of myeloperoxidase in patients 
with chest pain. N Engl J Med, 349, 1595-1604. 
BRINDLE, N. P. (1993) Growth factors in endothelial regeneration. Cardiovasc Res, 27, 
1162-1172. 
BRITO, P. M., DEVILLARD, R., NEGRE-SALVAYRE, A., ALMEIDA, L. M., DINIS, 
T. C., SALVAYRE, R. & AUGE, N. (2009) Resveratrol inhibits the mTOR mitogenic 
signaling evoked by oxidized LDL in smooth muscle cells. Atherosclerosis, 205, 126-134. 
BROWN, B. G., BOLSON, E. L. & DODGE, H. T. (1982) Arteriographic assessment of 
coronary atherosclerosis. Review of current methods, their limitations, and clinical 
applications. Arteriosclerosis, 2, 2-15. 
BROWN, M. S. & GOLDSTEIN, J. L. (1983) Lipoprotein metabolism in the macrophage: 
implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem, 52, 223-261. 
BU, D. X., TARRIO, M., MAGANTO-GARCIA, E., STAVRAKIS, G., TAJIMA, G., 
LEDERER, J., JAROLIM, P., FREEMAN, G. J., SHARPE, A. H. & LICHTMAN, A. H. 
(2011) Impairment of the programmed cell death-1 pathway increases atherosclerotic 
lesion development and inflammation. Arterioscler Thromb Vasc Biol, 31, 1100-1107. 
BUCKLEY, C., BUND, S. J., MCTAGGART, F., BRUCKDORFER, K. R., OLDHAM, 
A. & JACOBS, M. (1996) Oxidized low-density lipoproteins inhibit endothelium-
dependent relaxations in isolated large and small rabbit coronary arteries. J Auton 
Pharmacol, 16, 261-267. 
BUHL, E. S., JESSEN, N., POLD, R., LEDET, T., FLYVBJERG, A., PEDERSEN, S. B., 
PEDERSEN, O., SCHMITZ, O. & LUND, S. (2002) Long-term AICAR administration 
reduces metabolic disturbances and lowers blood pressure in rats displaying features of the 
insulin resistance syndrome. Diabetes, 51, 2199-2206. 
 203 
 
CAMPBELL, J. H. & CAMPBELL, G. R. (1994) The role of smooth muscle cells in 
atherosclerosis. Curr Opin Lipidol, 5, 323-330. 
CARLSON, C. A. & KIM, K. H. (1973) Regulation of hepatic acetyl coenzyme A 
carboxylase by phosphorylation and dephosphorylation. J Biol Chem, 248, 378-380. 
CARR, A. C., VANDENBERG, J. J. M. & WINTERBOURN, C. (1996) Chlorination of 
cholesterol in cell membranes by hypochlorous acid. Arch Biochem Biophys, 332, 63-69. 
CARR, A. C., VISSERS, M. C., DOMIGAN, N. M. & WINTERBOURN, C. C. (1997) 
Modification of red cell membrane lipids by hypochlorous acid and haemolysis by 
preformed lipid chlorohydrins. Redox Rep, 3, 263-271. 
CASSCELLS, W. (1992) Migration of smooth muscle and endothelial cells. Critical events 
in restenosis. Circulation, 86, 723-729. 
CASTELLANI, L. W., CHANG, J. J., WANG, X., LUSIS, A. J. & REYNOLDS, W. F. 
(2006) Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, 
developing hyperlipidemia and obesity in -463G males. J Lipid Res, 47, 1366-1377. 
CHAHINE, M. N., BLACKWOOD, D. P., DIBROV, E., RICHARD, M. N. & PIERCE, 
G. N. (2009) Oxidized LDL affects smooth muscle cell growth through MAPK-mediated 
actions on nuclear protein import. J Mol Cell Cardiol, 46, 431-441. 
CHAIT, A., BRAZG, R. L., TRIBBLE, D. L. & KRAUSS, R. M. (1993) Susceptibility of 
small, dense, low-density lipoproteins to oxidative modification in subjects with the 
atherogenic lipoprotein phenotype, pattern B. Am J Med, 94, 350-356. 
CHAN, A. Y., SOLTYS, C. L., YOUNG, M. E., PROUD, C. G. & DYCK, J. R. (2004) 
Activation of AMP-activated protein kinase inhibits protein synthesis associated with 
hypertrophy in the cardiac myocyte. J Biol Chem, 279, 32771-32779. 
CHANG, M. K., BINDER, C. J., MILLER, Y. I., SUBBANAGOUNDER, G., 
SILVERMAN, G. J., BERLINER, J. A. & WITZTUM, J. L. (2004) Apoptotic cells with 
oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med, 200, 1359-
1370. 
CHATTERJEE, S., BERLINER, J. A., SUBBANAGOUNDER, G. G., BHUNIA, A. K. & 
KOH, S. (2004) Identification of a biologically active component in minimally oxidized 
low density lipoprotein (MM-LDL) responsible for aortic smooth muscle cell proliferation. 
Glycoconj J, 20, 331-338. 
CHEN, J., MEHTA, J. L., HAIDER, N., ZHANG, X., NARULA, J. & LI, D. (2004) Role 
of caspases in ox-LDL-induced apoptotic cascade in human coronary artery endothelial 
cells. Circ Res, 94, 370-376. 
CHENG, G., SALERNO, J. C., CAO, Z., PAGANO, P. J. & LAMBETH, J. D. (2008) 
Identification and characterization of VPO1, a new animal heme-containing peroxidase. 
Free Radic Biol Med, 45, 1682-1694. 
CHEREPANOVA, O. A., PIDKOVKA, N. A., SARMENTO, O. F., YOSHIDA, T., GAN, 
Q., ADIGUZEL, E., BENDECK, M. P., BERLINER, J., LEITINGER, N. & OWENS, G. 
K. (2009) Oxidized phospholipids induce type VIII collagen expression and vascular 
smooth muscle cell migration. Circ Res, 104, 609-618. 
 204 
 
CHEUNG, P. C., SALT, I. P., DAVIES, S. P., HARDIE, D. G. & CARLING, D. (2000) 
Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role 
in AMP binding. Biochem J, 346 Pt 3, 659-669. 
CHURCH, D. F. & PRYOR, W. A. (1985) Free-radical chemistry of cigarette smoke and 
its toxicological implications. Environ Health Perspect, 64, 111-126. 
CLARKE, M. C., LITTLEWOOD, T. D., FIGG, N., MAGUIRE, J. J., DAVENPORT, A. 
P., GODDARD, M. & BENNETT, M. R. (2008) Chronic apoptosis of vascular smooth 
muscle cells accelerates atherosclerosis and promotes calcification and medial 
degeneration. Circ Res, 102, 1529-1538. 
CLARKE, M. C., TALIB, S., FIGG, N. L. & BENNETT, M. R. (2010) Vascular smooth 
muscle cell apoptosis induces interleukin-1-directed inflammation: effects of 
hyperlipidemia-mediated inhibition of phagocytosis. Circ Res, 106, 363-372. 
CLOWES, A. W. & SCHWARTZ, S. M. (1985) Significance of quiescent smooth muscle 
migration in the injured rat carotid artery. Circ Res, 56, 139-145. 
COATS, P., KENNEDY, S., PYNE, S., WAINWRIGHT, C. L. & WADSWORTH, R. A. 
(2008) Inhibition of non-Ras protein farnesylation reduces in-stent restenosis. 
Atherosclerosis, 197, 515-523. 
COLEMAN, R., HAYEK, T., KEIDAR, S. & AVIRAM, M. (2006) A mouse model for 
human atherosclerosis: long-term histopathological study of lesion development in the 
aortic arch of apolipoprotein E-deficient (E0) mice. Acta Histochem, 108, 415-424. 
COLLINS, R. G., VELJI, R., GUEVARA, N. V., HICKS, M. J., CHAN, L. & BEAUDET, 
A. L. (2000) P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency 
substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp 
Med, 191, 189-194. 
COMINACINI, L., RIGONI, A., PASINI, A. F., GARBIN, U., DAVOLI, A., 
CAMPAGNOLA, M., PASTORINO, A. M., LO CASCIO, V. & SAWAMURA, T. (2001) 
The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces 
the intracellular concentration of nitric oxide in endothelial cells through an increased 
production of superoxide. J Biol Chem, 276, 13750-13755. 
CORTON, J. M., GILLESPIE, J. G. & HARDIE, D. G. (1994) Role of the AMP-activated 
protein kinase in the cellular stress response. Curr Biol, 4, 315-324. 
COSTA, M. A. & SIMON, D. I. (2005) Molecular basis of restenosis and drug-eluting 
stents. Circulation, 111, 2257-2273. 
CRAUWELS, H. M., VAN HOVE, C. E., HOLVOET, P., HERMAN, A. G. & BULT, H. 
(2003) Plaque-associated endothelial dysfunction in apolipoprotein E-deficient mice on a 
regular diet. Effect of human apolipoprotein AI. Cardiovasc Res, 59, 189-199. 
CRIQUI, M. H. & RINGEL, B. L. (1994) Does diet or alcohol explain the French 
paradox? Lancet, 344, 1719-1723. 
CYRUS, T., WITZTUM, J. L., RADER, D. J., TANGIRALA, R., FAZIO, S., LINTON, 
M. F. & FUNK, C. D. (1999) Disruption of the 12/15-lipoxygenase gene diminishes 
atherosclerosis in apo E-deficient mice. J Clin Invest, 103, 1597-1604. 
 205 
 
D'USCIO, L. V., BAKER, T. A., MANTILLA, C. B., SMITH, L., WEILER, D., SIECK, 
G. C. & KATUSIC, Z. S. (2001) Mechanism of endothelial dysfunction in apolipoprotein 
E-deficient mice. Arterioscler Thromb Vasc Biol, 21, 1017-1022. 
DAUGHERTY, A., DUNN, J. L., RATERI, D. L. & HEINECKE, J. W. (1994) 
Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human 
atherosclerotic lesions. J Clin Invest, 94, 437-444. 
DAVIES, S. P., HAWLEY, S. A., WOODS, A., CARLING, D., HAYSTEAD, T. A. & 
HARDIE, D. G. (1994) Purification of the AMP-activated protein kinase on ATP-gamma-
sepharose and analysis of its subunit structure. Eur J Biochem, 223, 351-357. 
DAVIGNON, J. & GANZ, P. (2004) Role of endothelial dysfunction in atherosclerosis. 
Circulation, 109, III27-32. 
DAVIS, B. J., XIE, Z., VIOLLET, B. & ZOU, M. H. (2006) Activation of the AMP-
activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by 
promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. 
Diabetes, 55, 496-505. 
DEVER, G., STEWART, L. J., PITT, A. R. & SPICKETT, C. M. (2003) Phospholipid 
chlorohydrins cause ATP depletion and toxicity in human myeloid cells. FEBS Lett, 540, 
245-250. 
DEVER, G., WAINWRIGHT, C. L., KENNEDY, S. & SPICKETT, C. M. (2006) Fatty 
acid and phospholipid chlorohydrins cause cell stress and endothelial adhesion. Acta 
Biochim Pol 53, 761-768. 
DEVER, G. J., BENSON, R., WAINWRIGHT, C. L., KENNEDY, S. & SPICKETT, C. 
M. (2008) Phospholipid chlorohydrin induces leukocyte adhesion to ApoE
-/-
 mouse arteries 
via upregulation of P-selectin. Free Radic Biol Med, 44, 452-463. 
DOLINSKY, V. W., MORTON, J. S., OKA, T., ROBILLARD-FRAYNE, I., BAGDAN, 
M., LOPASCHUK, G. D., DES ROSIERS, C., WALSH, K., DAVIDGE, S. T. & DYCK, 
J. R. (2010) Calorie restriction prevents hypertension and cardiac hypertrophy in the 
spontaneously hypertensive rat. Hypertension, 56, 412-421. 
DONG, Y., ZHANG, M., WANG, S., LIANG, B., ZHAO, Z., LIU, C., WU, M., CHOI, H. 
C., LYONS, T. J. & ZOU, M. H. (2010) Activation of AMP-activated protein kinase 
inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes, 59, 1386-
1396. 
DORAN, A. C., MELLER, N. & MCNAMARA, C. A. (2008) Role of smooth muscle cells 
in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol, 
28, 812-819. 
DRACHMAN, D. E., EDELMAN, E. R., SEIFERT, P., GROOTHUIS, A. R., 
BORNSTEIN, D. A., KAMATH, K. R., PALASIS, M., YANG, D., NOTT, S. H. & 
ROGERS, C. (2000) Neointimal thickening after stent delivery of paclitaxel: change in 
composition and arrest of growth over six months. J Am Coll Cardiol, 36, 2325-2332. 
DROBNIK, J., DABROWSKI, R., SZCZEPANOWSKA, A., GIERNAT, L. & LORENC, 
J. (2000) Response of aorta connective tissue matrix to injury caused by vassopressin-
induced hypertension or hypercholesterolemia. J Physiol Pharmacol, 51, 521-533. 
 206 
 
DUBEY, A., KANDULA, S. R. V. & KUMAR, P. (2008) Dimethyl sulfoxide pivaloyl 
chloride: A new reagent for oxidation of alcohols to carbonyls. Synthetic Commun, 38, 
746-753. 
DURAND, E., MALLAT, Z., ADDAD, F., VILDE, F., DESNOS, M., GUEROT, C., 
TEDGUI, A. & LAFONT, A. (2002) Time courses of apoptosis and cell proliferation and 
their relationship to arterial remodeling and restenosis after angioplasty in an 
atherosclerotic rabbit model. J Am Coll Cardiol, 39, 1680-1685. 
DZAU, V. J. & GIBBONS, G. H. (1988) Cell biology of vascular hypertrophy in systemic 
hypertension. Am J Cardiol, 62, 30G-35G. 
DZAU, V. J., BRAUN-DULLAEUS, R. C. & SEDDING, D. G. (2002) Vascular 
proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med, 8, 
1249-1256. 
ENSELEIT, F., HURLIMANN, D. & LUSCHER, T. F. (2001) Vascular protective effects 
of angiotensin converting enzyme inhibitors and their relation to clinical events. J 
Cardiovasc Pharmacol, 37 Suppl 1, S21-30. 
ERRIDGE, C. & SPICKETT, C. M. (2007) Oxidised phospholipid regulation of Toll-like 
receptor signalling. Redox Rep, 12, 76-80. 
ERRIDGE, C., KENNEDY, S., SPICKETT, C. M. & WEBB, D. J. (2008) Oxidized 
phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and 
TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of 
inhibition. J Biol Chem, 283, 24748-24759. 
EWART, M. A., KOHLHAAS, C. F. & SALT, I. P. (2008) Inhibition of tumor necrosis 
factor alpha-stimulated monocyte adhesion to human aortic endothelial cells by AMP-
activated protein kinase. Arterioscler Thromb Vasc Biol, 28, 2255-2257. 
EWART, M. A. & KENNEDY, S. (2011) AMPK and vasculoprotection. Pharmacol Ther, 
131, 242-253. 
EWART, M. A. & KENNEDY, S. (2012) Diabetic cardiovascular disease - AMP-activated 
protein kinase (AMPK) as a therapeutic target. Cardiovasc Hematol Agents Med Chem, 10, 
190-211. 
FATTORI, R. & PIVA, T. (2003) Drug-eluting stents in vascular intervention. Lancet, 
361, 247-249. 
FISCHMAN, D. L., LEON, M. B., BAIM, D. S., SCHATZ, R. A., SAVAGE, M. P., 
PENN, I., DETRE, K., VELTRI, L., RICCI, D., NOBUYOSHI, M. & ET AL. (1994) A 
randomized comparison of coronary-stent placement and balloon angioplasty in the 
treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med, 
331, 496-501. 
FOLEY, J. M., ADAMS, G. R. & MEYER, R. A. (1989) Utility of AICAr for metabolic 
studies is diminished by systemic effects in situ. Am J Physiol, 257, C488-494. 
FORD, D. A. & GROSS, R. W. (1989) Plasmenylethanolamine is the major storage depot 
for arachidonic acid in rabbit vascular smooth muscle and is rapidly hydrolyzed after 
angiotensin II stimulation. Proc Natl Acad Sci U S A, 86, 3479-3483. 
 207 
 
FORD, D. A. & HALE, C. C. (1996) Plasmalogen and anionic phospholipid dependence of 
the cardiac sarcolemmal sodium-calcium exchanger. FEBS Lett, 394, 99-102. 
FORD, R. J. & RUSH, J. W. (2011) Endothelium-dependent vasorelaxation to the AMPK 
activator AICAR is enhanced in aorta from hypertensive rats and is NO and EDCF 
dependent. Am J Physiol Heart Circ Physiol, 300, H64-75. 
FORD, R. J., TESCHKE, S. R., REID, E. B., DURHAM, K. K., KROETSCH, J. T. & 
RUSH, J. W. (2012) AMP-activated protein kinase activator AICAR acutely lowers blood 
pressure and relaxes isolated resistance arteries of hypertensive rats. J Hypertens, 30, 725-
733. 
FORRESTER, J. S., FISHBEIN, M., HELFANT, R. & FAGIN, J. (1991) A paradigm for 
restenosis based on cell biology: clues for the development of new preventive therapies. J 
Am Coll Cardiol, 17, 758-769. 
FRANCO-PONS, N., CASAS, J., FABRIAS, G., GEA-SORLI, S., DE-MADARIA, E., 
GELPI, E. & CLOSA, D. (2013) Fat necrosis generates proinflammatory halogenated 
lipids during acute pancreatitis. Ann Surg, 257, 943-951. 
FREIMAN, P. C., MITCHELL, G. G., HEISTAD, D. D., ARMSTRONG, M. L. & 
HARRISON, D. G. (1986) Atherosclerosis impairs endothelium-dependent vascular 
relaxation to acetylcholine and thrombin in primates. Circ Res, 58, 783-789. 
FRUHWIRTH, G. O., MOUMTZI, A., LOIDL, A., INGOLIC, E. & HERMETTER, A. 
(2006) The oxidized phospholipids POVPC and PGPC inhibit growth and induce apoptosis 
in vascular smooth muscle cells. BBA-Mol Cell Biol L, 1761, 1060-1069. 
FU, X., KASSIM, S. Y., PARKS, W. C. & HEINECKE, J. W. (2001) Hypochlorous acid 
oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for 
matrix metalloproteinase activation and atherosclerotic plaque rupture by 
myeloperoxidase. J Biol Chem, 276, 41279-41287. 
FUKUI, R., AMAKAWA, M., HOSHIGA, M., SHIBATA, N., KOHBAYASHI, E., 
SETO, M., SASAKI, Y., UENO, T., NEGORO, N., NAKAKOJI, T., II, M., 
NISHIGUCHI, F., ISHIHARA, T. & OHSAWA, N. (2000) Increased migration in late 
G(1) phase in cultured smooth muscle cells. Am J Physiol Cell Physiol, 279, C999-1007. 
FURNKRANZ, A., SCHOBER, A., BOCHKOV, V. N., BASHTRYKOV, P., KRONKE, 
G., KADL, A., BINDER, B. R., WEBER, C. & LEITINGER, N. (2005) Oxidized 
phospholipids trigger atherogenic inflammation in murine arteries. Arterioscler Thromb 
Vasc Biol, 25, 633-638. 
GARGALOVIC, P. S., IMURA, M., ZHANG, B., GHARAVI, N. M., CLARK, M. J., 
PAGNON, J., YANG, W. P., HE, A., TRUONG, A., PATEL, S., NELSON, S. F., 
HORVATH, S., BERLINER, J. A., KIRCHGESSNER, T. G. & LUSIS, A. J. (2006) 
Identification of inflammatory gene modules based on variations of human endothelial cell 
responses to oxidized lipids. Proc Natl Acad Sci U S A, 103, 12741-12746. 
GAUT, J. P. & HEINECKE, J. W. (2001) Mechanisms for oxidizing low-density 
lipoprotein - Insights from patterns of oxidation products in the artery wall and from mouse 
models of atherosclerosis. Trends Cardiovas Med, 11, 103-112. 
GEER, J. C. (1965) Fine structure of canine experimental atherosclerosis. Am J Pathol, 47, 
241-269. 
 208 
 
GEORGE, S. J. (2000) Therapeutic potential of matrix metalloproteinase inhibitors in 
atherosclerosis. Expert Opin Investig Drugs, 9, 993-1007. 
GERTHOFFER, W. T. (2007) Mechanisms of vascular smooth muscle cell migration. Circ 
Res, 100, 607-621. 
GERVAIS, M., PONS, S., NICOLETTI, A., COSSON, C., GIUDICELLI, J. F. & 
RICHER, C. (2003) Fluvastatin prevents renal dysfunction and vascular NO deficit in 
apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 23, 183-189. 
GHARAVI, N. M., BAKER, N. A., MOUILLESSEAUX, K. P., YEUNG, W., HONDA, 
H. M., HSIEH, X., YEH, M., SMART, E. J. & BERLINER, J. A. (2006) Role of 
endothelial nitric oxide synthase in the regulation of SREBP activation by oxidized 
phospholipids. Circ Res, 98, 768-776. 
GIBBONS, G. H. & DZAU, V. J. (1994) The emerging concept of vascular remodeling. N 
Engl J Med, 330, 1431-1438. 
GLASS, C. K. & WITZTUM, J. L. (2001) Atherosclerosis. the road ahead. Cell, 104, 503-
516. 
GODIN, D., IVAN, E., JOHNSON, C., MAGID, R. & GALIS, Z. S. (2000) Remodeling 
of carotid artery is associated with increased expression of matrix metalloproteinases in 
mouse blood flow cessation model. Circulation, 102, 2861-2866. 
GOIRAND, F., SOLAR, M., ATHEA, Y., VIOLLET, B., MATEO, P., FORTIN, D., 
LECLERC, J., HOERTER, J., VENTURA-CLAPIER, R. & GARNIER, A. (2007) 
Activation of AMP kinase alpha1 subunit induces aortic vasorelaxation in mice. J Physiol, 
581, 1163-1171. 
GOMEZ, D. & OWENS, G. K. (2012) Smooth muscle cell phenotypic switching in 
atherosclerosis. Cardiovasc Res, 95, 156-164. 
GÖRANSSON, O., MCBRIDE, A., HAWLEY, S. A., ROSS, F. A., SHPIRO, N., 
FORETZ, M., VIOLLET, B., HARDIE, D. G. & SAKAMOTO, K. (2007) Mechanism of 
action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol 
Chem, 282, 32549-32560. 
GORDON, D., REIDY, M. A., BENDITT, E. P. & SCHWARTZ, S. M. (1990) Cell 
proliferation in human coronary arteries. Proc Natl Acad Sci U S A, 87, 4600-4604. 
GOTTO, A. M., JR., POWNALL, H. J. & HAVEL, R. J. (1986) Introduction to the plasma 
lipoproteins. Methods Enzymol, 128, 3-41. 
GRASSIA, G., MADDALUNO, M., GUGLIELMOTTI, A., MANGANO, G., BIONDI, 
G., MAFFIA, P. & IALENTI, A. (2009) The anti-inflammatory agent bindarit inhibits 
neointima formation in both rats and hyperlipidaemic mice. Cardiovasc Res, 84, 485-493. 
GREIG, F. H., KENNEDY, S. & SPICKETT, C. M. (2012) Physiological effects of 
oxidized phospholipids and their cellular signaling mechanisms in inflammation. Free 
Radic Biol Med, 52, 266-280. 
GRIENDLING, K. K., SORESCU, D. & USHIO-FUKAI, M. (2000) NAD(P)H oxidase: 
role in cardiovascular biology and disease. Circ Res, 86, 494-501. 
 209 
 
GROSS, R. W. (1984) High plasmalogen and arachidonic acid content of canine 
myocardial sarcolemma: a fast atom bombardment mass spectroscopic and gas 
chromatography-mass spectroscopic characterization. Biochemistry, 23, 158-165. 
GRUNTZIG, A. R., SENNING, A. & SIEGENTHALER, W. E. (1979) Nonoperative 
dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N 
Engl J Med, 301, 61-68. 
HADOKE, P., WAINWRIGHT, C. L., WADSWORTH, R. M., BUTLER, K. & 
GIDDINGS, M. J. (1995) Characterization of the morphological and functional alterations 
in rabbit subclavian artery subjected to balloon angioplasty. Coron Artery Dis, 6, 403-415. 
HAMON, M., BAUTERS, C., MCFADDEN, E. P., WERNERT, N., LABLANCHE, J. M., 
DUPUIS, B. & BERTRAND, M. E. (1995) Restenosis after coronary angioplasty. Eur 
Heart J, 16 Suppl I, 33-48. 
HANDA, N., TAKAGI, T., SAIJO, S., TAKAYA, D., TOYAMA, M., TERADA, T., 
SHIROUZU, M., SUZUKI, A., LEE, S., YAMAUCHI, T., OKADA-IWABU, M., 
IWABU, M., KADOWAKI, T., MINOKOSHI, Y. & YOKOYAMA, S. (2011) Structural 
basis of compound C inhibition of human AMP-activated protein kinase α2 subunit kinase 
domain. Acta Crystallogr D Biol Crystallogr, 67, 480-487. 
HANKE, H., STROHSCHNEIDER, T., OBERHOFF, M., BETZ, E. & KARSCH, K. R. 
(1990) Time course of smooth muscle cell proliferation in the intima and media of arteries 
following experimental angioplasty. Circ Res, 67, 651-659. 
HANNAN, E. L., RACZ, M., HOLMES, D. R., WALFORD, G., SHARMA, S., KATZ, S., 
JONES, R. H. & KING, S. B. (2008) Comparison of coronary artery stenting outcomes in 
the eras before and after the introduction of drug-eluting stents. Circulation, 117, 2071-
2078. 
HARDIE, D. G. & CARLING, D. (1997) The AMP-activated protein kinase - fuel gauge 
of the mammalian cell? Eur J Biochem, 246, 259-273. 
HARDIE, D. G. (2004) The AMP-activated protein kinase pathway--new players upstream 
and downstream. J Cell Sci, 117, 5479-5487. 
HARDWICK, S. J., HEGYI, L., CLARE, K., LAW, N. S., CARPENTER, K. L., 
MITCHINSON, M. J. & SKEPPER, J. N. (1996) Apoptosis in human monocyte-
macrophages exposed to oxidized low density lipoprotein. J Pathol, 179, 294-302. 
HARTLEY, C. J., REDDY, A. K., MADALA, S., MARTIN-MCNULTY, B., VERGONA, 
R., SULLIVAN, M. E., HALKS-MILLER, M., TAFFET, G. E., MICHAEL, L. H., 
ENTMAN, M. L. & WANG, Y. X. (2000) Hemodynamic changes in apolipoprotein E-
knockout mice. Am J Physiol Heart Circ Physiol, 279, H2326-2334. 
HAUTMANN, M. B., MADSEN, C. S. & OWENS, G. K. (1997) A transforming growth 
factor beta (TGFbeta) control element drives TGFbeta-induced stimulation of smooth 
muscle alpha-actin gene expression in concert with two CArG elements. J Biol Chem, 272, 
10948-10956. 
HAVEL, R. J. (1984) The formation of LDL: mechanisms and regulation. J Lipid Res, 25, 
1570-1576. 
 210 
 
HAWLEY, S. A., DAVISON, M., WOODS, A., DAVIES, S. P., BERI, R. K., CARLING, 
D. & HARDIE, D. G. (1996) Characterization of the AMP-activated protein kinase kinase 
from rat liver and identification of threonine 172 as the major site at which it 
phosphorylates AMP-activated protein kinase. J Biol Chem, 271, 27879-27887. 
HAZELL, L. J. & STOCKER, R. (1993) Oxidation of low-density lipoprotein with 
hypochlorite causes transformation of the lipoprotein into a high-uptake form for 
macrophages. Biochem J, 290 (Pt 1), 165-172. 
HAZELL, L. J., VANDENBERG, J. J. M. & STOCKER, R. (1994) Oxidation of low-
density lipoprotein by hypochlorite causes aggregation that is mediated by modification of 
lysine residues rather than lipid oxidation. Biochem J, 302, 297-304. 
HAZELL, L. J., ARNOLD, L., FLOWERS, D., WAEG, G., MALLE, E. & STOCKER, R. 
(1996) Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin 
Invest, 97, 1535-1544. 
HAZELL, L. J., DAVIES, M. J. & STOCKER, R. (1999) Secondary radicals derived from 
chloramines of apolipoprotein B-100 contribute to HOCl-induced lipid peroxidation of 
low-density lipoproteins. Biochem J, 339, 489-495. 
HAZELL, L. J., BAERNTHALER, G. & STOCKER, R. (2001) Correlation between 
intima-to-media ratio, apolipoprotein B-100, myeloperoxidase, and hypochlorite-oxidized 
proteins in human atherosclerosis. Free Radic Biol Med, 31, 1254-1262. 
HAZEN, S. L., HALL, C. R., FORD, D. A. & GROSS, R. W. (1993) Isolation of a human 
myocardial cytosolic phospholipase A2 isoform. Fast atom bombardment mass 
spectroscopic and reverse-phase high pressure liquid chromatography identification of 
choline and ethanolamine glycerophospholipid substrates. J Clin Invest, 91, 2513-2522. 
HAZEN, S. L., HSU, F. F., DUFFIN, K. & HEINECKE, J. W. (1996) Molecular chlorine 
generated by the myeloperoxidase hydrogen peroxide chloride system of phagocytes 
converts low density lipoprotein cholesterol into a family of chlorinated sterols. J Biol 
Chem, 271, 23080-23088. 
HAZEN, S. L. & HEINECKE, J. W. (1997) 3-chlorotyrosine, a specific marker of 
myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein 
isolated from human atherosclerotic intima. J Clin Invest, 99, 2075-2081. 
HEINECKE, J. W., ROSEN, H. & CHAIT, A. (1984) Iron and copper promote 
modification of low density lipoprotein by human arterial smooth muscle cells in culture. J 
Clin Invest, 74, 1890-1894. 
HEINECKE, J. W., LI, W., MUELLER, D. M., BOHRER, A. & TURK, J. (1994) 
Cholesterol chlorohydrin synthesis by the myeloperoxidase-hydrogen peroxide-chloride 
system - Potential markers for lipoproteins oxidatively damaged by phagocytes. 
Biochemistry, 33, 10127-10136. 
HELDMAN, A. W., CHENG, L., JENKINS, G. M., HELLER, P. F., KIM, D. W., WARE, 
M., JR., NATER, C., HRUBAN, R. H., REZAI, B., ABELLA, B. S., BUNGE, K. E., 
KINSELLA, J. L., SOLLOTT, S. J., LAKATTA, E. G., BRINKER, J. A., HUNTER, W. 
L. & FROEHLICH, J. P. (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 
4 weeks in a porcine model of coronary restenosis. Circulation, 103, 2289-2295. 
 211 
 
HENRIKSEN, T., MAHONEY, E. M. & STEINBERG, D. (1981) Enhanced macrophage 
degradation of low density lipoprotein previously incubated with cultured endothelial cells: 
recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A, 
78, 6499-6503. 
HENRIKSEN, T., MAHONEY, E. M. & STEINBERG, D. (1983) Enhanced macrophage 
degradation of biologically modified low density lipoprotein. Arteriosclerosis, 3, 149-159. 
HESSLER, J. R., ROBERTSON, A. L., JR. & CHISOLM, G. M., 3RD (1979) LDL-
induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and 
endothelial cells in culture. Atherosclerosis, 32, 213-229. 
HEVONOJA, T., PENTIKAINEN, M. O., HYVONEN, M. T., KOVANEN, P. T. & ALA-
KORPELA, M. (2000) Structure of low density lipoprotein (LDL) particles: basis for 
understanding molecular changes in modified LDL. Biochim Biophys Acta, 1488, 189-210. 
HOUWELING, M., KLEIN, W. & GEELEN, M. J. (2002) Regulation of 
phosphatidylcholine and phosphatidylethanolamine synthesis in rat hepatocytes by 5-
aminoimidazole-4-carboxamide ribonucleoside (AICAR). Biochem J, 362, 97-104. 
HSIAI, T. K., CHO, S. K., REDDY, S., HAMA, S., NAVAB, M., DEMER, L. L., 
HONDA, H. M. & HO, C. M. (2001) Pulsatile flow regulates monocyte adhesion to 
oxidized lipid-induced endothelial cells. Arterioscler Thromb Vasc Biol, 21, 1770-1776. 
HUBER, J., VALES, A., MITULOVIC, G., BLUMER, M., SCHMID, R., WITZTUM, J. 
L., BINDER, B. R. & LEITINGER, N. (2002) Oxidized membrane vesicles and blebs from 
apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-
endothelial interactions. Arterioscler Thromb Vasc Biol, 22, 101-107. 
HUBER, J., FURNKRANZ, A., BOCHKOV, V. N., PATRICIA, M. K., LEE, H., 
HEDRICK, C. C., BERLINER, J. A., BINDER, B. R. & LEITINGER, N. (2006) Specific 
monocyte adhesion to endothelial cells induced by oxidized phospholipids involves 
activation of cPLA2 and lipoxygenase. J Lipid Res, 47, 1054-1062. 
HUNDAL, R. S., GOMEZ-MUNOZ, A., KONG, J. Y., SALH, B. S., MAROTTA, A., 
DURONIO, V. & STEINBRECHER, U. P. (2003) Oxidized low density lipoprotein 
inhibits macrophage apoptosis by blocking ceramide generation, thereby maintaining 
protein kinase B activation and Bcl-XL levels. J Biol Chem, 278, 24399-24408. 
HURLEY, R. L., ANDERSON, K. A., FRANZONE, J. M., KEMP, B. E., MEANS, A. R. 
& WITTERS, L. A. (2005) The Ca
2+
/calmodulin-dependent protein kinase kinases are 
AMP-activated protein kinase kinases. J Biol Chem, 280, 29060-29066. 
IDO, Y., CARLING, D. & RUDERMAN, N. (2002) Hyperglycemia-induced apoptosis in 
human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase 
activation. Diabetes, 51, 159-167. 
IGATA, M., MOTOSHIMA, H., TSURUZOE, K., KOJIMA, K., MATSUMURA, T., 
KONDO, T., TAGUCHI, T., NAKAMARU, K., YANO, M., KUKIDOME, D., 
MATSUMOTO, K., TOYONAGA, T., ASANO, T., NISHIKAWA, T. & ARAKI, E. 
(2005) Adenosine monophosphate-activated protein kinase suppresses vascular smooth 
muscle cell proliferation through the inhibition of cell cycle progression. Circ Res, 97, 837-
844. 
 212 
 
INOUE, T., KATO, T., HIKICHI, Y., HASHIMOTO, S., HIRASE, T., MOROOKA, T., 
IMOTO, Y., TAKEDA, Y., SENDO, F. & NODE, K. (2006) Stent-induced neutrophil 
activation is associated with an oxidative burst in the inflammatory process, leading to 
neointimal thickening. Thromb Haemost, 95, 43-48. 
INOUE, T. & NODE, K. (2009) Molecular basis of restenosis and novel issues of drug-
eluting stents. Circ J, 73, 615-621. 
ISHIBASHI, S., BROWN, M. S., GOLDSTEIN, J. L., GERARD, R. D., HAMMER, R. E. 
& HERZ, J. (1993) Hypercholesterolemia in low density lipoprotein receptor knockout 
mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest, 92, 883-893. 
ISHIGAMI, M., SWERTFEGER, D. K., GRANHOLM, N. A. & HUI, D. Y. (1998) 
Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle 
cell migration and proliferation by suppressing signal transduction and preventing cell 
entry to G1 phase. J Biol Chem, 273, 20156-20161. 
ISHII, N., MATSUMURA, T., KINOSHITA, H., MOTOSHIMA, H., KOJIMA, K., 
TSUTSUMI, A., KAWASAKI, S., YANO, M., SENOKUCHI, T., ASANO, T., 
NISHIKAWA, T. & ARAKI, E. (2009) Activation of AMP-activated protein kinase 
suppresses oxidized low-density lipoprotein-induced macrophage proliferation. J Biol 
Chem, 284, 34561-34569. 
ISNER, J. M., KEARNEY, M., BORTMAN, S. & PASSERI, J. (1995) Apoptosis in 
human atherosclerosis and restenosis. Circulation, 91, 2703-2711. 
JABER, A. J. & WILKINS, C. L. (2005) Hydrocarbon polymer analysis by external 
MALDI fourier transform and reflectron time of flight mass spectrometry. J Am Soc Mass 
Spectrom, 16, 2009-2016. 
JACOBS, R. L., LINGRELL, S., DYCK, J. R. & VANCE, D. E. (2007) Inhibition of 
hepatic phosphatidylcholine synthesis by 5-aminoimidazole-4-carboxamide-1-beta-4-
ribofuranoside is independent of AMP-activated protein kinase activation. J Biol Chem, 
282, 4516-4523. 
JANG, J. H., LEE, T. J., YANG, E. S., MIN DO, S., KIM, Y. H., KIM, S. H., CHOI, Y. 
H., PARK, J. W., CHOI, K. S. & KWON, T. K. (2010) Compound C sensitizes Caki renal 
cancer cells to TRAIL-induced apoptosis through reactive oxygen species-mediated down-
regulation of c-FLIPL and Mcl-1. Exp Cell Res, 316, 2194-2203. 
JAWIEN, J., NASTALEK, P. & KORBUT, R. (2004) Mouse models of experimental 
atherosclerosis. J Physiol Pharmacol, 55, 503-517. 
JERLICH, A., FABJAN, J. S., TSCHABUSCHNIG, S., SMIRNOVA, A. V., 
HORAKOVA, L., HAYN, M., AUER, H., GUTTENBERGER, H., LEIS, H. J., 
TATZBER, F., WAEG, G. & SCHAUR, R. J. (1998) Human low density lipoprotein as a 
target of hypochlorite generated by myeloperoxidase. Free Radic Biol Med, 24, 1139-
1148. 
JERLICH, A., PITT, A. R., SCHAUR, J. & SPICKETT, C. M. (2000) Pathways of 
phospholipid oxidation by HOCl in human LDL detected by LC-MS. Free Radic Biol 
Med, 28, 673-682. 
 213 
 
JIANG, X. C., PAULTRE, F., PEARSON, T. A., REED, R. G., FRANCIS, C. K., LIN, 
M., BERGLUND, L. & TALL, A. R. (2000) Plasma sphingomyelin level as a risk factor 
for coronary artery disease. Arterioscler Thromb Vasc Biol, 20, 2614-2618. 
JIN, J., MULLEN, T. D., HOU, Q., BIELAWSKI, J., BIELAWSKA, A., ZHANG, X., 
OBEID, L. M., HANNUN, Y. A. & HSU, Y. T. (2009) AMPK inhibitor Compound C 
stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 
breast carcinoma cells. J Lipid Res, 50, 2389-2397. 
JOHNSTONE, S. R., ROSS, J., RIZZO, M. J., STRAUB, A. C., LAMPE, P. D., 
LEITINGER, N. & ISAKSON, B. E. (2009) Oxidized phospholipid species promote in 
vivo differential cx43 phosphorylation and vascular smooth muscle cell proliferation. Am J 
Pathol, 175, 916-924. 
JUKEMA, J. W., AHMED, T. A., VERSCHUREN, J. J. & QUAX, P. H. (2012a) 
Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol, 9, 79-90. 
JUKEMA, J. W., VERSCHUREN, J. J., AHMED, T. A. & QUAX, P. H. (2012b) 
Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol, 9, 53-62. 
KANG, J. H., KIM, H. T., CHOI, M. S., LEE, W. H., HUH, T. L., PARK, Y. B., MOON, 
B. J. & KWON, O. S. (2006) Proteome analysis of human monocytic THP-1 cells primed 
with oxidized low-density lipoproteins. Proteomics, 6, 1261-1273. 
KANNEL, W. B., NEATON, J. D., WENTWORTH, D., THOMAS, H. E., STAMLER, J., 
HULLEY, S. B. & KJELSBERG, M. O. (1986) Overall and coronary heart disease 
mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. 
Multiple Risk Factor Intervention Trial. Am Heart J, 112, 825-836. 
KANTOR, B., ASHAI, K., HOLMES, D. R., JR. & SCHWARTZ, R. S. (1999) The 
experimental animal models for assessing treatment of restenosis. Cardiovasc Radiat Med, 
1, 48-54. 
KARAGIANNIDES, I., ABDOU, R., TZORTZOPOULOU, A., VOSHOL, P. J. & 
KYPREOS, K. E. (2008) Apolipoprotein E predisposes to obesity and related metabolic 
dysfunctions in mice. FEBS J, 275, 4796-4809. 
KATRANTZIS, M., BAKER, M. S., HANDLEY, C. J. & LOWTHER, D. A. (1991) The 
oxidant hypochlorite (OCl
-
), a product of the myeloperoxidase system, degrades articular 
cartilage proteoglycan aggregate. Free Radic Biol Med, 10, 101-109. 
KAWASAKI, T., DEWERCHIN, M., LIJNEN, H. R., VREYS, I., VERMYLEN, J. & 
HOYLAERTS, M. F. (2001) Mouse carotid artery ligation induces platelet-leukocyte-
dependent luminal fibrin, required for neointima development. Circ Res, 88, 159-166. 
KEMP, B. E., MITCHELHILL, K. I., STAPLETON, D., MICHELL, B. J., CHEN, Z. P. & 
WITTERS, L. A. (1999) Dealing with energy demand: the AMP-activated protein kinase. 
Trends Biochem Sci, 24, 22-25. 
KENNEDY, S., MCPHADEN, A. R., WADSWORTH, R. M. & WAINWRIGHT, C. L. 
(2000) Correlation of leukocyte adhesiveness, adhesion molecule expression and 
leukocyte-induced contraction following balloon angioplasty. Br J Pharmacol, 130, 95-
103. 
 214 
 
KENNEDY, S., PRESTON, A. A., MCPHADEN, A. R., MILLER, A. M., 
WAINWRIGHT, C. L. & WADSWORTH, R. M. (2004) Correlation of changes in nitric 
oxide synthase, superoxide dismutase and nitrotyrosine with endothelial regeneration and 
neointimal hyperplasia in the balloon-injured rabbit subclavian artery. Coron Artery Dis, 
15, 337-346. 
KENNEDY, S., WADSWORTH, R. M. & WAINWRIGHT, C. L. (2006) Locally 
administered antiproliferative drugs inhibit hypercontractility to serotonin in balloon-
injured pig coronary artery. Vascul Pharmacol, 44, 363-371. 
KIM, J. E., KIM, Y. W., LEE, I. K., KIM, J. Y., KANG, Y. J. & PARK, S. Y. (2008) 
AMP-activated protein kinase activation by 5-aminoimidazole-4-carboxamide-1-beta-D-
ribofuranoside (AICAR) inhibits palmitate-induced endothelial cell apoptosis through 
reactive oxygen species suppression. J Pharmacol Sci, 106, 394-403. 
KLEBANOFF, S. J. (1980) Oxygen metabolism and the toxic properties of phagocytes. 
Ann Intern Med, 93, 480-489. 
KLEBANOFF, S. J. (2005) Myeloperoxidase: friend and foe. J Leukoc Biol, 77, 598-625. 
KNOTT, T. J., PEASE, R. J., POWELL, L. M., WALLIS, S. C., RALL, S. C., JR., 
INNERARITY, T. L., BLACKHART, B., TAYLOR, W. H., MARCEL, Y., MILNE, R. & 
ET AL. (1986) Complete protein sequence and identification of structural domains of 
human apolipoprotein B. Nature, 323, 734-738. 
KOSEGAWA, I., KATAYAMA, S., KIKUCHI, C., KASHIWABARA, H., NEGISHI, K., 
ISHII, J., INUKAI, K. & OKA, Y. (1996) Metformin decreases blood pressure and obesity 
in OLETF rats via improvement of insulin resistance. Hypertens Res, 19, 37-41. 
KOTHAPALLI, D., LIU, S. L., BAE, Y. H., MONSLOW, J., XU, T., HAWTHORNE, E. 
A., BYFIELD, F. J., CASTAGNINO, P., RAO, S., RADER, D. J., PURE, E., PHILLIPS, 
M. C., LUND-KATZ, S., JANMEY, P. A. & ASSOIAN, R. K. (2012) Cardiovascular 
protection by apoE and apoE-HDL linked to suppression of ECM gene expression and 
arterial stiffening. Cell Rep, 2, 1259-1271. 
KU, D. N., GIDDENS, D. P., ZARINS, C. K. & GLAGOV, S. (1985) Pulsatile flow and 
atherosclerosis in the human carotid bifurcation. Positive correlation between plaque 
location and low oscillating shear stress. Arteriosclerosis, 5, 293-302. 
KUMAR, A. & LINDNER, V. (1997) Remodeling with neointima formation in the mouse 
carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol, 17, 2238-2244. 
KUMAR, A. P., PIEDRAFITA, F. J. & REYNOLDS, W. F. (2004) Peroxisome 
proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in 
macrophages by an estrogen-dependent mechanism involving the -463GA promoter 
polymorphism. J Biol Chem, 279, 8300-8315. 
KUMAR, V., BUTCHER, S. J., OORNI, K., ENGELHARDT, P., HEIKKONEN, J., 
KASKI, K., ALA-KORPELA, M. & KOVANEN, P. T. (2011) Three-dimensional cryoEM 
reconstruction of native LDL particles to 16A resolution at physiological body 
temperature. PLoS One, 6, e18841. 
KUNJATHOOR, V. V., FEBBRAIO, M., PODREZ, E. A., MOORE, K. J., 
ANDERSSON, L., KOEHN, S., RHEE, J. S., SILVERSTEIN, R., HOFF, H. F. & 
FREEMAN, M. W. (2002) Scavenger receptors class A-I/II and CD36 are the principal 
 215 
 
receptors responsible for the uptake of modified low density lipoprotein leading to lipid 
loading in macrophages. J Biol Chem, 277, 49982-49988. 
KUTTER, D., DEVAQUET, P., VANDERSTOCKEN, G., PAULUS, J. M., MARCHAL, 
V. & GOTHOT, A. (2000) Consequences of total and subtotal myeloperoxidase 
deficiency: Risk or benefit? Acta Haematol-Basel, 104, 10-15. 
LASKOWITZ, D. T., LEE, D. M., SCHMECHEL, D. & STAATS, H. F. (2000) Altered 
immune responses in apolipoprotein E-deficient mice. J Lipid Res, 41, 613-620. 
LEE, P. C., GIBBONS, G. H. & DZAU, V. J. (1993) Cellular and molecular mechanisms 
of coronary artery restenosis. Coron Artery Dis, 4, 254-259. 
LEITINGER, N., TYNER, T. R., OSLUND, L., RIZZA, C., SUBBANAGOUNDER, G., 
LEE, H., SHIH, P. T., MACKMAN, N., TIGYI, G., TERRITO, M. C., BERLINER, J. A. 
& VORA, D. K. (1999) Structurally similar oxidized phospholipids differentially regulate 
endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci U S A, 96, 12010-
12015. 
LEITINGER, N. (2005) Oxidized phospholipids as triggers of inflammation in 
atherosclerosis. Mol Nutr Food Res, 49, 1063-1071. 
LESSIG, J., SCHILLER, J., ARNHOLD, J. & FUCHS, B. (2007) Hypochlorous acid-
mediated generation of glycerophosphocholine from unsaturated plasmalogen 
glycerophosphocholine lipids. J Lipid Res, 48, 1316-1324. 
LEVICK, J. R. (2003) An Introduction to Cardiovascular Physiology 4th Edition, U K, 
Hodder Arnold. 
LI, C. & KEANEY, J. F., JR. (2010) AMP-activated protein kinase: a stress-responsive 
kinase with implications for cardiovascular disease. Curr Opin Pharmacol, 10, 111-115. 
LI, D. & MEHTA, J. L. (2000) Upregulation of endothelial receptor for oxidized LDL 
(LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery 
endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. 
Arterioscler Thromb Vasc Biol, 20, 1116-1122. 
LI, D., WANG, D., WANG, Y., LING, W., FENG, X. & XIA, M. (2010a) Adenosine 
monophosphate-activated protein kinase induces cholesterol efflux from macrophage-
derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice. J Biol 
Chem, 285, 33499-33509. 
LI, D., ZHANG, Y., MA, J., LING, W. & XIA, M. (2010b) Adenosine monophosphate 
activated protein kinase regulates ABCG1-mediated oxysterol efflux from endothelial cells 
and protects against hypercholesterolemia-induced endothelial dysfunction. Arterioscler 
Thromb Vasc Biol, 30, 1354-1362. 
LI, F. Y., LAM, K. S., TSE, H. F., CHEN, C., WANG, Y., VANHOUTTE, P. M. & XU, 
A. (2012) Endothelium-selective activation of AMP-activated protein kinase prevents 
diabetes mellitus-induced impairment in vascular function and re-endothelialization via 
induction of heme oxygenase-1 in mice. Circulation, 126, 1267-1277. 
LIBBY, P., SCHWARTZ, D., BROGI, E., TANAKA, H. & CLINTON, S. K. (1992) A 
cascade model for restenosis. A special case of atherosclerosis progression. Circulation, 
86, III47-52. 
 216 
 
LIBBY, P., EGAN, D. & SKARLATOS, S. (1997) Roles of infectious agents in 
atherosclerosis and restenosis: an assessment of the evidence and need for future research. 
Circulation, 96, 4095-4103. 
LIBBY, P. & SIMON, D. I. (2001) Inflammation and thrombosis: the clot thickens. 
Circulation, 103, 1718-1720. 
LIBBY, P. (2002) Inflammation in atherosclerosis. Nature, 420, 868-874. 
LINDNER, V. & REIDY, M. A. (1991) Proliferation of smooth muscle cells after vascular 
injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad 
Sci U S A, 88, 3739-3743. 
LINDNER, V., FINGERLE, J. & REIDY, M. A. (1993) Mouse model of arterial injury. 
Circ Res, 73, 792-796. 
LIPPI, G., FRANCHINI, M., FAVALORO, E. J. & TARGHER, G. (2010) Moderate red 
wine consumption and cardiovascular disease risk: Beyond the "French Paradox''. Semin 
Thromb Hemost, 36, 59-70. 
LITHELL, H. (1994) Pathogenesis and prevalence of atherosclerosis in hypertensive 
patients. Am J Hypertens, 7, 2S-6S. 
LIU, C., LIANG, B., WANG, Q., WU, J. & ZOU, M. H. (2010) Activation of AMP-
activated protein kinase alpha1 alleviates endothelial cell apoptosis by increasing the 
expression of anti-apoptotic proteins Bcl-2 and survivin. J Biol Chem, 285, 15346-15355. 
LIU, C., DESIKAN, R., YING, Z., GUSHCHINA, L., KAMPFRATH, T., DEIULIIS, J., 
WANG, A., XU, X., ZHONG, J., RAO, X., SUN, Q., MAISEYEU, A., 
PARTHASARATHY, S. & RAJAGOPALAN, S. (2012) Effects of a novel pharmacologic 
inhibitor of myeloperoxidase in a mouse atherosclerosis model. PLoS One, 7, e50767. 
LOIDL, A., SEVCSIK, E., RIESENHUBER, G., DEIGNER, H. P. & HERMETTER, A. 
(2003) Oxidized phospholipids in minimally modified low density lipoprotein induce 
apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells. 
J Biol Chem, 278, 32921-32928. 
LOIDL, A., CLAUS, R., INGOLIC, E., DEIGNER, H. P. & HERMETTER, A. (2004) 
Role of ceramide in activation of stress-associated MAP kinases by minimally modified 
LDL in vascular smooth muscle cells. Biochim Biophys Acta, 1690, 150-158. 
LONGNUS, S. L., WAMBOLT, R. B., PARSONS, H. L., BROWNSEY, R. W. & 
ALLARD, M. F. (2003) 5-Aminoimidazole-4-carboxamide 1-beta -D-ribofuranoside 
(AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am J Physiol 
Regul Integr Comp Physiol, 284, R936-944. 
LOPEZ, J. M., SANTIDRIAN, A. F., CAMPAS, C. & GIL, J. (2003) 5-Aminoimidazole-
4-carboxamide riboside induces apoptosis in Jurkat cells, but the AMP-activated protein 
kinase is not involved. Biochem J, 370, 1027-1032. 
MA, Z., LI, J., YANG, L., MU, Y., XIE, W., PITT, B. & LI, S. (2004) Inhibition of LPS- 
and CpG DNA-induced TNF-alpha response by oxidized phospholipids. Am J Physiol 
Lung Cell Mol Physiol, 286, L808-816. 
 217 
 
MACMAHON, S., SHARPE, N., GAMBLE, G., CLAGUE, A., MHURCHU, C. N., 
CLARK, T., HART, H., SCOTT, J. & WHITE, H. (2000) Randomized, placebo-controlled 
trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or 
other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of 
Atherosclerosis with Ramipril. J Am Coll Cardiol, 36, 438-443. 
MAGGI, E., MARCHESI, E., RAVETTA, V., FALASCHI, F., FINARDI, G. & 
BELLOMO, G. (1993) Low-density lipoprotein oxidation in essential hypertension. J 
Hypertens, 11, 1103-1111. 
MALLAT, Z. & TEDGUI, A. (2000) Apoptosis in the vasculature: mechanisms and 
functional importance. Br J Pharmacol, 130, 947-962. 
MALLE, E., WAEG, G., SCHREIBER, R., GRONE, E. F., SATTLER, W. S. & GRONE, 
H. J. (2000) Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system 
in human atherosclerotic lesions - Colocalization of myeloperoxidase and hypochlorite-
modified proteins. Eur J Biochem, 267, 4495-4503. 
MALLE, E., MARSCHE, G., ARNHOLD, J. & DAVIES, M. J. (2006) Modification of 
low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous 
acid. BBA-Mol Cell Biol L, 1761, 392-415. 
MANCUSO, A. J., HUANG, S. L. & SWERN, D. (1978) Oxidation of long-chain and 
related alcohols to carbonyles by dimethyl-sulfoxide activated by oxalyl chloride. J Org 
Chem, 43, 2480-2482. 
MARSCHE, G., HAMMER, A., OSKOLKOVA, O., KOZARSKY, K. F., SATTLER, W. 
& MALLE, E. (2002) Hypochlorite-modified high density lipoprotein, a high affinity 
ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent 
selective lipid uptake and reverse cholesterol transport. J Biol Chem, 277, 32172-32179. 
MARSCHE, G., HELLER, R., FAULER, G., KOVACEVIC, A., NUSZKOWSKI, A., 
GRAIER, W., SATTLER, W. & MALLE, E. (2004) 2-Chlorohexdecanal derived from 
hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural 
inhibitor of endothelial nitric oxide biosynthesis. Arterioscler Thromb Vasc Biol, 24, 2303-
2306. 
MARTINI, F. H. (2006) Fundamentals of Anatomy & Physiology 7th Edition, USA, 
Pearson Benjamin Cummings. 
MATTER, C. M., MA, L., VON LUKOWICZ, T., MEIER, P., LOHMANN, C., ZHANG, 
D., KILIC, U., HOFMANN, E., HA, S. W., HERSBERGER, M., HERMANN, D. M. & 
LUSCHER, T. F. (2006) Increased balloon-induced inflammation, proliferation, and 
neointima formation in apolipoprotein E (ApoE) knockout mice. Stroke, 37, 2625-2632. 
MCMILLEN, T. S., HEINECKE, J. W. & LEBOEUF, R. C. (2005) Expression of human 
myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation, 111, 
2798-2804. 
MEHRAN, R., DANGAS, G., ABIZAID, A. S., MINTZ, G. S., LANSKY, A. J., 
SATLER, L. F., PICHARD, A. D., KENT, K. M., STONE, G. W. & LEON, M. B. (1999) 
Angiographic patterns of in-stent restenosis: classification and implications for long-term 
outcome. Circulation, 100, 1872-1878. 
 218 
 
MERRILL, G. F., KURTH, E. J., HARDIE, D. G. & WINDER, W. W. (1997) AICA 
riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake 
in rat muscle. Am J Physiol, 273, E1107-1112. 
MESSNER, M. C., ALBERT, C. J. & FORD, D. A. (2008a) 2-Chlorohexadecanal and 2-
chlorohexadecanoic acid induce COX-2 expression in human coronary artery endothelial 
cells. Lipids, 43, 581-588. 
MESSNER, M. C., ALBERT, C. J., MCHOWAT, J. & FORD, D. A. (2008b) 
Identification of lysophosphatidylcholine-chlorohydrin in human atherosclerotic lesions. 
Lipids, 43, 243-249. 
METHVEN, L., SIMPSON, P. C. & MCGRATH, J. C. (2009) Alpha1A/B-knockout mice 
explain the native alpha1D-adrenoceptor's role in vasoconstriction and show that its 
location is independent of the other alpha1-subtypes. Br J Pharmacol, 158, 1663-1675. 
MILLER, A. M., MCPHADEN, A. R., WADSWORTH, R. M. & WAINWRIGHT, C. L. 
(2001) Inhibition by leukocyte depletion of neointima formation after balloon angioplasty 
in a rabbit model of restenosis. Cardiovasc Res, 49, 838-850. 
MITRA, A. K., DHUME, A. S. & AGRAWAL, D. K. (2004) "Vulnerable plaques" - 
ticking of the time bomb. Can J Physiol Pharm, 82, 860-871. 
MITRA, A. K. & AGRAWAL, D. K. (2006) In stent restenosis: bane of the stent era. J 
Clin Pathol, 59, 232-239. 
MOORE, K. J., KUNJATHOOR, V. V., KOEHN, S. L., MANNING, J. J., TSENG, A. A., 
SILVER, J. M., MCKEE, M. & FREEMAN, M. W. (2005) Loss of receptor-mediated lipid 
uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in 
hyperlipidemic mice. J Clin Invest, 115, 2192-2201. 
MOORE, K. J. & TABAS, I. (2011) Macrophages in the pathogenesis of atherosclerosis. 
Cell, 145, 341-355. 
MORROW, V. A., FOUFELLE, F., CONNELL, J. M., PETRIE, J. R., GOULD, G. W. & 
SALT, I. P. (2003) Direct activation of AMP-activated protein kinase stimulates nitric-
oxide synthesis in human aortic endothelial cells. J Biol Chem, 278, 31629-31639. 
MOSSE, P. R., CAMPBELL, G. R., WANG, Z. L. & CAMPBELL, J. H. (1985) Smooth 
muscle phenotypic expression in human carotid arteries. I. Comparison of cells from 
diffuse intimal thickenings adjacent to atheromatous plaques with those of the media. Lab 
Invest, 53, 556-562. 
MOTOSHIMA, H., GOLDSTEIN, B. J., IGATA, M. & ARAKI, E. (2006) AMPK and cell 
proliferation -AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol, 574, 
63-71. 
MOUMTZI, A., TRENKER, M., FLICKER, K., ZENZMAIER, E., SAF, R. & 
HERMETTER, A. (2007) Import and fate of fluorescent analogs of oxidized phospholipids 
in vascular smooth muscle cells. J Lipid Res, 48, 565-582. 
MOUSSA, I., REIMERS, B., MOSES, J., DIMARIO, C., DIFRANCESCO, L., 
FERRARO, M. & COLOMBO, A. (1997) Long-term angiographic and clinical outcome of 
patients undergoing multivessel coronary stenting. Circulation, 96, 3873-3879. 
 219 
 
MULLER, W. A. (2003) Leukocyte-endothelial-cell interactions in leukocyte 
transmigration and the inflammatory response. Trends Immunol, 24, 327-334. 
NABEL, E. G. (2002) CDKs and CKIs: molecular targets for tissue remodelling. Nat Rev 
Drug Discov, 1, 587-598. 
NAGATA, D., MOGI, M. & WALSH, K. (2003) AMP-activated protein kinase (AMPK) 
signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J 
Biol Chem, 278, 31000-31006. 
NAGATA, D., TAKEDA, R., SATA, M., SATONAKA, H., SUZUKI, E., NAGANO, T. 
& HIRATA, Y. (2004) AMP-activated protein kinase inhibits angiotensin II-stimulated 
vascular smooth muscle cell proliferation. Circulation, 110, 444-451. 
NAKASHIMA, Y., PLUMP, A. S., RAINES, E. W., BRESLOW, J. L. & ROSS, R. (1994) 
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial 
tree. Arterioscler Thromb, 14, 133-140. 
NAM, M., LEE, W. H., BAE, E. J. & KIM, S. G. (2008) Compound C inhibits clonal 
expansion of preadipocytes by increasing p21 level irrespectively of AMPK inhibition. 
Arch Biochem Biophys, 479, 74-81. 
NELSON, P. R., YAMAMURA, S., MUREEBE, L., ITOH, H. & KENT, K. C. (1998) 
Smooth muscle cell migration and proliferation are mediated by distinct phases of 
activation of the intracellular messenger mitogen-activated protein kinase. J Vasc Surg, 27, 
117-125. 
NICHOLLS, S. J. & HAZEN, S. L. (2005) Myeloperoxidase and cardiovascular disease. 
Arterioscler Thromb Vasc Biol, 25, 1102-1111. 
NICHOLLS, S. J. & HAZEN, S. L. (2009) Myeloperoxidase, modified lipoproteins, and 
atherogenesis. J Lipid Res, 50 Suppl, S346-351. 
NOGUCHI, N., NAKANO, K., ARATANI, Y., KOYAMA, H., KODAMA, T. & NIKI, E. 
(2000) Role of myeloperoxidase in the neutrophil-induced oxidation of low density 
lipoprotein as studied by myeloperoxidase-knockout mouse. J Biochem, 127, 971-976. 
NUSSHOLD, C., KOLLROSER, M., KOFELER, H., RECHBERGER, G., REICHER, H., 
ULLEN, A., BERNHART, E., WALTL, S., KRATZER, I., HERMETTER, A., HACKL, 
H., TRAJANOSKI, Z., HRZENJAK, A., MALLE, E. & SATTLER, W. (2010) 
Hypochlorite modification of sphingomyelin generates chlorinated lipid species that induce 
apoptosis and proteome alterations in dopaminergic PC12 neurons in vitro. Free Radic 
Biol Med, 48, 1588-1600. 
OLOFSSON, K. E., ANDERSSON, L., NILSSON, J. & BJORKBACKA, H. (2008) 
Nanomolar concentrations of lysophosphatidylcholine recruit monocytes and induce pro-
inflammatory cytokine production in macrophages. Biochem Biophys Res Commun, 370, 
348-352. 
OWENS, G. K., KUMAR, M. S. & WAMHOFF, B. R. (2004) Molecular regulation of 
vascular smooth muscle cell differentiation in development and disease. Physiol Rev, 84, 
767-801. 
PANASENKO, O. M., VAKHRUSHEVA, T., TRETYAKOV, V., SPALTEHOLZ, H. & 
ARNHOLD, J. (2007) Influence of chloride on modification of unsaturated 
 220 
 
phosphatidylcholines by the myeloperoxidase/hydrogen peroxide/bromide system. Chem 
Phys Lipids 149, 40-52. 
PELAT, M., DESSY, C., MASSION, P., DESAGER, J. P., FERON, O. & BALLIGAND, 
J. L. (2003) Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart 
rate and blood pressure variability in apolipoprotein E
-/-
 mice in vivo. Circulation, 107, 
2480-2486. 
PERLMAN, H., MAILLARD, L., KRASINSKI, K. & WALSH, K. (1997) Evidence for 
the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. 
Circulation, 95, 981-987. 
PEYTON, K. J., YU, Y., YATES, B., SHEBIB, A. R., LIU, X. M., WANG, H. & 
DURANTE, W. (2011) Compound C inhibits vascular smooth muscle cell proliferation 
and migration in an AMP-activated protein kinase-independent fashion. J Pharmacol Exp 
Ther, 338, 476-484. 
PIDKOVKA, N. A., CHEREPANOVA, O. A., YOSHIDA, T., ALEXANDER, M. R., 
DEATON, R. A., THOMAS, J. A., LEITINGER, N. & OWENS, G. K. (2007) Oxidized 
phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in 
vitro. Circ Res, 101, 792-801. 
PIEDRAHITA, J. A., ZHANG, S. H., HAGAMAN, J. R., OLIVER, P. M. & MAEDA, N. 
(1992) Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene 
targeting in embryonic stem cells. Proc Natl Acad Sci U S A, 89, 4471-4475. 
PITT, B., BYINGTON, R. P., FURBERG, C. D., HUNNINGHAKE, D. B., MANCINI, G. 
B., MILLER, M. E. & RILEY, W. (2000) Effect of amlodipine on the progression of 
atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation, 
102, 1503-1510. 
PLUMP, A. S., SMITH, J. D., HAYEK, T., AALTO-SETALA, K., WALSH, A., 
VERSTUYFT, J. G., RUBIN, E. M. & BRESLOW, J. L. (1992) Severe 
hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by 
homologous recombination in ES cells. Cell, 71, 343-353. 
PODREZ, E. A., SCHMITT, D., HOFF, H. F. & HAZEN, S. L. (1999) Myeloperoxidase-
generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin 
Invest, 103, 1547-1560. 
PODREZ, E. A., ABU-SOUD, H. M. & HAZEN, S. L. (2000a) Myeloperoxidase-
generated oxidants and atherosclerosis. Free Radic Biol Med, 28, 1717-1725. 
PODREZ, E. A., FEBBRAIO, M., SHEIBANI, N., SCHMITT, D., SILVERSTEIN, R. L., 
HAJJAR, D. P., COHEN, P. A., FRAZIER, W. A., HOFF, H. F. & HAZEN, S. L. (2000b) 
Macrophage scavenger receptor CD36 is the major receptor for LDL modified by 
monocyte-generated reactive nitrogen species. J Clin Invest, 105, 1095-1108. 
PORTMAN, O. W. & ALEXANDER, M. (1969) Lysophosphatidylcholine concentrations 
and metabolism in aortic intima plus inner media: effect of nutritionally induced 
atherosclerosis. J Lipid Res, 10, 158-165. 
PRUTZ, W. A. (1996) Hypochlorous acid interactions with thiols, nucleotides, DNA, and 
other biological substrates. Arch Biochem Biophys, 332, 110-120. 
 221 
 
RAINES, E. W. & ROSS, R. (1993) Smooth muscle cells and the pathogenesis of the 
lesions of atherosclerosis. Br Heart J, 69, S30-37. 
RANG, H. P., DALE, M. M., RITTER, J. M. & FLOWER, R. J. (2007) Rang and Dale's 
Pharmacology 6th Edition, USA, Churchill Livingstone Elsevier. 
RATCLIFFE, H. L. & LUGINBUHL, H. (1971) The domestic pig: a model for 
experimental atherosclerosis. Atherosclerosis, 13, 133-136. 
RAUSCH, P. G. & MOORE, T. G. (1975) Granule enzymes of polymorphonuclear 
neutrophils: A phylogenetic comparison. Blood, 46, 913-919. 
RAVANDI, A., BABAEI, S., LEUNG, R., MONGE, J. C., HOPPE, G., HOFF, H., 
KAMIDO, H. & KUKSIS, A. (2004) Phospholipids and oxophospholipids in 
atherosclerotic plaques at different stages of plaque development. Lipids, 39, 97-109. 
REDDICK, R. L., ZHANG, S. H. & MAEDA, N. (1994) Atherosclerosis in mice lacking 
apoE. Evaluation of lesional development and progression. Arterioscler Thromb, 14, 141-
147. 
REDDY, S., HAMA, S., GRIJALVA, V., HASSAN, K., MOTTAHEDEH, R., HOUGH, 
G., WADLEIGH, D. J., NAVAB, M. & FOGELMAN, A. M. (2001) Mitogen-activated 
protein kinase phosphatase 1 activity is necessary for oxidized phospholipids to induce 
monocyte chemotactic activity in human aortic endothelial cells. J Biol Chem, 276, 17030-
17035. 
REGAN, C. P., ADAM, P. J., MADSEN, C. S. & OWENS, G. K. (2000) Molecular 
mechanisms of decreased smooth muscle differentiation marker expression after vascular 
injury. J Clin Invest, 106, 1139-1147. 
RIVARD, A. & ANDRES, V. (2000) Vascular smooth muscle cell proliferation in the 
pathogenesis of atherosclerotic cardiovascular diseases. Histol Histopathol, 15, 557-571. 
RIVERA, L., MORON, R., ZARZUELO, A. & GALISTEO, M. (2009) Long-term 
resveratrol administration reduces metabolic disturbances and lowers blood pressure in 
obese Zucker rats. Biochem Pharmacol, 77, 1053-1063. 
ROBASZKIEWICZ, A., GREIG, F. H., PITT, A. R., SPICKETT, C. M., BARTOSZ, G. & 
SOSZYNSKI, M. (2010) Effect of phosphatidylcholine chlorohydrins on human 
erythrocytes. Chem Phys Lipids, 163, 639-647. 
ROMAN, M. J., PICKERING, T. G., SCHWARTZ, J. E., PINI, R. & DEVEREUX, R. B. 
(1995) Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll 
Cardiol, 25, 83-90. 
RONG, J. X., BERMAN, J. W., TAUBMAN, M. B. & FISHER, E. A. (2002) 
Lysophosphatidylcholine stimulates monocyte chemoattractant protein-1 gene expression 
in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol, 22, 1617-1623. 
RONG, J. X., SHAPIRO, M., TROGAN, E. & FISHER, E. A. (2003) Transdifferentiation 
of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. 
Proc Natl Acad Sci U S A, 100, 13531-13536. 
ROSS, R. (1995) Cell biology of atherosclerosis. Annu Rev Physiol, 57, 791-804. 
 222 
 
ROSS, R. (1999a) Mechanisms of disease. Atherosclerosis - An inflammatory disease. N 
Engl J Med, 340, 115-126. 
ROSS, R. (1999b) Atherosclerosis is an inflammatory disease. Am Heart J, 138, S419-
S420. 
SAMSAMSHARIAT, S. Z., BASATI, G., MOVAHEDIAN, A., POURFARZAM, M. & 
SARRAFZADEGAN, N. (2011) Elevated plasma myeloperoxidase levels in relation to 
circulating inflammatory markers in coronary artery disease. Biomark Med, 5, 377-385. 
SANTOS, N. C., FIGUEIRA-COELHO, J., MARTINS-SILVA, J. & SALDANHA, C. 
(2003) Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and 
molecular aspects. Biochem Pharmacol, 65, 1035-1041. 
SCHENK, E. A., GAMAN, E. M. & FEIGENBOUM, A. D. (1966) Spontaenous aortic 
lesions in rabbits. I. Morphological characteristics. Circ Res, 19, 80-88. 
SCHULTZ, J. & KAMINKER, K. (1962) Myeloperoxidase of the leucocyte of normal 
human blood. I. Content and localization. Arch Biochem Biophys, 96, 465-467. 
SCHULZ, E., DOPHEIDE, J., SCHUHMACHER, S., THOMAS, S. R., CHEN, K., 
DAIBER, A., WENZEL, P., MUNZEL, T. & KEANEY, J. F., JR. (2008) Suppression of 
the JNK pathway by induction of a metabolic stress response prevents vascular injury and 
dysfunction. Circulation, 118, 1347-1357. 
SCHWARTZ, R. S., HUBER, K. C., MURPHY, J. G., EDWARDS, W. D., CAMRUD, A. 
R., VLIETSTRA, R. E. & HOLMES, D. R. (1992) Restenosis and the proportional 
neointimal response to coronary artery injury: results in a porcine model. J Am Coll 
Cardiol, 19, 267-274. 
SCOTT, J. W., HAWLEY, S. A., GREEN, K. A., ANIS, M., STEWART, G., SCULLION, 
G. A., NORMAN, D. G. & HARDIE, D. G. (2004) CBS domains form energy-sensing 
modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin 
Invest, 113, 274-284. 
SENOKUCHI, T., MATSUMURA, T., SAKAI, M., MATSUO, T., YANO, M., 
KIRITOSHI, S., SONODA, K., KUKIDOME, D., NISHIKAWA, T. & ARAKI, E. (2004) 
Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase mediate 
macrophage proliferation induced by oxidized low-density lipoprotein. Atherosclerosis, 
176, 233-245. 
SHAO, B., ODA, M. N., BERGT, C., FU, X., GREEN, P. S., BROT, N., ORAM, J. F. & 
HEINECKE, J. W. (2006) Myeloperoxidase impairs ABCA1-dependent cholesterol efflux 
through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. 
J Biol Chem, 281, 9001-9004. 
SHAO, B., PENNATHUR, S. & HEINECKE, J. W. (2012) Myeloperoxidase targets 
apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in 
human atherosclerotic lesions. J Biol Chem, 287, 6375-6386. 
SHI, R., HU, C., YUAN, Q., YANG, T., PENG, J., LI, Y., BAI, Y., CAO, Z., CHENG, G. 
& ZHANG, G. (2011) Involvement of vascular peroxidase 1 in angiotensin II-induced 
vascular smooth muscle cell proliferation. Cardiovasc Res, 91, 27-36. 
 223 
 
SHIH, P. T., ELICES, M. J., FANG, Z. T., UGAROVA, T. P., STRAHL, D., TERRITO, 
M. C., FRANK, J. S., KOVACH, N. L., CABANAS, C., BERLINER, J. A. & VORA, D. 
K. (1999) Minimally modified low-density lipoprotein induces monocyte adhesion to 
endothelial connecting segment-1 by activating beta1 integrin. J Clin Invest, 103, 613-625. 
SHIMOKAWA, H. & VANHOUTTE, P. M. (1989) Impaired endothelium-dependent 
relaxation to aggregating platelets and related vasoactive substances in porcine coronary 
arteries in hypercholesterolemia and atherosclerosis. Circ Res, 64, 900-914. 
SIGWART, U., PUEL, J., MIRKOVITCH, V., JOFFRE, F. & KAPPENBERGER, L. 
(1987) Intravascular stents to prevent occlusion and restenosis after transluminal 
angioplasty. N Engl J Med, 316, 701-706. 
SIMON, B. C., CUNNINGHAM, L. D. & COHEN, R. A. (1990) Oxidized low density 
lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig 
coronary artery. J Clin Invest, 86, 75-79. 
SKALEN, K., GUSTAFSSON, M., RYDBERG, E. K., HULTEN, L. M., WIKLUND, O., 
INNERARITY, T. L. & BOREN, J. (2002) Subendothelial retention of atherogenic 
lipoproteins in early atherosclerosis. Nature, 417, 750-754. 
SONG, P., WANG, S., HE, C., LIANG, B., VIOLLET, B. & ZOU, M. H. (2011) 
AMPKalpha2 deletion exacerbates neointima formation by upregulating Skp2 in vascular 
smooth muscle cells. Circ Res, 109, 1230-1239. 
SPICKETT, C. M., RENNIE, N., WINTER, H., ZAMBONIN, L., LANDI, L., JERLICH, 
A., SCHAUR, R. J. & PITT, A. R. (2001) Detection of phospholipid oxidation in 
oxidatively stressed cells by reversed-phase HPLC coupled with positive-ionization 
electroscopy MS. Biochem J, 355, 449-457. 
SPICKETT, C. M. (2007) Chlorinated lipids and fatty acids: An emerging role in 
pathology. Pharmacol Ther, 115, 400-409. 
SPICKETT, C. M., REIS, A. & PITT, A. R. (2011) Identification of oxidized 
phospholipids by electrospray ionization mass spectrometry and LC-MS using a QQLIT 
instrument. Free Radic Biol Med, 51, 2133-2149. 
SPIGUEL, L. R., CHANDIWAL, A., VOSICKY, J. E., WEICHSELBAUM, R. R. & 
SKELLY, C. L. (2010) Concomitant proliferation and caspase-3 mediated apoptosis in 
response to low shear stress and balloon injury. J Surg Res, 161, 146-155. 
STAPLETON, D., GAO, G., MICHELL, B. J., WIDMER, J., MITCHELHILL, K., TEH, 
T., HOUSE, C. M., WITTERS, L. A. & KEMP, B. E. (1994) Mammalian 5'-AMP-
activated protein kinase non-catalytic subunits are homologs of proteins that interact with 
yeast Snf1 protein kinase. J Biol Chem, 269, 29343-29346. 
STAPLETON, D., WOOLLATT, E., MITCHELHILL, K. I., NICHOLL, J. K., 
FERNANDEZ, C. S., MICHELL, B. J., WITTERS, L. A., POWER, D. A., 
SUTHERLAND, G. R. & KEMP, B. E. (1997) AMP-activated protein kinase isoenzyme 
family: subunit structure and chromosomal location. FEBS Lett, 409, 452-456. 
STARY, H. C., BLANKENHORN, D. H., CHANDLER, A. B., GLAGOV, S., INSULL, 
W., JR., RICHARDSON, M., ROSENFELD, M. E., SCHAFFER, S. A., SCHWARTZ, C. 
J., WAGNER, W. D. & ET AL. (1992) A definition of the intima of human arteries and of 
its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the 
 224 
 
Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb, 12, 120-
134. 
STARY, H. C., CHANDLER, A. B., GLAGOV, S., GUYTON, J. R., INSULL, W., JR., 
ROSENFELD, M. E., SCHAFFER, S. A., SCHWARTZ, C. J., WAGNER, W. D. & 
WISSLER, R. W. (1994) A definition of initial, fatty streak, and intermediate lesions of 
atherosclerosis. A report from the Committee on Vascular Lesions of the Council on 
Arteriosclerosis, American Heart Association. Arterioscler Thromb, 14, 840-856. 
STARY, H. C., CHANDLER, A. B., DINSMORE, R. E., FUSTER, V., GLAGOV, S., 
INSULL, W., JR., ROSENFELD, M. E., SCHWARTZ, C. J., WAGNER, W. D. & 
WISSLER, R. W. (1995) A definition of advanced types of atherosclerotic lesions and a 
histological classification of atherosclerosis. A report from the Committee on Vascular 
Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler 
Thromb Vasc Biol, 15, 1512-1531. 
STARY, H. C. (2000) Natural history and histological classification of atherosclerotic 
lesions: an update. Arterioscler Thromb Vasc Biol, 20, 1177-1178. 
STEINBERG, D. H., GAGLIA, M. A., SLOTTOW, T. L. P., ROY, P., BONELLO, L., DE 
LABRIOLLE, A., LEMESLE, G., TORGUSON, R., KINESHIGE, K., XUE, Z. Y., 
SUDDATH, W. O., KENT, K. M., SATLER, L. F., PICHARD, A. D., LINDSAY, J. & 
WAKSMAN, R. (2009) Outcome differences with the use of drug-eluting stents for the 
treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. Am J 
Cardiol, 103, 491-495. 
STEINBRECHER, U. P., PARTHASARATHY, S., LEAKE, D. S., WITZTUM, J. L. & 
STEINBERG, D. (1984) Modification of low density lipoprotein by endothelial cells 
involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc 
Natl Acad Sci U S A, 81, 3883-3887. 
STEINBRECHER, U. P., ZHANG, H. F. & LOUGHEED, M. (1990) Role of oxidatively 
modified LDL in atherosclerosis. Free Radic Biol Med, 9, 155-168. 
STEMMER, U., DUNAI, Z. A., KOLLER, D., PURSTINGER, G., ZENZMAIER, E., 
DEIGNER, H. P., AFLAKI, E., KRATKY, D. & HERMETTER, A. (2012) Toxicity of 
oxidized phospholipids in cultured macrophages. Lipids Health Dis, 11, 110. 
STOLL, G. & BENDSZUS, M. (2006) Inflammation and atherosclerosis: Novel insights 
into plaque formation and destabilization. Stroke, 37, 1923-1932. 
STONE, J. D., NARINE, A., SHAVER, P. R., FOX, J. C., VUNCANNON, J. R. & 
TULIS, D. (2013) AMP-activated protein kinase inhibits vascular smooth muscle cell 
proliferation and migration and vascular remodeling following injury. Am J Physiol Heart 
Circ Physiol, 304, H369-H381. 
SUBBANAGOUNDER, G., WATSON, A. D. & BERLINER, J. A. (2000) Bioactive 
products of phospholipid oxidation: isolation, identification, measurement and activities. 
Free Radic Biol Med, 28, 1751-1761. 
SUBBANAGOUNDER, G., DENG, Y. J., BORROMEO, C., DOOLEY, A. N., 
BELINER, J. A. & SALOMON, R. G. (2002) Hydroxy alkenal phospholipids regulate 
inflammatory functions of endothelial cells. Vasc Pharmacol, 38, 201-209. 
 225 
 
SUN, W., LEE, T. S., ZHU, M., GU, C., WANG, Y., ZHU, Y. & SHYY, J. Y. (2006) 
Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation, 114, 2655-
2662. 
SUZUKI, H., KURIHARA, Y., TAKEYA, M., KAMADA, N., KATAOKA, M., 
JISHAGE, K., UEDA, O., SAKAGUCHI, H., HIGASHI, T., SUZUKI, T., TAKASHIMA, 
Y., KAWABE, Y., CYNSHI, O., WADA, Y., HONDA, M., KURIHARA, H., 
ABURATANI, H., DOI, T., MATSUMOTO, A., AZUMA, S., NODA, T., TOYODA, Y., 
ITAKURA, H., YAZAKI, Y., KODAMA, T. & ET AL. (1997) A role for macrophage 
scavenger receptors in atherosclerosis and susceptibility to infection. Nature, 386, 292-296. 
SWERTFEGER, D. K., BU, G. & HUI, D. Y. (2002) Low density lipoprotein receptor-
related protein mediates apolipoprotein E inhibition of smooth muscle cell migration. J 
Biol Chem, 277, 4141-4146. 
SWINDLE, M. M., SMITH, A. C. & HEPBURN, B. J. (1988) Swine as models in 
experimental surgery. J Invest Surg, 1, 65-79. 
TANNER, F. C., YANG, Z. Y., DUCKERS, E., GORDON, D., NABEL, G. J. & NABEL, 
E. G. (1998) Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ 
Res, 82, 396-403. 
TEIRSTEIN, P. S., MASSULLO, V., JANI, S., POPMA, J. J., MINTZ, G. S., RUSSO, R. 
J., SCHATZ, R. A., GUARNERI, E. M., STEUTERMAN, S., MORRIS, N. B., LEON, M. 
B. & TRIPURANENI, P. (1997) Catheter-based radiotherapy to inhibit restenosis after 
coronary stenting. N Engl J Med, 336, 1697-1703. 
TENNANT, G. M., WADSWORTH, R. M. & KENNEDY, S. (2008) PAR-2 mediates 
increased inflammatory cell adhesion and neointima formation following vascular injury in 
the mouse. Atherosclerosis, 198, 57-64. 
THEILMEIER, G., QUARCK, R., VERHAMME, P., BOCHATON-PIALLAT, M. L., 
LOX, M., BERNAR, H., JANSSENS, S., KOCKX, M., GABBIANI, G., COLLEN, D. & 
HOLVOET, P. (2002) Hypercholesterolemia impairs vascular remodelling after porcine 
coronary angioplasty. Cardiovasc Res, 55, 385-395. 
THORNE, G. D., ISHIDA, Y. & PAUL, R. J. (2004) Hypoxic vasorelaxation: Ca
2+
-
dependent and Ca
2+
-independent mechanisms. Cell Calcium, 36, 201-208. 
THUKKANI, A. K., HSU, F. F., CROWLEY, J. R., WYSOLMERSKI, R. B., ALBERT, 
C. J. & FORD, D. A. (2002) Reactive chlorinating species produced during neutrophil 
activation target tissue plasmalogens - Production of the chemoattractant, 2-
chlorohexadecanal. J Biol Chem, 277, 3842-3849. 
THUKKANI, A. K., ALBERT, C. J., WILDSMITH, K. R., MESSNER, M. C., 
MARTINSON, B. D., HSU, F.-F. & FORD, D. A. (2003a) Myeloperoxidase-derived 
reactive chlorinating species from human monocytes target plasmalogens in low density 
lipoprotein. J Biol Chem, 278, 36365-36372. 
THUKKANI, A. K., MCHOWAT, J., HSU, F.-F., BRENNAN, M.-L., HAZEN, S. L. & 
FORD, D. A. (2003b) Identification of α-chloro fatty aldehydes and unsaturated 
lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation, 
108, 3128-3133. 
 226 
 
THUKKANI, A. K., MARTINSON, B. D., ALBERT, C. J., VOGLER, G. A. & FORD, D. 
A. (2005) Neutrophil-mediated accumulation of 2-ClHDA during myocardial infarction: 2-
ClHDA-mediated myocardial injury. Am J Physiol Heart Circ Physiol, 288, H2955-
H2964. 
THYBERG, J. & HULTGARDH-NILSSON, A. (1994) Fibronectin and the basement 
membrane components laminin and collagen type IV influence the phenotypic properties 
of subcultured rat aortic smooth muscle cells differently. Cell Tissue Res, 276, 263-271. 
TOWLER, M. C. & HARDIE, D. G. (2007) AMP-activated protein kinase in metabolic 
control and insulin signaling. Circ Res, 100, 328-341. 
TSOYI, K., JANG, H. J., NIZAMUTDINOVA, I. T., KIM, Y. M., LEE, Y. S., KIM, H. J., 
SEO, H. G., LEE, J. H. & CHANG, K. C. (2011) Metformin inhibits HMGB1 release in 
LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J 
Pharmacol, 162, 1498-1508. 
ULLEN, A., FAULER, G., KOFELER, H., WALTL, S., NUSSHOLD, C., BERNHART, 
E., REICHER, H., LEIS, H. J., WINTERSPERGER, A., MALLE, E. & SATTLER, W. 
(2010) Mouse brain plasmalogens are targets for hypochlorous acid-mediated modification 
in vitro and in vivo. Free Radic Biol Med, 49, 1655-1665. 
VAN DEN BERG, J. J., WINTERBOURN, C. C. & KUYPERS, F. A. (1993) 
Hypochlorous acid-mediated modification of cholesterol and phospholipid: analysis of 
reaction products by gas chromatography-mass spectrometry. J Lipid Res, 34, 2005-2012. 
VAN LEEUWEN, M., GIJBELS, M. J., DUIJVESTIJN, A., SMOOK, M., VAN DE 
GAAR, M. J., HEERINGA, P., DE WINTHER, M. P. & TERVAERT, J. W. (2008) 
Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLr
-/-
 
mice. Arterioscler Thromb Vasc Biol, 28, 84-89. 
VAN TITS, L. J., STIENSTRA, R., VAN LENT, P. L., NETEA, M. G., JOOSTEN, L. A. 
& STALENHOEF, A. F. (2011) Oxidized LDL enhances pro-inflammatory responses of 
alternatively activated M2 macrophages: a crucial role for Krüppel-like factor 2. 
Atherosclerosis, 214, 345-349. 
VASQUEZ-VIVAR, J., KALYANARAMAN, B., MARTASEK, P., HOGG, N., 
MASTERS, B. S., KAROUI, H., TORDO, P. & PRITCHARD, K. A., JR. (1998) 
Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. 
Proc Natl Acad Sci U S A, 95, 9220-9225. 
VELASCO, G., GEELEN, M. J. & GUZMAN, M. (1997) Control of hepatic fatty acid 
oxidation by 5'-AMP-activated protein kinase involves a malonyl-CoA-dependent and a 
malonyl-CoA-independent mechanism. Arch Biochem Biophys, 337, 169-175. 
VINCENT, M. F., ERION, M. D., GRUBER, H. E. & VAN DEN BERGHE, G. (1996) 
Hypoglycaemic effect of AICAriboside in mice. Diabetologia, 39, 1148-1155. 
VISSERS, M. C. M., PULLAR, J. M. & HAMPTON, M. B. (1999) Hypochlorous acid 
causes caspase activation and apoptosis or growth arrest in human endothelial cells. 
Biochem J, 344 Pt 2, 443-449. 
VISSERS, M. C. M., CARR, A. C. & WINTERBOURN, C. C. (2001) Fatty acid 
chlorohydrins and bromohydrins are cytotoxic to human endothelial cells. Redox Rep, 6, 
49-56. 
 227 
 
VUCICEVIC, L., MISIRKIC, M., JANJETOVIC, K., HARHAJI-TRAJKOVIC, L., 
PRICA, M., STEVANOVIC, D., ISENOVIC, E., SUDAR, E., SUMARAC-
DUMANOVIC, M., MICIC, D. & TRAJKOVIC, V. (2009) AMP-activated protein kinase-
dependent and -independent mechanisms underlying in vitro antiglioma action of 
compound C. Biochem Pharmacol, 77, 1684-1693. 
WALKER, L. N., BOWEN-POPE, D. F., ROSS, R. & REIDY, M. A. (1986) Production of 
platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells 
accompanies proliferation after arterial injury. Proc Natl Acad Sci U S A, 83, 7311-7315. 
WALTON, K. A., COLE, A. L., YEH, M., SUBBANAGOUNDER, G., KRUTZIK, S. R., 
MODLIN, R. L., LUCAS, R. M., NAKAI, J., SMART, E. J., VORA, D. K. & 
BERLINER, J. A. (2003) Specific phospholipid oxidation products inhibit ligand 
activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol, 23, 1197-1203. 
WANG, Q., ZHANG, M., LIANG, B., SHIRWANY, N., ZHU, Y. & ZOU, M. H. (2011a) 
Activation of AMP-activated protein kinase is required for berberine-induced reduction of 
atherosclerosis in mice: the role of uncoupling protein 2. PLoS One, 6, e25436. 
WANG, S., LIANG, B., VIOLLET, B. & ZOU, M. H. (2011b) Inhibition of the AMP-
activated protein kinase-alpha2 accentuates agonist-induced vascular smooth muscle 
contraction and high blood pressure in mice. Hypertension, 57, 1010-1017. 
WARDLE, R. L., GU, M., ISHIDA, Y. & PAUL, R. J. (2006) Ca
2+
-desensitizing hypoxic 
vasorelaxation: pivotal role for the myosin binding subunit of myosin phosphatase 
(MYPT1) in porcine coronary artery. J Physiol, 572, 259-267. 
WATSON, A. D., BERLINER, J. A., HAMA, S. Y., LA DU, B. N., FAULL, K. F., 
FOGELMAN, A. M. & NAVAB, M. (1995) Protective effect of high density lipoprotein 
associated paraoxonase. Inhibition of the biological activity of minimally oxidized low 
density lipoprotein. J Clin Invest, 96, 2882-2891. 
WATSON, A. D., LEITINGER, N., NAVAB, M., FAULL, K. F., HORKKO, S., 
WITZTUM, J. L., PALINSKI, W., SCHWENKE, D., SALOMON, R. G., SHA, W., 
SUBBANAGOUNDER, G., FOGELMAN, A. M. & BERLINER, J. A. (1997) Structural 
identification by mass spectrometry of oxidized phospholipids in minimally oxidized low 
density lipoprotein that induce monocyte/endothelial interactions and evidence for their 
presence in vivo. J Biol Chem, 272, 13597-13607. 
WEIDINGER, F. F., MCLENACHAN, J. M., CYBULSKY, M. I., GORDON, J. B., 
RENNKE, H. G., HOLLENBERG, N. K., FALLON, J. T., GANZ, P. & COOKE, J. P. 
(1990) Persistent dysfunction of regenerated endothelium after balloon angioplasty of 
rabbit iliac artery. Circulation, 81, 1667-1679. 
WEISS, D., KOOLS, J. J. & TAYLOR, W. R. (2001) Angiotensin II-induced hypertension 
accelerates the development of atherosclerosis in apoE-deficient mice. Circulation, 103, 
448-454. 
WELT, F. G. & ROGERS, C. (2002) Inflammation and restenosis in the stent era. 
Arterioscler Thromb Vasc Biol, 22, 1769-1776. 
WILDSMITH, K. R., ALBERT, C. J., ANBUKUMAR, D. S. & FORD, D. A. (2006) 
Metabolism of myeloperoxidase-derived 2-chlorohexadecanal. J Biol Chem, 281, 16849-
16860. 
 228 
 
WINDER, W. W., HOLMES, B. F., RUBINK, D. S., JENSEN, E. B., CHEN, M. & 
HOLLOSZY, J. O. (2000) Activation of AMP-activated protein kinase increases 
mitochondrial enzymes in skeletal muscle. J Appl Physiol, 88, 2219-2226. 
WINTERBOURN, C. C., VANDENBERG, J. J. M., ROITMAN, E. & KUYPERS, F. A. 
(1992) Chlorohydrin formation from unsaturated fatty-acids reacted with hypochlorous 
acid. Arch Biochem Biophys, 296, 547-555. 
WITZTUM, J. L. & STEINBERG, D. (1991) Role of oxidized low density lipoprotein in 
atherogenesis. J Clin Invest, 88, 1785-1792. 
WITZTUM, J. L. (1994) The oxidation hypothesis of atherosclerosis. Lancet, 344, 793-
795. 
WOODS, A., SALT, I., SCOTT, J., HARDIE, D. G. & CARLING, D. (1996) The alpha1 
and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver 
but exhibit differences in substrate specificity in vitro. FEBS Lett, 397, 347-351. 
WOODS, A., JOHNSTONE, S. R., DICKERSON, K., LEIPER, F. C., FRYER, L. G., 
NEUMANN, D., SCHLATTNER, U., WALLIMANN, T., CARLSON, M. & CARLING, 
D. (2003a) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. 
Curr Biol, 13, 2004-2008. 
WOODS, A. A., LINTON, S. M. & DAVIES, M. J. (2003b) Detection of HOCl-mediated 
protein oxidation products in the extracellular matrix of human atherosclerotic plaques. 
Biochem J, 370, 729-735. 
XUE, B. & KAHN, B. B. (2006) AMPK integrates nutrient and hormonal signals to 
regulate food intake and energy balance through effects in the hypothalamus and peripheral 
tissues. J Physiol, 574, 73-83. 
YAN, Z. Q. & HANSSON, G. K. (2007) Innate immunity, macrophage activation, and 
atherosclerosis. Immunol Rev, 219, 187-203. 
YANG, C. Y., CHEN, S. H., GIANTURCO, S. H., BRADLEY, W. A., SPARROW, J. T., 
TANIMURA, M., LI, W. H., SPARROW, D. A., DELOOF, H., ROSSENEU, M. & ET 
AL. (1986) Sequence, structure, receptor-binding domains and internal repeats of human 
apolipoprotein B-100. Nature, 323, 738-742. 
YANG, J., CHENG, Y., JI, R. & ZHANG, C. (2006) Novel model of inflammatory 
neointima formation reveals a potential role of myeloperoxidase in neointimal hyperplasia. 
Am J Physiol Heart Circ Physiol, 291, H3087-3093. 
YANG, R., POWELL-BRAXTON, L., OGAOAWARA, A. K., DYBDAL, N., 
BUNTING, S., OHNEDA, O. & JIN, H. (1999) Hypertension and endothelial dysfunction 
in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol, 19, 2762-2768. 
YEH, M., LEITINGER, N., DE MARTIN, R., ONAI, N., MATSUSHIMA, K., VORA, D. 
K., BERLINER, J. A. & REDDY, S. T. (2001) Increased transcription of IL-8 in 
endothelial cells is differentially regulated by TNF-alpha and oxidized phospholipids. 
Arterioscler Thromb Vasc Biol, 21, 1585-1591. 
YEH, M., COLE, A. L., CHOI, J., LIU, Y., TULCHINSKY, D., QIAO, J. H., FISHBEIN, 
M. C., DOOLEY, A. N., HOVNANIAN, T., MOUILLESEAUX, K., VORA, D. K., 
YANG, W. P., GARGALOVIC, P., KIRCHGESSNER, T., SHYY, J. Y. & BERLINER, J. 
 229 
 
A. (2004) Role for sterol regulatory element-binding protein in activation of endothelial 
cells by phospholipid oxidation products. Circ Res, 95, 780-788. 
YIN, M., ZHANG, L., SUN, X. M., MAO, L. F. & PAN, J. (2010) Lack of apoE causes 
alteration of cytokines expression in young mice liver. Mol Biol Rep, 37, 2049-2054. 
YOSHIDA, T., GAN, Q. & OWENS, G. K. (2008) Kruppel-like factor 4, Elk-1, and 
histone deacetylases cooperatively suppress smooth muscle cell differentiation markers in 
response to oxidized phospholipids. Am J Physiol Cell Physiol, 295, C1175-1182. 
YU, S., WONG, S. L., LAU, C. W., HUANG, Y. & YU, C. M. (2011) Oxidized LDL at 
low concentration promotes in-vitro angiogenesis and activates nitric oxide synthase 
through PI3K/Akt/eNOS pathway in human coronary artery endothelial cells. Biochem 
Biophys Res Commun, 407, 44-48. 
YU, W., LIU-BRYAN, R., STEVENS, S., DAMANAHALLI, J. K. & TERKELTAUB, R. 
(2012) RAGE signaling mediates post-injury arterial neointima formation by suppression 
of liver kinase B1 and AMPK activity. Atherosclerosis, 222, 417-425. 
ZADELAAR, S., KLEEMANN, R., VERSCHUREN, L., DE VRIES-VAN DER WEIJ, J., 
VAN DER HOORN, J., PRINCEN, H. M. & KOOISTRA, T. (2007) Mouse models for 
atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol, 27, 1706-
1721. 
ZETTLER, M. E., PROCIUK, M. A., AUSTRIA, J. A., MASSAELI, H., ZHONG, G. M. 
& PIERCE, G. N. (2003) OxLDL stimulates cell proliferation through a general induction 
of cell cycle proteins. Am J Physiol Heart Circ Physiol, 284, H644-H653. 
ZHANG, R., BRENNAN, M. L., FU, X., AVILES, R. J., PEARCE, G. L., PENN, M. S., 
TOPOL, E. J., SPRECHER, D. L. & HAZEN, S. L. (2001) Association between 
myeloperoxidase levels and risk of coronary artery disease. JAMA, 286, 2136-2142. 
ZHAO, X., ZMIJEWSKI, J. W., LORNE, E., LIU, G., PARK, Y. J., TSURUTA, Y. & 
ABRAHAM, E. (2008) Activation of AMPK attenuates neutrophil proinflammatory 
activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol 
Physiol, 295, L497-504. 
ZHOU, G., MYERS, R., LI, Y., CHEN, Y., SHEN, X., FENYK-MELODY, J., WU, M., 
VENTRE, J., DOEBBER, T., FUJII, N., MUSI, N., HIRSHMAN, M. F., GOODYEAR, L. 
J. & MOLLER, D. E. (2001) Role of AMP-activated protein kinase in mechanism of 
metformin action. J Clin Invest, 108, 1167-1174. 
ZHU, B., KUHEL, D. G., WITTE, D. P. & HUI, D. Y. (2000) Apolipoprotein E inhibits 
neointimal hyperplasia after arterial injury in mice. Am J Pathol, 157, 1839-1848. 
ZIOUZENKOVA, O., ASATRYAN, L., AKMAL, M., TETTA, C., WRATTEN, M. L., 
LOSETO-WICH, G., JURGENS, G., HEINECKE, J. & SEVANIAN, A. (1999) Oxidative 
cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification 
in blood. Relevance to atherogenesis caused by hemodialysis. J Biol Chem, 274, 18916-
18924. 
 
  
 230 
 
Appendices 
Appendix 1: 
F.H. Greig, S. Kennedy and C.M. Spickett (2012) Physiological effects of oxidized 
phospholipids and their cellular signaling mechanisms in inflammation. Free Radic Biol 
Med, 52, 266-280. 
Appendix 2: 
A. Robaszkiewicz, F.H. Greig, A.R. Pitt, C.M. Spickett, G. Bartosz and M. Soszyński 
(2010) Effect of phosphatidylcholine chlorohydrins on human erythrocytes. Chem Phys 
Lipids, 163, 639-647. 
